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Abstract 
Background 
Fetal growth restriction (FGR) is associated with reduced uterine blood flow (UBF). In normal 
sheep pregnancies, adenovirus (Ad) mediated over-expression of vascular endothelial growth 
factor (VEGF) in the uterine arteries (UtA) increases UBF. It was hypothesised that enhancing 
UBF would improve fetal substrate delivery in an ovine paradigm of FGR characterised by 
reduced UBF from mid-gestation.  
Methods 
Singleton pregnancies were established using embryo transfer in adolescent ewes 
subsequently overnourished to generate FGR (n=81). Ewes were randomised mid-gestation to 
receive bilateral UtA injections of 5x1011 particles Ad.VEGF-A165 or inactive treatment (saline or 
5x1011 particles Ad.LacZ, a control vector). Fetal growth/wellbeing were evaluated using serial 
ultrasound. Late-gestation study: UBF was monitored using indwelling flowprobes until 
necropsy at 0.9 gestation. Vasorelaxation, neovascularisation in perivascular adventitia and 
placental mRNA expression of angiogenic factors/receptors were examined. A group of 
control-fed ewes with normally-developing fetuses was included (n=12). Postnatal study: 
Pregnancies continued until spontaneous delivery near to term. Lambs were weighed and 
measured weekly and underwent metabolic challenge at 7 weeks, dual-energy X-ray 
absorptiometry at 11 weeks, and necropsy at 12 weeks postnatal age. DNA methylation of 
somatotropic genes was examined in hepatic tissues. 
Results 
Ultrasonographic fetal growth velocity was greater in Ad.VEGF-A165-treated versus control-
treated FGR fetuses at 3-4 weeks post-injection. In late gestation fewer fetuses were markedly 
growth-restricted following Ad.VEGF-A165 therapy. There was evidence of mitigated brain 
sparing. No effect was seen on UBF/neovascularisation although  Ad.VEGF-A165-transduced 
vessels showed enhanced vasorelaxation. Flt1/KDR expression was increased in the maternal 
placental compartment. At birth  Ad.VEGF-A165-treated lambs tended to be heavier with 
increased placental efficiency. Postnatal growth, lean tissue accretion and insulin secretion 
were also increased, however no epigenetic changes were observed. 
Conclusions 
Ad.VEGF-A165 safely increases fetal growth in this ovine model of FGR. This work has supported 
a successful application to translate this therapy into the clinic. 
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Chapter 1                                                                                                               
General Introduction 
1.1    Fetal growth restriction 
Fetal growth restriction (FGR) is defined as the failure of a fetus to achieve its own genetically 
pre-determined growth potential. FGR complicates around 8% of pregnancies in the general 
population of developed countries (Mandruzzato et al. 2008) and is a major cause of perinatal 
mortality and morbidity (Bernstein et al. 2000; Halliday 2009). The biomedical, psychological, 
social and economic impact of this complication of pregnancy is huge (Nardozza et al. 2012). 
1.1.1    Terminology  
In clinical practice, diagnosis of FGR can be difficult as the intrinsic growth potential of a given 
fetus is generally not known and depends on a number of different factors including ethnicity, 
parity, fetal gender, maternal height and weight in early pregnancy and the mother's own birth 
weight (Gardosi et al. 1992; Gardosi et al. 1995; McCowan & Horgan 2009). Paternal weight 
also makes a modest contribution (Wilcox et al. 1995). The majority of significantly growth-
restricted fetuses are also “small for gestational age” (SGA) at birth. This related but not 
synonymous term is applied when the birth weight falls below a certain threshold, for example 
the 10th, 5th or 3rd percentile for a given gestational age. However it is important to recognise 
that not all SGA babies are in fact growth-restricted. For example, by definition 10% of normal 
babies will weigh less than the 10th percentile at birth. Consequently SGA fetuses represent a 
heterogeneous group in which those with true FGR are diluted with fetuses that are normally 
grown yet "constitutionally small". Only 30-50% of those babies whose birth weight falls below 
the 10th percentile for gestational age are growth-restricted (Ott 1988) and vice versa not all 
fetuses with FGR are necessarily SGA (Chard et al. 1992). Another term often used is "low birth 
weight" (LBW), defined as a birth weight less than 2500g. This classification is even less useful 
in clinical practice than SGA as it does not account at all for the gestational age. Consequently 
a LBW baby may be small as the result of FGR, constitutional smallness or simply prematurity.  
1.1.2    Causes of FGR 
FGR is a description of fetal condition rather than a diagnosis, and there are a wide range of 
underlying causes, associations and contributory factors. Broadly speaking these fall into one 
of three main categories, which are fetal, maternal and uteroplacental. It should be noted 
however that there is often some degree of overlap and that many causes will lead to a 
common end-point of reduced uteroplacental perfusion and hence attenuated fetal nutrient 
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delivery. For example, numerous maternal medical co-morbidities can adversely affect 
placentation and/or uterine blood flow (UBF). In clinical practice it is more useful to make the 
basic distinction between placentally mediated and non placentally mediated FGR with respect 
to management (see Section 1.1.4). 
1.1.2.1    Fetal factors 
There are many intrinsic fetal causes of FGR, which broadly fall into one of four categories: 
chromosomal aberrations, genetic syndromes, structural anomalies and congenital infections. 
Chromosomal abnormalities including trisomy 21 (Down's syndrome), trisomy 18 (Edward's 
syndrome), trisomy 13 (Patau's syndrome) and monosomy X (Turner's syndrome) are present 
in 7% and 19% cases of fetuses with AC measurements below the 10th and 5th percentiles, 
respectively (Snijders et al. 1993a; Heydanus et al. 1994). In the latter three examples, slowing 
of fetal growth is usually apparent by the second trimester (Dicke & Crane 1991; FitzSimmons 
et al. 1994). This is also true of triploidy (Jauniaux et al. 1996), particularly when the extra set 
of chromosomes is paternally derived (McFadden & Kalousek 1991). Additional chromosome 
problems associated with FGR include confined placental mosaicism (particularly trisomy 15, 
16 and trisomy 9q), uniparental disomy (particularly of chromosomes 6, 14 and 16) and partial 
chromosomal deletions such as 4q (Wolf-Hirschhorn syndrome) or 5q (Cri du Chat syndrome) 
(Fujimoto & Wilson 1990; Sanlaville et al. 2000; Maulik 2006; Wilkins-Haug et al. 2006). 
FGR may complicate a large number of different genetic syndromes, many of which are single 
gene disorders demonstrating Mendelian (mostly autosomal dominant or autosomal recessive) 
inheritance. Specific examples include Cornelia de Lange, Brachmann de Lange, Russell-Silver, 
Mulibrey Nanism, Rubenstein-Taybi, Dubowitz, Seckel, De Sanctis-Cachione, Johanson-Blizzard, 
Roberts and Fanconi pancytopaenia syndrome (Gross 1997). Most of these genetic syndromes 
are characterised by multiple physical abnormalities, some of which are detectable by fetal 
ultrasound. The availability of various online dysmorphology databases, such as the London 
Dysmorphology Database (LDDD) and the recently developed Phenotip (www.phenotip.com) 
can aid pattern recognition and diagnosis of the rarer genetic syndromes (Guest et al. 1999).  
Structural fetal anomalies may be associated with one of the chromosomal problems or single 
gene disorders described above, but even in karyotypically normal and non-syndromic fetuses, 
congenital malformations account for a further 1–2% of FGR cases (Hendrix & Berghella 2008). 
Commonly associated abnormalities include cardiac defects (Fallot's tetralogy, hypoplastic left 
heart syndrome, pulmonary stenosis, ventricular septal defects), anencephaly, abdominal wall 
defects (gastroschisis and exomphalos) and congenital diaphragmatic hernia. In addition, some 
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soft markers are associated with FGR. Soft markers, also known as normal variants, constitute 
ultrasonographic features that are present in both normal and affected fetuses, but are more 
prevalent in the latter group and thereby increase the likelihood of a particular condition, e.g. 
FGR or aneuploidy. For example, the finding of hyperechogenic bowel and a single umbilical 
artery at the second trimester anomaly scan are each associated with a greater than two-fold 
increase in the risk of FGR (Hua et al. 2010; Goetzinger et al. 2011).  
Finally, intrauterine infection is responsible for approximately 5–10% of cases (Knox 1978). The 
infective agents that are most frequently encountered in obstetric practice in association with 
FGR are collectively referred to as the TORCH complex, which consists of TOxoplasma gondii, 
Rubella, Cytomegalovirus (CMV) and Herpes simplex virus (Kinney & Kumar 1988). Although 
congenital rubella infection is becoming less common in the UK due to widespread vaccination, 
there remains a strong association with FGR if susceptible women become exposed during 
pregnancy. The most common infective cause of FGR in developed countries is CMV (Cox & 
Marton 2009), however endemic malarial infection (mainly due to Plasmodium falciparum) is 
currently responsible for a larger proportion of infective FGR worldwide (Berghella 2007). 
1.1.2.2    Maternal factors 
A large number of maternal risk factors have been identified for the development of FGR, and 
are listed in Table 1.1. These include discrete pathologies such as chronic medical conditions, 
environmental factors such as living at high altitude or exposure to various toxins, and other 
socioeconomic markers of maternal deprivation which put the pregnancy at higher risk of 
adverse perinatal outcomes, for example being unmarried or unemployed. In addition to these 
maternal factors, it is recognised that paternal factors also have an impact. For example, 
parous women embarking on a further pregnancy with a new partner are 20-30% more likely 
to have FGR even if the first pregnancy was unaffected (Krulewitch et al. 1997) and the risk of 
SGA is elevated if the father himself was born SGA (Shah 2010a). 
A further important consideration here is maternal constraint, which is a physiological rather 
than pathological process, but one which may significantly impact the growth potential of a 
given fetus. Maternal constraint (see Gluckman and Hanson (2004) for a review) essentially 
refers to the non-genetic and non-pathological maternal factors that restrict fetal growth in all 
pregnancies, whether or not they are complicated by FGR or SGA. Maternal constraint may 
reflect increased demand (for example  multiple gestation) and/or reduced supply of nutrients 
(variations in maternal diet within the normal nutritional range). Classically however uterine 
size is though to play a particularly important role. This is best illustrated by the seminal work
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Table 1.1 – Maternal risk factors for fetal growth restriction and smallness for gestational age 
Risk Factor Reference 
Diabetes mellitus with associated vascular disease Howarth et al. 2007 
Impaired renal function Fink et al. 1998 
Antiphospholipid syndrome Yasuda et al. 1995 
Chronic (essential) hypertension Allen et al. 2004 
Systemic lupus erythematosus Yasmeen et al. 2001 
Congenital heart disease Drenthen et al. 2007 
Advanced maternal age (>35 years old) Odibo et al. 2006 
Nulliparity Shah 2010b 
Underweight, overweight or obese (BMI <20, >25 or >30) Gardosi & Francis 2009 
2009)Gardosi & Francis 2009 Smoking Kramer et al. 1999 
IVF conception Jackson et al. 2004 
Excessive exercise or low pre-pregnancy fruit intake McCowan et al. 2010 
Previous history of SGA, stillbirth or pre-eclampsia Ananth et al. 2007 
Inter-pregnancy interval <6 months or >5 years Conde-Agudelo et al. 2006 
Mother born SGA Shah et al. 2009 
African ethnicity Kramer 1987  
Asian ethnicity Alexander et al. 2007 
Social deprivation Blumenshine et al. 2010 
Being unmarried Shah et al. 2011 
Pregnancy-induced hypertension Allen et al. 2004 
Pre-eclampsia Ananth et al. 2007 
Heavy first trimester PV bleeding (threatened miscarriage) 
 
Weiss et al. 2004 
Placental abruption Tikkanen 2011 
2011)2000)(Phillips et al. 
2000) 
Caffeine intake >300mg per day CARE Study Grou  2008 
Low maternal weight gain Lang et al. 1996 
Cocaine use Gouin et al. 2011 
Moderate or excessive alcohol intake Jaddoe et al. 2007 
Domestic violence Shah & Shah 2010 
Environmental pollutants Liu et al. 2003 
Maternal stress Lederman et al. 2004 
Living at high altitude Moore 2003 
Human immundeficiency virus (HIV) infection Brocklehurst & French 1998 
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of Walton and Hammond (1938) who established reciprocal crosses between Shire horses and 
Shetland ponies. In these experiments, Shetland pony fetuses developing in Shire horse uteri 
grew larger than expected. Conversely, Shire horse fetuses developing in Shetland pony uteri 
did not reach their genetic full potential. 
1.1.2.3    Uteroplacental factors 
Aside from the fetomaternal causes detailed above, most cases of FGR (>60%) occur secondary 
to uteroplacental insufficiency (Ghidini 1996). This term is widely used to describe the scenario 
in which there is reduced uterine blood flow (UBF) and/or failure of normal placental growth 
and development. As a result transplacental exchange of oxygen and nutrients is insufficient to 
meet the demands of the growing fetus. This particular form of FGR varies greatly in its timing 
and severity but, with the exception of very early onset cases, it is usually asymmetrical in its 
pattern (Cox & Marton 2009). During normal pregnancy, adequate uterine perfusion depends 
critically on physiological adaptation of the maternal cardiovascular system and establishment 
of functional uteroplacental and fetoplacental circulations. Key to this process in the human is 
invasion of the maternal spiral arteries and replacement of the vascular smooth muscle layer 
(tunica media) by the extravillous trophoblast (Figure 1.1). The end result is a high capacitance, 
passively dilated vascular bed, which is capable of accommodating the major increases in UBF 
that are required as pregnancy advances, from 50ml/min at 10 weeks to 500ml/min in mid-
gestation to 1300ml/min at term (Lang et al. 2003). At the same time maternal cardiac output 
increases by 30–40% (Ueland et al. 1969) and plasma volume is expanded by ~50% (Nelson-
Piercy 2010). Failure of these adaptive processes results in abnormally high resistance to flow 
in the uterine arteries (UtA), which in clinical practice can be recognised using UtA Doppler 
ultrasound. High impedance leads to reduced blood flow, particularly in end-diastole, which 
results in a raised pulsatility index (PI), resistance index (RI) and systolic to diastolic ratio (SDR). 
These indices can be calculated using the formulae presented in Section 2.1.3.2. An early 
diastolic notch (see Figure 1.2) in the waveform is also associated with impaired trophoblast 
invasion (Harrington et al. 1997), particularly when it persists beyond 24 weeks of gestation 
(Pijnenborg et al. 1983). In addition, it is increasingly recognised that additional factors are 
important for UtA adaptation during pregnancy, including changes in maternal arterial 
stiffness, endothelial function, endogenous hormone levels (mainly oestrogen), nitric oxide 
availability and sympathetic tone (Owman 1981; Everett & Lees 2012). This may be particularly 
true of species such as the sheep, in which trophoblast invasion does not occur and yet similar 
increases in UBF to the human are observed, and in which UBF correlates positively with fetal 
growth (Lang et al. 2003). Human FGR is characterised by reduced UBF from as early as mid-
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gestation, as illustrated in Figure 1.3 (Konje et al. 2003), and deliberate restriction of UBF by 
gel-foam embolisation or ligation of the UtA in mid to late gestation results in FGR in sheep, 
rat, mouse and guinea pig pregnancies (Ochi et al. 1998; Carter 2007), which illustrates the 
importance of adequate UBF in sustaining normal fetal growth. In sheep, an early diastolic 
notch is also observed in the UtA waveform of embolised pregnancies (Ochi et al. 1998). 
 
Figure 1.1 – Uterine artery invasion by extravillous trophoblast in normal pregnancy and FGR 
 
Comparison between uterine arteries in the non-pregnant (uninvaded) state, normal pregnancy 
and pathological pregnancy - pre-eclampsia and intrauterine growth restriction (IUGR). Both 
the extent and depth of trophoblast invasion is suboptimal in the latter, resulting in inadequate 
spiral artery transformation, increased vascular resistance and reduced uterine blood flow. As 
well as restricting nutrient delivery to the fetus, ischaemia in the placenta can lead to systemic 
endothelial dysfunction in the mother that results in the maternal syndrome of pre-eclampsia. 
Figure reproduced with permission from Moffett-King (2002). 
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Figure 1.2 – Abnormal uterine artery Doppler waveform 
 
Maternal uterine artery Doppler waveform demonstrating reduced end-diastolic flow and an 
early diastolic notch (illutstrated by the white arrows), suggestive of impaired trophoblast 
invasion, increase uteroplacental vascular resistance and reduced uterine blood flow. 
 
Figure 1.3 – Uterine blood flow in growth-restricted versus normally developing pregnancies 
 
Serial measurements of volume blood flow in the uterine artery measured by transabdominal 
ultrasound between 20 and 38 weeks gestation in human pregnancies complicated by fetal 
growth restriction (FGR) compared with appropriate-for-gestational-age (AGA) controls. The 
criteria for FGR were an estimated fetal weight (and eventual birth weight) between the 3rd 
and 10th centile for gestational age and evidence of centile crossing (reduced growth velocity).  
Graph produced using data tables from Konje et al. (2003). 
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In addition to the uteroplacental blood flow, an adequately matched fetoplacental blood flow 
is needed to ensure fetal substrate supply, as mismatch between the two placental circulations 
effectively decreases the available area for gaseous and nutrient exchange. The establishment 
of a fetoplacental circulation depends on the development and patency of a complex network 
of secondary and tertiary villi (Kingdom et al. 1997). FGR is associated with a poorly developed 
villous tree, leading to a reduction in umbilical venous blood flow (Rigano et al. 2001) followed 
by progressive obliteration of small muscular arteries within the tertiary stem villi. This process 
is accompanied by increased resistance to blood flow within the umbilical artery (UA), which is 
reflected by a progressive reduction in end-diastolic flow (EDF) and increasing values of PI, RI 
and/or SDR (Trudinger et al. 1985; Giles et al. 1985). UA Doppler indices only start to become 
elevated when >30% of the fetal villous architecture is abnormal (Morrow et al. 1989). UA EDF 
is usually maintained until ~60-70% of the villous tree has been obliterated, at which point it 
becomes absent, then reversed (Wilcox et al. 1989) - see Figure 1.4 and Section 1.1.4.6 below. 
 
Figure 1.4 – Normal and abnormal umbilical artery Doppler waveforms 
 
Doppler waveforms of the umbilical artery (UA) taken from human pregnancies complicated by 
fetal growth restriction. A = normal UA waveform showing positive end-diastolic flow (EDF).      
B = abnormal UA waveform demonstrating absent EDF. C = abnormal UA waveform featuring 
reversed EDF. 
 
The placenta in FGR may demonstrate any number of different morphological abnormalities. 
FGR characterised by UA Doppler abnormalities is associated with reduced placental size with 
fewer small arteries on histological examination (McCowan et al. 1987; Bracero et al. 1989). 
Intermediate and terminal villi exhibit a reduced volume and surface area (Jackson et al. 1995) 
and the exchange barrier may be increased secondary to thickening of the basal lamina, villous 
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cytotrophoblast hyperplasia and focal degeneration in the vessel wall (van der Veen & Fox 
1983; Fok et al. 1990; Macara et al. 1996). Microscopic examination of the placenta in FGR may 
reveal other contributory microvascular disease processes such as fibrinoid necrosis, atherosis, 
chronic vasculitis and thrombosis (Salafia 1997).  
1.1.3    Consequences of FGR 
Faced with a reduced substrate supply, the fetus mounts a number of adaptive responses in 
order to maximise the limited resources. Unfortunately this initial phase of compensation is 
frequently followed by relative decompensation leading to tissue damage in utero. Moreover 
some of these adaptive processes, whilst they might improve the chance of fetal survival, are 
responsible for some of the increased morbidity that is seen in neonatal and later life. A major 
factor in such adaptation is the degree of hypoxia in the fetus, which is believe to be the main 
trigger for the cardiovascular redistribution that results in fetal brain sparing and intrauterine 
programming of cardiovascular dysfunction (Giussani et al. 2012), discussed further in Sections 
1.1.3.4 and 1.1.3.8 below. Severely growth-restricted fetuses with evidence of compromise 
such as abnormal UA Dopplers are frequently hypoxaemic, and this has been demonstrated by 
umbilical venous blood gas analysis following cordocentesis (Pardi et al. 1993) - see Figure 1.5. 
1.1.3.1    Metabolic impact 
Attenuated uteroplacental blood flow directly limits the transplacental supply of nutrients to 
the fetus, resulting in reduced availability of key macronutrients, principally glucose, amino 
acids and free fatty acids. Fetal nutrient levels are significantly reduced relative to maternal 
levels, reflecting the elevated maternal-fetal concentration gradients secondary to impaired 
placental transfer (Hay 2006; Avagliano et al. 2012). Fetal hypoglycaemia has been shown to 
be directly proportion to the partial pressure of oxygen (pO2) in mid to late gestation, which 
reflects the degree of hypoxia (Nicolini et al. 1989). Aiming to reinstate normoglycaemia, fetal 
pancreatic secretion of glucagon and insulin are increased and decreased, respectively, during 
the late second and early third trimester (Hubinont et al. 1991). Importantly, the degrees of 
hypoglycaemia and hypoinsulinaemia during fetal life are often disproportionate, suggesting 
an element of pancreatic dysfunction (Economides et al. 1991). The proportions of pancreatic 
insulin-secreting beta-cells have been shown to be decreased in the growth-restricted fetus 
(van Assche & Aerts 1979), which may contribute to the increased risk of diabetes in later life 
following FGR (see Section 1.1.3.8). Interestingly in the early stages of fetal hypoxia, relative 
hyperglycaemia is observed secondary to reduced fetal glucose consumption (Jones et al. 
1983) and presumably by increased glucose production via breakdown of glycogen stores and 
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Figure 1.5 – Evidence of hypoxaemia in severely growth-restricted fetuses 
 
Measurements of venous partial pressure of oxygen (pO2) in umbilical cord blood obtained via 
cordocentesis in growth-restricted fetuses with biometric markers (abdominal circumference 
and head circumference) below the 5th percentile for gestational age. The fetuses were divided 
into three subgroups: Group 1 fetuses had a normal fetal heart rate (FHR) and umbilical artery 
(UA) pulsatility indices (PI). Group 2 had a normal FHR but UA PI values more than 2 standard 
deviations (2SD) above normal. Group 3 had an abnormal FHR and UA PI >2SD above normal. 
Figure reproduced with permission from Pardi et al. (1993). 
. .  
hepatic gluconeogenesis. However this does not appear to be maintained in the longer term. 
Fortunately the fetal brain is able to utilise alternative fuels such as ketones and lactate, which 
confers some degree of protection against the deleterious effects of hypoglycaemia (Vannucci 
& Vannucci 2000). FGR appears to be associated with impaired glucose tolerance as insulin 
levels do not change following  glucose challenge in severe human FGR (Nicolini et al. 1990).  
Amino acid concentrations are similarly reduced in the fetal circulation. Whilst the fetus is able 
to generate some amino acids through protein breakdown, reduced concentrations of most of 
the amino acids are apparent in umbilical cord blood (Cetin et al. 1992), particularly those that 
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are essential (Cetin et al. 1990). Transplacental flux of two essential amino acids, leucine and 
phenylalanine, has been measured and is attenuated in FGR (Paolini et al. 2001). Whilst 
placental transfer of essential fatty acids is also reduced, leading to lower circulating levels of 
linoleic acid and arachidonic acid, there is evidence that growth-restricted fetuses have 
increased levels of free (non-esterified) fatty acids and triglycerides relative to normally 
growing fetuses (Economides et al. 1991; Alvino et al. 2008). This is likely to reflect a relatively 
catabolic state in which fat stores are broken down to provide substrates for fetal metabolism, 
as an alternative to glucose, and for gluconeogenesis. Free fatty acid levels within the amniotic 
fluid are also three times higher in FGR pregnancies (Urban & Iwaszkiewicz-Pawlowska 1986). 
Furthermore umbilical cord blood concentrations of albumin, cholesterol and magnesium are 
significantly lower at birth following FGR, which is indicative of impaired micronutrient transfer 
(Nieto-Diaz et al. 1996). 
1.1.3.2    Endocrine effects 
In addition to the changes in plasma insulin and glucagon levels discussed above in relation to 
fetal metabolism, FGR has a wide impact upon the maturation and activity of various fetal 
endocrine pathways. Those alterations in hormone levels that have been demonstrated in 
human pregnancies complicated by FGR are summarised in Table 1.2. Insulin-like growth factor 
(IGF-1) and IGF-2 are both down-regulated, whilst the IGF binding proteins (BP) are variably 
affected: FGR increases IGFBP-1 and 2 and decreases IGFBP-3 (Cianfarani et al. 1998; Street et 
al. 2006). With respect to thyroid function, growth-restricted fetuses are hypothyroid with low 
thyroxine (T4) levels in spite of raised thyroid stimulating hormone (TSH) levels. Tri-
iodothyronine (T3) levels, however, are unaffected (Thorpe-Beeston et al. 1991). Although 
plasma renin levels are increased, aldosterone concentrations are not different between FGR 
and control pregnancies (Ville et al. 1994). FGR activates the hypothalamic-pituitary-adrenal 
(HPA) axis, thus increasing circulating concentrations of corticotrophin releasing hormone 
(CRH), adrenocorticotrophic  hormone (ACTH) and cortisol. Finally, the observed changes in 
osteocalcin and 1,25-dihydroxyvitamin D concentrations in FGR are associated with reduced 
bone mineral density in neonatal life (Namgung et al. 1993). Other fetal parameters which are 
affected by FGR include the catecholamines, ghrelin, leptin and transforming growth factor-1β 
(detailed in Table 1.2). 
1.1.3.3    Haematological changes 
FGR has widespread effects on the circulatory system including redistribution of the cardiac 
output (see Section 1.1.3.4 below) as well as alterations in the composition of the fetal blood. 
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Table 1.2 – Effect of FGR on fetal concentrations of various hormones from human studies 
Hormone Effect  
of FGR 
Reference 
Insulin* ↓ Economides et al. 1991 
Insulin-like growth factor (IGF)-1 ↓ Ostlund et al. 2002 
Transforming growth factor (TGF)-1β ↓ 
Corticotrophin-releasing hormone (CRH) ↑ Goland et al. 1993 
Adrenocorticotrophic hormone (ACTH) ↑ 
Cortisol ↑ 
Osteocalcin  ↓ Verhaeghe et al. 1995 
1,24 dihydroxyvitamin D ↓ Namgung et al. 1993 
Thyroid stimulating hormone (TSH)* ↑ Thorpe-Beeston & Nicolaides 1993 
Total thyroxine (T4)* ↓ 
Free thyroxine (T4)* ↓ 
Growth hormone ↑ Nieto-Diaz et al. 1996 
Renin* ↑ Weiner & Robillard 1988 
Adrenaline* ↑ 
Noradrenaline* ↑ Greenough et al. 1990 
Leptin ↓ Martos-Moreno et al. 2009 
Ghrelin ↑ 
Insulin-like growth factor (IGF)-2 ↓ Smerieri et al. 2011 
 
* Indicates those parameters that were measured during fetal life by means of cordocentesis. 
All remaining parameters were measured in umbilical cord blood sampled at birth. 
 
These changes largely occur secondary to a reduction in pH, pO2 and % oxygen saturation and 
an increase in the partial pressure of carbon dioxide (pCO2), bicarbonate and lactate (Weiner & 
Williamson 1989; Economides et al. 1991). In order to maximise oxygen carriage, erythopoietin 
secretion and red blood cell production (from both medullary and extramedullary sources) is 
stimulated, leading to polycythaemia (Snijders et al. 1993b; Maier et al. 1994). Erythroblast 
and nucleated red blood cell (NRBC) counts are increased and these correlate with the degree 
of intrauterine hypoxia (Thilaganathan & Nicolaides 1992; Thilaganathan et al. 1994; Bernstein
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 et al. 1997). In advanced cases, erythopoiesis can become dysfunctional (Stallmach et al. 
1998) resulting in anaemia, which is also associated with higher cobalamin and reduced ferritin 
levels (Abbas et al. 1994). FGR is frequently complicated by thrombocytopaenia (van den Hof & 
Nicolaides 1990; Baschat et al. 1999), platelet activation and aggregation (Ohshige et al. 1999), 
increased thrombin concentrations (Trudinger et al. 2003) and increased whole blood viscosity, 
all of which can predispose to occlusion of small vessels within the placenta and thereby 
further exacerbate uteroplacental insufficiency. 
1.1.3.4    Cardiovascular redistribution 
In response to reduced oxygen and metabolic nutrient supply, the fetus adapts by altering the 
partitioning of blood flow, and thereby substrate delivery, in a way that preferentially supplies 
the essential organs. Arguably the most important organ of all is the fetal brain. Accordingly, in 
response to hypoxaemia, the fetal cerebral circulation dilates, reducing the resistance to blood 
flow and decreasing left ventricular afterload. This becomes apparent on Doppler ultrasound 
as a reduced PI and increased peak systolic velocity in the middle cerebral artery (Mari & Deter 
1992; Mari 2009). At the same time, an opposite effect is occurring in the periphery. The trunk 
vessels constrict, increasing the peripheral vascular impedance and right ventricular afterload 
(al-Ghazali et al. 1989). The relative changes in the left and right ventricular outflows results in 
a greater proportion of the cardiac output being distributed to the fetal head and brain, whilst 
blood from the descending aorta is preferentially streamed to the placenta for re-oxygenation 
rather than to the periphery for musculoskeletal growth. The consequence of these alterations 
in blood flow and nutrient partitioning is a prioritisation of fetal brain growth at the expense of 
body growth, the so-called "brain sparing effect", which produces an asymmetrical pattern of 
FGR. Brain sparing can be identified at post-mortem examination by an increased brain to liver 
weight ratio (Cox & Marton 2009) and on ultrasound by increased biparietal diameter (BPD) to 
abdominal circumference (AC) ratios. The degree of fetal brain sparing is closely related to the 
degree of placental vascular resistance (Cheema et al. 2006). In addition to fetal brain sparing, 
blood flow is also preferentially diverted to the heart and adrenal glands (Baschat et al. 1997; 
Tekay & Jouppila 2000). This may result in ventricular wall hypertrophy and activation of the 
hypothalamic-pituitary-adrenal axis, respectively, and is associated with an increase in adrenal 
secretion of catecholamines (Weiner & Robillard 1988). By contrast, blood flow in the vessels 
supplying the less essential organs is reduced, for example the pulmonary, mesenteric and 
renal arteries (Veille & Kanaan 1989; Mari et al. 1995; Rizzo et al. 1996). The latter is 
associated with oligohydramnios and, whilst the former functions are not required during fetal 
life, pulmonary and gastrointestinal hypoperfusion can result in respiratory compromise and 
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susceptibility to necrotising enterocolitis in the neonatal period, respectively. In addition blood 
flow to the limbs in reduced, classically resulting in a short femur (Papageorghiou et al. 2008). 
1.1.3.5    Perinatal mortality 
The risk of stillbirth and neonatal death is largely dependent on the cause of FGR and its onset 
and severity. Published studies imply an overall five- to ten-fold increase in perinatal mortality 
(McIntire et al. 1999; Lackman et al. 2001). However this thesis is primarily concerned with the 
particular problem of early-onset severe FGR secondary to uteroplacental insufficiency, which 
is especially challenging to manage clinically (see Section 1.1.4) and is associated with very 
poor perinatal outcomes indeed. A recent retrospective analysis of cases characterised by an 
AC or EFW below the 5th centile and either abnormal UA Dopplers or reduced growth velocity 
which were referred to the Fetal Medicine Unit at University College London Hospital over a 12 
year period (2000 to 2012) found that, of a total of 78 pregnancies that were chromosomally 
and structurally normal, 31 (40%) resulted in miscarriage, intrauterine fetal death or stillbirth, 
and the remaining 47 (60%) required delivery for fetal indications prior to 32 weeks gestation 
(DJ Carr, unpublished data). It has been shown that the chance of fetal survival is dependent 
upon the gestational age and the estimated fetal weight (EFW) on ultrasound (Baschat 2004). 
Viability is considered to have been achieved when the pregnancy reaches 24 completed 
weeks gestation and EFW is >500g. However it is the gestational age that it the most important 
independent predictor of neonatal survival and, perhaps more importantly, intact survival 
without disability (Baschat et al. 2007). For example, an increase in gestational age at delivery 
from 25 to 26 weeks is associated with a doubling (approximately) of intact survival (see Figure 
1.6). It is also important to note, that in addition to the mortality from antenatally diagnosed 
FGR, many cases go undetected and can later result in an otherwise "unexplained" stillbirth 
(Cousens et al. 2011). Prenatally detected cases may therefore represent the tip of the iceberg. 
1.1.3.6    Neonatal morbidity 
Survivors of severe FGR are at increased risk of a wide range of medical complications during 
the neonatal period, which often relates to one or more of the following: (a) the effects of the 
intrauterine starvation per se; (b) the potentially adverse side-effects of adaptive mechanisms 
designed to promote growth of important organs such as the brain at the expense of others 
such as the lung and bowel; and (c) iatrogenic prematurity, if early delivery has been indicated 
because of concerns that continuing the pregnancy is likely to result in fetal demise. Growth-
restricted and/or premature babies are at a particularly high risk of hypothermia as they tend 
to be long and skinny with a low ponderal index (Doctor et al. 2001). Consequently they have a 
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Figure 1.6 – Survival of placentally growth-restricted neonates born before 32 weeks gestation 
 
Total survival (black diamonds) and intact survival rates (black bars) until discharge in growth 
restricted neonates by gestational age. Reproduced with permission from Baschat et al. (2007). 
 
large body surface area relative to their size through which they rapidly lose heat. They also 
usually have greatly reduced body fat stores secondary to in utero malnutrition, such that their 
ability to generate heat via non-shivering thermogenesis is reduced. It is particularly important 
to avoid hypothermia as it exacerbates other complications such as hypoglycaemia. Growth-
restricted neonates tend to remain hypoglycaemic following delivery, which vice versa can 
exacerbate hypothermia, resulting in a vicious cycle. Prematurity is associated with feeding 
difficulties (due to an absent or weak suck reflex) and these neonates often require tube 
feeding or parenteral nutrition. However care must be taken when feeding not to overload the 
gut in view of the risk of necrotising enterocolitis, a potentially life-threatening complication 
associated with impaired intestinal vascular development (Aucott et al. 2004). Polycythaemia, 
although of benefit to the fetus by maximising oxygen delivery to the tissues, greatly increases 
the risk of neonatal jaundice as the excess red cell mass is broken down. If not managed 
vigilantly with phototherapy it can lead to bilirubin-induced brain damage (kernicterus). 
Growth-restricted neonates are also at risk of intraventricular haemorrhage (Simchen et al. 
2000), which is a further mechanism through which an adverse neurological outcome may 
result. FGR is associated wtih bronchopulmonary dysplasia and respiratory distress syndrome 
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(Tyson et al. 1995) and increases susceptibility to infection partly through impaired immunity, 
which is in turn reflected by reduced immunoglobulin G concentrations, phagocytic indices and 
neutrophil counts (Chandra & Matsumura 1979). 
1.1.3.7    Impact on child health 
Prenatally growth-restricted individuals who survive through the neonatal period also have an 
increased risk of ill health during childhood and beyond. The problems seen with respiratory 
adaptation to extra-uterine life following FGR, which may require prolonged oxygen therapy ± 
ventilatory support, confer an increased risk of chronic lung disease (Regev et al. 2003). Lung 
function is worse in preterm growth-restricted babies compared with preterm AGA babies 
when measured around 8 years of age (Morsing et al. 2012) and FGR is also associated with an 
increased risk of asthma (Henderson & Warner 2012). Adverse effects on cardiovascular health 
are also apparent relatively early following FGR, reflected by smaller aortic dimensions and 
increased resting heart rate in adolescents (Brodszki et al. 2005). These changes probably 
contribute to the adverse cardiovascular risk profile observed in adult life (see Section 1.1.3.8). 
Of particular concern is the risk of poor neurodevelopmental outcome following FGR. At 5 to 8 
years of age, cognitive function is reduced following FGR and is notably poorer amongst boys 
(Morsing et al. 2011). Within the brain, it has been shown that FGR reduces grey matter, white 
matter and hippocampal volumes (Lodygensky et al. 2008) and adversely affects complexity of 
the cortex (Tolsa et al. 2004). The latter is associated with immature behavioural scores and an 
attention deficit. Poorer neurological outcomes appear to be particularly prevalent following 
severe early-onset FGR, where rates of up to 53% have been reported (Baschat et al. 2007). 
The risk of cerebral palsy with a birth weight below the 10th percentile is increased six-fold 
(Jarvis et al. 2003) and prevalence following FGR is reported to be ~22% (Spinillo et al. 2006). 
Prenatally growth-restricted children also show an increased rate of visual problems at 4 years 
of age (Matilainen et al. 1987) and FGR is associated with hearing deficits (Baschat et al. 2009) 
and increased rates of childhood obesity by the age of nine (Chakraborty et al. 2007). 
1.1.3.8    Impact on adult health 
In the longer term, survivors of FGR are at an increased risk of adult-onset cardiovascular and 
metabolic disease - coronary artery disease, stroke, hypertension and type 2 diabetes mellitus 
(Barker et al. 1993; Barker 2006; Ross & Beall 2008). The process by which prenatal exposures 
can impact on health and disease in later life is known as "intrauterine programming" and has 
given rise to a rapidly expanding research field - Developmental Origins of Health and Disease 
(DoHaD). The developmental origins hypothesis proposes that early life nutrition (during the 
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fetal and neonatal period and infancy) leads to alterations in gene expression that set baseline 
metabolic function and influence vulnerability to later life exposures.  
A number of different epidemiological studies have illustrated the link between birth weight 
and adult disease. A cohort study of 10,636 men born in Hertfordshire between 1911 and 1930 
revealed that the prevalence of adult-onset diabetes and impaired glucose tolerance showed a 
bimodal peak, being highest in those who were LBW or macrosomic at birth (Hales et al. 1991). 
The risk of coronary heart disease fell in a stepwise pattern with increased birth weight. There 
was also a strong relationship between infant weight at one year of age and impaired glucose 
tolerance. A similar trend was seen in women between glucose tolerance and birth weight but 
not infant weight, suggesting that men are at greater risk from prenatal nutritional insults. 
These findings have since been reproduced in several hundred studies worldwide in various 
different populations and ethnicities - see Barker (2006) for a summary. Some of these studies 
have specifically assessed confounding by collecting data on lifestyle. For example, the US 
Nurses' Health Study found that controlling factors such as smoking, alcohol intake, exercise 
and employment status did not significantly distort the relationship between birth weight and 
adult-onset diseases (Rich-Edwards et al. 1997). Nevertheless, it is clear that adult lifestyle 
factors are additive and further increase LBW-related cardiovascular risk. For example, 
impaired glucose tolerance is greatest amongst individuals born SGA who become obese in 
later life (McCance et al. 1994). It is also possible that survivors of FGR are more susceptible to 
the negative impact of various environmental exposures. For example, men who had a high 
ponderal index at birth suggestive of FGR demonstrate an association between low income 
and coronary heart disease that is not apparent in men who had an appropriate-for-
gestational-age birth weight (Barker et al. 2001). Adults born SGA also demonstrate elevated 
serum cortisol concentrations in response to stress (Phillips et al. 2000). 
Another good illustration of the importance of fetal nutrient supply on adult health was the 
natural experiment of the Dutch Hunger Winter, which was a period of famine in a German- 
occupied region of the Netherlands in 1944, shortly before the end of World War II. During the 
period food rationing was in place, average energy intake was reduced to as little as 400-800 
calories per day (Schulz 2010). Late gestational exposure reduced mean birth weight by only 
approximately ~240g compared to non-exposed controls, a modest perturbation, however the 
impact of prenatal famine exposure on adult health was considerable - see Painter et al. (2005) 
for an overview. The specific risks varied with the timing of exposure. Individuals prenatally 
exposed to famine in early gestation had a greater incidence of coronary heart disease, 
hyperlipidaemia, clotting disorders, and obesity. Exposure in mid-gestation conferred an 
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increased risk of obstructive lung disease and microalbuminuria and those exposed in late 
gestation had reduced glucose tolerance. This suggests that there exist "windows" during 
which the development of specific fetal organs is vulnerable to nutritional insults. More recent 
data from this cohort has also shown accelerated cognitive ageing in those exposed to famine 
in early gestation (de Rooij et al. 2010). 
A number of different mechanisms have been proposed to explain these programming effects 
including epigenetic changes (DNA methylation, histone modifications and microRNAs), which 
are discussed in detail in Chapter 6. Epigenetic modifications can lead to potentially permanent 
alterations in gene function in the absence of changes in the genomic DNA sequence through 
differential effects on gene transcription. In the Dutch Hunger Winter cohort, those exposed to 
famine in early gestation demonstrated permanent alterations in the methylation status of the 
IGF-2 gene (Heijmans et al. 2008). Other possible contributors include structural alterations in 
various organs and tissues as a consequence of compromised fetal growth in utero. For 
example it is known that FGR reduces the number of glomeruli in the kidney at birth and that 
this may at least partially explain the increased risk of hypertension (Brenner & Chertow 1993). 
As already mentioned, there is also a reduction in pancreatic beta-cell mass which contributes 
to an insulin-resistant phenotype. It may well be beneficial during intrauterine life for a fetus 
to develop relative insulin resistance in an attempt to maintain circulating glucose levels. 
However in postnatal life, when nutrient supply is often restored, this may lead to a diabetic 
phenotype (Phillips 1996). It is apparent that a relative mismatch between the prenatal and 
postnatal environments is a particular risk factor for the development of an adverse metabolic 
profile in later life (Hanson & Gluckman 2011). Children born small who show catch up growth 
in the early years (particularly between 4 and 8 years of age) with upward centile crossing are 
at greatest risk of insulin resistance and cardiovascular disease (Bavdekar et al. 1999) and lack 
of catch up growth is associated with a reduced risk of disease (Hofman et al. 1997). In the 
developing world greater risks are associated with moves towards greater nutrient availability 
in postnatal life e.g. rural to urban migration, adoption and elevated social status (Yajnik 2004). 
1.1.3.9    Financial implications 
In addition to the biomedical, psychological and social impact of FGR, the economic burden is 
huge. As well as the longer term child and adult health implications discussed above, the cost 
of prolonged neonatal intensive care provision when early delivery is indicated is considerable. 
One recent estimation of the overall cost to society of preterm birth in the England and Wales 
in 2006 was almost £3 billion, with individual costs per survivor as high as £225,000 for those 
born at 24 weeks gestation (Mangham et al. 2009). FGR contributes a significant proportion of 
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preterm birth, particularly of the iatrogenic type. The cost of neonatal care is inversely related 
to birth weight, which reflects fetal growth as well as the gestational age at delivery. Table 1.3 
illustrates the average cost of the hospital stay per neonate, stratified by birth weight category 
and presented separately for term versus preterm birth, recorded annually across a five-year 
period at a single tertiary level hospital in the UK. It can be seen that the cost for a baby born 
weighing less than 1000g is more than double that of a baby born weighing 1000-1499g. This 
suggests that relatively modest increases in fetal growth might have a major financial impact. 
In the longer term when FGR is associated with neurosensory disability, individual healthcare 
costs may exceed £50,000 per annum (Petrou et al. 2006). When the increased health burden 
of adult-onset diseases is also considered, the financial impact over a lifetime is immeasurable. 
1.1.4    Management of FGR 
1.1.4.1    Prevention 
Preventive strategies are mainly aimed at women with a previous history of FGR or its known 
risk factors. The overall recurrence rate of FGR is approximately 20% (Patterson et al. 1986), 
although this can vary dramatically depending on the underlying cause. Short inter-pregnancy 
intervals are associated with 30% incidence of SGA and 40% incidence of LBW, and the optimal 
time period between the previous pregnancy and subsequent conception appears to be 18 to 
24 months (Zhu et al. 1999). A Cochrane review including 56 randomised controlled trials and 
nine cluster randomised trials of various interventions to promote smoking cessation during 
pregnancy found that stopping smoking reduced the incidence of low birth weight by 17% and 
increased mean birthweight by 54g (Lumley et al. 2009). Furthermore a diet rich in leafy green 
vegetables prior to pregnancy has been shown to reduce the risk of SGA by 56% (McCowan et 
al. 2010). Treatment of mild or moderate hypertension with pharmacological agents does not 
reduce the incidence of SGA (Abalos et al. 2007) and may precipitate a fall in placental 
perfusion. This is an important consideration in the management of both pre-existing and 
gestational hypertension, in which the target blood pressure should be around 140/90 to avoid 
acute fetal compromise. However it is important to avoid sustained elevations in systolic and 
diastolic blood pressure (>160 and >110 mmHg, respectively) to avoid maternal haemorrhagic 
stroke (Cantwell et al. 2011). Anti-platelet agents such as aspirin also have a role in the 
prevention of recurrence of FGR. The latest Cochrane review of 59 randomised controlled trials 
(n=37,560 women) and an individual patient data-analysis found a reduction in SGA of 10–11% 
(Askie et al. 2007; Duley et al. 2007). Aspirin is also used in clinical practice for the prevention 
of pre-eclampsia, a related placental disorder that is characterised by gestational hypertension 
and proteinuria and shares the same underlying pathogenesis as uteroplacental FGR. It
45 
 
Table 1.3 – Costs of neonatal care provision associated with low birth weight (<2500g) according to birth  weight category and gestational age at delivery 
AVERAGE COST UNTIL DISCHARGE FROM HOSPITAL (£) 
Year All 
≤2500g 
Term 
≤2500g 
Term        
2000- 2499g 
Term        
1500- 1999g 
Term        
1000-1499g 
All Preterm 
≤2500g 
Preterm 
2000- 2500g 
Preterm 
1500-1999g 
Preterm 
1000-1499g 
Preterm 
500-999g 
Preterm 
<500g 
2008 13074 2620 2674 1574 5622 14634 3828 8215 15596 34754 52452 
2007 12861 2022 2087 1660  13948 4396 7337 14142 33529  
2006 13991 3158 3001 3863  15068 4750 8248 22217 35909  
2005 15236 2420 2446 2378  16731 4605 9409 21036 49524 24055 
2004 16896 3329 3081 4199  18094 4162 8346 213599 43688 36418 
5-Yr 
Ave 
14411 2709 2659 2735 5622 15734 4348 8310 18871 39494 37640 
 
Immediate costs of neonatal care until hospital discharge for preterm babies according to birth weight, based on data from a single large NHS university hospital in 
central England. Over the five year period shown (2004-2008), the average length of stay at each level of neonatal care (intensive care, high dependency care, 
transitional care or postnatal ward) was calculated for each baby and then stratified according to year, birthweight and gestational age at delivery: term = >37 
weeks of gestation;  preterm = <37 weeks gestation. Table reproduced with permission from Morris et al. (2010).  
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been shown that aspirin must be started before 16 weeks to be effective for this indication 
(Bujold et al. 2010) and the same is probably true for FGR. Unfortunately the latter is usually 
diagnosed in the mid second trimester (early onset) or during the third trimester (late onset), 
which is simply too late for aspirin to be effective.  
1.1.4.2    Prediction 
When pregnant women attend for their booking visit, which should ideally be before 10 weeks 
gestation (NICE 2008), a full obstetric and medical history is taken along with measurements of 
height and weight, used to calculate the body mass index (BMI), and blood pressure. At this 
point a number of risk factors or pre-existing maternal conditions may be identified that confer 
an increased risk of FGR (detailed above in Table 1.1). Previous obstetric history is particularly 
relevant. Having previously had an SGA infant increases the risk four-fold (Wolfe et al. 1987), 
and this risk is further elevated after two or more previous SGA babies (Kleijer et al. 2005). A 
baseline risk assessment is important given that routine antenatal care in the UK for "low risk" 
women includes only two ultrasound scans, for pregnancy dating and fetal anomaly screening 
at 10–14 and 18–22 weeks, respectively. This model of antenatal care is justifiable as routine 
ultrasound during the third trimester does not improve maternal or perinatal outcome in an 
unselected or low-risk population (Bricker et al. 2008).  
It is currently recommended that women with one or more of the following major risk factors 
for SGA/FGR (odds ratio for SGA >2.0 from published studies) at booking should undergo serial 
ultrasound assessment of fetal growth in the third trimester (RCOG 2013): 
 Maternal age >40 years 
 Smoker >10 cigarettes per day 
 Cocaine use 
 Daily vigorous exercise 
 Previous SGA 
 Previous stillbirth 
 Maternal or paternal SGA 
 Chronic hypertension 
 Diabetes and vascular disease 
 Renal impairment 
 Antiphospholipid syndrome 
Women who have three or more minor risk factors (remainder of those detailed in Table 1.1)
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should undergo further screening with UtA Doppler ultrasound at 20 to 24 weeks gestation. As 
discussed in Section 1.1.2.3, UtA Doppler waveforms are a reflection of downstream resistance 
to blood flow in the maternal placental circulation. Persistence of an early diastolic notch or 
low end-diastolic velocity (which are characteristic features of the non-pregnant and first 
trimester waveforms) after 24 weeks of gestation indicate impaired adaptation, which is 
associated with inadequate trophoblast invasion of the spiral arteries (Kirkegaard et al. 2011). 
UtA Doppler can be performed earlier, as abnormalities between 10 and 14 weeks gestation 
are also associated with impaired trophoblast invasion (Lin et al. 1995) and a large prospective 
observational study (FASTER) performed in this gestational age range demonstrated that a UtA 
RI value above the 75th percentile was associated with a 5.5-fold increase in the risk of FGR 
(Dugoff et al. 2005). However despite a relatively high specificity (91–96%) and negative 
predictive value (91–99%), the sensitivity of UtA Doppler at this stage of gestation is very poor 
(12–25%), limiting its use as a screening test (Prefumo et al. 2004). Routine UtA Doppler in the 
second trimester shows no maternal or fetal benefit and is therefore not warranted (Ghi et al. 
2010). However for women at increased risk of SGA/FGR, UtA Doppler screening has a greater 
predictive value when performed in the early second trimester (Chan et al. 1995). Women who 
have a high UtA PI (± notching) at this stage have a ~14-fold increased risk of FGR (Cnossen et 
al. 2008) and should therefore be offered growth scans from 26–28 weeks gestation, as per 
those with a major risk factor (RCOG 2013). 
In recent years, much effort has been directed at developing serum screening tests for FGR. A 
variety of different biomarkers have been evaluated including markers of angiogenesis (such as 
placental growth factor (PlGF), soluble fms-like tyrosine kinase 1 (sFlt-1), soluble endoglin, 
vascular endothelial growth factor (VEGF) and angiopoietin) and markers of endothelial 
dysfunction and oxidative stress (such as soluble vascular cell adhesion molecule-1, soluble 
intercellular adhesion molecule-1, pentraxin 3 and homocysteine). A recent systematic review 
and meta-analysis of 53 studies of 37 different biomarkers in a total of 39,974 women 
concluded that no marker is sufficiently accurate for clinical use (Conde-Agudelo et al. 2013). 
Nevertheless it is recognised that low maternal serum levels of pregnancy-associated plasma 
protein A (PAPP-A), defined as less than 0.415 multiples of the median (MoM) for gestational 
age, during the first trimester confers a two- to three-fold increase in the risk of uteroplacental 
FGR (Gagnon et al. 2008). Consequently women with low PAPP-A levels picked up through the 
Down's syndrome screening programme, in which PAPP-A is used as a serum marker, should 
have regular fetal growth scans during the third trimester. However, despite this association, 
PAPP-A is not suitable as a routine screening test for FGR. Currently all pregnant women 
routinely have regular abdominal measurements of the symphysio-fundal height (SFD) at each 
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antenatal visit from 24 weeks gestation onwards. This also represents a form of screening for 
fetal growth disorders, although the sensitivity of SFD to detect an SGA pregnancy has been 
reported to be as low as 27% (Persson et al. 1986). 
1.1.4.3    Diagnosis 
The initial suspicion of FGR is usually raised when an SGA fetus is diagnosed antenatally on 
ultrasound examination. In the UK, SGA has been defined by the Royal College of Obstetricians 
and Gynaecologists (RCOG) as a fetal abdominal circumference (AC) or estimated fetal weight 
(EFW) value below the 10th percentile for gestational age. SGA is "severe" if the AC/EFW plot 
below the 3rd centile (RCOG 2013). Fetal weight can be estimated ultrasonographically using 
one of many published regression equations (Hoopmann et al. 2010), although this approach is 
subject to various methodological and analytical flaws. It is well recognised that there is a 
significant margin of error with respect to ultrasound derived EFW, particularly at the 
extremes of fetal weight, i.e. in FGR and fetal macrosomia, which is variably defined as a birth 
weight greater than the 90th percentile for gestational age, or >4.5kg or >4kg irrespective of 
gestational age (Platz & Newman 2008). Customised fetal growth charts are available which 
incorporate various maternal factors (e.g, maternal height and weight in early pregnancy, 
parity and ethnicity) to take the estimated intrinsic fetal growth potential into account, and 
these may improve the sensitivity to detect a genuinely SGA fetus (Gardosi et al. 1992) and/or 
growth-restricted fetus (de Jong et al. 1998). Fetuses that are found to be SGA are considered 
more likely to be truly growth-restricted if they additionally show evidence of fetal 
compromise, which usually comprises one or more of the following findings: (a) reduced 
longitudinal growth velocity; (b) abnormal UA Dopplers; or (c) abnormal amniotic fluid volume. 
Longitudinal fetal growth velocity can be measured by repeating measurements of AC and/or 
EFW at 2–3 week intervals. In addition the pattern of growth (symmetrical versus 
asymmetrical) can be determined by additionally comparing head and long bone growth by 
measurement of biparietal diameter (BPD), head circumference (HC) and femur length (FL). 
Normative growth charts are available for all these parameters (Chitty et al. 1994a; Chitty et al. 
1994b; Chitty et al. 1994c) and measurements that are found to be crossing centiles are 
indicative of restricted growth (see Figure 1.7). By contrast, a fetus that is SGA but growing 
parallel to the centile lines with normal UA Dopplers and amniotic fluid indices is much more 
likely to be constitutionally small (see Section 1.1.1). 
1.1.4.4    Investigation 
Once a fetus is suspected to be growth-restricted, a number of investigations are normally
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Figure 1.7 – Ultrasound growth chart demonstrating EFW trajectory in severe early-onset FGR  
 
Example of centile chart used for the longitudinal assessment of fetal growth. Ultrasonographic 
estimated fetal weight (EFW) is shown on the y axis and gestational age in weeks on the x axis. 
The white line represents the 50th percentile and the upper and lower red lines represent the 
97th and 3rd percentiles, respectively. The symbols indicate the growth trajectory of an 
individual severely growth-restricted fetus, whose EFW is consistently below the 3rd percentile 
and tailing off (reduced growth velocity) before a viable weight (>500g) has been achieved. 
 
considered in view of the many potential fetal and maternal causes that need to be ruled out 
(see Sections 1.1.2.1 and 1.1.2.2). Maternal factors are identified through history taking and 
clinical examination. In order to identify anomalous fetuses, a detailed ultrasound examination 
is performed to look for structural abnormalities and markers of aneuploidy. Uteroplacental 
blood flow and Doppler waveforms are interrogated to determine if there is any evidence of 
uteroplacental insufficiency (see Section 1.1.2.3). If there is any ultrasonographic evidence of a 
chromosomal abnormality then a fetal karyotype will be offered (amniocentesis or chorionic 
villus sampling). Karyotyping may be offered routinely in severe early-onset cases of SGA/FGR, 
in which the prevalence of chromosomal abnormality is up to 20% (Anandakumar et al. 1996; 
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Niknafs & Sibbald 2001). Hyperechogenic bowel should specifically be examined for, as it is 
more prevalent in FGR and its presence confers an almost ten-fold increased risk of perinatal 
mortality (Goetzinger et al. 2011). If there is a pattern suggestive of any particular genetic 
syndrome then an opinion from a clinical geneticist might be sought and targeted genetic 
testing (if available) may be indicated. A TORCH screen (see Section 1.1.2.1 above) should also 
be performed to exclude maternal viral infections.  
1.1.4.5    Treatment 
If a specific maternal medical condition is found then optimisation of treatment is appropriate, 
although this may or may not benefit fetal growth. For example, treating simple iron deficiency 
anaemia with ferrous sulphate supplements may improve maternal haemoglobin levels and 
therefore increase the oxygen carrying capacity of the blood reaching the placenta, however 
maternal vascular disorders that are known to adversely impact placentation are likely to have 
already caused irreversible damage to the placental circulation by mid-gestation (Ackerman et 
al. 1999). If a specific fetal diagnosis is made then the prognosis and management will be 
dictated by the underlying pathology. Depending on the likelihood of handicap, termination of 
pregnancy may be offered.  
The remainder of this section deals specifically with FGR due to uteroplacental insufficiency, as 
this is the focus of this PhD thesis. Unfortunately there is currently no effective treatment for 
this type of FGR (Sibai et al. 2005). A large number of different therapeutic approaches have 
been evaluated in clinical trials and are detailed in Table 1.4. However none of these therapies 
have been sufficiently effective to be used in clinical practice. In uteroplacental insufficiency, 
attenuated UBF ultimately limits the supply of oxygen and nutrients to the developing fetus. In 
simple terms, fetal nutrient supply is equal to the product of UBF and substrate availability. 
Consequently there are two basic approaches that can be used to achieve an increase in fetal 
nutrient supply. Attempts to increase substrate availability by maternal supplementation using 
various macro- and micro-nutrients have been disappointing and this probably reflects the fact 
that, with the specific exception of maternal undernutrition, the issue is not generally a lack of 
availability of these nutrients within the maternal circulation but rather an impairment of 
placental transfer to the fetal circulation. In support of this hypothesis, it has been shown that  
balanced nutrient supplementation in women with proven nutritional deficiency reduces SGA, 
stillbirth and neonatal death rates by 32%, 45% and 38%, respectively, but does not benefit the 
majority of women (Ota et al. 2012) when applied as a preventive strategy during pregnancy. 
High protein supplementation of the mother during pregnancy is worryingly associated with 
increased rates of SGA, prematurity and neonatal death (Rush et al. 1980).  
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Table 1.4 – Treatments that are ineffective in placentally-mediated fetal growth restriction 
Treatment Reference 
Bed rest Crowther et al. 1990 
Maternal hyperoxygenation Nicolaides et al. 1987 
Low-dose aspirin* Leitich et al. 1997 
β-adrenergic receptor agonists Gulmezoglu & Hofmeyr 2001 
L-arginine Winer et al. 2009 
Calcium channel blockers Gulmezoglu & Hofmeyr 2000a 
2000b)(Thakor et al. 
2010)(Thakor et al. 
2010)(Thakor et al. 2010) 
Melatonin and vitamin C Thakor et l. 2010 
Plasma volume expansion Karsdorp et al. 1992 
Transcutaneous electrical nerve stimulation (TENS) Gulmezoglu & Hofmeyr 2000b 
Hormone administration Say et al. 2003a 
Maternal infusion of amino acids Ronzoni et al. 2002 
Salt restriction Steegers et al. 1991 
Iron supplementation Pena-Rosas et al. 2012 
Folate supplementation Mahomed 2000 
Calcium supplementation Hofmeyr et al. 2010 
Vitamin D supplementation Mahomed & Gulmezoglu 2000 
Magnesium supplementation Makrides et al. 2006 
Zinc supplementation Mori et al. 2012 
Fish oil supplementation Berghella 2007 
Diet rich in fish, low-fat meat, grains, fruit and vegetables Khoury et al. 2005 
Maternal glucose supplementation Viehweg et al. 1987 
Maternal carnitine supplementation Genger et al. 1988 
Maternal solcoseryl supplementation Herre et al. 1976 
Balanced energy/protein supplementation Say et al. 2003b 
High protein supplementation Rush et al. 1980 
Isocaloric protein supplementation Viegas et al. 1982 
Multiple micronutrient supplementation Roberfroid et al. 2008 
Maternal nutritional advice Kafatos et al. 1989 
Abdominal decompression Hofmeyr 2012 
* Most likely ineffective if commenced after 16 weeks gestation, i.e. once FGR is diagnosed 
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The alternative of direct fetal nutrient supplementation would bypass the problem of placental 
transfer but is invasive and therefore unlikely to be feasible clinically. This approach has been 
investigated in various animal models of FGR. Continuous intra-amniotic infusion of dextrose 
and amino acids in FGR rabbits does not impact fetal growth and lipid administration leads to 
chronic lipid aspiration and further exacerbates FGR (Flake et al. 1986). Direct intragastric 
supplementation of amino acids and glucose has also been performed in fetal sheep, which did 
marginally increase fetal weight but is highly impractical clinically (Charlton & Johengen 1985).  
A related treatment that has shown some promise but is unlikely to be translated into clinical 
practice is intra-amniotic infusion of growth factors. Eremia et al. (2007) showed an increase in 
fetal weight after IGF-1 was infused directly into the amniotic cavity three times a week (using 
indwelling catheters) from 100 to 128 days gestation of sheep pregnancy following placental 
embolisation. The same group more recently evaluated the efficacy of a once weekly injection 
of IGF-1 in the same model and demonstrated increased fetal growth rates (Wali et al. 2012). A 
similar approach in the FGR rabbit, by infusion of recombinant human IGF-1, increased serum 
IGF-1 and placental weight but did not significantly impact fetal weight (Skarsgard et al. 2001). 
However, an intra-amniotic infusion of epidermal growth factor in FGR rabbits did normalise 
fetal growth and small intestinal proliferation compared to controls (Cellini et al. 2004). The 
main drawback of this approach is that, in human pregnancy, invasive procedures are highly 
likely to result in uterine infection and/or preterm birth if repeated at regular intervals. 
Consequently the translational potential of these intra-amniotic therapies remains limited. 
Incidentally, systemic treatment of FGR with growth factors does not look promising. Twice 
daily injections of growth hormone during late gestation growth-restricted sheep pregnancies 
modestly increased fetal growth but resulted in profound increases in adiposity (Wallace et al. 
2006c) and fetal brain injury (De Boo et al. 2008).   
Meanwhile other researchers have investigated the alternative approach of increasing UBF, for 
example using vasodilator agents such the nitric oxide donor L-arginine (Sieroszewski et al. 
2004) or the phosphodiesterase type 5 inhibitor sildenafil citrate (Viagra®). The latter agent is 
currently being evaluated within a New Zealand based randomised clinical trial called STRIDER 
(Sildenafil TheRapy In Dismal prognosis Early-onset intrauterine growth Restriction). Results of 
sildenafil treatment have so far been mixed and have raised a number of doubts and concerns. 
Sildenafil enhances vasodilatation and reduce vasoconstriction in human myometrial arteries 
harvested at caesarean section from growth-restricted pregnancies (Wareing et al. 2005) and 
increases UBF in non-pregnant sheep (Zoma et al. 2004). However, in non-pregnant women, it 
enhanced UBF when baseline values were normal but not if they were low (Hale et al. 2010), 
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as would be anticipated in uteroplacental insufficiency. No benefit of sildenafil has been shown 
in early-onset pre-eclampsia (Samangaya et al. 2009), however a study of 10 pregnancies 
complicated by severe early-onset FGR showed a significant increase in the fetal AC after oral 
sildenafil treatment in mid-gestation compared to contemporaneous control pregnancies that 
were not offered treatment, with a mean interval between eligibity and delivery of 31.5 days 
(von Dadelszen et al. 2011). There was no effect on any other pregnancy outcomes, although 
this very small study was clearly underpowered to detect any differences in perinatal mortality 
or neonatal morbidity. Some concerns were raised by the fact that the most compromised 
fetus in the study, which (unlike all the others) already showed reversed EDF in the UA at 
enrolment, died within 48 hours of commencing treatment. Sildenafil citrate crosses the 
placenta in relatively large amounts and therefore might affect fetal physiological 
compensation to FGR. In normal and hypoxic rat pregnancies, sildenafil increased fetal weight 
in the presence of  hypoxia, but worryingly reduced fetal weight in non-hypoxic conditions 
(Refuerzo et al. 2006). The route of delivery appears to be an important consideration. For 
example, intravenous administration of sildenafil in a sheep model of FGR at 110 to 115 days 
gestation acutely reduced UBF and impaired fetal oxygenation in both growth-restricted and 
control fetuses (Miller et al. 2009). Furthermore, in a rat model of Nɯ-nitro-I-arginine methyl 
ester induced FGR, sildenafil treatment further reduced fetal growth (Nassar et al. 2012). This 
illustrates the potential hazard of systemically delivered vasodilators that result in widespread 
maternal vasodilatation, which can drop maternal blood pressure and further compromise 
uteroplacental perfusion in an effect called the placental “steal” phenomenon. Satterfield et 
al. (2010) administered sildenafil subcutaneously three times a day over a longer time period, 
from 28 to 115 days gestation, to undernourished sheep dams. Although they did not measure 
UBF in their study, there was an improvement in amino acid availability and fetal weight. 
Women in the STRIDER trial who are allocated to receive sildenafil treatment will take 50mg 
orally three times per day from entry until 32 weeks gestation or delivery, whichever is sooner.  
1.1.4.6    Surveillance 
As there is currently no effective treatment for FGR secondary to uteroplacental insufficiency 
(see Section 1.1.4.5), contemporary management is comprised of fetal surveillance and timely 
delivery. With regards to timing, the risks of iatrogenic prematurity must be balanced against 
the risks of irreversible tissue damage secondary to severe hypoxia or even intrauterine fetal 
death. Unfortunately it appears that delivering the fetus per se does not affect the overall 
outcomes. The GRIT (Growth Restriction Intervention Trial) study was a clinical trial in which 
patients were randomised to early versus delayed delivery in cases of FGR in which clinicians 
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felt uncertainty about the appropriate timing of delivery (GRIT Study Group 2003). There were 
196 fetuses enrolled between 24 and 30 weeks, and 352 fetuses between 30 and 36 weeks 
gestation. The early delivery group were delivered within 48 hours of receiving steroids after a 
mean interval of 0.9 (range 0.4 to 1.3) days post randomisation. The delayed delivery group 
were delivered at 4.9 (range 2.0 to 10.8) days post randomisation. There were a greater 
number of stillbirths in the delayed delivery group and a greater number of neonatal deaths in 
the early delivery group. Consequently overall perinatal mortality rates were equivalent. 
Furthermore, at two years of age, death rates, severe disability and neurological outcomes 
were not different between groups (Thornton et al. 2004). The DIGITAT trial had a similar 
design to GRIT, but enrolled FGR pregnancies near to term. There were similarly no differences 
in perinatal mortality rates (Boers et al. 2010), neonatal morbidity (Boers et al. 2012) or 
neurodevelopmental outcomes at two years of age (van Wyk et al. 2012).  
Currently the mainstay of fetal surveillance in FGR is Doppler examination of the umbilical and 
fetal vessels (Baschat 2010). Although occasional exceptions to the rule occur, there is a 
relatively predictable sequence of Doppler abnormalities that occur during fetal deterioration 
in early-onset severe FGR, which may act as a trigger for delivery depending on the gestational 
age at the time when these emerge (Baschat et al. 2001; Hecher et al. 2001; Ferrazzi et al. 
2002). It is currently recommended that UA Doppler waveform analysis should be used as the 
primary surveillance tool in fetuses with confirmed or suspected FGR as, in the presence of 
maintained end-diastolic flow (EDF) and the absence of other complications, delivery can 
generally be delayed until >37 weeks gestation (RCOG 2013). By contrast, absence or reversal 
of EDF indicates that >70% of the fetal placental circulation is obliterated (Morrow et al. 1989; 
Wilcox et al. 1989; Kingdom et al. 1997) and pooled data from clinical trials indicate that 
absent or reversed EDF is associated with a 60-fold increase in perinatal mortality rates 
(Thornton & Lilford 1993). Meta-analyses of randomised controlled studies of UA Doppler in 
high risk populations have shown that its use significantly reduces the incidence of intrauterine 
fetal death (Giles & Bisits 1993; Divon 1995). For example, Alfirevic and Neilson (1995) showed 
a 38% reduction in perinatal mortality when UA Doppler was utilised for fetal surveillance. 
When EDF is absent or reversed then additional monitoring and administration of steroids for 
fetal lung maturation is normally considered. The fetus will generally be delivered if the 
pregnancy is more than 30–32 weeks gestation (RCOG 2013). Prior to 30 weeks, fetal venous 
Dopplers are ideally used to decide on timing of delivery (see below). 
The middle cerebral artery (MCA) Doppler is a useful adjunct to the UA, and may reveal fetal 
brain sparing (see Section 1.1.3.4). Under normal circumstances the MCA is characterised by 
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high impedance to flow with minimal EDF velocities. An increase in EDF velocity is an early sign 
of fetal hypoxemia (Gudmundsson et al. 1996) and is a sign of redistribution of fetal blood flow 
in chronic hypoxemia (Wladimiroff et al. 1986; Mari & Deter 1992). The PI of the MCA can also 
be expressed relative to the UA PI as a cerebro-umbilical Doppler ratio, which increases its 
ability to predict adverse perinatal outcomes (Gramellini et al. 1992). Notably when EDF is 
increased in isolation in the MCA, it is not associated with metabolic acidosis (Wladimiroff et 
al. 1986) or with adverse neurological outcomes (Chan et al. 1996), therefore the MCA is rarely 
used alone to decide on timing of delivery. 
In the presence of UA Doppler abnormalities an additional assessment should be made of the 
fetal venous system, including the ductus venosus (DV), inferior vena cava (IVC) and umbilical 
vein (UV). In the advanced stages of fetal decompensation, venous back flow during atrial 
contraction is seen in the DV (Hecher et al. 1995) and IVC (Rizzo et al. 1995). DV waveform 
abnormalities in particular are strongly correlated with fetal acidaemia (Baschat et al. 2007; 
Mari et al. 2007). A pulsatile UV waveform is a particularly ominous sign and may represent 
fetal congestive heart failure (Gudmundsson et al. 1991; Tulzer et al. 1994). Although there are 
no specific published guidelines, many obstetricians would recommend delivering fetuses with 
abnormal DV Dopplers from 26–28 weeks gestation (DM Peebles, personal communication). 
Currently a multi-centre randomised controlled trial called TRUFFLE (Trial of Umbilical and 
Fetal Flow in Europe) is underway, which aims to evaluate the use of venous Dopplers to time 
delivery. Perinatal outcomes are being compared between fetuses delivered on the basis of 
early versus late venous Doppler changes.  
In addition to Doppler evaluation, FGR pregnancies should also ideally undergo assessment of 
fetal growth velocity (using the AC or EFW) and quantification of amniotic fluid volume, which 
can be done by measuring either the amniotic fluid index (AFI) or deepest vertical pool (DVP) 
of amniotic fluid. Reduced amniotic fluid volume reflects reduced perfusion of the fetal kidney 
as a response to circulatory redistribution (see Section 1.1.3.4). A reduced DVP is associated 
with increased perinatal mortality (Bastide et al. 1986) and fetal distress (Chauhan et al. 1999). 
A further means of assessing fetal wellbeing is the use of cardiotocography (CTG). In the UK, it 
is recommended that computerised analysis of the CTG, which pays particular attention to the 
short term fetal heart variability, should be used in place of conventional interpretation (RCOG 
2013). Computerised CTG has been shown in a Cochrane review to reduce perinatal mortality 
by 4.2% compared with 1.9% for the traditional CTG (Grivell et al. 2012). In the United States, 
CTG is often combined with ultrasound assessment of fetal breathing movements, gross body 
movements, fetal tone and amniotic fluid volume as a "biophysical profile". Evidence suggests 
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that this test is a poorer predictor of fetal acidaemia with relatively high false negative rates in 
small fetuses (Kaur et al. 2008) therefore it is not currently recommended. A limitation of all 
these CTG based tests is that fetal heart rate (FHR) abnormalities do not develop until the later 
phases of fetal compromise. For example, >60% of fetuses with an abnormal FHR pattern will 
already be hypoxic and acidotic (Pardi et al. 1993) by this stage. Hence whilst the CTG remains 
an important tool to pick up fetuses that are already in a critical state, they should not be used 
in isolation for surveillance.  
When delivery is indicated, mode of delivery depends on the gestational age and the likelihood 
of an individual fetus being able to tolerate labour. If a trial of labour is considered appropriate 
then continuous electronic fetal monitoring throughout is recommended in view of the high 
risk of a pathological CTG and possible fetal hypoxia. A skilled neonatal team needs to be 
present at delivery due to a high risk of neonatal mortality and morbidity (see Section 1.1.3.6). 
1.1.5    Animal models of FGR 
Given the current lack of effective treatments for FGR, there is an on-going need to use animal 
models of the condition in preclinical studies aimed at developing new therapeutic approaches 
for future clinical trials. There are a wide variety of different animal models of FGR available for 
translational research, however unfortunately none of them is able to completely replicate the 
pathology that is observed in the human. 
The closest model to human pregnancy is the non-human primate. The main advantage is that, 
unlike many other animals, their pregnancies are characterised by trophoblastic invasion of the 
spiral arteries as per the human (Blankenship & Enders 2003), and there have been reports of 
a naturally occurring pre-eclampsia type syndrome (Palmer et al. 1992). Disadvantages include 
the prohibitively high cost, the high complication rate associated with pregnancy interventions,  
the lack of facilities in the UK and specific ethical concerns due to their similarity to the human. 
In the USA, some centres have conducted research into FGR using non-human primate models 
such as the nutrient-restricted baboon (Li et al. 2013). Alternative large animal models include 
the sheep (discussed in detail below) and the goat (He et al. 2013). 
Small animal models of FGR are used much more frequently. Up until 2001, ~75% of preclinical 
studies in FGR animal models had been performed in the rat or mouse (Schroeder 2003). In 
addition to nutritional and surgical models, there are a number of different transgenic models 
of FGR in the mouse, including placental-specific IGF-2 and eNOS knockout (Hefler et al. 2001; 
Constancia et al. 2002). The main limitations of rodents are a relatively short gestation period 
(21 days) and the relative immaturity of the pups at birth, equivalent to the third trimester of 
57 
 
human pregnancy. They are a particularly poor species for studying the neurological impact of 
prenatal insults and/or therapy, as the majority of brain development occurs in postnatal life. 
Trophoblast invasion is shallow in rodents and UtA transformation depends more on maternal 
factors like natural killer cells, than trophoblast invasion (Carter 2007; Greenwood et al. 2000). 
1.1.5.1    Sheep models of fetal growth restriction 
The sheep has frequently been utilised as a model for human pregnancy and has a wide range 
of benefits over small animals including the ability to study singleton pregnancies, comparable 
maternal size, adiposity, maternal to fetal weight ratio and birth weight, similar organogenesis 
for all major body systems and equivalent rates of fetal protein accretion. Unlike most small 
animals, the sheep fetus accumulates fat prenatally and is relatively mature at birth. Sheep 
have a relatively long gestation period (145 to 147 days, depending on the particular genotype) 
and fetuses can be chronically catheterised for serial assessment of physiological parameters. 
The relative increase in uteroplacental perfusion that is seen during normal sheep pregnancy is 
similar to the human, approximately two- to three-fold (Konje et al. 2003; Meschia 1983) and 
the rates of oxygen and glucose uptake are also similar (Barry & Anthony 2008). Although the 
human and sheep placenta are similar functionally and much of our understanding of human 
placental physiology is derived from sheep experiments, there are some important differences 
in structure and the layers separating maternal and fetal blood (discussed in Section 7.1.1.4). 
There are a number of different ways of generating FGR in sheep, as summarised in Table 1.5. 
These sheep models produce variable degrees of fetal growth constraint - 17 to 42% compared 
to normally grown controls. With the notable exception of maternal undernutrition, the effect 
on fetal growth appears to be placentally mediated in most of these experimental paradigms, 
however the associated impact on uterine blood flow is variable. For the work detailed in this 
thesis, the model of choice was considered to be the one that is characterised by the largest 
reduction in uterine perfusion, excluding those which involve permanent surgical interference. 
1.1.5.2    The overnourished adolescent sheep paradigm 
Paradoxically, overnourishing the pregnant adolescent sheep has consistently been shown to 
result in significant placental and therefore fetal growth restriction, relative to the normally 
growing fetuses of control ewes fed a moderate intake (Wallace et al. 2006a). High intakes in 
these overnourished adolescent dams (which are ultimately still growing during pregnancy) 
result in enhanced maternal growth and nutrient partitioning away from the gravid uterus at 
the expense of the pregnancy. Elevated peripheral concentrations of glucose, insulin, IGF-1 
and thyroid hormones maintain the drive towards maternal tissue deposition (principally 
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Table 1.5 – Sheep models of fetal growth restriction 
Model / Insult Effect on fetal weight 
(days gestation) 
Effect on placental weight 
(days gestation) 
Effect on uterine blood 
flow (days gestation) 
Reference(s) 
Overnourished adolescent ewe  ↓ 34% (134) ↓ 45% (134) ↓ 42% (88) Wallace et al. 2002 / 2008b 
2008 (Wallace et al. 
2008)(Wallace et al. 2008) 
Undernourished adolescent ewe ↓ 17% (130) = = Luther et al. 2007 
2005)(Luther et al. 2005) Undernourished adult ewe ↓ 16% (140) = = Leury et al. 1990 
Multiple pregnancy* ↓ 11% (130) ↓ 63% (130) ↓ 23% (130) Christenson & Prior 1978 
Maternal hyperthermia                     
(from 40 to 120 days gestation) 
↓ 42% (134) ↓ 51% (134) ↓ 26% (134) Regnault et al. 2003 
Single umbilical artery ligation (SUAL) 
(performed at 105-119 days gestation) 
↓ 34% (140) ↓ 23–34% (140) ↓ 15% (114) Oyama et al. 1992        
Miller et al. 2009 
Uteroplacental embolisation            
(performed at 104-119 days gestation) 
↓ 28% (110) - ↓ 38–74% (119) Ochi et al. 1995      
Murotsuki et al. 1997 
7Murotsuki,J. 1997; Pre-mating carunclectomy ↓ 32% (114) ↓ 71% (140) ↓ 39–71% (121) Owens et al. 1986       
Phillips et al. 2001 
 
Maternal anaemia ↓ 40% (138) - ↓ 22–41% (114) Mostello et al. 1991 
Progressive uterine artery occlusion ↓ 39–71% (138) ↓ 27–34% (138) ↓ 30–45% (138) Lang et al. 2000 
 
* Mean fetal / placental weight and uterine blood flow (UBF) reduced (total fetal / placental weight and uterine blood flow  increased - triplets > twins > singletons 
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adipose tissue) resulting in maternal obesity (Wallace et al. 2000). Despite the abundance of 
nutrients in the maternal circulation, by late gestation fetal concentrations of glucose, insulin 
and IGF-1 are significantly reduced and fetuses are hypoxaemic. In vivo assessments of glucose 
and oxygen uptakes have demonstrated that these are reduced in proportion to placental 
weight (Wallace et al. 2002), which suggests that it is the small size of the placenta per se 
which becomes the major constraint to fetal growth during the final third of gestation. 
Whilst these adverse effects of overnutrition are unique to the adolescent, this is nevertheless 
an excellent model for the study of FGR irrespective of maternal age as it replicates many of 
the key features of human FGR due to uteroplacental insufficiency. Although the fetal growth 
trajectory itself is not compromised until relatively late in pregnancy, stigmata of placental 
dysfunction are evident from as early as day 50 of gestation, at which point various indices of 
placental vascular development are significantly reduced in overnourished relative to control 
intake pregnancies (Redmer et al. 2009) At 81 days gestation, placental mRNA expression of 
several important angiogenic factors (VEGF, angiopoietin 1 and 2, nitric oxidase synthase 
(NOS)-3) and the VEGF receptor FLT1 is reduced (Redmer et al. 2005) and there is evidence of 
reduced placental proliferation and possibly increased placental apoptosis (Lea et al. 2005). As 
illustrated in Figure 1.8, from mid-gestation onwards there is a major (~42%) reduction in UBF 
(Wallace et al. 2008b) indicating uteroplacental insufficiency, which is similar to that observed 
in human FGR pregnancies (Section 1.1.2.3). Circulating levels of oestradiol-17β, progesterone 
and ovine placental lactogen are also reduced, indicating impaired secretory function (Lea et 
al. 2007; Wallace et al. 2008a). Collectively these observations imply an early insult on 
uteroplacental development, which precedes the subsequent reduction in placental mass (30–
40% lower than controls in late gestation). Maternal switchover studies suggest that it is the 
second third of gestation in which high nutritional intakes exert their strongest effects on 
pregnancy outcome in this paradigm. After switching from a high to a control intake from 50 
days gestation there is relatively normal fetal and placental growth. By contrast, switching 
from a control intake to a high intake at the same stage produces a degree of FGR similar to 
that of continuously overnourished ewes (Wallace et al. 1999). Furthermore, switching from a 
high to a low intake from 90 days gestation onwards also results in a similar degree of FGR as 
continuously overnourished ewes, indicating that fetal growth cannot be “rescued” once 
placental growth has been perturbed (Redmer et al. 2012).  
This model utilises embryo transfer techniques to establish singleton pregnancies and thereby 
avoids multiple gestations. Embryos are sourced from multiparous donor ewes, as these have 
an inherently higher viability than those derived from adolescents (Quirke & Hanrahan 1977; 
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Figure 1.8 – Uterine blood flow in overnourished versus control-fed pregnant adolescent ewes 
from 88 to 135 days gestation   
 
Average uterine blood flow recorded for 2 hours 3 times per week, measured using indwelling 
ultrasonic flow probes from 88 to 135 days gestation in singleton-bearing adolescent ewes fed 
a control-intake (n=9, closed circles) to promote normal placental and thereby fetal growth, or 
overnourished (n=10, open circles) to induce fetal growth restriction. All data are mean ± SEM. 
*** p<0.001, ** p<0.01, * p<0.05. Reproduced with permission from Wallace et al. (2008b). 
 
McMillan & McDonald 1985). The superovulated donor ewes undergo laparoscopic 
intrauterine insemination because this ensures 100% fertilisation, unlike cervical insemination 
where only 36% of recovered oocytes are fertilised (Robinson et al. 1969). Thus intrauterine 
insemination maximises the number of high grade embryos recovered per ewe and these 
embryos are then transferred in singleton into oestrus synchronised adolescent recipients. 
Donor superovulation and the use of a single sire maximises the genetic homogeneity of the 
resultant pregnancies. Precise gestational age is known, which avoids the need to rely on 
estimated dates of conception and ultrasound pregnancy dating following mating. Following 
embryo transfer, recipients of equivalent age are evenly allocated to high or control intakes on 
the basis of baseline body weight, adiposity and ovulation rate, thus controlling for many of 
the periconceptual factors known to influence fetal and placental growth. A further advantage 
of this model is that it does not require any surgical interference in order to reduce UBF. The 
uterine and umbilical circulations remain intact, thus there remains the potential to target UBF 
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therapeutically. Moreover, fetuses exhibit normal fetal weight-specific metabolic responses to 
short-term experimental increases in glucose, implying that they can respond favourably to 
enhanced nutrient supply (Wallace et al. 2007). 
1.2    Prenatal Ad.VEGF gene therapy 
Over the course of the last eight years, the research group at UCL have been developing a 
novel maternal gene therapy approach to locally transfect the uteroplacental circulation, with 
the aim of enhancing UBF and thereby fetal nutrient supply. The potential to locally target UBF 
and therefore avoid systemic vasodilatation and placental steal (as discussed above) is a 
significant benefit of this therapy. Clinical grade adenoviruses encoding the human gene for 
vascular endothelial growth factor (VEGF) are available and have already been used in a 
number of clinical trials in the field of cardiovascular biology and medicine, which are outlined 
in Table 1.6. In adult patients, this therapy appears safe. Unfortunately successful therapeutic 
angiogenesis in ageing, diseased vessels has been limited to date (Zachary & Morgan 2011) but 
the uterine artery of young, otherwise healthy women may represent a more promising target.  
 
Table 1.6 – Adult clinical trials of adenoviral vascular endothelial growth factor gene therapy 
VEGF 
Isoform 
Indication Route of 
Administration 
Reference(s) 
VEGF-A165 Peripheral arterial disease 
(following percutaneous 
transluminal angioplasty)  
Intra-arterial Makinen et al. 2002 
VEGF-A165 Coronary artery disease 
(following percutaneous 
coronary intervention) 
Intra-arterial  Hedman et al. 2003 
VEGF-A121 Peripheral arterial disease Intramuscular Rajagopalan et al. 2003 
VEGF-A121 Coronary artery disease 
(± coronary artery bypass 
graft, CABG) 
Intramyocardial   
(after CABG or via 
mini-thoracotomy  
Rosengart et al. 1999  
Stewart et al. 2006 
VEGF-A121 Coronary artery disease Transendocardial 
(via catheterisation) 
Kastrup et al. 2011 
 
Abbreviations: VEGF = vascular endothelial growth factor; CABG = coronary artery bypass graft 
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1.2.1    Adenoviral vectors 
Gene therapy involves the use of delivery systems called vectors to administer genetic material 
into cells for potential therapeutic benefit. There are a number of different delivery systems 
available, which are broadly categorised as viral or non-viral in nature. Different viral species 
can be adapted including retroviruses, lentiviruses, adenoviruses and adenovirus-associated 
viruses. For most gene therapy applications, an integrating vector is desirable as the typical 
aim is to permanently correct or to replace the function of genes that are mutated or missing, 
respectively. Examples include cystic fibrosis and glycogen storage disorders (David & 
Waddington 2012). One of the main barriers to long term gene therapy using viruses is the 
host immune response, which may be pre-existing or develop de novo. One of the potential 
benefits of fetal gene therapy is that treatment can be given at a time when the immune 
system is relatively immature. Non-viral vectors are much less widely used and are specifically 
engineered for their purpose. An example might be ORMOSIL (organically modified silica) 
nanoparticles, which have been successfully used for gene transfer of GFP (green fluorescent 
protein) to the mouse brain (Bharali et al. 2005). 
In the experiments described in this thesis, clinical grade adenovirus vectors were used. The 
adenovirus is a non-enveloped icosahedral particle that measures approximately 70-90nm in 
diameter, with an outer protein shell and an inner nucleoprotein core. Adenoviruses are not 
ideal for most gene therapy applications due to their transient expression (up to a few weeks), 
however for this particular programme of work the adenovirus was considered to be ideal for 
this very reason (see Section 1.2.3 below). Adenoviruses provide highly efficient gene transfer 
without being permanently integrated into the host’s genome, hence insertional mutagenesis 
is avoided. Adenovirus infection per se appears to be safe in pregnancy. The virus causes the 
common cold in humans, which is not generally regarded as problematic during pregnancy. 
Even when adenovirus has been detected in amniotic fluid samples, suggesting transplacental 
fetal infection, there is no associated increase in pregnancy loss rates (Wenstrom et al. 1998). 
In any case the adenoviral vectors used in the studies detailed herein had been rendered first 
generation replication deficient by complete and partial deletions of the E1 and E3 regions, 
respectively. The E1 region was replaced by the transgene, VEGF. 
1.2.2    Vascular endothelial growth factor 
VEGF is a naturally occurring homodimeric glycoprotein that is important for the formation of 
new blood vessels during embryonic development (vasculogenesis) and the sprouting of new 
vessels from existing vessels (angiogenesis). The latter serves to increase vascular density and 
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is important in the development of collateral circulations and revascularisation following injury 
or ischaemia. There are currently six different members of the VEGF family, designated A to F, 
with the original VEGF protein now known as VEGF-A. VEGF-A is particularly important for the 
process of placental angiogenesis (Arroyo & Winn 2008) and is to date the most investigated 
form of VEGF. VEGF-B has a particular role in embryonic angiogenesis, particularly in the heart, 
whilst VEGF-C and VEGF-D contribute significantly to lymphangiogenesis. VEGF-E and VEGF-F 
are of viral and snake venom origin, respectively (Giacca & Zacchigna 2012). Moreover, 
alternative splicing of VEGF-A produces a number of different isoforms, which are represented 
by the number of amino acids they contain. Isoforms comprised of 206, 189, 183, 165, 148, 
145 and 121 amino acids have been described. VEGF-A165 is the dominant and most potent 
isoform in the human. 
The three principal actions of VEGF are vasodilatation, new vessel formation and protection of 
existing vasculature from insults, such as shear stress secondary to erratic blood flow (Zachary 
2003). As implied by its name, the main target of VEGF protein is the vascular endothelial cell 
and its actions are mediated via the two VEGF receptors, Flt-1 (1) and KDR (2), as well as the 
neuropilin receptor 1. Actions through the latter receptor may explain its pleiotrophic effects. 
Vasodilatation may be achieved through one of three different pathways involving nitric oxide 
(NO), bradykinin and endothelium-derived hyperpolarizing factor (EDHF), respectively. Most of 
the biologically important actions of VEGF are mediated through the KDR receptor (Holmes et 
al. 2007). VEGF phosphorylates KDR, which results in activation of phospholipase Cγ, formation 
of inositol 1,4,5-triphosphate, elevation of intracellular calcium and activation of endothelial 
nitric oxide synthase (eNOS) (He et al. 1999). VEGF can also generate NO through a calcium 
independent pathway (Fulton et al. 1999). NO relaxes vascular smooth muscle via activation of 
soluble guanylate cyclase and increased intracellular levels of cyclic guanosine monophosphate 
(cGMP) (Ignarro 1989). By contrast, prostayclin induces vasorelaxation via activation of soluble 
adenylate cylase and increased intracellular levels of cyclic adenosine monophosphate (cAMP) 
(Moncada & Vane 1978). EDHF-mediated vascular relaxation is less well understood from a 
mechanistic point of view, but is represented by the residual vasodilatory effect that is seen 
after both NO and prostacyclin have been pharmacologically blocked. The precise role of VEGF 
receptor 1 (Flt-1) is less well understood, but is believed to include modulation of the actions 
of KDR. There is a soluble version of Flt-1 (sFlt-1) that serves as a decoy receptor, binding free 
VEGF in the bloodstream and reducing its circulating levels, thereby antagonising VEGF action.  
VEGF is also important for the physiological changes during normal pregnancy. The extravillous 
trophoblast secretes a number of different angiogenic factors and local vasodilators including 
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VEGF, which contributes to the fall in vascular resistance, together with transformation of the 
spiral arteries (see Section 1.1.2.3). Placental secretion of VEGF occurs preferentially into the 
maternal circulation, leading to a maternal serum concentration that is ten times higher than 
that in the fetal circulation. The placenta also secretes sFlt-1 at concentrations which are >20 
times higher on the maternal versus fetal sides, resulting in a low level of free VEGF in the 
maternal circulation (Maynard et al. 2003; Brownbill et al. 2008). Maternal serum sFlt-1 levels 
are higher in pre-eclampsia and FGR (Sibai et al. 2005), which has the effect of further reducing 
the bioavailability of VEGF. Accordingly, maternal serum levels of VEGF are significantly lower 
than in normal pregnancy (Bersinger & Odegard 2005; Savvidou et al. 2006). Interestingly, this 
increase in sFlt-1 precedes the onset of pre-eclampsia but is only seen in FGR once established. 
1.2.3    Work that has led up to the project 
Previous work evaluating the effects of bilateral uterine artery injections of Ad.VEGF in normal 
sheep pregnancy demonstrated a significant short-term increase in uterine blood flow (UBF) 
when assessed by Doppler ultrasound. Uterine arteries (UtA) harvested at 4–7 days following 
treatment with Ad.VEGF exhibited a reduced contractile response to phenylephrine as well as 
enhanced bradykinin induced relaxation (David et al. 2008). More recently the longer term 
impact of Ad.VEGF on UBF has been evaluated using indwelling ultrasonic flow probes, which 
are the gold standard for the assessment of blood flow in vivo (Sokol et al. 1996) and which 
have several advantages over volume flow assessment using Doppler ultrasound, a technqiue 
which is associated with a high degree of variability (Abi-Nader et al. 2010). Figure 1.9 depicts 
the sustained increase in UBF (relative to baseline values) that was observed after a unilateral 
UtA injection of Ad.VEGF in mid-gestation compared with a contralateral injection of a non- 
vasoactive control vector, Ad.LacZ (= adenovirus encoding the β-galactosidase gene). Ad.VEGF 
therapy approximately doubled the normal gestational increase in UBF over a >4-week period 
(Mehta et al. 2011). Examination of the long-term UtA similarly revealed less vasoconstriction, 
and there was evidence of increased perivascular adventitial neovascularisation and reduced 
intima-to-media ratios. There was also an upregulation of both VEGF receptors (Flt-1 and KDR) 
and endothelial nitric oxide synthase (eNOS) when measured using immunohistochemistry and 
Western blotting, respectively, at the short-term but not long-term time points. There were no 
adverse effects on maternal or fetal heart rate or blood pressure, and no other concerns about 
safety were raised. This initial work provided proof of principle that Ad.VEGF can enhance UBF, 
however it remained unknown whether the same effects could be achieved when UBF is low 
(i.e. in the state of uteroplacental insufficiency). It was also not known whether or not this 
would impact fetal growth or wellbeing in pregnancies complicated by fetal growth restriction.  
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Figure 1.9 - Effect of Ad.VEGF gene therapy on uterine blood flow in normal sheep pregnancy 
 
Serial changes in uterine artery blood flow (UABF) following injection with Ad.VEGF or inactive 
control vector (Ad.LacZ). The percentage increase in UABF relative to a mid-gestation baseline 
(adjusted to 0) is shown, as well as gradients of the gestational increase over a 4-week period 
post-injection. Error bars indicate SEM. Reproduced with permission from Mehta et al. (2011). 
 
 
1.3    Aims of thesis 
The aims of the research detailed in this PhD thesis were to evaluate the efficacy, safety and 
mechanisms of action of prenatal Ad.VEGF gene therapy in an established sheep model of FGR 
and to consider the ethical issues and translational aspects of this therapy. The overnourished 
adolescent sheep paradigm was chosen as it replicates many of the key features of human FGF 
secondary to uteroplacental insufficiency, including a major reduction in UBF by mid-gestation, 
without the need for any permanent surgical interference at a vascular or placental level. 
More specifically, the aims were to evaluate the effects of Ad.VEGF gene therapy for FGR on:   
 In vivo measurements of uterine blood flow 
 Uterine artery vascular reactivity, intima: media ratios and adventitial neovascularisation 
 Fetal growth velocity (measured by serial ultrasound) 
 Fetal weight, body composition, organ weights and gross morphology in late gestation 
 Gestation length and lamb birth weight following spontaneous delivery approaching term 
 Neonatal mortality and morbidity, and level of neonatal care required to ensure survival 
 Postnatal growth rates to weaning, body composition and metabolic function in early life 
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Chapter 2                                                                                                             
General Materials and Methods 
2.1    Animal Procedures 
All regulated procedures were licensed under the UK Animals (Scientific Procedures) Act 1986 
and approved by the Rowett Institute’s local ethical review committee. Sheep were housed in 
individual pens under natural lighting conditions at the Rowett Institute of Nutrition and 
Health, University of Aberdeen, Scotland (57oN 2oW). 
2.1.1    Establishment of singleton pregnancies 
Adult Scottish Greyface ewes (Border Leicester x Scottish Blackface) were used as donors of 
embryos for transfer into adolescent recipient ewe lambs (Dorset Horn x Scotch Mule 
(Bluefaced Leicester x Scottish Blackface)) of known age, birthweight and growth status. 
Embryo transfers were carried out on 10 separate days during the mid-breeding season. 
2.1.1.1    Oestrus synchronisation and ovulation induction 
Oestrus cycles of the adolescent recipients (n=177) and adult donors (n=40) were synchronised 
by withdrawal of progestogen sponges. Synchronisation was carried out in 10 batches (each 
consisting of 3 to 4 donors and 16 to 21 recipients) across a 2 week period preceding each 
embryo transfer day.  
Prior to sponge insertion recipient ewe lambs were sheared and weighed. Adiposity was 
assessed and a body condition score (BCS) assigned following palpation of the lumbar 
vertebral spinous processes between the lowermost rib and the level of the kidneys, according 
to the criteria of Russel et al. (1969). Body condition scoring was carried out by a single 
experienced assessor (Raymond Aitken). Synchronisation of recipients was commenced on Day 
–15 relative to the onset of oestrus (Day 0) by insertion of vaginal sponges containing 60mg 
medroxyprogesterone acetate (Veramix®, Intervet UK Ltd, Welwyn Garden City, Herts, UK). 
Sponges were dusted with terramycin antibiotic powder and well lubricated prior to insertion. 
Ewe lambs were examined daily to ensure that the sponges remained in situ in view of the risk 
of displacement secondary to adolescent anatomical variation. Thirteen days later (on Day –2) 
at 14:00, sponges were removed and 600IU pregnant mare serum gonadotrophin (PMSG, 
Intervet UK Ltd) was administered by intramuscular (i.m.) injection to stimulate ovulation. 
Donor ewes (2 to 3 years old and of known breeding history) were also weighed and body 
condition scored prior to the start of synchronisation on Day –14, when vaginal sponges 
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containing 40mg fluorogestone acetate (Chronogest®, Intervet UK Ltd) were inserted using a 
sponge applicator. Seven days later (Day –7) these sponges were removed and immediately 
replaced with fresh ones of the same type. A superovulation regime was commenced at 08:00 
on Day –4 with the i.m. administration of 1.125mg ovine follicle-stimulating hormone (oFSH) 
(Ovagen®, Immuno-Chemical Products Ltd, Auckland, New Zealand) immediately followed by 
125μg i.m. cloprostenol (Estrumate®, Schering-Plough Ltd, Welwyn Garden City, Herts, UK), a 
synthetic prostaglandin-F2α. At 18:00 a second dose of oFSH was given together with 400IU 
i.m. PMSG. Further twice daily doses of oFSH were administered at 08:00 and 18:00 on the 
following 3 days (Day –3 to –1) and sponges were removed on Day –2 at 18:00. Beginning on 
Day –1, each donor and recipient ewe was individually exposed to a vasectomised ram three 
times daily until onset of oestrus had been detected. 
2.1.1.2    Laparoscopic intrauterine insemination 
On Day 0 at 16:00 (46 hours following sponge removal) donor ewes underwent insemination 
directly into the uterine cavity under direct laparoscopic visualisation, as previously described 
by McKelvey et al. (1985). 
Fresh semen was harvested from a single sire (Dorset Horn) of proven fertility using an 
artificial vagina warmed to 37oC. Semen production had been checked during the previous 
week and viability assessed by staining and scoring on the day before use. After collection 
semen was diluted 1:3 by volume with phosphate buffered saline and stored in a double-
walled glass vessel at 35oC. Sperm motility was evaluated and rechecked immediately prior to 
insemination into each of the 3 to 4 donor ewes per batch. Food and water were withheld 
overnight prior to laparoscopy. Ewes initially underwent sedation with 6mg i.m. acepromazine 
(ACP Injection®, Novartis Animal Health UK Ltd, Frimley, Surrey, UK), which was administered 
30 to 45 minutes before the procedure. They were restrained in a custom-made laparoscopy 
cradle, designed to provide a large degree of “head-down”, allowing the bowel to fall away 
from the pelvis under gravity and thereby negate the risk of injury (Figure 2.1). The ventral 
abdomen was shaved and prepared with 4% chlorhexidine gluconate (HiBiSCRUB®, Regent 
Medical, Manchester, UK). Trochars were inserted at two sites following local subcutaneous 
(s.c.) infiltration of 10ml 2.0%  lidocaine hydrochloride mixed with 0.001% adrenaline (Lignol®, 
Arnolds Veterinary Products, Shrewsbury, Shropshire, UK). The abdominal cavity was 
insufflated with carbon dioxide and a 5mm laparoscope (Panoview Lumina SL 8933.441, 
Richard Wolf UK Ltd, Wimbledon, UK) was introduced via the primary port to visualise the 
uterus. Under direct vision 0.3ml of diluted semen was deposited into the lumen of each 
uterine horn using a long finely drawn sterile glass pipette introduced via the secondary port.
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Figure 2.1 – Preparation for laparoscopic procedures 
 
Photograph of an anaesthetised adult donor ewe positioned "head-down” for laparoscopic 
intrauterine insemination in a custom-made cradle. 
 
Once insemination was complete the peritoneal cavity was deflated, the trochars removed and 
Michel clips applied over the port site incisions. Antibiotics were administered in the form of 
4ml i.m. Duphapen®+Strep (Fort Dodge Animal Health UK Ltd, Southampton, UK), containing 
200mg procaine benzylpenicillin and 250mg dihydrostreptomycin per ml. 
2.1.1.3    Embryo recovery 
Four days following insemination, multiple embryos were recovered from donor ewes at 
laparotomy using a standard surgical technique of retrograde flushing of each oviduct, as 
described (Hunter et al. 1955). As many donors as necessary were flushed in order to provide 
enough embryos of sufficient quality for transfer into 12 to 16 adolescent recipients per batch. 
This varied between 1 and 4 donors per day. 
Food and water were withheld overnight. Surgery was performed under general anaesthesia, 
which was induced and maintained via inhalation of isoflurane (IsoFlo®, Abbott Laboratories 
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Ltd, Queenborough, Kent, UK) in a mixture of oxygen and nitrous oxide. After mask induction 
all ewes were intubated using a size 8.0 endotracheal (ET) tube (Phoenix Medical Ltd, Preston, 
UK) but artificial ventilation (using a Manley Pulmovent MPP 200) was only provided if 
necessary. Once adequately anaesthetised, ewes were positioned in dorsal recumbency, 
closely shaved and prepared with povidone-iodine (Vetasept®, Animalcare Ltd, York, UK). Once 
draped a 10cm midline incision was made on the anterior abdominal wall immediately above 
the mammary gland and a combination of sharp and blunt dissection was used to safely enter 
the peritoneal cavity. The uterus and ovaries were located and exteriorised and the ovulation 
rate was determined by counting the number of corpora lutea on the surface of each ovary 
(Figure 2.2A). Each oviduct in turn was cannulated using a fine glass catheter, which was 
carefully threaded into the fimbria and advanced approximately 3cm into the oviduct (Figure 
2.2B). 15–20ml ovum culture media (OCM) (ICN Biomedicals, Ohio, USA) warmed to 37oC was 
injected into the lumen of the ipsilateral uterine horn approximately 5cm from the utero-tubal 
junction. Media was then milked out through the cannula into a sterile glass embryo dish.  
Embryo yield was immediately determined by assessment of developmental stage using a 
stereomicroscope (magnification x40). Once bilateral recovery was complete the rectus sheath 
was closed with interrupted horizontal mattress sutures using monofilament absorbable 
polydioxanone (0 PDS®II, W9381H, Ethicon, Norderstedt, Germany). 1ml Duphapen®+Strep 
was administered directly into the wound during closure of the skin with continuous braided 
absorbable polyglactin (2 Vicryl®, W9297, Ethicon). A moisture vapour permeable spray 
dressing (Opsite®, Smith and Nephew Medical Ltd, Hull, UK) was applied over the wound. 
Perioperatively ewes received systemic antibiotics and analgesia in the form of 4ml i.m. 
Duphapen®+Strep and 40mg s.c. meloxicam (Metacam®, Boehringer Ingelheim, Ingelheim, 
Germany), respectively. Embryos were held at 33oC in fresh OCM until transferred to recipients 
within 6 hours of recovery (Section 2.1.1.4). Induction of anaesthesia and embryo recovery 
took approximately 45 minutes per animal and ewes were standing within 5 minutes of 
extubation. Ewes routinely received a further two doses of Duphapen®+Strep (4ml) on post-
operative days 1 and 2 and were gradually re-alimented to feed over a 4 day period to prevent 
the development of ketoacidosis. Further analgesia was provided in the event of inappetance 
or signs of pain. Ewes received 125μg i.m. cloprostenol between post-operative days 10 and 12 
following insemination to induce luteolysis. 
2.1.1.4    Embryo transfer 
Recovered embryos of appropriate quality and stage were synchronously transferred into the 
uteri of adolescent recipients using the laparoscopically assisted technique of Tervit (1989).
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Figure 2.2 – Embryo recovery at laparotomy 
   
Photographs of open embryo recovery procedure: [A] View of the exteriorised uterus, adjacent 
superovulated ovary and fallopian tube, cannulated using a fine glass catheter; [B] Injection of 
ovum culture medium into the uterine cavity and retrograde flushing of embryos into a dish. 
 
Food and water were withheld overnight. General anaesthesia was induced and maintained as 
described for the embryo recovery procedures (Section 2.1.1.3) and ewe lambs were 
positioned and prepared for laparoscopy as described for the intrauterine insemination 
procedures (Section 2.1.1.2). At laparoscopy the ovaries were visualised and ovulation rate 
was determined (Figure 2.3A). In the event of regressed corpora lutea or complete failure of 
ovulation, embryo transfer was not carried out. Otherwise the uterine horn ipsilateral to the 
ovary with the greatest number of corpora lutea was selected for transfer. The ewe was 
draped and a 1–2cm mini-laparotomy incision was made on the anterior abdominal wall 
approximately 10cm anterior to the udder and slightly to the right of the midline. The tip of 
the selected uterine horn was carefully exteriorised through this incision using a pair of 
endoscopic grasping forceps (Richard Wolf UK Ltd) and gently held in a warm saline-soaked 
swab. An appropriate embryo (high quality early morula) was selected and loaded into a fine 
glass pipette attached to a syringe, held in 0.2ml OCM. The pipette was inserted through the 
wall of the chosen horn approximately 1.5cm anterior to the utero-tubal junction (Figure 2.3B) 
and discharged into the uterine lumen. The horn was then carefully returned to the abdominal 
cavity and the rectus sheath and skin closed using interrupted 0 PDS®II.  
B
  A 
A 
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Figure 2.3 – Laparoscopically assisted embryo transfer 
  
Photographs of embryo transfer procedure on an adolescent recipient ewe: [A] Laparoscopy to 
determine recipient ovulation rate and to select the uterine horn for embryo transfer; [B] 
Exteriorisation of chosen uterine horn through a mini-laparotomy incision and transfer of 
embryo into the uterine cavity using a fine glass pipette. 
 
Perioperatively ewes received 3ml i.m. Duphapen®+Strep and 20mg s.c. meloxicam. Induction 
of anaesthesia and embryo transfer took approximately 20 minutes per animal and ewes were 
standing within 5 minutes of extubation. Ewes received two further doses of i.m. 
Duphapen®+Strep (3ml) on postoperative day 1 and 2. 
2.1.1.5    Pregnancy diagnosis 
Pregnancy rate following embryo transfer was determined on day 45 of gestation by 
transabdominal ultrasound using a B-mode linear array scanner (Aloka SSD-210 DXII, BCF 
Technology Ltd, West Lothian, UK) with a 5.0MHz transducer and ultrasound coupling gel 
(Ultra/Phonic™, Pharmaceutical Innovations Inc, Newark, NJ, USA). Viability was confirmed by 
the presence of fetal heart activity. 
2.1.2    Nutritional management 
Immediately following embryo transfer, ewes were allocated to one of two nutritional 
regimes: a high intake diet designed to overnourish the mother at the expense of the 
A B 
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pregnancy; or a control intake diet designed to meet but not exceed the requirements of 
pregnancy and thereby optimise fetal and placental growth. Control-intake and overnourished 
ewes received different quantities of the same complete diet, the composition of which is 
detailed in Table 2.1. All ingredients other than home produced barley were bought in and 
freshly mixed in feed mill at the Rowett Institute. The complete diet supplied a total of 12MJ 
metabolisable energy and 140g crude protein per kg and had an average dry matter of 86%. 
The feed was sub-sampled five times per week and the complete sample was submitted 
weekly to the Rowett Institute’s Analytical Department for the determination of crude protein 
content (nitrogen x 6.25) using the Kjeldahl procedure (Davidson et al. 1970). The amount of 
soya protein used varied depending on the quality of the hay and barley and was usually 
adjusted within the range 165–175kg on the basis of nitrogen content. Vitamins and minerals 
were supplemented by adding Norvite 317 (Insch, Aberdeenshire, UK). The diet was offered in 
two equal feeds at 08:00 and 16:00 daily. Before the morning ration was provided, any feed 
left in the trough overnight was weighed and recorded as a daily feed refusal. Ewes were 
weighed once a week and maternal BCS was recorded fortnightly - described in Section 2.1.1.1. 
The level of feed for control-intake ewes was calculated to promote normal maternal weight 
gain and to maintain baseline maternal adiposity throughout gestation. Control-intake ewes 
received their entire ration immediately following embryo transfer. Thereafter the amount of 
feed was adjusted to promote a low to moderate maternal weight gain (approximately 50–65g 
per day) during the first two-thirds of gestation. From 100 days gestation onwards, step-wise 
increases in maternal intake were allowed in order to meet the increasing demands of the 
developing fetus. 
 
Table 2.1 – Composition of the sheep diet (per kg) 
Rolled barley 422.5g 
Coarsely chopped hay 300.0g 
Soybean meal 167.5g 
Molasses 100.0g 
Salt 3.5g 
Limestone 2.5g 
Dicalcium phosphate 2.5g 
Vitamins and minerals 1.5g 
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The level of feed for overnourished ewes was calculated to promote rapid maternal growth, 
and provided (on average) 2.25 times the amount of metabolisable energy as the control diet. 
Following embryo transfer, these ewes had their level of feed gradually increased over a two 
week period until the daily level of feed refused was approximately 15% of the total offered, 
equivalent to ad libitum intakes. Thereafter the amount of feed was individually reviewed 
three times per week and adjusted where appropriate on the basis of weekly increases in live 
weight and the level of daily feed refusals. 
2.1.3    Ultrasound examination 
Serial ultrasound examinations were systematically performed to assess fetal growth and 
wellbeing throughout the second half of pregnancy, beginning with a baseline assessment in 
mid-gestation. All scans were performed by a single operator (David Carr) using a GE Logiq™ 
400 CL machine (GE Medical Systems Ltd, Milwaukee, WI, USA) with cine-loop facility, pulsed 
wave and colour flow Doppler functionality, and a 3.0–5.0MHz curvilinear abdominal probe.  
Ewes were examined whilst standing upright in a modified milking crate and loosely restrained 
by head collar (Figure 2.4). One-to-one attention and hay was provided by an additional 
member of the research team in order to reduce anxiety. Prior to applying ultrasound coupling 
gel, the abdominal wool was clipped anterior to the udder after application of a cleaning 
solution containing (per litre) 750ml 100% ethanol, 150ml deionised water and 100ml 5% 
chorhexidine gluconate (HiBiTANE™, Regent Medical). Each ultrasound examination lasted a 
maximum of 30 minutes, during which time all fetal measurements were repeated until a 
minimum of three values in reasonable agreement with each other (coefficient of variation 
<5%) were obtained. 
2.1.3.1    Fetal biometry 
After confirming the presence of fetal heart activity, a transverse view of the fetal abdomen 
was obtained at the level of the lowermost rib, just above the umbilical cord insertion. Care 
was taken to ensure the presence of a complete rib, the stomach bubble and the intrahepatic 
portion of the umbilical vein in the section. The abdominal circumference (AC) was measured 
in this plane using an ellipse (Figure 2.5A) and the trunk (transverse abdominal) diameter (TD) 
was determined at the same level (Figure 2.5B).  
Remaining in the axial plane, the transducer was then moved caudally to the level of the fetal 
kidneys and panned up and down to identify the widest mid-section in this plane (Figure 2.6A). 
The right kidney was selected for all renal measurements unless satisfactory views were
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Figure 2.4 – Ultrasound examination 
 
Photograph of the set up for scanning, showing a ewe standing upright in a modified milking 
crate ready for transabdominal ultrasound examination  
 
unobtainable, in which case the left was substituted. At the widest point of the kidney, the 
transverse and anteroposterior renal diameters (TRD and APRD) were measured at right angles 
to one another by placing the callipers on the borders of the renal tissue. The probe was then 
rotated through 90o to obtain a longitudinal view of the same kidney in parasagittal section, 
taking care to visualise the full length of the organ. In this plane the renal length (RL) was 
measured between the superior and inferior poles of the kidney (Figure 2.6B). From these 
three measurements the renal volume (RV) was then calculated, using the ellipsoid equation 
[RV = RL x TRD x APRD x π/6], as previously described (Jeanty et al. 1982). 
After rotating back into a transverse section, the transducer was moved from the level of the 
kidneys down to the fetal pelvis, where the iliac crests and head of the femur were identified. 
Fixing on the proximal end of the femoral bone, the probe was then rotated and angled to 
visualise the full length of the calcified shaft, keeping the long axis of the bone close to 90o
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Figure 2.5 – Abdominal measurements 
  
Ultrasound images: [A] Transverse section of the fetal abdomen at the level of the lowermost 
rib for the measurement of abdominal circumference; [B] Measurement of the trunk diameter. 
 
Figure 2.6 – Renal measurements 
   
Ultrasound images: [A] Transverse view of the fetal abdomen demonstrating the widest 
midpoint of the right kidney for measurement of the transverse and anteroposterior renal 
diameters;  [B] Parasagittal section through the right kidney for measurement of renal length. 
 
relative to the ultrasound beam (i.e. parallel to the top of the screen) in order to minimise 
artefact. The femur length (FL) was then measured (Figure 2.7A) between the two metaphyses. 
Rotating 90o into an axial view of the femur, the bony shaft was followed down to its distal end 
in order to identify the adjacent tibial bone. After fixing on the proximal end of the tibia, the 
above steps were repeated in order to visualise the full tibial shaft and to measure the tibia 
length (TL) (Figure 2.7B). 
A B 
A B 
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Figure 2.7 – Long bone measurements 
  
Ultrasound images: [A] View of the full length of the calcified shaft of the femur for the 
measurement of femur length; [B] Equivalent view for the measurement of the tibia length. 
 
Thereafter the fetal head was located by following the cervical vertebrae from the fetal chest 
up to the base of the skull. The probe was orientated so that the long axis of the fetal head 
was at right angles to the ultrasound beam. Care was taken to visualise the full length of the 
fetal head and to ensure the correct section through the cranium, in which the midline 
structures of the brain were equidistant from the two parietal bones. In this view the biparietal 
diameter (BPD) was measured as the widest distance between the proximal and distal parietal 
bones (outer to outer surface, as shown in Figure 2.8A). The occipito-snout length (OSL) was 
also measured in this plane, from the occipital bone at the posterior aspect of the skull (outer 
surface) to the anterior border of the soft tissue at the tip of the snout (Figure 2.8B). 
2.1.3.2    Umbilical artery Dopplers 
The umbilical cord diameter was first measured within 1cm of its insertion into the fetal 
abdomen. The cord was then followed distally to identify the nearest appropriate straight 
section for Doppler waveform analysis. The colour flow mode was enabled and the orientation 
was adjusted so that the umbilical vessels were directed towards the transducer with the angle 
of insonation (θ) as close to zero as possible (direction of blood flow parallel with ultrasound 
beam) and always below 30o. The pulsed wave Doppler mode was then enabled and the gate 
was positioned over the umbilical artery, distinguishable from the umbilical vein by its 
characteristic pulsatile waveform. The velocity scale was adjusted to ensure that the waveform 
was maximised whilst still visible in its entirety, and the gain was altered until a “clean” 
waveform with minimum background noise was observed. A series of waveforms of uniform
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Figure 2.8 – Head measurements 
 
Ultrasound images: [A] Section through the fetal head for the measurement of the biparietal 
diameter; [B] Measurement of the occipito-snout length. 
 
appearance were then recorded in the absence of fetal or maternal movements. The 
maximum velocity envelope (outline) of three consecutive waveforms was traced manually in 
order to determine the maximum (peak systolic) velocity (Vmax), minimum (end-diastolic) 
velocity (Vmin) and time-averaged maximum velocity (TAMAX) (Figure 2.9). The vessel was 
subsequently re-examined and the above steps repeated at least two more times. 
Measurements were then averaged for accuracy.  
 
Figure 2.9 – Umbilical artery Dopplers 
  
Measurement of umbilical artery Doppler indices: [A] Ultrasound image of waveform captured 
during Doppler examination of a free loop of umbilical cord, with angle of insonation less than 
30 degrees; [B] Close-up of three consecutive waveforms illustrating measurement of maximum 
velocity (Vmax), minimum velocity (Vmin) and the time-averaged maximum velocity (TAMAX).
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From these velocities the following flow-independent indices were calculated: 
 Pulsatility index (PI)   =  (Vmax – Vmin) / TAMAX 
 Resistance index (RI)   =  (Vmax – Vmin) / Vmax 
 Systolic : diastolic ratio (SDR) =  Vmax / Vmin 
2.1.3.3    Placentation and amniotic fluid volume 
An initial sweep was made through the gravid horn to survey the approximate number, size 
and general distribution of the placentomes. Based on the overall appearances, placental 
quality was subjectively categorised as excellent, good, moderate or poor. In order to more 
objectively assess placental morphometry, 10 representative placentomes of average size 
were randomly selected for measurement. A longitudinal mid-section (side-on) view of each 
chosen placentome was obtained, with its characteristic oval appearance (Figure 2.10A). In this 
plane the placentome length and width were measured at right angles. The cross-sectional 
area (CSA) of each placentome was then calculated using the formula: CSA =  [π x (placentome 
length x 0.5) x (placentome width x 0.5)] / 100. Finally, the CSAs of all 10 placentomes were 
added together to give a “placentome index”.  
Amniotic fluid was first assessed subjectively by sweeping through the entire uterus and 
categorising fluid levels as normal, increased or reduced. With the ewe standing straight and 
upright, a search was made for deep pockets of accumulated fluid, and the deepest vertical 
pool (DVP) was identified and quantified by averaging 3 vertical measurements (Figure 2.10B).  
 
Figure 2.10 – Assessment of placentation and amniotic fluid 
   
Ultrasound images: [A] Measurement of the width and length of an individual placentome;     
[B] Measurement of the deepest vertical pool of amniotic fluid.  
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2.1.4    Gene therapy administration 
2.1.4.1    Vectors 
Adenoviral constructs containing the gene for the human vascular endothelial growth factor 
(VEGF) A-165 (Ad.VEGF-A165) or a marker gene encoding the beta-galactosidase enzyme LacZ 
(Ad.LacZ) were produced in individual lots by the A.I. Virtanen Institute for Molecular Sciences 
(AIVI), University of Kuopio, Finland. The functionality of each lot was tested by Ark 
Therapeutics Ltd (Kuopio, Finland) using in vitro assays prior to shipping to the Rowett Institute 
of Nutrition and Health, Aberdeen. HeLa cells were first transduced in vitro using each vector 
lot. Thereafter the cells and conditioned growth media were separately collected for 
laboratory analysis. VEGF-A165 protein concentrations were quantified in the media 
supernatant using enzyme-linked immunosorbent assay (ELISA). VEGF expression was also 
assessed semi-quantitatively by visual inspection of band size following Western blotting. Beta-
galactosidase expression was assessed in the transduced HeLa cells after straining with X-gal 
solution (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside).  
Following delivery, vectors were stored at –80oC prior to use. The viral titre of each lot was 
known and allowed for the calculation of the precise volume required to provide 1 x 1012 
particles for injection into each uterine artery. Aliquots of vector were thawed out and the 
required volume (µL) was added to 10ml sterile normal saline by John Milne immediately prior 
to administration at laparotomy (see Section 2.1.4.2). Syringes and needles used to draw up 
and/or administer adenoviral vectors were subsequently placed into a designated sharps bin 
and disinfected overnight in 2% Virkon® (Antec International Ltd, Sudbury, Suffolk, UK) before 
disposal as clinical waste. 
2.1.4.2    Surgery 
On the day before surgery the afternoon feed was omitted and water withdrawn from 17:00. 
Ewes were weighed to ensure accurate dosing of analgesia, antibiotics and anaesthetic agents. 
On the morning of surgery fetal viability was confirmed by transabdominal ultrasound prior to 
transfer to the surgical preparation room, where a 14-gauge jugular venous catheter was 
inserted.  Induction of anaesthesia was achieved using 4–5mg/kg intravenous (i.v.) propofol 
(PropoFlo®, Abbott Laboratories Ltd). A 7.5mm ET tube was inserted, through which 
anaesthesia was maintained using isoflurane in a mixture of oxygen and nitrous oxide. Ewes 
were ventilated with an Aestiva 5 unit (Datex-Ohmeda, Madison, WI, USA). Antibiotics were 
administered in the form of 10mg/kg i.m. benzylpenicillin (Crystapen®, Genus Pharmaceuticals, 
Berkshire, UK) and 0.4ml/kg i.m. Duphapen®+Strep. Analgesia was provided in the form of 
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0.006mg/kg i.m. buprenorphine (Vetergesic®, Schering-Plough Ltd) and 0.5mg/kg s.c. 
meloxicam. The ventral abdomen and an additional area for the application of a diathermy 
electrode were closely shaved. 
Ewes were positioned on the operating table in dorsal recumbency, legs loosely restrained by 
ankle ties, and completely draped. The abdomen was prepared with povidone-iodine. 
Maternal heart rate, respiratory rate, oxygen saturations and the concentration of isoflurane 
in the inspired and expired air were monitored throughout surgery. Once the ewe was 
anaesthetically stable and taking care to avoid the mammary vein, a 12–15cm midline incision 
was made on the lower abdominal skin and continued through the subcutaneous fat layer to 
the rectus sheath beneath. Any bleeding vessels were ligated with artery forceps and 
cauterised as necessary. The rectus sheath and parietal peritoneum were carefully incised in 
the midline using a scalpel and the incision was extended with scissors to open the peritoneal 
cavity. Uterine position was assessed and the gravid horn identified by bilateral inspection, 
taking care to avoid excessive handling of the uterus. Large gauze swabs soaked in saline were 
used to gently retract the omentum, bowel and non-gravid uterine horn in order to visualise 
the lower lateral aspect of the gravid horn. The main trunk of the uterine artery was identified 
in its course along the posterior aspect of the uterus and passage over the anterior wall within 
the mesometrium, and the visceral peritoneum overlying the vessel was carefully opened as 
proximally as possible. The artery beneath was then mobilised by carefully separating it from 
the underlying tissue using Metzenbaum scissors, an aneurysm needle, right-angled artery 
forceps and fine cotton buds as required. A vessel loop (Ethicon) was fed beneath the artery 
and used to gently elevate and stabilise the artery, which was then occluded digitally. A 23-
gauge butterfly needle attached to the prepared syringe (containing 10ml normal saline ± 
adenoviral particles; see above) was carefully inserted through the vessel wall just distal to the 
occlusion and proximal to the first arterial bifurcation, as shown in Figure 2.11.  
After drawing back to ensure the needle tip was in the vessel lumen, the solution was steadily 
injected over a period of 1 minute, after which the needle was carefully removed and a second 
digital occlusion applied directly over the injection site. Bimanual occlusion was maintained for 
a further 4 minutes to maximise transfection of the downstream endothelium and to prevent 
excessive systemic spread (for ewes receiving adenoviral particles). After 4 minutes the 
occlusion over the injection site was released and the area inspected for any signs of bleeding. 
Haemorrhage from the artery was managed by a further digital occlusion for 1 minute, or 
longer if necessary. Haemorrhage from the dissected peritoneal edges was managed using 
pressure with a small gauze swab and/or figure-of-eight sutures using nonabsorbable braided
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Figure 2.11 – Gene therapy administration 
 
Photograph showing the main trunk of a uterine artery being injected using a butterfly needle 
at laparotomy. The artery has been dissected out, elevated using a vessel loop and is being 
digitally occluded just proximal to the site of injection. 
 
silk (3.0 Mersilk®, W192, Ethicon). Once haemostasis had been achieved the non-gravid 
uterine artery was identified and injected in the same manner. Thereafter the uterus was 
restored to its original position and hydrated with sterile normal saline warmed to 37oC. The 
rectus sheath and parietal peritoneum were closed using interrupted 2 Mersilk® (W595, 
Ethicon) and the subcutaneous fat layer was closed with interrupted 2.0 Vicryl® (W9463, 
Ethicon) to obliterate the dead space and thereby reduce the risk of infection. The skin was 
closed with continuous 2.0 Vicryl® and the wound sprayed with Opsite®. An abdominal 
bandage comprising a double fold of Tubigrip® L (Molnlycke Health Care, Dunstables, Beds, UK) 
was applied around the trunk in order to provide support and to limit direct contact of the 
surgical wound with dirt in the pen and thereby reduce the risk of infection.  
In the recovery area, ewes were extubated and kept under observation in a heated pen. An 
upright position was encouraged to prevent bloating. Two doses of 3ml Duphapen®+Strep 
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were administered on day 1 and day 2 post-op. Additional antibiotics in the form of procaine-
penicillin (Duphapen Fort®, Fort Dodge Animal Health) were administered if there was 
perceived to be a higher risk of infection. Further analgesia (meloxicam and/or buprenorphine) 
was provided if there were signs of pain or inappetance. Overnourished ewes were gradually 
re-alimented to pre-surgery intakes. Normal step-up was commenced for control-intake ewes. 
2.2    Laboratory Techniques 
2.2.1    Processing of blood samples 
Samples of maternal and lamb venous blood were obtained by jugular venepuncture at various 
stages throughout pregnancy and the postnatal period, whilst fetal blood samples were 
obtained at necropsy from the umbilical cord or by cardiac puncture (Section 4.2.5.1). Samples 
taken into 10ml BD Vacutainer® tubes containing either 18.0mg K2-EDTA or 170 IU lithium-
heparin (Becton Dickinson, Plymouth, Devon, UK), 5ml assay tubes (Sarstedt, Nümbrecht, 
Germany) containing 50μl heparin or 2.5ml syringes containing 25μl heparin (both at 10 IU/ml 
concentration, Leo Laboratories Ltd, Princes Risborough, Bucks, UK) were placed on ice before 
being spun down at 3000rpm (2000g) for 20 minutes at 4oC in a refrigerated centrifuge (ALC 
4237R or Jouan KR422). The resultant plasma was pipetted off and stored at –20oC. Samples 
taken in 10ml plain tubes (BD Vacutainer®) were left at room temperature for 8 hours then, 
after ringing, stored overnight at 4oC. The following morning they were centrifuged at 3000 
rpm (2000g) for 90 minutes at 4oC. The resultant serum was pipetted off and stored at -20oC. 
2.2.2    Preparation of fixative solutions 
Carnoy’s solution was made up as follows: 
 Absolute ethanol   6 parts 
 Chloroform    3 parts 
 10% glacial acetic acid  1 part 
4% neutral buffered formalin (NBF) solution was made up as follows: 
 Na2HPO4     6.5g  
 NaH2POH2O    4.0g  
 Formaldehyde    100ml 
 Deionised water (d.H2O)  900ml  
Both of these fixative solutions were stored at 4oC and used within 7 days. 
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2.2.3    Processing of fixed tissue samples 
Tissues immersion-fixed in Carnoy’s solution were transferred into 70% ethanol at 6 hours 
following collection, then rinsed and placed into fresh 70% ethanol at 24 hours. Tissues which 
had been immersion-fixed in NBF solution were transferred into d.H2O at 48 hours following 
collection. At approximately 72 hours they were rinsed and placed into fresh d.H2O for a 
further 24 hours before being rinsed again and transferred into 70% ethanol at 96 hours. 
Within 2 weeks of collection, tissues were trimmed if required prior to being enclosed in 
histological processing cassettes (Histosette® I (M490-6) or Macrosette® (M512), Simport, 
Beloell, QC, Canada). Small tissues such as fetal ovaries and narrow uterine artery sections 
were first wrapped in velin tissue. Up to 60 cassettes per day were subsequently processed 
through sequential baths of the following solutions during a 19-hour automated cycle (Citadel 
1000, Shandon, Pittsburgh, PA, USA):  
 70% ethanol  60 min      
 80% ethanol  90 min  
 95% ethanol  90 min  
 100% ethanol  x 4 60 / 60 / 90 / 90 min  
 Histo-Clear™II* x 3 60 / 90 / 90 min              
 Paraffin wax  x 2 180 / 180 min                        (*National Diagnostics, Hull, UK) 
Tissues were subsequently embedded in paraffin wax blocks using a HistoEmbedder (Leica 
Microsystems, Wetzlar, Germany). 
2.2.4    Measurement of nutrients and metabolic hormones 
2.2.4.1    Glucose  
Glucose and lactate concentrations were measured directly in amniotic fluid and maternal, 
fetal and lamb plasma samples using a dual biochemistry analyser (Model 2700, Yellow Springs 
Instruments, Yellow Springs, OH, USA). Determinations were made in duplicate and repeated if 
the coefficient of variation exceeded 5%. 
2.2.4.2    Insulin 
Insulin concentrations were determined in duplicate in maternal, fetal and lamb plasma 
samples using a double antibody radioimmunoassay technique, as previously described by 
MacRae et al. (1991).  
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Insulin assay buffer was first prepared by adding 0.5% bovine serum albumin to 0.05M 
phosphate buffer, adjusting the pH to 7.4 and storing at 4oC. Eight standard solutions (ranging 
from 0.205 to 26.3 μU/ml) were prepared from a stock solution of porcine insulin (Ref. I-3505, 
Sigma Aldrich Co. Ltd., Poole, Dorset, UK). To start, 500μl of first antibody), raised in guinea pig 
to porcine insulin (Ref. 65-104, ICN Biomedicals Ltd, Thame, Oxfordshire, UK), at 1:75000 initial 
dilution, was added to 100μl of each standard solution, 100μl of each plasma sample and to 
two tubes containing 100μl assay buffer only (for total binding). Tubes were vortexed before 
being incubated at room temperature overnight (a minimum of 16 hours). The following 
morning, 100μl of 125I-Insulin tracer (prepared in house using a standardised chloramine-T 
iodination technique) at 150000–200000 cpm/100μl was added to each tube as well as to two 
empty tubes (for total counts) and to two tubes containing 600μl assay buffer only (for non-
specific binding). Tubes were vortexed before being incubated for 6 hours at room 
temperature. Thereafter 500μl of a second antibody mixture, containing goat anti-guinea pig 
serum IgG at 1:150 dilution (Scottish Antibody Production Unit (SAPU), Lanarkshire, UK) and 
normal guinea pig serum at 1:500 dilution (SAPU), was added to each tube. Tubes were 
vortexed again before being incubated overnight at 4oC. The following morning tubes were 
centrifuged at 3000 rpm (1900g) for 20 minutes at 4oC. The supernatant from each tube was 
decanted off and the residual pellets were counted on an automatic gamma counter (Wallac 
Wizard™ 1470, PerkinElmer Inc, Cambridge, UK) for 1 minute. A calibration curve for the assay 
was produced following logistic transformation. The limit of sensitivity of the assay was 2μU 
insulin/ml and the intra- and inter-assay coefficients of variation were 6.0% and 9.8%, 
respectively. The inter-assay coefficient of variation was calculated using quality control (QC) 
plasma samples (known concentrations of insulin ranging from high to low values) at the 
beginning and end of each assay. All maternal and fetal samples were analysed in a single 
assay, whilst the lamb plasma samples were processed across a series of 4 consecutive assays. 
2.2.4.3    IGF-1 
Insulin-like growth factor 1 (IGF-1) concentrations were determined in duplicate following 
extraction from maternal, fetal and lamb plasma samples using a radioimmunoassay 
technique, as previously described by Bruce et al. (1991). 
IGF-1 assay buffer was first prepared by dissolving 9.0g NaCl, 7.1g Na2HPO4, 3.7g sodium EDTA, 
5ml polysorbate (Tween) 20 and 1g sodium azide in 1 litre of d.H2O, adjusting the pH to 7.5 
and storing at 4oC. Neutralising buffer was prepared by dissolving 8.5g Na2HPO4 in 1 litre of 
assay buffer and storing at room temperature. Dummy extract solution was prepared by 
adding 2ml d.H2O, 0.5ml 2.4M formic acid and 10ml ethanol to 75ml neutralising buffer and 
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storing at room temperature. To being the extraction procedure, 50μl of each plasma sample 
was pipetted into an eppendorf tube, to which was added 12.5μl of 2.4M formic acid followed 
by 250μl ethanol. Tubes were capped, vortexed and stored at room temperature for 30 
minutes. Next they were centrifuged at 2200rpm (1000g) for 30 minutes at 4oC, following 
which 50μl of each supernatant was transferred to a 5ml assay tube and diluted with 300μl 
neutralising buffer. Assay tubes were capped, vortexed and stored overnight at 4oC. The 
following morning, 20μl of each neutralised extract was transferred to a new assay tube and 
diluted with 80μl dummy extract solution. Seven standard solutions (ranging from 0.0025 to 
0.16 pmol/ml) were prepared from a stock solution of IGF-1 (Ref. IP9010, Peninsula 
Laboratories Europe Ltd, St. Helens, Merseyside, UK). To begin the assay, 300μl of anti-serum, 
raised in rabbit to human IGF-1 (Ref. M280(1) provided by Dr G. Holder (University Hospitals 
Birmingham NHS Trust, Birmingham, UK), at 1:2400 initial dilution, was added to each sample 
tube, to 100μl of each standard solution and to two tubes containing 100μl dummy extract 
solution only (for total binding). At the same time 300μl of assay buffer was added to a further 
two tubes containing 100μl dummy extract solution only (for non-specific binding). Tubes were 
vortexed and incubated at room temperature for 5 hours. Thereafter 100μl of 125I-IGF-1 tracer 
(prepared in house using a standardised N-bromo-succinimide iodination technique) at 
120000–150000 cpm/100μl was added to all tubes as well as to two empty tubes (for total 
counts). Tubes were vortexed again before being incubated overnight at 4oC. The following 
day, 100μl of 1% bovine gamma-globulin and 2ml 16.25% polyethylene glycol (PEG) solution 
(containing 0.01g/ml sodium azide) was added to all tubes except total counts. Tubes were 
vortexed and incubated at room temperature for 1 hour before being centrifuged at 3000 rpm 
(1900g) for 30 minutes at 4oC. The supernatant from each tube was decanted off and the 
residual pellets were counted immediately using an automatic gamma counter (Wallac 
Wizard™ 1470) for 1 minute each. A calibration curve for the assay was produced following 
logistic transformation. The limit of sensitivity of the assay was 5 pmol/ml and the intra- and 
inter-assay coefficients of variation were 8.8% and 7.4%, respectively. The inter-assay 
coefficient of variation was calculated using four different QC plasma samples (known 
concentrations of IGF-1) at the beginning and end of each assay. All maternal and fetal samples 
were analysed in a single assay, whilst serial lamb plasma samples were processed across two 
consecutive assays. 
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Chapter 3                                                                                                               
Ultrasound Assessment in Normal and Growth-Restricted Sheep Pregnancies 
3.1 Introduction 
One of the main objectives of the work reported in this thesis was to determine the effects of 
gene therapy on fetal growth trajectories as well as the primary outcome measures of uterine 
blood flow in late gestation and birth weight near to term (see Chapters 4 and 5, respectively). 
Consequently it was important to validate the methodology used for the ultrasound 
assessment of ovine fetal growth. 
3.1.1  Background 
As detailed in Section 1.1.4.3, the most widely used ultrasound measurements for the 
evaluation of longitudinal fetal growth in human pregnancy are the biparietal diameter (BPD), 
head circumference (HC), abdominal circumference (AC) and femur length (FL). These 
biometric parameters are surrogate markers of fetal body weight and in clinical practice are 
also used singly or in combination, for the point estimation of fetal weight in utero using one of 
a large range of published regression equations, albeit with considerable systematic errors of 
up to 25%, particularly in cases of FGR or macrosomia (Platz & Newman 2008). In sheep, 
ultrasound has previously been used to track fetal growth longitudinally by measurement of 
BPD, AC and FL, as well as TL, thorax height and abdominal diameter (Barbera et al. 1995a; 
Galan et al. 1999; Parraguez et al. 2005). Direct measurement of the HC using an ellipse is not 
feasible because, unlike the human fetus, the ovine fetal head is not oval in the 
transventricular plane. An alternative method of determining the HC in clinical practice is to 
calculate it from the BPD and occipito-frontal diameter, which are measured at right angles to 
one another. Although an equivalent anteroposterior head measurement has been described 
in the sheep (OSL) there are no published regression equations to be able to derive an 
equivalent of the HC. With respect to the remaining parameters, it has not specifically been 
established which of these best reflect ovine fetal growth, which has been shown to follow a 
different pattern compared to the human (Barbera et al. 1995b). It is also generally not known 
which biometric parameters can be measured most accurately, although it has been shown 
that the BPD and renal length correlate strongly with equivalent measurements made at post-
mortem in fetal sheep (Ward et al. 2006). Regarding the estimation of fetal weight, there are 
no ovine-specific equations published in the literature. Previous work using ultrasound in the 
overnourished adolescent paradigm demonstrated that the fetal trunk diameter, renal width 
and renal length at 116 days gestation were the strongest predictors of fetal body weight
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Figure 3.1 – Historical cross-sectional fetal weight data in the overnourished adolescent model 
 
Fetal weight in 236 singleton-bearing adolescent ewes that were fed a control intake (closed 
bars, n=115) or high intake (open bars, n=121) from the first week of gestation until necropsy 
(term = 145 days). Data summarised from 6 different studies (Redmer et al. 2005, Redmer et al. 
2009, Wallace et al. 2002, Da Silva et al. 2003, Wallace JM and Aitken RP, unpublished data)       
* p<0.05, ** p<0.01, *** p<0.001 
 
at 134 days gestation (Bourke et al. 2002). Although renal measurements are not used for the 
assessment of fetal growth per se in clinical practice, these experimental findings implied that 
an assessment of renal size might be promising for the estimation of ovine fetal weight, hence 
an evaluation of renal biometry was included here. We planned to extend the previously used 
two-dimensional measurements (renal width and length) to include the anteroposterior kidney 
diameter, thus allowing for the additional calculation of renal volume. 
Longitudinal fetal growth velocity by means of ultrasound has not been evaluated to date in 
the overnourished adolescent ewe. Impressions about the timing and pattern of FGR in this 
model have been derived from cross-sectional data from various studies that were terminated 
at different stages of gestation (Figure 3.1). These results indicate that the FGR observed 
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following overnourishment of the growing adolescent is relatively late in its onset, equivalent 
to the third trimester of human pregnancy. However a major limitation of this type of cross-
sectional data is that each time point is derived from a different cohort of pregnancies and it is 
well recognised that there is a significant degree of year-on-year variation in the birth weights 
of both normal and experimentally growth-restricted lambs. Ultrasound represents a non-
invasive method of repeatedly assessing growth in a single cohort of ongoing pregnancies and 
might be expected to facilitate detection of more subtle alterations in the longitudinal pattern 
of fetal growth. 
As discussed in Section 1.1.5.2, not all pregnancies of overnourished adolescent ewes result in 
a significant degree of FGR. Approximately 52% of fetuses are born with a birth weight that 
falls more than 2SD below the mean birthweight of contemporaneous ewes receiving a control 
dietary intake (Wallace et al. 2006a). In these markedly FGR pregnancies, both fetal and 
placental weight are reduced by approximately 48%. Historically the remaining 48% of fetuses 
are less perturbed, with 23% and 10.5% reductions in placental and fetal weights, respectively. 
Whilst these represent statistically significant deviations from control-intake pregnancies, this 
is biologically much less significant and consequently such pregnancies have been classified as 
non-FGR (Wallace et al. 2004b). Hence a non-invasive means of distinguishing  at an early stage 
between those pregnancies that are destined to be markedly FGR and non-FGR, respectively, 
in late gestation would be extremely useful as it would potentially allow putative therapeutic 
interventions to be evaluated in the most severely compromised pregnancies. 
3.1.2  Aims 
 To investigate the accuracy of different fetal ultrasound parameters, and determine which: 
(a)  can be most accurately measured, i.e. correlate best with fetal measurements with the 
narrowest limits of agreement 
(b) are the best surrogate markers of fetal weight, i.e. correlate best with fetal body weight 
at necropsy 
 To develop estimated fetal weight equations for the sheep and to evaluate their precision 
 To compare measurements of the following between control- and high-intake pregnancies: 
- longitudinal fetal growth velocity - using  a range of different biometric parameters 
- UA Doppler indices 
- ultrasound indices of placental size (placentome index) 
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- ultrasound indices of amniotic fluid volume (deepest vertical pool of liquor) 
 To develop reference charts of normal fetal growth for this genotype (for future studies) 
 To retrospectively compare the prenatal growth trajectories of fetuses of high-intake ewes 
eventually categorised as FGR or non-FGR and to determine when these become divergent 
3.2 Materials and Methods 
A secondary analysis was performed on the ultrasound data collected from sheep pregnancies 
comprising the control groups for the two main studies detailed within this thesis. Thirty-nine 
ewes were included from the late gestation study (Chapter 4) and consisted of 12 control- and 
27 high-intake pregnancies that were treated with control saline or control vector (Ad.LacZ).  It 
was originally considered that Ad.LacZ might potentially have a detrimental effect of fetal 
growth, as a consequence of adenoviral infection of the uterine circulation in the absence of a 
potentially therapeutic transgene. However, a comparison of high-intake pregnancies treated 
Ad.LacZ versus saline did not reveal any significant differences between these two control 
treatments (see Section 4.2.7). Therefore it was considered valid to include both Ad.LacZ- and 
saline-treated ovenourished (FGR) pregnancies for the secondary analyses detailed herein. 
Additional ultrasound data was collected from three further control-intake ewes that did not 
undergo surgery and inclusion into the main cohort, but whose pregnancies were 
contemporaneously established and nutritionally managed in exactly the same way as their 
operated counterparts. Thirteen high-intake ewes that received control saline in the postnatal 
study (Chapter 5) and which underwent full ultrasound evaluation were also included. 
Pregnancies in either study that received active gene therapy (Ad.VEGF-A165) with the aim of 
altering fetal growth (n=35) were excluded from this subanalysis. 
3.2.1 Establishment of singleton pregnancies and nutritional management 
Oestrus synchronisation of adolescent recipient and adult donor ewes was carried out during 
the mid breeding season (detailed in Section 2.1.1.1). Donor ewes underwent superovulation,  
laparoscopic intrauterine insemination with semen from a single sire (see Section 2.1.1.2) and 
embryo recovery four days later (Section 2.1.1.3). Embryos were synchronously transferred 
into the uteri of the adolescent recipient ewes to generate exclusively singleton pregnancies of 
precisely known gestational age and maximum genetic homogeneity (see Section 2.1.1.4). 
Immediately following the embryo transfer and throughout gestation, adolescent recipient 
ewes received a control- or high-intake of the same complete diet (detailed in Section 2.1.2) to 
generate normal and compromised placental and fetal growth trajectories, respectively. 
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3.2.2 Ultrasound and pregnancy outcome data collection 
Ewes within the late gestation and postnatal studies underwent serial ultrasound examination 
at approximately weekly intervals between 79±0.1 and 133±0.1 days, and between 83±0.1 and 
126±0.3 days gestation, respectively. The following ultrasound parameters were measured or 
caculated as described in Section 2.1.3: abdominal circumerence (AC), trunk diameter (TD), 
biparietal diameter (BPD), occipito-snout length (OSL), renal length (RL), anteroposterior renal 
diamter (APRD), transverse renal diameter (TRD), renal volume (RV); femur length (FL), tibia 
length (TL), placentome index, the deepest vertical pool (DVP) of amiotic fluid, and umbilical 
arterial (UA) maximum (or peak systolic) velocity (Vmax), minimum (or end-diastolic) velocity 
(Vmin), time-averaged maximum velocity (TAMAX), pulsatility index (PI), resistance index (RI) 
and systolic to diastolic ratio (SDR). In addition, the BPD:AC and BPD:FL ratios were determined 
as indices of fetal brain sparing (see Section 1.1.3.4). 
3.2.2.1 Necropsy group 
The 39 pregnancies from the late gestation study (Chapter 4) were necropsied at 131±0.2 days 
gestation, as described in Section 4.2.5. Fetuses were dried and weighed. The biparietal head 
diameter was measured using callipers at the widest point between the two parietal bones. 
Abdominal girth was measured at the level of the umbilical cord insertion and at right angles 
to the spine, taking care to reproduce the same plane each time. Girth was also measured at 
the level of the lowermost rib in an attempt to reproduce the ultrasound AC plane. During fetal 
dissection the femur and tibia were removed, cleared of overlying tissue and the length of the 
shaft of each bone was measured using callipers. All major fetal internal organs were weighed. 
Whole placentomes (fetal cotyledons plus maternal caruncles) were completely dissected from 
the membranes and their combined weight was recorded. Additional ultrasound data from the 
extra 3 control-intake ewes was included in this group for the purpose of assessing longitudinal 
fetal growth velocity however, as these ewes did not undergo necropsy, correlation with post-
mortem measurements was limited to the other 39 ewes. 
3.2.2.2 Delivery group 
The 13 pregnancies in the postnatal study (Chapter 5) were allowed to continue uninterrupted 
and resulted in spontaneous delivery near term (141±0.4 days gestation). One ewe required an 
emergency caesarean section due to cervical dystocia. Lambing was managed according to the 
protocols described in Section 5.2.4. After initial resuscitation (where required), lambs were 
dried and weighed. The abdominal girth at the level of the umbilicus was measured as 
described above. Following delivery the placenta was dissected and weighed. Total fetal 
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Figure 3.2 – Study timeline  
 
Study timeline showing the chronology and synchronicity of 10 different batches of sheep 
pregnancies in which fetoplacental growth was evaluated using transabdominal ultrasound. 
Points at which interim analyses of ultrasound data was performed are indicated. 
 
cotyledon weight was determined and the total fetal placental weight calculated as the sum of 
the fetal cotyledon and residual membrane weights. 
3.2.3 Data analysis 
Ultrasound data was sequentially analysed at three different stages during the course of the 10 
individual batches of pregnancies making up the two main studies for this thesis (Figure 3.2). 
3.2.3.1 First interim analysis 
An initial interim analysis was performed following completion of the first 2 batches of sheep 
experiments in March 2010. At this point simultaneous management of a further 5 batches of 
sheep experiments was about to commence, which meant that the time available for scanning 
was greatly reduced. Consequently it became clear that it would not be feasible to measure 
complete fetal biometry during the second study (batches 4 to 7), as to date this had required 
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approximately 30 minutes per animal per week. Consequently the aim of the first interim 
analysis was to determine which parameters should continue to be measured and which 
should be abandoned. In order to decide this the various fetal biometric parameters were 
ranked on the basis of: 
1. The strength of their correlation with relevant physical measurements at necropsy 
2. The strength of their correlation with fetal body weight at necropsy 
3. The significance level of any differences between control- and high-intake pregnancies 
3.2.3.2 Second interim analysis 
A second interim analysis was performed after completion of the first 7 experimental batches 
in June 2010. At this stage ultrasound data was available for 50% of the necropsy group (n=19) 
and the reference arm of the completed delivery group (n=16), allowing for further correlation 
of the various parameters with physical measurements and necropsy/birth weight, as well as 
the generation of estimated fetal weight equations based on data from fetuses and lambs of a 
wide range of different sizes (range 2622–6260g and 1720–6050g for the necropsy and 
delivery groups, respectively). Comparisons between control- and high-intake groups were 
postponed until the final analysis in view of the relatively unbalanced numbers at this stage 
(n=6 versus n=26, respectively). 
3.2.3.3 Third and final analysis 
After completion of all 10 experimental batches, ultrasonographic fetal growth velocity, UA 
Dopplers and indices of placental size and amniotic fluid volume were compared between 
control-intake and high-intake pregnancies within the necropsy group (n=15 versus n=27, 
respectively). The high-intake pregnancies were further subcategorised into marked FGR or 
non-FGR groups based on whether the necropsy weight fell >2SD below the control-intake 
mean. Ultrasound measurements were compared between marked FGR and non-FGR groups 
to determine at what stage any significant differences became apparent. 
3.2.3.4 Statistical methods 
As this was a secondary analysis of data collected during the two gene therapy studies detailed 
in this thesis, the number of control (untreated) pregnancies available used for these purposes 
was limited by the power calculations for each primary study, which were based on anticipated 
changes in UBF and lamb birth weight, respectively (see Sections  4.2.1 and 5.2.1 for details). 
Nevertheless a retrospective power calculation was made using the parameters which showed 
93 
 
the largest and smallest differences between nutritional treatment (AC and  BPD, respectively) 
based on the maximum variability (SD) at 126 days gestation and the percentage differences 
observed between control- and high- intake pregnancies at this stage. For the BPD, given the 
inter-animal variability of 0.99mm, it was calculated that 7 or 9 animals were needed to detect 
a 3.1% reduction in this measurement (1.7mm) with 80% or 90% power, respectively. For the 
AC, given the inter-animal variability of 8.25mm, it was estimated that only 4 animals were 
required to detect a 8.1% reduction in this measurement (23mm) at both 80% and 90% power. 
All data are presented as mean ± standard error of the mean (SEM) unless otherwise specified. 
Analysis was carried out using the Statistical Package for the Social Sciences (SPSS) versions 
17.0 to 21.0 (SPSS Inc., Chicago, IL, USA). Due to the variable time interval between the final 
detailed ultrasound scan and either necropsy or spontaneous delivery (4.6±1.83 and 8.0±2.49 
days, respectively) a statistical adjustment was made to the necropsy and birth weight in order 
to estimate the fetal weight in utero on the day of the final ultrasound examination. Fetal 
weight was adjusted using the following formula, which was derived from serial necropsy 
studies in late gestation, as previously described (Wallace et al. 2008b): 
Adjusted fetal weight (AFW) = weight at necropsy or birth / 1.01305 per day of gestation 
Ultrasound measurements were correlated with both AFW and actual necropsy/birth weights 
(as well as relevant post-mortem measurements of the fetus) using Pearson's product moment 
test. Limits of agreement were also calculated (where appropriate) by subtracting ultrasound 
measurements from their respective necropsy measurements, and then determining the 95% 
confidence intervals for the mean difference. Comparisons were made between the control-
intake and high-intake groups and marked FGR and non-FGR subgroups using Student's t test. 
In order to generate equations for the estimation of fetal weight, AFW values were first 
logarithmically transformed and plotted against the raw values for each ultrasound parameter 
as this provided the best fit for the data. All possible combinations of five different biometric 
parameters (AC, RV, BPD, FL and TL) as well as their quadratic and cubic terms were entered 
into a multiple parameter model. Stepwise forward and backward regression analyses were 
used to identify the combination of terms providing the highest R2 values and lowest standard 
error of the estimate (SE). The adjusted R2 value was used to determine whether incorporating 
additional parameters genuinely improved the model or not. This is because raw R2 values can 
be increased by simply adding in more independent variables, without any corresponding 
improvement in the goodness of fit. By contrast, increases in adjusted R2 indicate that an 
additional parameter is adding something extra and refining the model, rather than simply 
increasing its complexity. 
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3.3 Results 
3.3.1 Evaluation of ultrasonographic fetal biometry 
3.3.1.1 Interim analysis 1 
Table 3.1 shows the results from the first interim analysis after the completion of the first two 
batches (13 pregnancies in total). Each biometric parameter was assigned a rank according to 
the strength of its correlation with relevant post-mortem measurements, its correlation with 
fetal body weight, and the significance level of the difference between control- and high-intake 
pregnancies (p value corresponding to the respective t value, with 12 degrees of freedom). The 
AC, TD and RV were the parameters with the highest overall ranking. On the basis of these 
preliminary results, the decision was made to omit measurements of BPD, FL and TL for the 
postnatal study cohort (batches 4 to 7), whilst all fetal biometric parameters continued to be 
measured for the remaining batches contributing to the late-gestation study (batches 8 to 10). 
It should be noted that it was not feasible to include the OSL in this evaluation as, although the 
measurement was easy to obtain in mid-gestation, it subsequently became very difficult as the 
pregnancy progressed beyond 0.8 gestation. At 119±0.1 and 126±0.1 days gestation it was not 
possible  to visualise both the occiput and snout in the same plane, hence OSL measurements 
could not be obtained in 8 (62%) and 11 (85%) pregnancies, respectively. Consequently it was 
not appropriate to correlate OSL with post-mortem fetal measurements or fetal body weight, 
or to make any meaningful comparisons between nutritional groups. 
3.3.1.2 Interim analysis 2 - correlation with fetal measurements at necropsy/birth 
Table 3.2 details the correlation of the various ultrasound indices with their respective physical 
measurements and organ weights at necropsy (19 pregnancies in total). In addition limits of 
agreement were determined for ultrasound versus post-mortem fetal measurements where 
the units of measurement were the same (i.e. BPD, TL, FL and AC/girth). The AC demonstrated 
the strongest correlation with post-mortem biometry. An attempt to reproduce the ultrasound 
plane at post-mortem examination when measuring abdominal girth did not improve the level 
of correlation more than that of girth at the level of the umbilicus, which is ultimately a more 
reproducible landmark, and the TD correlated less strongly than the AC for all parameters. 
Although the ultrasound BPD measurement correlated strongly with fetal brain weight, the 
correlation between post-mortem and ultrasound BPD measurements was the least strong of 
all the parameters. The limits of agreement for the BPD included both positive and negative 
values, indicating that it is possible to both over- and under-estimate the BPD by ultrasound.
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Table 3.1 – Comparison of ultrasonographic fetal biometry at 126 days gestation with post 
mortem fetal biometry at 131 days gestation in the first two experimental batches (interim 
analysis 1, n=13 pregnancies) 
Ultrasound 
parameter 
Correlation with 
post-mortem 
measurements 
Correlation with 
fetal weight 
at necropsy 
Difference between 
control- and high- 
intake ewes (t-test) 
Overall 
Rank 
 r value Rank r value Rank  p value Rank  
AC 0.660 1 0.682 1 <0.001 1 1 
TD 0.618 3 0.604 2 0.001 2 2 
RV 0.620 2 0.582 4 0.169 5 3 
BPD 0.533 6 0.602 3 0.070 3 4 
TL 0.586 4 0.524 5 0.357 6 =5 
FL 0.549 5 0.509 6 0.168 4 =5 
 
All correlations shown are statistically significant at p<0.05. Correlations with post-mortem 
measurements as follows: AC and umbilical girth; TD and umbilical girth; RV and renal weight; 
BPD and biparietal head diameter; FL and length of femoral shaft; TL and length of tibial shaft. 
Abbreviations: AC = abdominal circumference; RV = renal volume;  BPD = biparietal diameter; 
TL = tibia length; FL = femur length. Correlations performed using Pearson's product moment 
test. Control and high-intake comparisons made using Student's t-test. 
 
By contrast, limits of agreement for AC, TL and FL were exclusively positive, which was to be 
expected given: (1) the time lapse between ultrasound and necropsy (up to 10 days); and (2) 
that there are systematic differences in the measurements of these parameters on ultrasound 
versus at post-mortem. Notably all limits of agreement were wide, which likely reflects the 
relatively small numbers of animals from which these were generated. 
In the delivery cohort, AC also correlated well with umbilical girth (r=0.776, n=13, p<0.001). No 
ultrasound BPD measurements were available for comparison with neonatal biparietal head 
diameter measurements and it was not feasible to measure femur or tibia length in live lambs. 
3.3.1.3 Interim analysis 2 - correlation with fetal body weight at necropsy/birth 
Table 3.3 details the correlations between the various fetal ultrasound measurements and
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Table 3.2 – Comparison of ultrasonographic fetal biometry at 126 days gestation with post 
mortem fetal biometry at 131 days gestation in the first three experimental batches (interim 
analysis 2, n=19 pregnancies) 
Ultrasound 
parameter 
Measurement  
at post-mortem 
Correlation 
coefficient (r) 
95% limits of 
agreement (mm) 
AC Girth (level of umbilicus) 0.833 22.0 – 104.0 
AC Girth (ultrasound plane) 0.827 14.9 – 78.6 
AC Liver weight 0.799 N/A 
TD Girth (level of umbilicus) 0.801 N/A 
TD Girth (ultrasound plane) 0.794 N/A 
TD Liver weight 0.783 N/A 
BPD Brain weight 0.774 N/A 
RV Renal weight 0.754 N/A 
FL Length of femoral bone 0.747 19.3 – 36.3 
TL Length of tibial bone 0.719 15.0 – 36.0 
BPD Biparietal head diameter 0.654 -13.9 – 50.3 
 
All correlations shown are statistically significant at p<0.001. Abbreviations: AC = abdominal 
circumference; TD = trunk diameter, BPD = biparietal diameter; RV = renal volume; FL = femur 
length; TL = tibia length. Correlations performed using Pearson's product moment test. Limits 
of agreement are provided where paired ultrasound and necropsy parameters have the same 
units of measurement. 
 
necropsy/birth weight (both raw and adjusted values) across both cohorts (n=32). Adjustment 
for time interval marginally improved the correlation for all parameters except the BPD. The 
AC correlated most strongly with fetal weight, followed by RV, whilst BPD correlated least well. 
3.3.2 Estimated fetal weight equations 
3.3.2.1 Interim analysis 2 - generation of regression equations 
Linear stepwise forward and backward regression was used to generate fetal weight equations 
based on the following five parameters: AC, RV, BPD, FL and TL. The OSL was not included here 
given the limitations described above (Section 3.3.1.1) and the TD was excluded in view of its 
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Table 3.3 – Correlations between ultrasonographic fetal biometry at 126/133 days gestation 
and necropsy/birth weight at 131/141 days gestation (interim analysis 2, n=32 pregnancies) 
Ultrasound 
parameter 
Correlation (r) with 
necropsy/birth weight 
Correlation (r) with 
adjusted fetal weight 
AC 0.809 0.839 
RV 0.789 0.800 
TD 0.764 0.791 
FL 0.761 0.766 
TL 0.709 0.714 
BPD 0.672 0.659 
 
All correlations shown are statistically significant at p<0.001. Abbreviations: AC = abdominal 
circumference; RV = renal volume; TD = trunk diameter; FL = femur length; TL = tibia length; 
BPD = biparietal diameter. Correlations performed using Pearson's product moment test. 
 
Table 3.4 – Strongest estimated fetal equations for each fetal ultrasound parameter, based on 
final measurements in late gestation (interim analysis 2, n=32 pregnancies) 
Ultrasound 
parameter(s) 
Regression equation  R2 
 
SE Adjusted    
R2 
BPD Log EFW = 1.2 + 0.044 BPD 0.45 0.079 0.41 
TL Log EFW = 2.502 + 0.014 TL 0.54 0.068 0.51 
FL Log EFW = 2.351 + 0.022 FL 0.63 0.061 0.61 
RV Log EFW = 2.568 + 0.18 RV – 0.007 RV2 0.67 0.072 0.64 
AC Log EFW = – 0.885 + 0.028 AC + 0.00004263 AC2 0.72 0.067 0.70 
AC+RV Log EFW = 2.115 + 0.003 AC + 0.12 RV – 0.005 RV2 0.75 0.064 0.72 
 
Regression equations generated by linear regression. Abbreviations: SE = standard error of the 
estimate; BPD = biparietal diameter; EFW = estimated fetal weight; TL = tibia length; FL = 
femur length; RV = renal volume; AC = abdominal circumference. 
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similarity to the AC but relatively weaker correlation with fetal weight (Section 3.3.1.3). The AC 
and RV both demonstrated a quadratic relationship with log10AFW, whilst the BPD, FL and TL 
demonstrated a linear relationship. Table 3.4 shows the derived formulae and values for each 
individual biometric parameter as well as the strongest multiple-parameter combination. 
Mathematically the AC and RV were the best predictors of fetal weight, both independently 
and in combination with one another. Addition of a third, fourth or fifth biometric parameter 
did not significantly increase the adjusted R2 value beyond that of the two-parameter AC+RV 
model (data not shown). 
3.3.2.2 Interim analysis 2 - accuracy of regression equations (internal validation) 
The three best equations from Table 3.4 were subsequently applied to each individual fetus 
within the data set to generate an estimated fetal weight (EFW) value. Each of these estimates 
was compared with both the raw necropsy/birth weight (NBW) and the AFW to determine the 
prediction error, both as an absolute value (in g) and as a percentage of actual weight. These 
results are shown in Table 3.5. Each error was taken as a positive value for the purposes of 
calculating the mean and SEM. In addition, the proportion of estimates falling within 5, 10, 15, 
20 and 25% of the actual values were determined, and the correlation between NBW/AFW and 
EFW was examined. Prediction error for each equation was compared using one-way ANOVA. 
There were no statistically significant differences in performance between the three estimated 
fetal weight equations, although the combined AC+RV equation produced the lowest errors. 
The two strongest parameters (AC and RV) were further evaluated by comparing the necropsy 
and delivery groups, which differed by a week in the gestational age at the final ultrasound 
examination (126±0.1 and 133±0.1 days gestation, respectively). The correlation between 
AC/RV, AFW and the absolute prediction error of each regression equation were determined 
separately for the necropsy and delivery groups and are shown in Table 3.6. The AC 
demonstrated a stronger correlation with fetal weight at 126±0.1 compared with 133±0.1 days 
gestation, whilst the RV showed the opposite trend. However differences in absolute 
prediction error between the three equations were not statistically different between groups. 
A further analysis was performed to determine whether or not the prediction error of these 
equations varied at the extremes of fetal weight. Overall, NBW was weakly correlated with 
mean prediction error using the AC (r=0.533, p=0.02) but not the RV or AC+RV equations 
(r=0.095 and 0.147 respectively). Fetuses were stratified into 4 birth weight quartiles according 
to unadjusted NBW (n=8 each). The mean absolute prediction errors for the AC, RV and AC+RV 
combined equations were calculated for each group and the results are shown in Figure 3.3. 
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Table 3.5 – Performance of the three strongest fetal weight estimation equations, based on 
final ultrasound measurements in late gestation (interim analysis 2, n=32 pregnancies) 
Ultrasound parameter(s) RV AC AC + RV 
Adjusted fetal weight: 
Mean absolute prediction error (g) 458 ± 54.4 470 ± 63.2 396 ± 53.5 
Mean percentage prediction error 13.2 ± 1.8% 12.4 ± 1.4% 11.1 ± 1.4% 
Correlation (r) – EFW versus AFW 0.809 0.833 0.856 
Estimates within 5% 18.8% 15.6% 28.1% 
Estimates within 10% 46.9% 40.6% 50.0% 
Estimates within 15% 68.8% 68.8% 71.9% 
Estimates within 20% 81.3% 87.5% 84.4% 
Estimates within 25% 90.6% 90.6% 96.9% 
Necropsy/birth weight: 
Mean absolute prediction error (g) 576 ± 69.4 656 ± 94.4 550 ± 75.6 
Mean percentage prediction error 14.1 ± 1.6% 15.4 ± 1.8% 13.2 ± 1.6% 
Correlation (r) – EFW versus NBW 0.797 0.802 0.835 
Estimates within 5% 18.8% 15.6% 28.1% 
Estimates within 10% 37.5% 25.0% 37.5% 
Estimates within 15% 53.1% 46.9% 65.6% 
Estimates within 20% 75.0% 75.0% 78.1% 
Estimates within 25% 87.5% 84.4% 81.3% 
 
Abbreviations: RV = renal volume; AC = abdominal circumference; EFW = estimated fetal 
weight; AFW = adjusted fetal weight; NBW = necropsy/birth weight. Data presented as mean ± 
SEM. Correlations performed using Pearson’s product moment test. 
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Table 3.6 – Performance of AC, RV and AC+RV estimated fetal weight equations according to  
gestational age at ultrasound assessment - necropsy versus delivery cohorts (interim analysis 2, 
n=32 pregnancies) 
Ultrasound 
Parameter(s) 
Correlation coefficient (r) Absolute Prediction Error (g) 
 Necropsy 
Groupa 
Delivery 
Groupb  
All Necropsy 
Groupa  
Delivery 
Groupb 
All 
AC 0.852 0.776 0.839 455 ± 63.7 490 ± 128.2 470 ± 63.2 
RV 0.725 0.869 0.800 516 ± 68.7 374 ± 86.4 458 ± 54.4 
AC+RV    398 ± 63.6 392 ± 96.5 396 ± 53.5 
 (a) Fetuses in the necropsy group were scanned at ~126 and necropsied at ~131 days 
gestation. (b) Lambs in the delivery cohort were scanned at  ~133 and delivered at ~141 days 
gestation. Mathematical corrections were made for the interval between the day of ultrasound 
scan and day of necropsy/birth, as described in Section 3.2.3.4. Abbreviations: AC = abdominal 
circumference; RV = renal volumes. Data presented as mean ± SEM.  Correlations performed 
using Pearson's product moment test. 
 
Groups were compared using one-way ANOVA. Post-hoc pairwise comparisons (test of LSD) 
between the highest and lowest quartiles demonstrated a significantly higher error using the 
AC-only equation in the largest fetuses (670±60.7g versus 300±44.7g, respectively, p=0.036). 
There were no other significant differences between quartiles and prediction error associated 
with the RV-only and the AC+RV equations was broadly similar across the full range of NBW. 
3.3.2.3 Final analysis - accuracy of regression equations (external validation) 
It is well recognised that mathematical models perform significantly better within the dataset 
from which they are derived and should therefore be externally validated in a separate dataset 
(Harrell et al. 1984). Accordingly, upon completion of the final 3 batches, performance of the 
hitherto strongest equation (AC+RV) was examined again in this completely new cohort of 23 
pregnancies, comprised of 9 control- and 16 high-intake ewes with necropsy weights ranging 
from 3190 to 5996g. The resultant prediction errors are presented in Table 3.7 and compared 
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Figure 3.3 – Performance of AC/RV estimated fetal weight equations by birth weight quartile 
 
Bar chart comparing the mean prediction errors of 3 different estimated fetal weight equations 
by necropsy/birth weight quartile for 32 fetuses of singleton-bearing adolescent dams. 
Equations were derived from the abdominal circumference (AC, closed bars), renal volume (RV, 
open bars) or AC+RV combined (hatched bars). Mean prediction error was significantly greater 
for the AC-only equation when comparing the largest (b) versus smallest (a) fetuses  (p=0.036). 
 
against those from evaluation within the original dataset. There were no statistically significant 
differences between the degree of precision in the two different datasets and the magnitude 
of error was broadly similar between them. 
3.3.3 Fetal growth velocity 
Serial measurements of AC, TD, BPD, OSL, RL, TRD, APRD, RV, TL and FL were plotted against 
gestational age and compared between control- and high-intake ewes at each time point using 
Student's t test to characterise the temporal pattern of fetal growth restriction induced by 
overnourishment of the adolescent ewe. 
3.3.3.1 Abdominal circumference and trunk diameter 
Figure 3.4A shows serial measurements of the AC between 83±0.1 and 126±0.3 days gestation.
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Table 3.7 – Comparison of AC+RV equation performance in 2 different datasets (final analysis, 
n=55 pregnancies) 
Dataset  Internal Validation 
Dataset (n=32) 
External Validation 
Dataset (n=23) 
Adjusted fetal weight: 
Mean absolute prediction error (g) 396 ± 53.5 449 ± 61.9 
Mean percentage prediction error 11.1 ± 1.4% 10.6 ± 1.5% 
Correlation (r) – EFW versus AFW 0.856 0.849 
Estimates within 5% 28.1% 26.3% 
Estimates within 10% 50.0% 47.4% 
Estimates within 15% 71.9% 78.9% 
Estimates within 20% 84.4% 89.4% 
Estimates within 25% 96.9% 100.0% 
Necropsy/birth weight: 
Mean absolute prediction error (g) 550 ± 75.6 637 ± 76.5 
Mean percentage prediction error 13.2 ± 1.6% 14.4 ± 1.8% 
Correlation (r) – EFW versus NW 0.835 0.879 
Estimates within 5% 28.1% 10.5% 
Estimates within 10% 37.5% 31.6% 
Estimates within 15% 65.6% 47.4% 
Estimates within 20% 78.1% 68.4% 
Estimates within 25% 81.3% 89.4% 
 
Abbreviations: RV = renal volume; AC = abdominal circumference; EFW = estimated fetal 
weight; AFW = adjusted fetal weight; NW = necropsy/birth weight. Data presented as mean ± 
SEM. Correlations performed using Pearson’s product moment test. 
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Figure 3.4 – Fetal growth velocity: abdominal circumference and trunk diameter 
 
 
Serial ultrasonographic measurements of abdominal circumference [A] and trunk diameter [B] 
(mean ± SEM) from 83±0.1 to 126±0.3 days gestation in singleton-bearing adolescent ewes 
receiving a control (●, n=15) or high-intake (○, n=27) of the same complete diet. * p<0.05, ** 
p<0.01, *** p<0.001 
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At baseline examination there were no significant differences between nutritional groups. By 
98±0.1 days gestation, AC measurements were reduced in high-intake versus control-intake 
pregnancies (198±2.6mm vs. 206±3.6mm, p=0.035) and remained lower at all subsequent time 
points (p<0.001). Unsurprisingly the TD followed a similar pattern to the AC, with significant 
differences observed at the same stages (Figure 3.4B). 
3.3.3.2 Biparietal diameter and occipito-snout length 
Serial measurements of the BPD between 83±0.1 and 126±0.3 days gestation are illustrated in 
Figure 3.5A. Unlike the AC and TD, significant differences between nutritional groups did not 
become apparent until 112±0.1 days gestation, at which point measurements were lower in 
high- relative to control-intake groups (48.1±0.26mm vs. 49.4±0.21mm, p=0.002). Differences 
in the BPD remained significant at 119±0.1 and 126±0.3 days gestation (50.3±0.26mm vs. 
52.2±0.30mm, p<0.001, and 53.0±0.40mm vs. 54.5±0.29mm, p=0.008, respectively). Serial 
measurements of OSL are plotted in Figure 3.5B. Interestingly, differences in OSL by nutritional 
groups were apparent at an earlier stage than for the BPD - measurements were reduced in 
high- versus control-intake groups at 105±0.1 days gestation (95.5±0.64mm vs. 98.8±1.07mm, 
p=0.008) and remained lower at 112±0.1 days gestation (103.0±0.74mm vs. 106.2±0.82mm, 
p=0.013). Thereafter no significant differences were seen, which is most likely a reflection of 
incomplete data secondary to the technical difficulty obtaining this measurement in late 
gestation (highlighted in Section 3.3.1.1). It was not possible to measure OSL in 25 (60%) and 
33 (79%) of these 42 pregnancies at 112±0.1 and 126±0.3 days gestation, respectively. 
3.3.3.3 Renal measurements 
Figures 3.6 and 3.7 illustrate serial measurements of the three individual renal dimensions (RL, 
TRD and APRD) and the calculated values of RV between 83±0.1 and 126±0.3 days gestation. 
As per the other parameters, at baseline there were no significant differences between 
control- and high-intake pregnancies. RV was reduced at 105±0.1 days gestation in fetuses of 
high-intake compared to control-intake ewes (4.4±0.18cm3 vs. 5.2±0.15cm3, p=0.01) and 
measurements remained lower at all subsequent time points (p<0.001) (Figure 3.7B). These 
differences were mirrored in each of the individual parameters contributing to the calculation 
of RV (Figures 3.6A, 3.6B and 3.7A). 
3.3.3.4 Femur length and tibia length 
Serial measurements of the FL and TL from 83±0.1 until 126±0.3 days gestation are shown in 
Figure 3.8. There were no significant differences between nutritional groups at baseline for 
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Figure 3.5 – Fetal growth velocity: biparietal diameter and occipto-snout length 
 
 
Serial ultrasonographic measurements of biparietal diameter [A] and occipito-snout length [B] 
(mean ± SEM) from 83±0.1 to 126±0.3 days gestation in singleton-bearing adolescent ewes 
receiving a control (●, n=15) or high-intake (○, n=27) of the same complete diet. * p<0.05, ** 
p<0.01, *** p<0.001 
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Figure 3.6 – Fetal growth velocity: renal length and transverse renal diameter 
 
 
Serial ultrasonographic measurements of renal length [A], transverse renal diameter [B] (mean 
± SEM) from 83±0.1 to 126±0.3 days gestation in singleton-bearing adolescent ewes receiving a 
control (●, n=15) or high-intake (○, n=27) of the same complete diet. ** p<0.01, *** p<0.001 
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Figure 3.7 – Fetal growth velocity: anteroposterior renal diameter and renal volume 
 
 
Serial ultrasonographic measurements of anteroposterior renal diameter [A] and renal volume 
[B] (mean ± SEM) from 83±0.1 to 126±0.3 days gestation in singleton-bearing adolescent ewes 
receiving a control (●, n=15) or high-intake (○, n=27) of the same complete diet. * p<0.05, ** 
p<0.01, *** p<0.001 
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Figure 3.8 – Fetal growth velocity: femur length and tibia length 
 
 
Serial ultrasonographic measurements of femur length [A] and tibia length [B] (mean ± SEM) 
from 83±0.1 to 126±0.3 days gestation in singleton-bearing adolescent ewes receiving a control 
(●, n=15) or high-intake (○, n=27) of the same complete diet. * p<0.05, ** p<0.01, *** p<0.001 
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either parameter. Thereafter FL measurements were the first to show a divergence, and were 
lower in high- relative to control-intake pregnancies at 98±0.1 days (30.2±0.38mm vs. 
31.7±0.51mm, p=0.029). Differences in FL remained significant at all further examinations 
(p<0.001–0.038). By contrast, differences in TL did not become apparent until 105±0.1 days 
gestation (50.1±0.54mm vs. 52.3±0.70mm, p=0.016). Whilst measurements remained lower at 
112±0.1 and 119±0.1 days gestation (p=0.012 and p=0.003, respectively), at 126±0.3 days 
gestation the difference between nutritional groups was no longer detectable (p=0.117). 
Measurement of TL technically became more challenging in late gestation as it required 
visualisation of the full length of an increasingly large bone (maximum 84.6mm) in a single 
plane. However, unlike the OSL, measurements of TL were still achievable in 100% of 
pregnancies at 126±0.3 days gestation. 
3.3.4 Ultrasound indices of fetal brain sparing 
Figure 3.9 shows serial measurements of BPD:AC ratios and BPD:FL ratios (calculated from the 
parameters  above) from 83±0.1 until 126±0.3 days gestation. These indices reflect the size of 
the fetal head (largely determined by fetal brain growth) relative to the size of the fetal body, 
the AC being representative of abdominal fat and liver glycogen stores and the FL representing 
skeletal growth and development. In normally developing control-intake pregnancies, BPD:AC 
and BPD:FL progressively fell with advancing gestation, which likely reflects the relatively rapid 
growth of the AC and FL compared to that of the BPD (Figures 3.4A, 3.5A and 3.8A). BPD:AC 
and BPD:FL ratios also fell with increasing gestational age in high-intake pregnancies but were 
seen to lag behind, such that they were significantly higher compared with the control-intake 
group at 105±0.1 days gestation (0.206±0.0016 vs. 0.196±0.0022, p=0.001; and 1.23±0.015 vs. 
1.18±0.013, p=0.001, respectively). With the single exception of the BPD:FL ratio at 112±0.1 
days gestation, both parameters remained elevated in high- relative to control-intake groups 
at all subsequent time-points (p<0.001 to p=0.049). 
3.3.5 Ultrasound indices of placental size and amniotic fluid volume 
Serial measurements of placentome index from 83±0.1 until 126±0.3 days gestation are shown 
in Figure 3.10A. At baseline examination the placentome index was already reduced in high- 
versus control-intake groups (4.0±0.17cm2 vs. 5.2±0.25cm2, p=0.001) and remained lower at all 
subsequent examinations (p<0.001). Measurements of placentome index progressively fell 
with advancing gestation in both groups, in a parallel fashion. Consequently the lines of best fit 
were similar in slope and differed significantly only in their intercept (y=15.3+0.17x+0.0006x2 
and y=12.2+0.14x+0.0005x2 for the high-intake and control-intake pregnancies, respectively). 
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Figure 3.9 – Ultrasound indices of fetal brain sparing 
 
 
Biparietal diameter (BPD) : abdominal circumference (AC) ratios [A] and BPD : femur length (FL) 
ratios [B] (mean ± SEM) as measured by serial ultrasound from 83±0.1 to 126±0.3 days 
gestation in singleton-bearing adolescent ewes receiving a control (●, n=15) or high-intake (○, 
n=27) of the same complete diet. * p<0.05, ** p<0.01, *** p<0.001  
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Figure 3.10 – Ultrasound indices of placental size and amniotic fluid volume 
 
 
Serial ultrasonographic measurements of placentome index [A] and deepest vertical pool of 
amniotic fluid [B] (mean ± SEM) from 83±0.1 to 126±0.3 days gestation in singleton-bearing 
adolescent ewes receiving a control (●, n=15) or high-intake (○, n=27) of the same complete 
diet. * p<0.05, ** p<0.01, *** p<0.001  
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At necropsy at 131±0.3 days gestation, placentome index at 126±0.1 days gestation correlated 
reasonably well with total placentome weight in the high- but not in the control-intake group 
(r=0.685, n=27, p<0.001; and r=-0.201, n=15, p=0.531, respectively). In the high-intake group 
baseline placentome index at 83±0.1 days gestation also correlated, albeit weakly, with total 
placentome weight at 131±0.3 days gestation (r=0.501, n=27, p=0.018). 
Conversely, in the delivery group, total fetal cotyledon weight and total fetal placental weight 
following spontaneous birth near term (141±0.4 days gestation) demonstrated a correlation 
with ultrasound measurements of placentome index at 79±0.1 days gestation (r=0.637, n=13, 
p=0.026; and r=0.626, n=13, p=0.022, respectively) but not thereafter. Unlike in the necropsy 
group, there was no obvious relationship between final measurements of placentome index at 
133±0.1 days gestation and either total fetal cotyledon weight (r=0.218, n=13, p=0.520) or 
total fetal placental weight (r=0.295, n=13, p=0.378) at birth. Placentome index also 
demonstrated strong correlations with necropsy/birth weight. In the delivery group, 
placentome index at 79±0.1 days gestation showed a positive correlation with eventual lamb 
birth weight (r=0.642, n=13 p=0.013) and, whilst the correlation with eventual placental weight 
was lost with advancing gestation, positive correlations with birthweight were maintained 
throughout pregnancy (r=0.660–0.712, n=13, p=0.004–0.011). Likewise within the necropsy 
group, placentome index also correlated with eventual fetal weight at 131±0.3 days gestation 
at all stages of gestation (r=0.481–0.627, n=42, p<0.001–0.009). 
Serial measurements of the deepest vertical pool of amniotic fluid in the necropsy group are 
illustrated in Figure 3.10B. The amount of amniotic fluid decreased with advancing gestation. 
There were no significant differences according to the nutritional allocation at any stage and 
no significant correlations with any other fetal or placental ultrasound parameters were seen. 
In the delivery group, measurements of DVP similarly decreased as pregnancy advanced, from 
3.9±0.11cm at 79±0.1 days gestation to 2.6±0.19cm at 133±0.1 days gestation (p<0.001). 
3.3.6 Umbilical artery Doppler indices 
Figures 3.11 to 3.13 illustrate serial measurements of the UA Doppler indices and the different 
velocities used to calculate them between 83±0.1 and 126±0.3 days gestation. At baseline 
examination UA PI, RI and SDR were already found to be higher in high- versus control-intake 
groups (1.46±0.039 vs. 1.30±0.063, p=0.027; 0.80±0.008 vs. 0.73±0.021, p=0.001; and 
5.17±0.295 vs. 3.72±0.263, p=0.002, respectively, Figures 3.12B, 3.13A and 3.13B). All three 
indices decreased with advancing gestation, however highly significant differences remained 
between nutritional treatments at all subsequent time points (p<0.001–0.004). Examining the
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Figure 3.11 – Umbilical artery Doppler maximum (peak systolic) and minimum (end-diastolic) 
velocities 
 
 
Serial ultrasonographic measurements of umbilical artery maximum (peak systolic) velocity [A] 
and minimum (end diastolic) velocity [B] (mean ± SEM) from 83±0.1 to 126±0.3 days gestation 
in singleton-bearing adolescent ewes receiving a control (●, n=15) or high-intake (○, n=27) of 
the same complete diet. * p<0.05 
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Figure 3.12 – Umbilical artery Doppler time-averaged maximum velocity and systolic to 
diastolic ratios 
 
 
Serial ultrasonographic measurements of umbilical artery time-averaged maximum velocity [A] 
and systolic to diastolic ratio [B] (mean ± SEM) from 83±0.1 to 126±0.3 days gestation in 
singleton-bearing adolescent ewes receiving a control (●, n=15) or high-intake (○, n=27) of the 
same complete diet. ** p<0.01, *** p<0.001 
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Figure 3.13 – Umbilical artery Doppler pulsatility index and resistance index 
 
 
Serial ultrasonographic measurements of umbilical artery pulsatility index [A] and resistance 
index [B] (mean ± SEM) from 83±0.1 to 126±0.3 days gestation in singleton-bearing adolescent 
ewes receiving a control (●, n=15) or high-intake (○, n=27) of the same complete diet. * p<0.05, 
** p<0.01, *** p<0.001 
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individual velocities, Vmax was higher at 83±0.1 and 98±0.1 days gestation in high- versus 
control-intake pregnancies (36.5±1.70 vs. 30.8±2.09 m/s, p=0.046, and 44.9±1.50 vs. 39.8±1.89 
m/s, p=0.044, respectively, Figure 3.11A). As there were no corresponding differences in Vmin 
or TAMAX at these points (Figures 3.11B and 3.12A), this increase in peak systolic velocity is 
likely to have been responsible for the elevated UA, PI and SDR values. There were no 
significant differences in TAMAX between nutritional groups at any stage (Figure 3.12A) and, 
although Vmin was found to be higher at 112±0.1 days gestation in the control- relative to the 
high-intake group (19.0±1.29 vs. 15.7±0.88 m/s, p=0.035, Figure 3.11B), this observation 
appeared to be out of sync with the general pattern and is likely to be artefactual in nature. 
UA Doppler indices were also inversely related to necropsy/birth weight and placental weight. 
In the delivery group, PI demonstrated a strong negative correlation with eventual lamb birth 
weight (r=-0.812, n=13, p=0.014) and total fetal placental weight (r=-0.820, n=13, p=0.001) at 
95.±0.1 and 101±0.1 days gestation, respectively, and these correlations were maintained at all 
subsequent time points (r=-0.606–0.847, p=<0.001–0.022). The equivalent correlations for RI 
and SDR were similar to those seen with the PI (r=-0.737–0.868 and 0.584–0.842, respectively). 
In the necropsy group, UA PI demonstrated a much weaker negative correlation with eventual 
fetal weight in late gestation that was significant only from 83±0.1 until 105±0.1 days gestation 
(r=-0.399–0.420, n=39, p=0.011–0.029). Total placentome and placental weights at necropsy 
also showed a weak inverse relationship with PI at all time points from 98±0.1 days gestation 
onwards (r=-0.316–0.449, n=39, p=0.004–0.048). 
3.3.7 Fetal growth curve modeling 
To further compare the longitudinal fetal growth trajctories between control- and high- intake 
pregnancies, mean and SD measurements of the most important ultrasound parameters (BPD, 
AC, RV, FL, TL, UA PI and placentome index) were plotted against gestational age and subjected 
to mathematical curve analyis using Graphpad Prism® version 5.04 (GraphPad Software Inc., La 
Jolla, CA, USA)  to determine the line of best fit for each individual parameter. Curves for high- 
and control-intake pregnancies were tested separately. The regression line with the strongest 
adjusted R2 value in every case was a quadratic equation of the form:  y = a + b(x) + c(x2), 
where y is the ultrasound parameter under investigation, x is the gestational age, a is the y 
intercept, b is the linear coefficient and c is the quadratic coefficient. The mean and SD of the 
values for a, b and c were calculated and compared between groups. The results are presented 
in Table 3.8. Y intercepts (values of a) for all fetal parameters except FL/RV were significantly 
greater in high- versus control-intake pregnancies, however it must be remembered that this is 
a mathematical extrapolation as the real value of all these measurements at 0 days gestation 
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Table 3.8 – Modeling of fetal growth curves - analysis of regression lines of best fit 
Ultrasound 
parameter 
Coefficient  Control Intake 
(n=15) 
High Intake  
(n=27) 
P Value 
Biparietal  
diameter 
(BPD) 
a -22.1 ± 1.97 -16.1 ± 1.34 0.014 
b 0.84 ± 0.038 0.75 ± 0.026 0.052 
c -0.00182 ± 0.000182   -0.00159 ± 0.000125 0.290 
Abdominal 
circumference  
(AC) 
a -156.7 ± 20.29 -34.1 ± 16.46 <0.001 
b 4.59 ± 0.393 2.24 ± 0.321 <0.001 
c -0.00835 ± 0.001878 0.00140 ± 0.001523 <0.001 
Renal  
volume 
(RV) 
a 12.1 ± 1.21 10.8 ± 0.76 0.344 
b 0.32 ± 0.023 0.26 ± 0.015 0.029 
c 0.00240 ± 0.000112 0.00190 ± 0.000070 <0.001 
Femur 
length 
(FL) 
a 0.2 ± 4.00 8.0 ± 2.21 0.070 
b 0.15 ± 0.078 0.28 ± 0.043 0.120 
c 0.00498 ± 0.000371 0.00526 ± 0.000205 0.476 
Tibia 
length 
(TL) 
a -43.0 ± 5.09 -22.6 ± 2.55 0.003 
b 0.71 ± 0.099 0.33 ± 0.049 0.004 
c 0.00196 ± 0.000471 0.00348 ± 0.000236 0.638 
Umbilical artery 
pulsatility index 
 (UA PI) 
a 5.1 ± 0.22 5.2 ± 0.13 0.678 
b -0.07 ± 0.004 -0.07 ± 0.002 1.000 
c 0.00028 ± 0.000020 0.00028 ± 0.000012 1.000 
Placentome  
Index 
a 15.3 ± 1.22 12.2 ± 0.63 0.017 
b -0.18 ± 0.023 -0.14 ± 0.012 0.096 
c 0.00065 ± 0.000112 0.00051 ± 0.000058 0.226 
Al 
A ll data are presented as mean ± SEM. Abbreviations:  a = y intercept; b = linear coefficient;  c = 
quadratic coefficient (of quadatric best fit lines for each ultrasound parameter) 
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would of course be zero in both groups. However the fact that the intercepts differed between 
nutritional treatment reflects variations in the linear and quadratic components of growth 
(indicated by the b and c values, respectively) and also implies that fetuses of high-intake ewes 
might already be on a slower growth trajectory in mid-gestation, even though no significant 
differences were seen in any parameters when compared by Student's t test at this stage. The 
linear coefficients (values of b) for all fetal parameters except FL were greater in control-intake 
pregnancies, reflecting increased overall growth velocity. Meanwhile the quadratic coefficients 
(values of c) varied between parameters. For BPD, TL and FL values were positive, suggestive of 
a relative acceleration of growth with advancing gestation, and did not differ between control- 
and high-intake pregnancies, implying that retardation of head and long bone growth results 
from a pertubation of linear growth only. C values were also positive for RV, commensurate 
with acceleration of growth, however they were significantly reduced in high- versus control-
intake implying a relative failure of this acceleration of growth in late gestation in addition to 
compromised linear growth. Interestingly, the AC curve for the control-intake pregnancies was 
characterised by negative c values, suggesting a tailing off of growth (or deceleration) towards 
term. This may reflect the fact that these fetuses are probably growing at the maximum rate 
and may become relatively constrained by nutrient supply or uterine capacity in late gestation. 
By comparison, c values for the AC curve in high-intake pregnancies was positive, suggesting a 
relatively more sustained pattern in fetal growth (albeit at a reduced linear rate) without this 
apparent element of constraint. Clearly however these fetuses do not catch up to the normally 
growing controls given the striking differences in ultrasonographic AC measurements and post 
mortem measurements of umbilical girth that are observed between nutritional treatment at 
126 to 131 days gestation. 
3.3.8 Reference charts for fetal growth 
For use in future experiments, normative growth charts were produced for this genotype 
(Scottish Greyface x Dorset Horn) from the serial ultrasound data derived from the 15 normally 
developing (control-intake) pregnancies included herein. The charts were created based on the 
strongest performing abdominal, renal, head and long bone measurements as assessed above: 
AC, RV, BPD and FL, respectively. Regression lines were fitted to sequential values of the mean 
± 2SD for each stage of gestation in order to estimate the reference range in which ~95% of 
normally growing fetuses would be expected to lie. For the AC, BPD and FL the lines of best fit 
were linear, whilst for the RV a quadratic curve was more appropriate. The resultant charts are 
available in Appendices 1 and 2, and are also presented in Figures 3.14 and 3.15, in which the 
prenatal growth trajectory of a single growth-restricted fetus has been plotted to illustrate the
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Figure 3.14 – Reference charts for normal ovine fetal growth: abdominal circumference and 
biparietal diameter 
 
 
Reference charts for normal fetal growth derived from ultrasound measurements of abdominal 
circumference [A] and biparietal diameter [B] from 83±0.1 to 126±0.3 days gestation in 15 
singleton-bearing adolescent ewes receiving a control intake. Lines indicate mean ± 2SD. For 
illustration, the individual growth trajectory of a single growth-restricted fetus, induced by 
overnourishment of its adolescent mother, is plotted (open circles).  
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Figure 3.15 – Reference charts for normal ovine fetal growth: renal volume and femur length  
 
 
Reference charts for normal fetal growth derived from ultrasound measurements of the renal 
volume [A] and femur length [B] from 83±0.1 to 126±0.3 days gestation in 15 singleton-bearing 
adolescent ewes receiving a control intake. Lines indicate mean ± 2SD. For illustration, the 
individual growth trajectory of a single growth-restricted fetus, induced by overnourishment of 
its adolescent mother, is plotted (open circles).  
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practical utility of such charts. The progressive reduction in the growth velocity of this 
particular fetus can be clearly seen. Despite starting with baseline measurements around the 
50th percentile for gestational age at 83 days gestation, forward growth of the AC, RV and FL 
can be seen to diminish resulting in a crossing of centiles. Subsequent measurements of AC 
and RV consistently plotted below the 3rd percentile from ~105 days gestation onwards 
(Figures 3.14A and 3.15A) followed by FL from ~119 days gestation (Figure 3.15B). By contrast, 
growth of the fetal BPD was maintained within the normal range throughout gestation (Figure 
3.14B), commensurate with fetal brain sparing. 
3.3.9 Marked FGR versus non-FGR high-intake pregnancies 
The 27 high-intake pregnancies in the necropsy group were further subcategorised into 
marked FGR (n=17, 63%) and non-FGR (n=10, 37%) groups based on a –2SD cut-off relative to 
the mean fetal body weight in the control-intake group (<4222g). Pregnancies classified as 
non-FGR did not differ significantly from control-intake pregnancies here with respect to fetal 
weight (4824±208g vs. 5084±124g, p=0.248) although total placentome weight was reduced by 
22% (406±26.9g vs. 521±23.8g, p=0.005). By comparison, the markedly FGR group exhibited a 
28% reduction in fetal weight (3639±117g vs. 5084±124g, p=<0.001) as well as a 37% reduction 
in total placentome weight (330±23.8g vs. 521±23.8g, p=<0.001) relative to the control group 
at 131±0.3 days gestation. Ultrasound measurements from each time point in gestation were 
retrospectively compared across all three groups using one-way ANOVA and post-hoc test of 
LSD. There were no significant differences between marked FGR and non-FGR groups in 
placentome index or UA Doppler indices at any stage and no significant differences in fetal 
biometry between groups between 83±0.3 days and 119±0.1 days gestation. However at 
126±0.3 days gestation a number of differences between the two groups were apparent, and 
are summarised in Table 3.9. Measurements of AC, RV, FL and TL were all reduced in marked 
FGR versus non-FGR high-intake groups at this stage (p=0.017, p=0.031, p=0.002 and p=0.038, 
respectively for individual comparisons). Serial measurements of AC in non-FGR high-intake 
relative to control-intake and marked FGR high-intake pregnancies are illustrated in Figure 
3.16 to exemplify the relatively late emergence of measurable differences between these two 
groups of overnourished pregnancies . 
Given that the AC demonstrated the strongest correlation with fetal body weight (see Section 
3.3.1.3) we tested the ability of a –2SD ultrasound cut-off for the AC (approximately equivalent 
to the 3rd percentile and illustrated graphically by the lowermost line on the fetal growth chart 
in Figure 3.14A) to identify fetuses of high-intake ewes destined for the FGR group. By 126±0.1 
days gestation, 15 of 17 fetuses in the marked FGR high-intake group had an AC measurement
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Table 3.9 – Late gestation fetal biometry in marked versus mild FGR high-intake pregnancies 
(final analysis, n=42 pregnancies) 
Ultrasound parameter Control-intake  
(n=15) 
High-intake  
Non-FGR (n=10) 
High-intake  
FGR (n=17) 
P value 
AC (mm) 286 ± 2.1a 270 ± 4.4b 259 ± 2.5c <0.001 
TD (mm) 89.9 ± 0.70a 84.4 ± 1.56b 81.0 ± 0.81c <0.001 
RV (cm3) 10.0 ± 0.28a 8.8 ± 0.51b 7.7 ± 0.2c <0.001 
FL (mm) 59.1 ± 1.07a 59.3 ± 1.26a 54.4 ± 0.69b 0.001 
TL (mm) 76.5 ± 1.10a 76.4 ± 1.23a 72.8 ± 1.11b 0.034 
BPD (mm) 54.5 ± 0.29a 53.9 ± 0.76ab 52.5 ± 0.43b 0.005 
 
Abbreviations: AC = abdominal circumference; TD = trunk diameter; BPD = biparietal diameter; 
RV = renal volume; FL = femur length; TL = tibia length. Mean values within are row with unlike 
superscripts are significantly different (p>0.05). P value shown is for overall ANOVA. Significant 
post-hoc pairwise comparisons are detailed in the text. 
_____________________________________________________________________________ 
below this threshold, giving a sensitivity of 88%. However 5 of 10 the non-FGR overnourished 
pregnancies were also found to have a fetal AC measurement >2SD below the control-intake 
mean, suggesting a relatively poor specificity of just 50%. 
3.4 Discussion 
Firstly, from a practical point of view, this work has demonstrated that it is entirely feasible to 
assess fetal biometry in the fully awake and upright sheep, without having to resort to turning 
the animal supine, as is widely practised in biomedical research settings. It is also notable that, 
due to the nature of this model, overnourished sheep dams became relatively obese as the 
study progressed (see Section 4.3.1.1). This change in body habitus negatively affected the 
quality of the views obtained in proportion with the increasing thickness of the subcutaneous 
fat layer, although it remained feasible to measure complete fetal biometry (excluding OSL) in 
the majority of cases. Ultrasound examination of control-intake ewes was notably much easier 
and required far less vertical pressure on the maternal abdomen to ensure an adequate view 
of the fetus/placenta. 
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Figure 3.16 – Late gestation fetal biometry in marked versus mild FGR high-intake pregnancies 
(final analysis, n=42 pregnancies) 
 
Serial ultrasonographic measurements of abdominal circumference (mean ± SEM) from 83±0.1 
to 126±0.3 days gestation in singleton-bearing adolescent ewes receiving a control (closed 
circles, n=15) or high-intake (open triangles, n=27) of the same complete diet. The latter group 
was subdivided into those culminating in markedly growth-restricted (inverted triangles, n=17, 
defined as fetal weight >2SD below control mean) versus non growth-restricted fetuses (upright 
triangles, n=10). There were no significant differences in AC between marked FGR and non-FGR 
pregnancies except where indicated by the asterix. * p<0.05 
_____________________________________________________________________________ 
3.4.1 Fetal biometry 
Longitudinal ultrasound assessment of control- and high-intake adolescent sheep pregnancies 
has provided novel insights into both the timing and the pattern of FGR in this experimental 
paradigm. Despite the early differences in placentome index and UA Doppler indices, the first 
evidence of compromised fetal growth per se was a reduction in the AC and FL at 98 days 
gestation, followed by deviations in RV and TL at 105 days gestation. Meanwhile growth of the 
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fetal BPD was relatively well preserved until 112 days gestation, commensurate with fetal 
brain sparing (see Section 1.1.3.4). 
3.4.1.1 Abdominal circumference 
Overall our findings indicate that the AC is the strongest individual parameter amongst those 
investigated. In obstetric practice the AC is widely considered to be the most useful individual 
marker of fetal growth (Degani 2001) and it would appear that the same is true for the sheep, 
at least in late gestation. The AC is generally considered to be the parameter that best reflects 
fetal nutritional status as it is measured at the level of the intrahepatic portion of the umbilical 
vein and hence it potentially represents both subcutaneous fat and liver glycogen stores. The 
latter assumption is supported by the strong correlation seen here between the AC and fetal 
liver weight (p<0.001). The AC was the parameter that correlated most strongly with physical 
measurements of abdominal girth taken from fetuses at late gestation necropsy and at birth 
from live lambs. Measurements of girth at the level of the umbilicus or the lowermost rib were 
consistently greater than their respective ultrasound AC measurement, possibly due in part to 
lung inflation. The AC also correlated strongly with necropsy/birth weight (r=0.81–0.84) to a 
degree that is similar to that observed in humans, as illustrated by a clinical validation study 
(Nahum & Stanislaw 2003) which demonstrated that the correlation between birth weight and 
AC (r=0.78) was stronger than the HC, BPD and FL (r=0.65, 0.58 and 0.52, respectively). 
The AC was also the first parameter (together with the FL) to exhibit significant differences 
between control- and high-intake pregnancies, which were manifest from 98 days gestation 
onwards. Ultrasound studies of longitudinal fetal growth velocity in the hyperthermia sheep 
model of FGR also found the AC to be the first parameter to be reduced relative to normally 
growing controls, from as early as 73 days gestation (Barbera et al. 1995a; Galan et al. 1999). 
3.4.1.2 Renal volume 
In this thesis renal volume has been introduced as a promising marker of fetal growth in the 
sheep. Previous work using ultrasound at a single time point in this model of FGR 
demonstrated that renal length x width correlated well with renal weight (r=0.71) and fetal 
body weight (r=0.77) at 0.9 gestation (Bourke et al. 2002). The addition of a third renal 
dimension, thereby allowing the calculation of renal volume, has further improved the 
correlations with both renal weight (r=0.75) and fetal body weight (r=0.79). It is notable that 
renal weight correlates strongly with fetal body weight in both control-intake and high-intake 
pregnancies (r=0.90, p<0.001). This is a reflection of the fact that the ratio of renal weight to 
fetal body weight is not altered by the degree of growth restriction in this FGR paradigm, such 
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that relative renal weight (per kg fetus) is unchanged (Wallace et al. 2000). Furthermore, serial 
slaughter studies in this model have shown that relative renal weight remains constant 
throughout the second half of pregnancy, irrespective of nutritional manipulation (10.41g/kg 
at 0.5, 10.38g/kg at 0.6 and 10.71g/kg at 0.7 gestation, n=22 per stage, JM Wallace and RP 
Aitken, unpublished data). Reductions in renal weight are similarly proportionate to overall 
body weight in the carunclectomy, hyperthermia, umbilico-placental embolisation and single 
umbilical artery ligation sheep models of FGR (Williams et al. 2002; Mitchell et al. 2004; 
Limesand et al. 2006; Supramaniam et al. 2006). These observations suggest that the RV might 
be a good surrogate marker of fetal weight at earlier gestations and lends it credibility as a 
parameter to track longitudinal fetal growth. The same may not be true in human FGR, as 
there is some evidence that growth-restricted fetuses have proportionately smaller kidneys 
than appropriate-for-gestational-age fetuses (Silver et al. 2003). However it has been 
demonstrated in human fetuses that the ratio of the renal volume to estimated fetal weight 
(calculated using AC, BPD and FL measurements) remains constant throughout gestation 
(Gloor et al. 1997). 
Differences in RV between nutritional groups did not become apparent until slightly later than 
the AC, from 105 days gestation. This may be due in part to the greater variability associated 
with this particular measurement, given its cubic (as opposed to linear) nature. Furthermore 
intuitively reductions in RV would not be expected to manifest until there had been a degree 
of substrate deficiency severe enough to impact the growth and development of the major 
internal organs. This potentially renders it slightly less sensitive than the AC as a longitudinal 
marker of growth, although it may have a complementary role as a predictor of fetal weight 
(see Section 3.4.2). We have not strictly validated the use of renal measurements as markers 
of fetal growth prior to mid-gestation here, however the ovine fetal kidney is identifiable on 
ultrasound from as early as 40 days gestation, and the ovine renal length demonstrates a 
linear growth pattern (Ward et al. 2006). By contrast, human renal length and renal volume 
both demonstrate a logarithmic pattern of growth according to published growth charts of the 
fetal kidney during normal pregnancy (Chitty & Altman 2003). However, as already mentioned, 
measurement of the renal volume in human fetuses is usually carried out during the 
assessment of suspected renal pathology rather than to evaluate fetal growth per se in current 
clinical practice. 
3.4.1.3 Femur/tibia length 
It has previously been suggested that TL might be a better marker of longitudinal fetal growth 
in fetal sheep than FL because it demonstrates a greater acceleration in growth with advancing 
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gestation (Barbera et al. 1995b). However we consistently found that FL performed better than 
TL as a marker of fetal growth. In late gestation FL correlated better with necropsy 
measurements and fetal body weight than TL. With respect to longitudinal fetal growth 
velocity, FL was impacted by prenatal nutrition at an earlier stage than TL, being significantly 
reduced in the fetuses of high-intake ewes from 98 days gestation, whilst TL measurements 
did not differ significantly until 105 days gestation. Furthermore TL was the only parameter for 
which significant differences did not remain at 126 days gestation. The latter is likely to reflect 
difficulties in measuring TL in late pregnancy rather than an acceleration in growth because 
subsequent necropsy measurements of the tibial shaft differed significantly between 
treatment groups (p=0.003). In late gestation the tibia was technically more difficult to identify 
and measure than its proximal counterpart. Often the fetal legs were tucked under the 
abdomen, making it harder and more time-consuming to identify the tibia than the femur, the 
proximal end of which could systematically be located via the fetal bladder and pelvic girdle. In 
addition the tibia is a longer bone than the femur and can measure over 100mm in length at 
term (Barbera et al. 1995b). It became increasingly difficult as pregnancy progressed to 
confidently visualise the entire bony shaft in a single plane to ensure accurate measurement. 
Post-mortem measurements of FL and TL were consistently greater than their respective 
ultrasound measurements, which is unsurprising because only the calcified shaft of each bone 
is visualised on ultrasound, whereas the necropsy measurements include additional bony and 
cartilaginous elements. 
3.4.1.4 Head measurements 
Although it was possible to measure OSL in mid-pregnancy, by late gestation it was extremely 
difficult to visualise both the occiput and snout in the same plane and consequently it was not 
possible to obtain this measurement for the majority of examinations. Although quantification 
of BPD was relatively feasible, this measurement demonstrated the poorest overall correlation 
with post-mortem biometry. This would initially seem to contradict the findings of an earlier 
study that demonstrated a very strong correlation (r=0.99) between ultrasound and necropsy 
measurements of the BPD (Ward et al. 2006). However this group included specimens covering 
a wide range of gestational ages (40–140 days gestation), whereas here we have investigated 
variability in fetal size at a single point of gestation. Moreover 60% of the pregnancies studied 
by Ward et al. (2006) were twin gestations, which are more likely to be associated with smaller 
fetuses and greater variation in fetal lie relative to the cervix. The latter is relevant because 
satisfactory views were harder to obtain for the BPD than the other parameters when the fetal 
head was low in the pelvis. Conversely, with the fetus in breech presentation it was relatively 
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easy to obtain the BPD measurement, but more difficult to visualise the lower limbs. 
Limits of agreement indicated that ultrasound could both over- and under-estimate the BPD. 
Unlike TL, FL and AC, which are systematically greater at necropsy than on the ultrasound scan, 
ultrasonographic BPD measurements should theoretically differ from necropsy measurements 
only by the thickness of the periosteum and overlying skin. The difficulties in measurement of 
the BPD in late gestation with a cephalic presentation (described above) may have affected its 
accuracy. It is known that variable extrinsic compression of the fetal head can distort the 
human BPD measurement and for this reason it is not recommended as a marker of fetal 
growth in UK obstetric practice, the HC being preferred (Loughna et al. 2009). 
3.4.1.5 Fetal brain sparing effect 
As discussed in Section 1.1.3.4, FGR secondary to uteroplacental insufficiency is characterised 
by  fetal brain sparing, a phenomenon in which fetal brain growth is prioritised at the expense 
of fetal body growth. This usually indicates an adaptive response to reduced substrate supply, 
and results in an asymmetrical growth pattern (Halliday 2009). The fetuses of overnourished 
adolescent dams demonstrate increased ratios of biparietal head diameter to umbilical girth 
and higher fetal weight specific brain weights (Wallace et al. 2000; Wallace et al. 2002), 
commensurate with fetal brain sparing. Serial ultrasound has further characterised the pattern 
of asymmetrical growth in this paradigm of FGR. Indices of fetal body growth (AC and FL) were 
diminished from 98 days gestation onwards in high-intake versus control-intake pregnancies, 
whilst growth of the BPD was maintained until 112 days gestation. Consequently ultrasound 
markers of fetal brain sparing (BPD:AC and BPD:FL ratios) were significantly increased in the 
overnourished pregnancies. 
3.4.2 Fetal weight estimation 
A number of novel estimated fetal weight equations for sheep pregnancy have been presented 
and validated (both internally and externally) in this chapter. The three strongest equations 
were derived from the AC and RV (separately and in combination), which also happened to be 
the most accurately measured and sensitive longitudinal biometric parameters (Section 3.4.1). 
In clinical practice, the AC is widely considered to be the best single predictor of fetal weight 
(Smith et al. 1997; Kiserud & Johnsen 2009). We also found that the RV performed well in the 
estimation of fetal weight, both independently and in combination with the AC. However, 
incorporation of additional biometric parameters (FL, TL and BPD) did not improve the model 
any further. Although no further increase adjusted R2 values was achieved, interestingly 
128 
 
addition of FL increased unadjusted R2 values more than TL in all instances, providing further 
evidence that FL is indeed the better marker of fetal growth. Furthermore these two long bone 
measurements were not synergistic in this respect, as addition of both to the regression model 
actually decreased the unadjusted R2 values. BPD also performed poorly in the estimation of 
fetal weight. This is unsurprising because growth of the fetal head is relatively well preserved 
due to fetal brain sparing, which would be expected to distort the normal biological 
relationship between BPD and fetal weight.  
For the purposes of fetal weight prediction, comparison of the AC and RV equations suggested 
that these parameters may have relative advantages and disadvantages depending on overall 
fetal size and gestational age. In humans the absolute prediction error of the AC is known to 
increase with advancing gestation and fetal weight, whilst the percentage error remains fairly 
constant across a wide range of birth weights (Campbell & Wilkin 1975). In practice this means 
that inaccuracies in weight estimation are greatest in larger babies. After stratifying our data 
into weight quartiles we demonstrated a similar pattern for the AC in these sheep, specifically 
a trend towards increased error with higher birth weight and a significant difference in mean 
error between the highest and lowest quartiles (p=0.036). Meanwhile the mean error using 
the RV equation was relatively consistent across the full range of birth weights. With respect to 
gestational age, subgroup analysis at 126±0.1 versus 133±0.1 days gestation revealed that AC 
correlated better with fetal weight at the earlier time point, whilst RV correlated better at the 
later time point. We observed that resolution of the kidney generally improved with advancing 
gestation, possibly as a result of increasing perirenal fat deposition providing a better contrast. 
Consequently by late pregnancy the RV was both technically easier to measure and less prone 
to orientation error than the AC, which tended to become less circular due to external forces 
on the fetal body and was influenced by a variable degree of rumen distension approaching 
term. This may partially explain why the RV appears to be a better predictor of weight in larger 
fetuses and closer to full term. Realistically no definitive conclusions can be made from these 
observations in such a small number of pregnancies, and ultimately there were no statistically 
significant differences in mean prediction error between equations including one (AC or RV) or 
two (AC+RV) parameters. However it would seem appropriate to include both AC and RV in the 
estimation of fetal weight using the combined equation as this potentially takes the above 
trends into account. The mean prediction error using the AC+RV equation was equivalent at 
both 126±0.1 and 133±0.1 days gestation (398 and 392g, respectively) and in both the highest 
and lowest weight quartiles (367 and 339g, respectively). 
The estimated fetal weight equations presented herein are the first of their kind for sheep
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pregnancy. Equivalent formulae for clinical use in the human are usually generated using 
verylarge populations to ensure adequate precision. Nevertheless, despite being derived from 
a relatively small number of sheep pregnancies, the correlations with necropsy or birth weight 
and the prediction errors of these sheep-specific equations were remarkably similar between 
the internal and external validation datasets. The high level of maternal genetic homogeneity 
within each of these datasets and the identical paternal genetics across both (single sire) may 
have had an impact here, and it would be informative to test out these equations in a more 
genetically diverse group of fetuses and/or different sheep breed. Incidentally the correlations 
with fetal weight and mean prediction errors of the three strongest equations (r=0.80–0.90 
and 362–656g, respectively) are similar in magnitude to those reported in a clinical study by 
Nahum and Stanislaw (2003) that evaluated the performance of 25 different fetal weight 
equations (r=0.76–0.79 and 263–646g). This suggests that the inevitable degree of inaccuracy 
associated with fetal weight estimation is broadly similar between the sheep and the human. It 
is of interest that, of the 25 equations evaluated, 24 included the AC as a parameter and they 
also failed to demonstrate any significant differences in performance between those equations 
incorporating multiple parameters and those derived from the AC alone. 
3.4.3 Assessment of placentation 
Despite the lack of significant differences in fetal biometry at baseline ultrasound examination, 
we found that ultrasound indices of placental size were already attenuated at the point of the 
first ultrasound examination (83 days gestation) between control- and high-intake ewes. This 
observation was unexpected, as previous studies in which pregnancies were terminated at 80 
to 90 days gestation have not shown any differences in total placentome wet weight by this 
stage (Redmer et al. 2005; Redmer et al. 2009). However there is certainly evidence of altered 
placental vascular development and secretory function by mid-pregnancy (see Section 1.1.5.2) 
in overnourished adolescent pregnancies. Putative alterations in placental density, possibly 
due to compensatory changes in placental vascularity or differences in carbohydrate 
metabolism and water content (Redmer et al. 2009), might explain the lack of a difference in 
weight per se despite obvious differences in ultrasonographic appearances and indices of size 
mid-gestation.  
To date very few other studies have assessed ovine ultrasonographic placental biometry. Doize 
et al. (1997) evaluated transrectal measurements of the placentome diameter as a method of 
pregnancy dating in sheep and goats. Selecting between 2 and 5 average-sized placentomes, 
they demonstrated a rapid increase in placentome diameter up until 70–90 days gestation. 
Placentome measurements correlated with gestational age in does but not ewes and the 
130 
 
authors concluded that placental biometry was unsuitable for dating sheep pregnancies.  
Kaulfuss et al. (1998) used transrectal ultrasound to measure the maximum diameter of 10 
representative placentomes in four different breeds of sheep. They similarly observed that 
placentome dimensions reached a peak in mid-gestation and declined thereafter. This is 
consistent with the trends seen herein in both control- and high-intake ewes as well as the 
findings of serial slaughter studies in normal sheep pregnancy which indicate that placental 
weight peaks at around 80 days gestation (Robinson et al. 1977), shortly following the apex of 
placental proliferation at 77 days gestation (Ehrhardt & Bell 1995). The positive correlations 
between ultrasonographic placentome index from mid-gestation and total placentome weight 
in late gestation suggest that the early identification of compromised placentae by ultrasound 
is feasible. Moreover the positive correlation between placentome index at various stages and 
eventual fetal weight reinforces the observation that it is placental size per se which provides 
the major constraint to fetal growth in overnourished adolescent ewes (Wallace et al. 2006a). 
In keeping with this assumption, necropsy/birth weight was strongly correlated with placental 
weight, irrespective of nutritional manipulation (r=0.901, n=55, p<0.001). 
3.4.4 Umbilical artery Dopplers 
We observed that UA Doppler indices were already significantly increased by 83 days gestation 
in high-intake versus control-intake pregnancies and remained so through to late gestation. In 
normally developing sheep pregnancies UA Doppler indices decline with advancing gestation, 
with the most rapid fall in values between 66 and 109 days gestation (Newnham et al. 1987). 
Between 109 and 139 days gestation, earlier studies in chronically instrumented normal sheep 
pregnancy have shown that UA PI, RI and SDR continue to fall progressively and that all three 
correlate positively with directly measured umbilical vascular resistance and negatively with 
both umbilical and placental blood flow (Irion & Clark 1990a; Acharya et al. 2004). At ~133 
days gestation, growth-restricted pregnancies of overnourished adolescent ewes are 
characterised by a 37% reduction in umbilical blood flow, measured directly using the Fick 
principle (Wallace et al. 2002). It seems logical that the observed UA Doppler changes reflect 
either this reduction in absolute blood flow and/or putatively increased downstream vascular 
impedance to blood flow. Although umbilical blood flow has not been directly assessed using 
the same method in mid-gestation, measurement of uterine blood flow using indwelling flow 
probes has shown a 42% reduction relative to control-intake pregnancies as early as 88 days 
gestation (Wallace et al. 2008b). As umbilical and uterine blood flows are generally closely 
matched, at least in late gestation (Wallace et al. 2002), it is likely that a corresponding 
reduction in umbilical flow does exist in mid-gestation in the overnourished dams, especially 
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given the striking differences in UA Doppler indices seen here at 83 days gestation. One means 
of further investigating this non-invasively would be to measure vessel diameter and absolute 
velocities (requiring correction for the angle of insonation) in order to calculate volume blood 
flow, although the precision of this method has been questioned, at least with respect to 
uterine artery Doppler blood flow assessment (Abi-Nader et al. 2010). UA Doppler indices have 
been measured previously in two other established sheep models of FGR. Indices were found 
to be increased from 80 to 135 days gestation following maternal hyperthermia (Galan et al. 
1998; Galan et al. 2005; Barry et al. 2006), an intervention which has been shown to reduce 
absolute umbilical blood flow in late pregnancy (Thureen et al. 1992). By contrast, Doppler 
indices were not influenced by premating carunclectomy (Giles et al. 1989), which appears to 
restrict fetal growth via a reduction in total placentome number in the absence of specific 
effects on the fetoplacental circulation. 
Numerous other research groups have evaluated UA Dopplers in ovine pregnancies using 
internal or external Doppler probes or the inbuilt Doppler functionality of modern ultrasound 
machines. Correlations between UA Doppler indices, blood flow and resistance are maintained 
following maternal phenylephrine infusion (Acharya et al. 2004), progressive downstream UA 
constriction with ligatures (Maulik et al. 1989) and both acute and chronic placental 
embolization (Nimrod et al. 1989; Adamson et al. 1990; Muijsers et al. 1990; Gagnon et al. 
1994; Acharya et al. 2004). Terminal placental embolization studies in the sheep illustrate a 
progressive reduction in end-diastolic blood flow (reflected by increasing UA Doppler indices) 
following by absent and finally reversed end-diastolic flow shortly prior to fetal demise 
(Morrow et al. 1989). A similar sequence of changes is observed in human FGR (Baschat 2010).  
Both increased UA PI and reversed end-diastolic flow can also be experimentally induced by 
progressive umbilical venous compression (Fouron et al. 1991), an effect which is not 
ameliorated by maternal oxygen administration (Sonesson et al. 1993). Hence whilst there is 
strong evidence that UA Doppler indices reflect both umbilical blood flow and downstream 
fetal placental resistance, whether they additionally indicate fetal hypoxaemia is less clear. 
Indeed hypoxia induced by occlusion of the maternal common iliac artery (Muijsers et al. 
1990), epidural-induced maternal hypotension (Erkinaro et al. 2006) and reducing the oxygen 
content of inspired air (Morrow et al. 1990) have no effect on the UA waveform in spite of a 
slight increase in placental vascular resistance following the latter (van Huisseling et al. 1991b). 
By contrast, (Downing et al. 1991) demonstrated an increase in UA SDR, PI and RI during 
periods of hypoxaemia but concluded these changes may have been primarily due to effects 
on the fetal heart rate.  
132 
 
It is also less clear whether pharmacologically induced changes in fetal haemodynamics have 
significant effects on UA Doppler indices. No changes were demonstrated following increases 
in umbilical artery resistance (Adamson et al. 1990) using angiotensin II infusion or in fetal 
arterial hypertension induced by norepinephrine delivery (van Huisseling et al. 1991a), 
whereas infusion of the nitric oxide synthase inhibitor N-omega-nitro-D-arginine (Giles et al. 
1997) or the thromboxane analogue U-46619 (Trudinger et al. 1989; Irion and Clark 1990b), 
and maternal nicotine administration (Arbeille et al. 1992) increase UA PI, SDR and RI, 
respectively. In addition, UA Doppler indices are increased in ovine pregnancy-induced 
hypertension (Keith et al. 1992) and in fetal hypovolaemia but not fetal hypervolaemia (van 
Huisseling et al. 1992) or following isovolumic increases in red cell mass (Teyssier et al. 1998). 
The variable responses to a range of different biological conditions clearly illustrate the highly 
dynamic nature of UA Doppler indices as measurements, and this should be borne in mind 
when interpreting results. 
It is interesting that we observed a close negative correlation between UA Doppler indices in 
mid-pregnancy and eventual fetal and placental weights in late gestation. In contemporary 
obstetric practice umbilical artery Dopplers are widely used as the primary surveillance tool for 
pregnancies complicated by FGR (Baschat 2010), however a correlation with birth weight per 
se has not to my knowledge been reported in either humans or animals. In combination with 
similar findings for the placentome index (see Section 3.4.3), this suggests that ultrasound may 
have a role in identifying poor placentation and/or high resistance to fetoplacental blood flow 
as antecedents of the reduction in fetal growth velocity during the final third of gestation. 
3.4.5 Prediction of marked FGR 
Despite the promising correlations between mid-gestation placental biometry and UA 
Dopplers and eventual fetal weight described above, attempts at early identification of fetuses 
destined to become markedly FGR in late gestation using ultrasound markers was relatively 
disappointing. Markedly FGR and non-FGR high-intake pregnancies did not differ from one 
another with respect to placental biometry or UA Doppler indices at any stage of pregnancy. 
Furthermore no differences in fetal biometry between these two groups were detected 
between 83 and 119 days gestation. Rather it was only when examined at 126 days gestation 
that significant differences in any fetal measurements became apparent. This is perhaps 
unsurprising as by 121 days gestation the fetus has only achieved ~70% of its final weight 
(Figure 3.1), irrespective of nutritional group.  Hence whilst differences between control- and 
high-intake pregnancies begin to emerge at 98 days gestation, more subtle differences within 
the overnourished group would intuitively be harder to detect. It appears that despite an initial 
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reduction in placental biometry and increased UA Doppler indices relative to control-intake 
pregnancies, non growth-restricted fetuses of high-intake ewes are subsequently subjected to 
a lesser degree of placental constraint during the exponential period of fetal growth compared 
with their FGR counterparts. This assumption is reinforced by the significant differences 
between the two groups in total placentome weight observed at 131 days gestation. Given 
their significantly greater placental mass it is likely that overall placental transport capacity is 
relatively preserved in the late gestation mildly growth-restricted high-intake pregnancy at a 
time when the supply of nutrients from the maternal circulation is plentiful secondary to 
overnutrition, which consequently allows the fetus to thrive. The placenta has a certain 
intrinsic reserve capacity, and we have consistently observed that placental growth needs to 
be restricted by >20% before it significantly impacts fetal growth (Wallace et al. 2004b); JM 
Wallace, unpublished data) and this is consistent with estimates derived from experiments 
involving mid-pregnancy placentome ablation (Mellor et al. 1977). In spite of the lack of early 
differences between marked FGR and non-FGR high-intake pregnancies, fetal biometry 
nonetheless performed well in the identification of the most compromised pregnancies in late 
gestation, as an AC >2SD below the control-intake mean had a sensitivity of 88.2% to predict a 
markedly FGR fetus. 
3.5 Conclusions 
In summary, it has been shown that the AC and RV are the most accurately measured markers 
of fetal growth in sheep pregnancy and that they correlate best with fetal weight in late 
gestation and birth weight at term. Serial assessment of fetal growth velocity in high-intake 
pregnancies revealed a reduction in AC and FL from 98 days, RV and TL from 105 days and BPD 
from 112 days gestation, respectively. This asymmetrical pattern of growth resulted in 
elevated BPD:AC and BPD:FL ratios indicative of fetal brain sparing. 
Estimation of fetal weight using regression equations is feasible in the sheep and is subject to 
similar degrees of inaccuracy as human fetal weight estimation. Use of an equation derived 
from both AC and RV measurements is recommended, as these particular parameters may 
complement each other across a wide range of fetal size and gestational ages. Although there 
were no significant differences between nutritional groups in fetal biometry at mid-gestation, 
placentome index was reduced (p<0.001) and UA Doppler indices increased (p<0.01-0.05) in 
overnourished pregnancies from 83 days gestation onwards. These ultrasound parameters 
were correlated with necropsy/birth weight and placental weight, indicating that placental size 
and fetoplacental blood flow are important determinants of eventual fetal size in these 
compromised pregnancies. 
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Chapter 4                                                                                                               
Late Gestation Study of Ad.VEGF Gene Therapy in Growth-Restricted Sheep 
4.1 Introduction 
This chapter details the first of two studies aimed at evaluating the efficacy, safety and 
mechanism of action of Ad.VEGF gene therapy treatment in an ovine paradigm of FGR. 
4.1.1 Background 
Previous work evaluating the effects of Ad.VEGF in normal adult sheep pregnancy showed that 
local adenovirus-mediated over-expression of VEGF-A165 in the uterine arteries significantly 
increased UBF compared to transduction with a non-vasoreactive control vector (Ad.LacZ). This 
increase in UBF became significant as early as 7 days post-injection and was maintained for at 
least 28 days, at which point it reached a 37% increase over baseline compared to 20% on the 
Ad.LacZ injected side (Mehta et al. 2011). Vessels harvested at 4 to 7 days post-injection 
demonstrated altered vascular reactivity, more specifically a reduced vasoconstrictor response 
to phenylephrine and an enhanced vasorelaxation response to bradykinin (David et al. 2008), 
as well as an upregulation of eNOS and both VEGF receptors (FLT1 and KDR), measured by 
ELISA and immunohistochemistry, respectively (Mehta et al. 2011). Subsequently near to term 
(28 days following vector injection) eNOS expression was equivalent in Ad.VEGF-A165 and 
Ad.LacZ-transduced vessels. Vasorelaxation was also equivalent but vessels still contracted 
significantly less strongly. In addition there was a significant increase in neovascularization 
within the perivascular adventitia and reduced intima-to-media ratios. Additional experiments 
using endothelial cells isolated from the uterine arteries during mid-gestation sheep pregnancy 
and transfected with adenovirus vectors in vitro showed that Ad.VEGF-A165 upregulated levels 
of eNOS, iNOS and the phosphorylated (activated) form of eNOS, providing further evidence 
that VEGF over-expression increases the concentration of endogenous vasodilator substances. 
Whilst all of this is commensurate with a potentially beneficial effect of Ad.VEGF on fetal 
nutrient supply, the effect clearly needed to be evaluated in pregnancies complicated by FGR. 
It has been repeatedly shown that overnourishing the pregnant adolescent ewe, which is itself 
still growing during pregnancy, results in accelerated maternal tissue deposition and nutrient 
partitioning away from the gravid uterus at the expense of the pregnancy. This results in a 
major degree of placental followed by fetal growth restriction relative to the normally 
developing pregnancies of adolescent ewes receiving a moderate (control) dietary intake 
(Wallace et al. 2006a). This ovine paradigm is ideally suited for the evaluation of the effects of 
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Ad.VEGF in FGR pregnancy as it is replicates many of the key features of human FGR secondary 
to uteroplacental insufficiency without the need for any interference at a vascular or placental 
level (Wallace et al. 2005b). There is a major (42%) reduction in UBF that is manifest by mid-
gestation (Wallace et al. 2008b), which is associated with reduced placental vascularity, 
secretory function and mRNA expression of key angiogenic factors and receptors including 
VEGF and FLT1 (Redmer et al. 2005; Lea et al. 2007; Redmer et al. 2009). 
4.1.1 Aims 
The aims of this first study were to assess the effect of prenatal Ad.VEGF gene therapy on:   
 Uterine blood flow (measured using indwelling flow probes) 
 Fetal growth velocity (measured by ultrasound) 
 Fetal weight in late gestation 
 Fetal body composition, organ weights and gross organ morphology 
 Uterine artery vascular reactivity, IMR and adventitial neovascularisation 
 Placental mRNA expression of important angiogenic factors and receptors 
4.2 Materials and Methods 
4.2.1 Experimental design 
The primary outcome for this study was serial changes in UBF, measured using indwelling flow 
probes, from mid to late gestation. Secondary outcomes are detailed above. An endpoint in 
late pregnancy was chosen in order to quantify the maximum treatment effect following mid-
gestation vector delivery, to sample the placenta and to harvest the maternal uterine arteries 
for in vitro tests of vascular reactivity. This had to be achieved prior to delivery which can occur 
as early as day 135 of gestation in the FGR pregnancies.  Tissues were subsequently utilised to 
investigate putative downstream effects of Ad.VEGF on the uteroplacental circulation. 
A sample size calculation was performed based on preliminary data showing a 40% increase in 
UBF following Ad.VEGF delivery in normal adult sheep pregnancy (David et al. 2008) and prior 
evaluation of UBF in the overnourished adolescent model (Wallace et al. 2008b). Assuming 
inter-animal variability of 143ml/min, it was estimated that 11 animals per group would be 
required to detect a 50% increase in UBF (212ml/min) with 90% power. 
To investigate the efficacy of Ad.VEGF it was important to assess fetal growth relative to both 
normally growing fetuses and growth-restricted fetuses receiving inactive control treatments. 
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Therefore a contemporaneous control group of pregnant adolescent ewes fed a control 
dietary intake to promote normal maternal and fetal growth was included in order to account 
for the yearly variation in fetal growth observed in sheep. Two separate overnourished 
comparator groups were used to control for different aspects of the surgery to administer the 
gene therapy (Section 2.1.4.2). The first group received bilateral UtA injections of normal saline 
to control for the laparotomy, injection procedure and subsequent 5 minute occlusion of each 
UtA during vector administration (H+Saline group). The second group received bilateral UtA 
injections of 5x1011 particles of a control vector Ad.LacZ (adenovirus encoding the reporter 
gene LacZ) to control for any additional effects of adenovirus vector infection in compromised 
sheep pregnancy (H+Ad.LacZ group). Control-intake ewes also received saline in order to 
control for the surgical intervention (C+Saline group). 
4.2.2 Establishment of singleton pregnancies and nutritional management 
Oestrus cycles were synchronised in 108 potential adolescent recipients and 27 potential adult 
donor ewes in the lead up to 6 separate embryo recovery and transfer days in the mid 
breeding season (Section 2.1.1.1). Adolescent recipients weighed 44.5±0.22 kg (mean ± SEM) 
and had an initial body condition score (BCS) of 2.3±0.01. Donor ewes weighed 65.9±0.87 kg 
with a BCS of 2.3±0.02 and were superovulated prior to undergoing laparoscopic intrauterine 
insemination (Section 2.1.1.2) and embryo recovery (Section 2.1.1.3). Thirteen donors in total 
required to be flushed to provide sufficient embryos for transfer into 86 adolescent recipients 
(Section 2.1.1.4). 
Immediately following embryo transfer and throughout gestation, adolescent ewes were fed a 
control-intake (n=21) or high-intake (n=65) of the same complete diet, as described in Section 
2.1.2. Adolescent ewes were evenly allocated to nutritional groups on the basis of initial live 
weight and BCS, recipient ovulation rate and, where possible, donor source. Pregnancy 
diagnosis was carried out by ultrasound at 45 days gestation (Section 2.1.1.5) and confirmed 
viable pregnancies in 17 of 21 control-intake and 55 of 65 overnourished ewes, giving overall 
pregnancy rates of 81.0 and 84.6%, respectively. 
4.2.3 Ultrasound examination and gene therapy administration 
At 83±0.1 days gestation all ewes underwent ultrasound examination and measurement of 
fetal and placental biometry and umbilical artery Doppler indices, as described in Section 2.1.3. 
Subsequently, at 89±0.2 days gestation, 60 ewes underwent a midline laparotomy as described 
in Section 2.1.4.2, and administration of Ad.VEGF gene therapy or a control treatment (saline 
or Ad.LacZ). At induction of anaesthesia, a venous blood sample was taken into a 5ml syringe, 
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placed into an incubator at 37oC and allowed to clot. Subsequently at surgery, an ultrasonic 
perivascular flow probe was placed around the uterine artery supplying the gravid horn (see 
Section 4.2.4.1) and this blood clot was used to fill the dead space between the vessel and the 
probe, to improve transmission of the ultrasound signal. After fitting the flow probe, both 
uterine arteries were injected with either the active gene therapy (Ad.VEGF), control vector 
(Ad.LacZ) or control saline, as per the experimental design (described in Section 2.1.4.2). All 
control-intake ewes received saline (C+Saline group), whilst high-intake ewes were evenly 
allocated to one of three groups (H+Ad.VEGF, H+Saline or H+Ad.LacZ) on the basis of estimated 
fetal and placental size (values of TD, AC, RV and placentome index), the BPD:AC ratio (an 
index of fetal brain sparing) and the daily maternal live weight gain between embryo transfer 
and surgery. After allowing a full week’s postoperative recovery for all ewes, serial scans were 
performed at approximately weekly intervals from 98±0.1 until 126±0.3 days gestation. 
Abdominal wounds were inspected for signs of infection or dehiscence prior to each 
ultrasound examination and care was taken to minimise pressure from the transducer. All 
scans were carried out by a single operator (David Carr) accredited in advanced obstetric 
ultrasound who was kept blind to the treatment administered at surgery in order to avoid any 
bias in the ultrasound evaluation of fetal growth. 
4.2.4 Measurement of uterine blood flow 
4.2.4.1 Placement of uterine artery flow probes 
At laparotomy for gene therapy administration, each ewe had an ultrasonic perivascular flow 
probe (PSS Series, Transonic® Systems Inc., Ithaca, NY, USA) fitted around the uterine artery 
supplying the gravid uterine horn prior to injection of that artery. A straight section of the 
vessel was chosen, proximal to the first bifurcation and distal to the planned site of injection. 
At this location the visceral peritoneum was opened with fine scissors and the vessel was 
mobilised free from the underlying tissue. Either a 4mm or 6mm sized probe was selected 
depending on the size of the vessel, aiming for it to fill 75 to 95% of the space between the two 
lateral reflector brackets as per the manufacturer’s recommendations. To fit the probe, the 
screw securing the adjustable reflector bracket was first loosened, allowing the bracket to be 
displaced upwards. The reflective plate was then hooked underneath the vessel, the bracket 
slid back into its original position and the screw tightened, leaving the flow probe securely 
positioned around the vessel with a non-constrictive fit (Figure 4.1A).  
An autologous blood clot was used to fill the space between vessel and probe if necessary (see 
above). The flow probe unit was loosely anchored onto the adjacent peritoneum using
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Figure 4.1 – Placement and exteriorisation of uterine artery flow probes 
  
  
A Transonic® flow probe was fitted around the uterine artery supplying the gravid horn [A] 
during laparotomy. The flow probe cable was delivered through an incision in the right flank [B] 
using a custom-designed exteriorising device [C] and loosely secured to the adjacent skin [D]. 
  
nonabsorbable braided silk (3.0 Mersilk®, W192, Ethicon). Thereafter the connector at the far 
end of the probe cable was inserted into a custom-made exteriorising device, consisting of a 
hollowed out plastic cone with two small holes near its tip to accommodate a length of string 
for traction. The device was carefully slid along the lateral internal wall of the body cavity, with 
the tip guarded by the operator’s palm, until it reached a location corresponding to the desired 
exit point on the right flank, which had been shaven and cleaned in preparation. Controlled 
pressure was applied to pass the device through the body wall and into a 1.5cm skin incision 
made externally on the flank by a second operator (Figure 4.1B). Great care was taken to 
ensure that there was no omentum or bowel between the device and the parietal peritoneum 
during exteriorisation. Once the tip of the device had passed through the muscle and fat, the 
A B 
C D 
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tip was grasped externally and string was threaded through the custom-made holes. Gentle 
traction was then applied to deliver the device (and the flow probe cable) out through the 
incision (Figure 4.1C). A generous loop of cabling was left inside the body cavity to allow for 
subsequent gravid uterine growth. The flank incision was closed with interrupted braided 
absorbable polyglactin (2.0 Vicryl®, W9463, Ethicon). A “flag” made from surgical tape was 
attached to the flow probe cable at its exit point and loosely secured to the adjacent skin with 
2.0 Vicryl® to prevent any slack cabling inadvertently being pulled out (Figure 4.1D). Opsite® 
liquid spray dressing was applied to the wound and a custom-made fabric pouch (to house the 
flow probe cable and connector) was glued onto the skin using Kamar® adhesive (Kamar Inc., 
Steamboat Springs, CO, USA).  
4.2.4.2 Telemetric monitoring of uterine blood flow 
UBF was monitored on alternate days, beginning on the third post-operative day (92±0.2 days 
gestation) and ending with a final recording on the day prior to necropsy (130±0.2 days 
gestation). Ewes were monitored for 45 minutes each time. On the first occasion, UBF was 
recorded during the late afternoon in order to allow each ewe a full 72 hours post-operative 
recovery. Thereafter each individual animal was monitored at approximately the same time 
each day to minimise any confounding by potential circadian variation in UBF. Monitoring was 
also avoided at feeding times. During telemetric monitoring periods, ewes wore a custom-
made fabric back-pack housing a PhysioMeter™ PGPM110 unit and Intelligent battery pack 
containing 2 rechargeable V286 7.2 lithium-ion batteries (PhysioGear®I, Transonic® Systems 
Inc.). To begin monitoring, the 4-pin flow probe connector was removed from the pouch on 
the animal’s flank and connected to the PhysioMeter™ unit via a 4-pin AET8-4 interface cable. 
The backpack and any loose cabling were tucked away under the Tubigrip® bandage around 
the maternal abdomen (Figure 4.2A). Ewes were unrestrained and hence allowed to behave 
normally during monitoring. Real-time measurements of UBF (at a frequency of 128 per 
second) were transmitted to a trolley-mounted PC via a Bluetooth® connection (Figure 4.2B) 
and recorded using PhysioView™ P1U software (Transonic® Systems Inc., Figure 4.2C). Data 
was subsequently exported in *txt format and analysed using AcqKnowledge 3.9.1 software 
(BIOPAC Systems Inc., Goleta, CA, USA) to determine the mean and standard deviation. 
Previous studies using indwelling Transonic® flow probes to monitor UBF in normal sheep 
pregnancy (Mehta et al. 2011) and in overnourished adolescent dams (Wallace et al. 2008b) 
had used recording times of 1 and 2 hours, respectively. In view of the large number of ewes 
undergoing UBF monitoring at any given point in the present study (up to 25 animals), it was 
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Figure 4.2 – Telemetric monitoring of uterine blood flow 
 
 
Photograph of a pregnant ewe undergoing telemetric monitoring of uterine blood flow (UBF): 
the ewe is unrestrained with the wireless Physiogear® system tucked away in a pouch under an 
abdominal bandage [A]. Real-time measurements of volume flow (ml/min) are transmitted to a 
nearby PC via Bluetooth® [B]. The data acquisition screen shows measurements of UBF and 
records values at a rate of 128 per second [C].  
A B
  A 
 C
  A 
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necessary to reduce recording times to 45 minutes. In order to validate 45-minute recording 
times against longer periods of monitoring, UBF was recorded in 21 ewes for 2-hour periods on 
a total of 35 occasions. A representative blood flow profile, showing the typical variation in an 
individual ewe over a 2-hour period, is shown in Figure 4.3. From these 35 recordings, mean 
UBF was determined on a minute-by-minute basis and used to calculate the overall mean and 
standard deviation for periods of 45, 60 and 120 minutes. These values were subsequently 
compared by one-way analysis of variance (ANOVA). There were no statistically significant 
differences between average flows over 45, 60 and 120 minutes. Mean differences in absolute 
UBF were ±7.6 ml/min for 45 versus 60 minutes and ±17.8 ml/min for 45 versus 120 minutes. 
Coefficients of variation were 1.5% and 3.2%, respectively. 
  
Figure 4.3 – Representative uterine blood flow profile for an individual ewe over 2 hours 
 
Example of a typical uterine blood flow profile in an individual ewe over 2 hours at 130 days 
gestation, demonstrating the physiological variation in flow (mean 493ml/min, standard 
deviation 10.9ml/min) 
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4.2.5 Necropsy procedures 
4.2.5.1 Euthanasia 
At 131±0.3 days gestation ewes were humanely killed using an overdose of 20-40ml 
pentobarbital sodium (Euthatal®, Merial Animal Health Ltd, Harlow, UK) administered by i.v. 
injection into the jugular vein. Death was confirmed by the absence of corneal reflexes. 
Thereafter the animal was suspended by the back legs using a ceiling mounted electric hoist. A 
large midline abdominal incision was made, taking care not to traumatise the rumen or cut the 
flow probe cable along its course from the flank to the pelvis. The abdominal cavity was 
opened and the gravid uterus was delivered and held by an assistant. The main trunk of the 
UtA supplying the gravid horn was clamped just distal to the flow probe and bowel clamps 
were placed across the cervix and paracervical ligament, which were then cut, allowing the 
entire reproductive tract to be removed en bloc without the flow probes attached, and 
weighed. The ewe was subsequently exsanguinated by severing the main vessels of the neck 
and maternal blood was collected in a bucket and subsequently weighed. The uterus was 
opened at the tip of the gravid horn, as per veterinary caesarean section. After sampling 
amniotic fluid into a 50ml syringe, the fetus was delivered out of the tip of the horn. A fetal 
blood sample was taken by cardiac puncture into a 10ml K2-EDTA tube immediately prior to 
the administration of 5–10ml pentobarbital sodium via a three-way tap. Blood samples were 
kept on ice before being processed as described in Section 2.2.1. 
4.2.5.2 Fetal dissection 
Once death had been confirmed, the fetus was dried with a cotton towel, weighed and 
transferred to a dedicated station for dissection and sampling. Fetal sex was recorded. The 
biparietal head diameter was measured using callipers at the widest point between the two 
parietal bones. Abdominal girth at the level of the umbilicus was determined using a piece of 
string, which was wrapped around the lamb’s mid-section at the level of the cord insertion and 
at right angles to the spine, marked and subsequently measured against a ruler. Care was 
taken to reproduce the same plane each time. In addition, abdominal girth at the level of the 
lowermost rib was measured in an attempt to reproduce the level of the ultrasound AC plane.  
Next the fetus underwent a systematic post-mortem examination with careful documentation 
of any gross abnormalities. A sample fetal record sheet is shown in Appendix 3, including a 
checklist of samples to be snap-frozen and/or immersion fixed. All samples for freezing were 
placed into liquid nitrogen chilled isopentane until frozen through and then stored on dry ice 
until the end of each necropsy, when they were transferred to -80oC storage. All samples for 
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fixing were immersed in approximately 10 times their volume of neutral-buffered formalin 
(NBF) or Carnoy's solution, prepared as described in Section 2.2.2. Fixed tissues were 
subsequently processed to the wax block stage as described in Section 2.2.3. Widespread 
tissue sampling was carried out as described below, mainly as a precautionary measure. If 
Ad.VEGF treatment were to have any unexpected effects on gross organ morphology then a 
large tissue bank would be available for histopathological examination and additional analyses.  
To begin the dissection, the fetal head was removed and the skull opened using a hacksaw. 
The fetal brain was carefully extracted and snap-frozen whole. The pituitary gland was 
removed from the sella turcica and placed into Tissue-Tek® O.C.T. compound (Ted Sella Inc., 
Redding, CA, USA) prior to freezing. Before opening the abdomen, a sample of umbilical cord 
was taken for freezing. The abdominal wall was then incised and the peritoneal cavity entered. 
Firstly the pancreas was dissected off, weighed complete and separately sampled at its hepatic 
and splenic poles for freezing and fixing, respectively.  
Following removal en bloc, the complete gastrointestinal tract was placed into warm PBS (at 
39oC). Thereafter a length of fetal small intestine was selected for sampling and perfusion. 
Beginning at a location three mesenteric vein branches distal from the mesenteric-ileocaecal 
venous junction, a portion of fetal jejunum approximately 100cm in length was carefully 
excised together with its associated mesenteric vasculature. From the cranial end of this 
sample, a number of sections were taken and separately immersion-fixed in NBF and Carnoy’s 
solution. The remaining length of fetal jejunum was subsequently perfuse-fixed with Carnoy’s 
solution following cannulation of the mesenteric vascular arcade (see Figure 4.4). Sections of 
perfused jejunal tissue were then immersed in Carnoy’s solution. Next the stomach complex, 
small intestine and large intestine were stripped off the mesentery and the bowel contents 
were extruded. The weight of the stomach complex was recorded before the mid-abomasum 
was sampled for freezing, halfway between the pyloric valve and the junction of the 
abomasum and omasum. The small intestine was weighed and sampled for freezing at the 
third branch of the mesenteric vein, distal to the portal-mesenteric venous intersection. A 
further 100cm section of fetal small intestine was removed, separately weighed and added to 
the small intestine weight to account for lost mass due to sampling and perfusion. Finally the 
large intestine was weighed and the proximal colon was sampled for freezing. 
Next the liver was removed and weighed. A sample was taken from the right lobe for fixing, 
followed by generous samples from both lobes for freezing. The spleen was removed, weighed 
and sampled for fixing and freezing. Both kidneys were removed together with all perirenal fat, 
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Figure 4.4 – Perfusion-fixation of the fetal gastrointestinal tract  
 
Image showing cannula threaded into mesenteric vessels and used to perfuse the mesenteric 
circulation with Carnoy’s solution - note the whitish appearance of perfused-fixed jejunal tissue. 
  
which was subsequently stripped off, weighed and sampled for fixing and freezing. The kidneys 
were then cut transversely and mid-section slices were fixed and frozen. The adrenal glands 
were removed and cut in half, one transversely and one longitudinally. Half of each adrenal 
was fixed and the other half frozen. A sample of skin was taken from the anterior thigh for 
freezing and the underlying quadriceps muscle was sampled for fixing and freezing. Next the 
fetal chest was opened and the heart removed and weighed. A transverse cross-sectional slice 
was taken for fixing, which included both ventricular walls and the interventricular septum. 
The remaining right and left ventricular tissue was separately frozen. The lungs were 
disconnected from the trachea, removed and weighed. The right lower lobe was sampled for 
fixing and freezing by cutting perpendicularly to the main bronchus approximately 3cm above 
the inferior border of the lobe. The thymus was removed, weighed and sampled for fixing and 
freezing, followed by the thyroid gland, which was cut in half for fixing and freezing. Next the 
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gonads were also weighed and sampled. For female fetuses the entire reproductive tract was 
removed and the ovaries were trimmed off. One was fixed and one was frozen in Tissue-Tek®. 
For male fetuses the tip of the scrotal sac was cut off and the testes displaced out of the cut 
end. The pampiniform venous plexus and the head, body and tail of the epididymis were 
trimmed off and each testicle cut into two halves in cross-section. One half of each testis was 
fixed and the other frozen in Tissue-Tek®. Next the femur was dissected out and cleared of all 
associated muscles and ligaments. The length of the bony shaft was measured using callipers. 
The bone was subsequently cut in half and a sample of bone marrow extracted for freezing. 
The tibia was then dissected clean and its length measured in the same manner as the femur. 
The fetal eyes were removed from the skull and each one cut in half in coronal section. Each 
half was cut in two again to produce semicircular samples, and one of each (i.e. one from the 
anterior and one from the posterior half of the eyeball) were fixed. Retinal tissue was carefully 
scraped off the inner surface of the remaining posterior eyeball for freezing. Finally, the fetal 
carcass was weighed and stored at -20oC pending body composition analysis (Section 4.2.6.2). 
4.2.5.3 Uteroplacental dissection 
Following delivery of the fetus, the reproductive tract was moved to a dedicated dissection 
station where sampling of the uterine arteries was commenced immediately and in parallel 
with the fetal dissection described above. The uterine artery dissections were carried out as 
swiftly but carefully as possible to ensure that the vessels were in the best possible condition 
when subsequently examined in the organ bath (see Section 4.2.6.3). In particular, care was 
taken to avoid placing excessive tension on the vessels to ensure that the myofibres remained 
unstretched. Firstly the uterus was laid out on a tray and the visceral peritoneum was opened 
up with fine scissors to visualise the entire vascular tree, with its sequential branching pattern. 
Four reproducible levels of arterial branching were identified: the main UA trunk (UtA1); first 
branches (UtA2) and second branches (UtA3) at the level where the vessels entered the 
myometrium (see Figure 4.5). Starting with the gravid horn, samples of all these UtA branches 
were harvested. Each vessel was gently elevated using non-toothed tissue forceps and 
carefully separated off the underlying uterine tissue using Metzenbaum scissors. From all four 
branches (UtA1–4), two straight sections >1cm in length were taken and immersion fixed in 
NBF. In a subset of 22 animals, from branches UtA2 and UtA3 only, two straight sections 4cm 
in length were taken and placed into cold Krebs Ringer buffer (Ref. K0507, Sigma Aldrich) for 
subsequent organ bath analysis (see Section 4.2.6.3). All remaining samples from branches 
UtA1–4 were carefully cleared of associated connective tissue and blood before being frozen 
separately. Thereafter, the same dissection and sampling was repeated on the non-gravid side. 
146 
 
Figure 4.5 – Branching pattern of the uterine artery 
 
Uterine arterial tree (supplying the gravid uterine horn) perfused with Evans Blue dye in order 
to demonstrate the sequential branching pattern of the uterine artery (UtA) - the main trunk is 
designated UtA1, the first branches UtA2 and the second branches UtA3 
  
Once the uterine artery dissection and sampling was complete, 10 representative placentomes 
from the gravid uterine horn were cut off the membranes, weighed and categorised by their 
morphological appearance (see Figure 4.6) into subtypes (A to D) according to the classification 
of Vatnick et al. (1991). Two placentomes were snap frozen whole, whilst a further two were 
separated into fetal cotyledonary and maternal caruncular portions and frozen separately. The 
remaining placentomes were each cut into 5mm slices, following which half the slices were 
immersion fixed in NBF and half in Carnoy’s solution (prepared as described in Section 2.2.2). 
Finally, all remaining placentomes were removed from the membranes and separated into 
four groups according to their size (>5cm, 2–5cm, 1–2cm and <1cm). Placentomes were 
weighed by groups and individually subtyped. Weights and subtypes of the fixed, frozen and 
perfused placentomes (see above) were added in to complete these datasets. A sample 
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Figure 4.6 – Morphological classification of ovine placentomes 
 
Subtypes of sheep placentome according to the classification of Vatnick et al. (1991) illustrating 
increasing surface area for maternofetal exchange with conversion from A through D subtypes. 
Figure reproduced with permission from Braun et al. (2011) 
  
placental record sheet is shown in Appendix 4. The residual membranes were weighed and 
added to the total placentome weight to give the total placental weight. The residual uterus 
was also weighed, following which a sample of uterine wall was taken for freezing. 
4.2.5.4 Maternal dissection 
The weight of maternal blood collected in a bucket following exsanguination was recorded as 
an index of blood volume and the liver and perirenal fat depots were removed and weighed. 
The flow probe was recovered by carefully dissecting back from its exteriorisation point in the 
flank to its position around the transected uterine artery in the maternal pelvis. It was cleared 
of all adherent tissue and cleaned for subsequent retesting, sterilisation and reuse. The weight 
of the residual carcass was recorded. A sample maternal record sheet is shown in Appendix 5.  
4.2.6 Laboratory techniques 
For all the following analyses the individual investigator was blinded to the treatment group 
(both control versus high-intake and Ad.VEGF versus Saline/Ad.LacZ treatment) by means of 
block and sample coding until the analysis was complete. 
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4.2.6.1 Measurement of nutrients and metabolic hormones 
Glucose, insulin and insulin-like growth factor 1 (IGF-1) concentrations were determined in 
duplicate in fetal and pre-necropsy maternal plasma samples, as described in Section 2.2.4. 
Glucose was also measured in amniotic fluid samples using the same method. 
4.2.6.2 Fetal body composition analysis 
Fetal carcasses were initially stored at -20oC following necropsy. Subsequently each carcass 
was individually thawed out, weighed and cut into pieces of approximately 1kg. Each piece was 
processed through a mincer (Wolfking®, Slagelse, Denmark) before being combined in a bakers 
mixer for 5 minutes. After mixing thoroughly, three sub-samples of the homogenate 
(approximately 250g) were taken. After determining their exact weights, samples were placed 
onto aluminium trays and freeze-dried. Thereafter they were reweighed, ground using a coffee 
grinder and submitted to the Rowett Institute’s Analytical Department for the determination 
of ash, protein and fat content. The residual moisture content of the remaining fetal carcass 
following freeze- drying was also determined by drying to constant weight at 100oC. Ash 
content was determined by ashing at 600oC to constant weight, protein content (nitrogen x 
6.25) by the Kjeldahl procedure (Davidson et al. 1970) and fat content by the chloroform-
methanol technique, as previously described (Atkinson et al. 1972).  
4.2.6.3 Organ bath experiments 
In 22 animals, two samples of uterine artery branches UtA2 and UtA3 from both the gravid and 
non-gravid sides (four samples in total) were stored in cold Krebs Ringer buffer and couriered 
overnight from Aberdeen to London for analysis in an organ bath the following day by Vedanta 
Mehta. Vascular reactivity was assessed by generating dose response curves to phenylephrine 
and bradykinin, as previously described (David et al. 2008; Mehta et al. 2011). The set-up for 
these experiments is illustrated in Figure 4.7. There was no suitable organ bath equipment 
available locally, hence the need to transport the vessels to the Rayne Institute at UCL for 
analysis using previously validated techniques. To evaluate the suitability of overnight transfer, 
an intact rat aorta was shipped from Aberdeen to UCL under similar transportation conditions, 
and analysed in the organ bath to test its response 24 hours after harvest. It was noted that 
the aortic segments reacted to potassium chloride, phenylephrine and acetylcholine, although 
the magnitude of responses recorded was 15-20% less than fresh vessels. 
On arrival the vessels were prepared by carefully clearing them of any residual connective 
tissue under a dissecting microscope. Thereafter each vessel was cut into 3mm ring segments.
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Figure 4.7 – Schematic of organ bath equipment set-up 
 
Schematic diagram illustrating the organ bath set-up. A section of uterine artery is suspended 
between two pins in a chamber filled with Krebs buffer, maintained at 37oC using a 
thermocirculator. Increasing concentrations of agonists are added to the chamber to induce 
vasoconstriction/vasorelaxation, which is recorded in real time by a transducer linked to a PC. 
Figure reproduced with permission from the thesis of Dr Vedanta Mehta (PhD awarded 2011).                                            
  
Sixteen 25ml organ bath chambers were filled with Krebs Ringer buffer, to which 2.5mM 
calcium chloride (CaCl2) was added. Channels were calibrated using a 5g weight. A water 
thermocirculator was used to maintain the temperature within the chambers at 37oC and 
carbogen (95% oxygen, 5% carbon dioxide) gas was bubbled in to maintain the pH at a 
physiological level (7.3–7.4). Eight ring segments were mounted between vertically opposed 
pins in the series of chambers (taking care not to damage the vessel endothelium) and kept 
under gentle holding tension whilst being allowed to equilibrate. Subsequently the tension was 
increased gradually to 0.3g, 0.5g and 1.0g, at intervals of 5–10 minutes. Vessel segments were 
washed in between each increase in tension by flushing the chambers and refilling them with 
fresh Krebs Ringer buffer (+CaCl2). Next a viability check was performed by adding 0.3ml 4M 
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KCl solution to achieve a concentration of 48mM within each organ bath. The resultant 
increase in measured tension was allowed to plateau, at which point maximum contractility 
was recorded. Vessel segments were then washed repeatedly until tension returned to 
baseline. After waiting for a minimum of 10 minutes, the KCl challenge was repeated until 
maximum contractility no longer exceeded the previous measurement. Thereafter vessel 
segments were repeatedly washed to remove all KCl and allowed to recover for >30 minutes.  
To assess vascular contractility, a dose-response curve to phenylephrine (PE) was generated by 
adding sequential doses of PE at increasing concentrations to achieve 9 stepwise semi-
logarithmic concentrations within the organ bath (10-9, 3x10-9, 10-8, 3x10-8, 10-7, 3x10-7, 10-6, 
3x10-6 and 10-5). After each addition of PE the contractile response was allowed to plateau 
before the next dose was added. At the end, vessel segments were repeatedly washed and 
allowed to recover for at least 30 minutes. To assess vasorelaxation, a dose-response curve to 
bradykinin (BK) was generated by adding sequential doses of BK at increasing concentrations 
to achieve 9 concentrations within each bath (10-11, 3x10-11, 10-10, 3x10-10, 10-9, 3x10-9, 10-8, 
3x10-8 and 10-7). Prior to adding any BK, vessel segments were pre-contracted using PE. From 
the PE dose-response curve the degree of tension equivalent to 10-15% of maximum 
contractility to KCl (typically 2–3g) was calculated and the corresponding volume and 
concentration of PE to achieve this tension was added to the bath. The contraction was 
allowed to stabilise before adding BK. After each dose of BK the relaxation response was 
allowed to plateau before adding the next. 
4.2.6.4 Uterine artery sectioning, H&E staining, anti-vWF immunohistochemistry 
Duplicate paraffin-embedded sections of uterine artery at three levels of branching (UtA1 to 3) 
were cut into ribbons of three micron thickness using a microtome. Ribbons were floated in 
water heated to 37oC until completely stretched out, transferred in duplicate onto glass slides 
coated with polylysine (Ref. 631-0107, VWR, Leuven, Germany) to prevent undesired slippage 
of the tissue during subsequent processing, and allowed to air dry.  
One slide from each pair was stained with haematoxylin and eosin (H&E) at the Barts Cancer 
Institute, Queen Mary University London using a Leica ST5010 Autostainer XL coupled with a 
CV5030 automated glass coverslipper (Leica Microsystems). During this process the slides were 
immersed in haemotoxylin in PBS at pH 7.2 for 5 minutes and washed three times with fresh 
PBS before being transferred into 1% eosin in PBS (also at pH 7.2) for 5 seconds and washed 
again three times in PBS. The slides were then passed through an ascending alcohol gradient 
into xylene, mounted in di-n-butylphthalate in xylene (DPX), covered with glass slips and dried. 
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The second slide from each pair was immunostained using the endothelial marker anti-VWF in 
order to identify and count the small vessels within the perivascular adventitia, as previously 
described (Mehta et al. 2011). This particular technique was adapted from the methodology of 
(Bobryshev et al. 2001) but used trypsin digestion in place of proteinase K for the purpose of 
antigen retrieval. The aim of staining endothelial cells was to differentiate blood vessels from 
other structures that can appears similar on histology e.g. nerve fibres and lymph vessels. 
Prior to starting the immunohistochemistry, a 5mM Tris- (tris[hydroxymethyl]aminomethane, 
molecular weight = 121g) buffered saline solution was prepared by adding 0.3g Trizma® base 
(Ref. T-6066, Sigma Aldrich) to each 500ml distilled water and adjusting the pH to 7.8 with 1M 
hydrochloric acid. PBS solution (10mM sodium phosphate, pH 7.5, 0.9% saline) was prepared 
by dissolving 1 Gibco® PBS tablet (Ref. 18912-014, Invitrogen, Paisley, UK) per 500ml distilled 
water. In addition a 0.1% PBS/BSA solution was prepared by gently dissolving 0.1g bovine 
serum albumin (Ref. B-4287, Sigma Aldrich) per 100ml PBS solution. PBS and Tris-buffered 
saline were stored at room temperature, and PBS/BSA stored at 4°C pending use. To begin, the 
paraffin-embedded sections of UtA mounted on slides were dewaxed and hydrated by passing 
them sequentially through the following solutions: 
 Xylene   5 min 
 Xylene    5 min 
 100% ethanol    5 min 
 100% ethanol   5 min 
 95% ethanol   3 min 
 80% ethanol  2 min 
 Distilled water   5 min 
 Distilled water   5 min 
A 0.6% solution of hydrogen peroxide was prepared immediately before use by 1:50 dilution of 
a 30% stock solution (Ref. 216763, Sigma Aldrich) with distilled water. Slides were immersed 
for 15 minutes in order to block endogenous peroxidase activity and then rinsed in tap water. 
Each slide in turn was gently dried before a PAP (peroxidase-antiperoxidase) pen (Dako, 
Glostrup, Denmark) was used to draw a hydrophobic boundary around the vessel. Slides were 
returned to tap water pending the subsequent antigen retrieval step. Immediately before use, 
a 0.1% solution of trypsin (Difco Trypsin-250, 215240, Scientific Laboratory Supplies (SLS), 
Nottingham) and calcium chloride (Ref. C-7902, Sigma Aldrich) was prepared by gently 
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dissolving 50mg of each in 50ml 5mM Tris-buffered saline. Next 200μl of this solution was 
pipetted onto each slide and placed into an incubator for 10 minutes at 37°C. After incubation, 
slides were washed three times with PBS, for three minutes each. Meanwhile a 5% solution of 
non-immune goat serum was prepared by diluting a stock solution (Ref. X0907, Dako) 50-fold 
with PBS. Each slide was dried to remove any excess buffer then 200μl of serum was pipetted 
onto each slide and allowed to incubate for 30 minutes at room temperature to prevent non-
specific binding of antibody to proteins in tissue. Meanwhile the primary antibody, rabbit anti-
human vWF (A0082, Dako), was diluted with PBS/BSA, initially at varying concentrations (1:50, 
1:100, 1:200, 1:400 and 1:800) and subsequently at the optimum concentration of 1:200. 
200μl of solution was pipetted onto each slide. A negative control was included here by 
omitting the incubation with primary antibody i.e. pipetting on 200μl PBS/BSA only. Slides 
were incubated overnight in a humidified chamber at 4°C.  
The following morning, slides were washed three times with PBS/BSA for three minutes each 
time. Meanwhile the secondary antibody, goat anti-rabbit biotinylated IgG (E0432, Dako), was 
diluted 100-fold with PBS/BSA. Each slide was gently dried to removed excess PBS/BSA before 
200μl of solution was pipetted onto each vessel section and slides were incubated for 60 
minutes at room temperature. Thirty minutes into the incubation step 5ml of avidin-biotin 
complex (ABC) solution was prepared by adding one drop (50μl) of solutions "A" and "B" 
(VECTASTAIN® Standard Kit, Ref. PK-4000, Vector Laboratories, Peterborough, UK) into 5ml 
PBS, as per the manufacturer’s protocol. The solution was allowed to stand at room 
temperature for at least 30 minutes before use. Following the incubation step, slides were 
washed once with PBS/BSA and twice with PBS for three minutes each time. After gently 
drying off any excess buffer 200μl of ABC solution was pipetted onto each vessel section and 
slides were incubated for 60 minutes. Forty-five minutes into the incubation step, a 3,3’-
diaminobenzidine tetrahydrochloride (DAB) substrate solution (D5905, Sigma Aldrich) was 
prepared by adding 25mg (2½ tablets) DAB per 50ml of PBS in a Falcon tube, which was then 
vigorously vortexed until complete dissolution and kept in the dark pending use. Following the 
incubation step, slides were washed three times with PBS for three minutes each time. 
Immediately prior to use, 16.7μl of 30% hydrogen peroxide (Ref. 216763, Sigma Aldrich) was 
added for each 50ml of DAB solution required, vortexed and transferred into a cuvette. Slides 
were transferred into the solution and allowed to stain for 10 minutes. Thereafter the reaction 
was stopped by transferring the slides into distilled water. Sections were counterstained by 
immersing them in Mayer’s haematoxylin solution (Ref. 51275, Sigma Aldrich) for 2 minutes 
then transferring into tap water. Finally, slides were dehydrated by passing them sequentially 
through the following solutions: 
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 80% ethanol  2 min 
 95% ethanol   3 min 
 100% ethanol    5 min 
 100% ethanol   5 min 
 Xylene   5 min 
 Xylene    5 min 
Slides were mounted in DPX (Ref. 360294H, VWR International) and 50x20mm glass cover slips 
were manually applied (SLS Ltd, Nottingham). Slides were allowed to dry for 24 hours before 
the vessel counting and image analysis was performed (see below). Figure 4.8 illustrates two 
different sections of the same vessel stained with H&E and anti-vWF antibodies, respectively. 
4.2.6.5 Uterine artery image analysis 
To assess neovascularisation within the perivascular adventitia, anti-vWF stained sections were 
first examined under the microscope (Nikon Eclipse E600, Amstelveen, Netherlands) at x20 
magnification for vessel counting. All positively stained structures with a distinct lumen within 
the adventitia were counted in duplicate, as previously described (Mehta et al. 2011). An 
example of such a positively stained structure is provided in Figure 4.9A. Subsequently a 
photograph of the entire vessel (x2 magnification) was taken for image analysis in order to 
quantify the adventitial area. This extension of the previously described methodology aimed to 
give some indication of vessel density. Each image was analysed using Motic Images 2.0 (Motic 
China Group Co Ltd, Indusxiamen, China) by manually tracing around the following three areas: 
 Total vessel area (TVA)   (Figure 4.9B) 
 Intima + media + lumen area (IMLA)  (Figure 4.9C) 
 Lumen area (LA)    (Figure 4.9D) 
which allowed for the calculation of the following additional parameters: 
 Adventitial area (AA)  =  TVA – IMLA 
 Intima + media area (IMA) =  IMLA – LA 
The number of vessels in the perivascular adventitia was subsequently compared in absolute 
terms and expressed per unit adventitial area. 
To assess intima-to-media ratios (IMR), H&E stained sections were examined in duplicate at
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Figure 4.8 – Uterine artery sections stained with H&E and anti-vWF antibodies 
 
Sections of the main trunk of the uterine artery stained with: [A] haematoxylin and eosin; and 
[B] anti- von Willebrand factor antibodies (an endothelial cell marker); for the measurement of 
intima-to-media ratios and the asssessment neovascularisation in the perivascular adventitia. 
  
x20 magnification and photographs were taken of the vessel wall at the 3, 6, 9 and 12 o'clock 
positions, taking care that the borders between the intima and media, and the media and 
adventitia, were both clearly visible. Image J software (National Institutes of Health, Bethesda, 
MD, USA) was used to measure the thickness of a representative portion of the intima and 
media, immediately parallel to one another in a radial fashion, in each of the four images per 
vessel section (Figure 4.10). The coefficient of variation was calculated and any outlying 
measurements were repeated where this exceeded 10%. Finally the mean intimal and medial 
thickness and IMR were calculated for each duplicate section and averaged again.  
4.2.6.6 RNA extraction 
Separately frozen caruncular and cotyledonary tissues were powdered and 50mg of each 
sample transferred into 0.5ml Tri-Reagent (Sigma Aldrich Co. Ltd) in a 2ml microcentrifuge 
tube. Samples were kept on ice and processed using an Ultraturrex tissue homogeniser. After 
homogenisation tubes were allowed to stand for 5 minutes prior to the addition of 0.1ml 
chloroform. Tubes were shaken manually for 15 seconds, left to stand again for 5 minutes and 
then centrifuged at 12000g for 15 minutes at 4°C (Jouan KR422). Taking care to avoid the
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Figure 4.9 – Vessel enumeration and determination of adventitial area  
 
[A] View of perivascular adventitia at x20 magnification illustrating structures with a distinct 
lumen (some examples are indicated by the white arrows) that have been positively stained 
with the endothelial cell marker anti- von Willebrand factor - these represent adventitial blood 
vessels. The red arrow indicates the medial/adventitial border, which separates the muscular 
layer of the blood vessel from the compact adventitia. [B/C/D] Determination of adventitial 
area (AA) and intima+media area (IMA) by separate calculation of: [A] total vessel area (TVA); 
[B] intima+media+lumen area (IMLA); and [C] lumen area (LA) and subtraction as follows:       
AA = TVA – IMLA; IMA = IMLA – LA 
  
interphase, the upper aqueous phase was transferred into a 1.5ml microcentrifuge tube, to 
which was added 0.25ml isopropanol. After inverting several times to gently mix, tubes were 
left at room temperature for 10 minutes before being centrifuged again at 12000g for 10 
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Figure 4.10 – Measurement of intima-to-media ratios 
 
Series of four photographs taken at 3, 6, 9 and 12 o'clock demonstrating the measurement of 
intimal and medial thickness and calculation of intima-to-media-ratios. The mean of the four 
measurements was determined in duplicate for each vessel. 
  
minutes at 4°C (Jouan KR422). The supernatant was discarded and the resultant pellet was 
washed in 0.5ml cold 70% ethanol, vortexed and centrifuged for a third time at 7500g for 5 
minutes at 4°C (Jouan KR422). The supernatant was again discarded and pellets allowed to air 
dry for a short period, taking care not to allow them to dry out completely. Pellets were 
resuspended by vortexing in 40μl Ultrapure™ diethylpyrocarbonate (DEPC) treated water. A 
subsample of 1μl was added to 9μl in a 1.5ml microcentrifuge tube and used to determine the 
quality and quantity of total RNA by capillary electrophoresis using an Agilent 2100 Bioanalyser 
(Agilent Technologies, Wilmington, DE, USA). The remaining sample was stored at -80oC 
pending quantitative reverse transcription polymerase chain reaction (qRT-PCR). 
157 
 
4.2.6.7 Quantitative real-time reverse transcription polymerase chain reaction 
Extracted RNA was subsequently reverse transcribed in triplicate using Taqman Reverse 
Transcription reagents and Multiscribe Reverse Transcriptase (Applied Biosystems, 
Warrington, Cheshire). 
To reverse transcribe the extracted RNA, 23.1μl (~90ng) of each diluted sample was 
transferred to a 96-well plate. To each well was added 36.9μl RT Mastermix (Applied 
Biosystems). Samples were mixed, then 18μl of each was transferred into a new 96-well plate. 
Plates were processed through a 4-block thermal cycler (Techgene). Samples were initially 
heated to 25oC for 10 minutes, followed by 48oC for 30 minutes and 95oC for 5 minutes, and 
then held at 4oC. The RT plate was subsequently diluted 5-fold by adding 72μl nano water 
(ultrapure water prepared with an ELGASTAT UHQ PS water purification system) to each 18μl 
sample. This plate (termed "GOI RT-Prep") was used for the gene of interest determinations. 
Next 5μl of each diluted sample was transferred into a new 96-well plate and diluted 20-fold 
by adding 95μl nano water. This plate (termed "18s RT Prep") was used for the housekeeping 
gene determinations. Both plates were stored at -20oC pending the subsequent PCR step. 
A set of standards was prepared using RNA pooled from placentomes sampled from control-
intake ewes at 130 days gestation (consisting of 6 cotyledon and 6 caruncular samples, 
respectively). To begin, 123μl RT Mastermix was added to 77μl of standard at 3.9ng/μl dilution 
in a 0.5ml thin-walled PCR eppendorf tube and then processed through the thermal cycler 
exactly as described above. Following the reaction the standard was diluted five-fold by 
combining it with 800μl nano water in a fresh 1.5ml eppendorf tube. A 100μl aliquot of this top 
standard was then double diluted down six times (in 50μl nanowater each time) to produce a 
set of seven standards for the GOI RT Prep plate. A further 5μl aliquot was combined with 95μl 
nano water and similarly double diluted to produce seven standards for the 18s RT Prep plate. 
The real-time PCR step utilised custom-designed Taqman probes and primers that had been 
designed for ovine-specific gene sequences using Primer Express (Applied Biosystems), and 
validated in previous experiments (Wallace et al. 2004a; Redmer et al. 2005). Table 4.1 details 
the sequences for the forward and reverse primers and FAM-labelled probes for the following 
11 genes of interest (Genbank accession numbers are given in parentheses, where available): 
 Vascular endothelial growth factor A –VEGFA (X89506) 
 Fms-related tyrosine kinase 1 –FLT1   (AF488351) 
 Kinase insert domain receptor – KDR  (AF233076) 
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 Nitric oxide synthase – NOS3   (AF201926) 
 Fibroblast growth factor 2 – FGF2   (L36136) 
 Angiopoietin 1 – ANGPT1 
 Angiopoietin 2 – ANGPT2 
 Endothelial tyrosine kinase – TEK   (AY288926) 
 Soluble guanylate cyclase – GUCY1B3  (AF486295) 
 Glucose transporter 1 – GLUT1   (U89029) 
 Glucose transporter 3 – GLUT3   (L39214) 
For the PCR, 5μl of each sample from the GOI RT Prep and 18s RT Prep plates and 5μl of each 
standard was added to a 96-well plate using an 8-channel pipette and mixed well with 20μl of 
PCR Mastermix (Applied Biosystems). The volume of each forward/reverse primer and FAM-
labelled probe required to give a final concentration of 900nM (1.125μl per 12.5μl reaction) 
and 250nM (1.125μl per 12.5μl reaction), respectively, was calculated and the working stocks 
of 10μM were diluted accordingly. Finally, 10μl of each sample/standard (with PCR Mastermix) 
was transferred in duplicate into a new 96-well PCR plate, to which was added the necessary 
volume of each primer and probe. Polymerization and amplification reactions were carried out 
for 40 cycles of 95oC for 15 seconds and 60oC for 1 minute using an ABI 7500 Fast Real-Time 
PCR system (Applied Biosystems). mRNA expression was quantified by generating a relative 
standard curve from the serially diluted standard. Individual sample mRNA expression for each 
gene of interest was expressed relative to the sample's own internal 18S RNA using 18S PDAR 
kit reagents (Applied Biosystems). 
4.2.6.8 Assessment of small intestinal crypt cell proliferation 
To assess small intestinal crypt cell proliferation, paraffin-embedded sections of perfuse-fixed 
jejunal tissues were sectioned and immunostained for proliferating cell nuclear antigen (Ki-67) 
at North Dakota State University. Tissue sections were initially treated with a blocking buffer 
consisting of PBS and 1.5% by volume normal horse serum (Vector Laboratories, Burlingame, 
CA, USA) for 20 minutes before being incubated with primary mouse monoclonal anti-Ki-67 
antibody 1:100 concentration (Clone MM1, Vector Laboratories). Following treatment with the  
secondary antibody (ImmPress™ anti-mouse immunoglobulin (peroxidase) polymer detection 
kit, Ref. MP7402, Vector Laboratories) and DAB substrate, tissue sections were counterstained 
with hematoxylin. From each animal five tissue sections were photographed and subjected to 
image analysis using Image Pro Plus 5.0 software (MediaCybernetics, Inc., Silver Spring, MD).
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Table 4.1 - Forward/reverse primers and probes for placental RT-PCR analyses 
Oligonucleotide Nucleotide sequence 
VEGFA forward primer 5'-GGA TGT CTA CCA GCG CAG C-3' 
VEGFA reverse primer 5'-TCT GGG TAC TCC TGG AAG ATG TC-3' 
VEGFA probe 5'(6FAM)-TCT GCC GTC CCA TTG AGA CCC TG-(TAMRA)3' 
FLT1 forward primer 5-TGG ATT TCA GGT GAG CTT GGA-3' 
FLT1 reverse primer 5'-TCA CCG TGC AAG ACA GCT TC-3' 
FLT1 probe 5' (6FAM)-AAA ATG CCT GCG GAA GGA GAG GAC C-(TAMRA)3' 
KDR forward primer 5'-CTT CCA GTG GGC TGA TGA CC-3' 
KDR reverse primer 5'-GCA ACA AAC GGC TTT TCA TGT-3' 
KDR probe 5'(6FAM)-AGA AGA ACA GCA CGT TCG TCC GGG-(TAMRA)3' 
NOS3 forward primer 5'-CAG CGG CTG GTA CAT GAG C-3' 
NOS3 reverse primer 5'-TTG TAG CGG TGA GGG TCA CA-3' 
NOS3 probe 5'(6FAM)-CGG AGA TTG GCA CGC GGA ACC-(TAMRA)3' 
FGF2 forward primer 5'-CGA CGG CCG AGT GGA C-3' 
FGF2 reverse primer 5'-CTC TCT TCT GCT TGA AGT TGT AGT TTG-3' 
FGF2 probe 5'(6FAM)-TCC GCG AGA AGA GCG ACC CTC AC-(TAMRA)3' 
ANGPT1 forward primer 5'-AAA TGA AAA GCA GAA CTA CAG GTT GTA T-3' 
ANGPT1 reverse primer 5'-GCA AGA TCA GGC TGC TCT GTT-3' 
ANGPT1 probe 5'(6FAM)-TGA AGG GTC ACA CTG GGA CAG CAG G-(TAMRA)3' 
ANGPT2 forward primer 5'-AAA TAG GGA CCA ACC TGC TCA A-3' 
ANGPT2 reverse primer 5'-TGT TGT CTG ATT TAA TAC TTG GGC TT-3' 
 
ANGPT2 probe 
 
5'(6FAM)-CTG CAG AGC AGA TCC GGA AGT TAA CAG ATG T-(TAMRA)3' 
TEK forward primer 5'-CCT CGG AGG CAG GAA GAT G-3' 
TEK reverse primer 5'-TCA GGC AGG TCA TTC CCG-3' 
TEK probe 5'(6FAM)-TGC TTA TCG CCA TCC TCG GCT CA-(TAMRA)3' 
GUCY1B3 forward primer 5'-CCG AGC CGT GCA TCC A-3' 
GUCY1B3 reverse primer 5'-ATC TCC ATC ATG TCC AAG GCC -3' 
GUCY1B3 probe 5'(6FAM)-CAT GCA CGG TCC ATC TGC CAC C-(TAMRA)3' 
GLUT1 forward primer 5′-TGC TCA TTA ACC GCA ACG AG -3′ 
GLUT1 reverse primer 5′-GGT CCC ACG CAG CTT CTT C-3′ 
GLUT1 probe 5′(6FAM)-AGA ACC GGG CCA AGA GCG TGC-(TAMRA)3′ 
GLUT3 forward primer 5′-TTT GGA AGA ACG GTC AGA AAC A-3′ 
GLUT3 reverse primer 5′-CAG ACA AGG ACC ACA GGG ATG-3′ 
GLUT3 probe 5′(6FAM)-CCC CGT CCA GCG TGC TCC TC-(TAMRA)3′ 
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The number of proliferating and non-proliferating epithelial cells was counted and the labelling 
index was determined as the proportion of proliferating cells, expressed per unit of tissue area. 
Representative images from two individual fetuses selected from the H+Ad.VEGF and C+Saline 
groups are in presented in Figure 4.11. 
4.2.7 Statistical analyses 
After testing for normality of the data and equality of variance using Q-Q plots and Levene's 
test, respectively, comparisons were made between the two nutritional regimes (prior to the 
allocation of high-intake ewes to H+Ad.VEGF, H+Saline and H+Ad.LacZ groups) using Student’s 
t test. Subsequently, comparisons between the four main study groups were made using one-
way ANOVA. Following any significant F-test result (p<0.05) post-hoc pairwise comparisons 
were performed using the test of least significant difference (LSD). Post-hoc tests were also 
performed where F values tended towards significance (p<0.1). Correlations were assessed 
using Pearson’s product moment test. For the UtA analyses, General Linear Model was used to 
assess differences between study groups whilst taking into account the level of branching 
(UtA1-3) and uterine horn (gravid/non-gravid). All data are presented as mean ± standard error 
of the mean (SEM) unless otherwise stated. Formal statistical significance was considered to 
have been reached where p <0.05 and a tendency towards significance was defined as p<0.1. 
4.3 Results 
Full datasets (comprising UBF, serial ultrasound and necropsy data) were collected in 57 of 60 
animals. One ewe in the H+Saline group was euthanased on welfare grounds on post-operative 
day 3 following persistent inappetance and signs of distress. At post-mortem examination 
there was found to have been trauma to an avascular area of the bowel mesentery during 
exteriorisation of the flow probe. Another ewe in the H+Saline group (and carrying a very large 
fetus) developed a hernia as a late complication of surgery 4 weeks post-op. A decision was 
made to omit her fifth time point ultrasound scan (119 days gestation) due to the risk of bowel 
strangulation, however she remained well and a final ultrasound examination was performed 
on the day prior to necropsy (131 days gestation). At post-mortem a paramedian defect in the 
rectus sheath was identified, through which the abdominal viscera had herniated. The suture 
line remained intact. Finally, one ewe in the H+Ad.VEGF group was fitted with a flow probe 
which subsequently failed to function in vivo. Therefore UBF data in the latter group was 
limited to 17 of 18 animals. 
In addition, two animals were excluded from further analysis. One ewe in the H+Saline group 
was identified as an extreme outlier with respect to UBF measurements (756ml/min at 
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Figure  4.11 – Evaluation of small intestinal crypt cell proliferation by immunhistochemistry 
 
Sections of fetal jejunum immunostained with anti Ki-67 antibodies to determine the number of 
proliferating cells within the small intestinal crypts by image analysis. A = example taken from 
the growth-restricted fetus of a high-intake ewe treated with Ad.VEGF. B = example taken from 
a non-growth restricted fetus of a control-intake ewe treated with Saline. There were no 
significant differences between study groups for any indices. 
  
baseline in mid-pregnancy; >4 standard deviations above the mean of 324ml/min). A Q-Q plot 
demonstrated that her measurements lay well outside the normal distribution. A second ewe, 
also in the H+Saline group, was excluded after she was found to have a congenital abnormality 
of the reproductive tract (uterus didelphys) resulting in restriction of her pregnancy to a single 
uterine horn (see Section 4.3.4.6 for a full description). Data from all remaining pregnancies in 
the H+Saline (n=13), H+Ad.LacZ (n=14), H+Ad.VEGF (n=18) and C+Saline groups (n=14) is 
presented below. All data are reported as mean ± SEM unless otherwise specified. 
4.3.1 Baseline characteristics prior to gene therapy administration 
4.3.1.1 Maternal weight and adiposity 
Table 4.2 shows baseline characteristics in the four experimental groups at the time of embryo 
transfer, summarised retrospectively. Despite randomisation for live weight and BCS 
(adiposity) of adolescent recipients following embryo transfer, those actually conceiving after 
allocation to a control diet were initially heavier than those conceiving after allocation to a 
high intake diet (46.5±0.43 vs. 44.2±0.28 kg, p<0.001). All ewes had an initial BCS score of 
either 2¼ or 2½ and there were no significant differences in these proportions between study 
A B 
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Table 4.2 – Baseline maternal  characteristics at the time of embryo transfer and donor source 
A C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P 
Value 
Live weight (kg) 46.5 ± 0.43a 44.2 ± 0.45b 44.3 ± 0.60b 44.2 ± 0.45b 0.005 
BCS (units) 2 ± 0.04 2 ± 0.01 2 ± 0.02 2 ± 0.00 0.692 
Ovulation rate 2 ± 0.4 2 ± 0.3 2 ± 0.3 2 ± 0.1 0.701 
 
Embryo Donor ID 
B 1 2 3 4 5 6 7 8 9 10 11 12 13 
C+Saline 1 1  1 1 2 2    2 1 1 
H+Ad.VEGF 2 1  1 2 3 2  1 1 2  3 
H+Saline 2  1  1 3 1 2  1 1  1 
H+Ad.LacZ 2 1 1 1  2 1  1  3 1 1 
 
BCS values were compared using Chi square test. Remaining P values shown in Table A are for 
overall ANOVA. Mean values within a row with unlike superscripts are significantly different 
(p=<0.05 for individual comparisons, see text for details). 
  
groups. Despite these initial live weight differences, overnourished ewes soon overtook 
control-intake ewes in terms of body weight and adiposity, as per the experimental design 
(Figure 4.12). Thus, maternal live weight and adiposity score were greater in overnourished 
relative to control-intake ewes from ~42 days gestation (54.8±0.50 vs. 52.3±1.23 kg, p=0.037 
and 2.5±0.02 vs. 2.3±0.04, p<0.001, respectively).  
There were no significant differences in initial live weight or BCS at the time of embryo transfer 
between overnourished ewes subsequently allocated to H+Ad.VEGF, H+Saline or H+Ad.LacZ 
groups. With respect to maternal genetics, embryos derived from 9 of 13 adult donor ewes 
were represented in the animals that conceived in both control-intake and overnourished 
cohorts, and there was a reasonably even spread in embryo source across the H+Ad.VEGF, 
H+Saline and H+Ad.LacZ groups. Finally, recipient ovulation rate was evenly matched across all 
four groups. 
At the last time point prior to gene therapy administration at 89±0.2 days gestation, maternal 
live weight and BCS remained significantly greater in overnourished versus control-intake ewes  
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Figure 4.12 – Changes in maternal live weight and adiposity prior to gene therapy surgery  
 
 
Changes in maternal live weight [A] and body condition score [B] between embryo transfer and 
mid-gestation in  singleton-bearing adolescent dams offered a control-intake (C) or high-intake 
(H) diet to generate normal or compromised fetoplacental growth, respectively, and 
subsequently receiving bilateral uterine artery injections of Ad.VEGF, Ad.LacZ or saline. 
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(67.0±0.89 vs. 61.0±2.03 kg, p=0.005 and 2.7±0.19 vs. 2.4±0.04, p<0.001, respectively). 
Maternal live weight was not significantly different between overnourished ewes subsequently 
allocated to H+Ad.VEGF, H+Saline or H+Ad.LacZ groups, however BCS was marginally lower in 
H+Saline compared to H+Ad.VEGF and H+Ad.LacZ groups at this stage (2.6±0.02 vs. 2.7±0.03 
and 2.7±0.03; p<0.001).   
4.3.1.2 Maternal live weight gain and baseline ultrasound parameters 
Table 4.3 shows the maternal live weight gain (in g/day) between embryo transfer and 
baseline ultrasound measurements (taken at 83±0.1 days gestation) prior to gene therapy by 
experimental group. Following even allocation of overnourished ewes to H+Ad.VEGF, H+Saline 
and H+Ad.LacZ groups on the basis of fetal trunk diameter (TD), abdominal circumference (AC), 
renal volume (RV), placentome index, biparietal diameter (BPD):AC ratio and maternal live 
weight gain, there were unsurprisingly no significant differences between the three groups in 
any of these parameters. There were also no significant differences in any of the other fetal 
biometric parameters (BPD, occipito-snout length (OSL), femur length (FL) or tibia length (TL)), 
deepest vertical pool (DVP) of amniotic fluid or umbilical cord diameter (UCD) between the 
H+Ad.VEGF, H+Saline and H+Ad.LacZ groups. In addition there were no differences in fetal 
biometry between overnourished and control-intake pregnancies. Thus at this stage of 
gestation mean fetal size was equivalent between all four groups. In contrast, placentome 
index was lower in H+Ad.VEGF, H+Saline and H+Ad.LacZ relative to C+Saline groups (p=0.001, 
p=0.0001 and p<0.001, respectively). Overall, prior to gene therapy administration, 
overnourished ewes had higher values of UA PI, RI and SDR than control-intake ewes 
(1.45±0.03 vs. 1.32±0.072, p=0.038; 0.79±0.006 vs. 0.74±0.025, p=0.002; and 4.96±0.195 vs. 
3.75±0.312, p=0.005, respectively). The significance levels for individual comparisons of 
H+Ad.VEGF, H+Saline and H+Ad.LacZ groups against the C+Saline group varied between indices 
(see Table 4.3) however importantly there were no significant differences between 
H+Ad.VEGF, H+Saline and H+Ad.LacZ groups in any of the UA Doppler indices measured. 
4.3.2 Uterine blood flow 
4.13A illustrates serial measurements of UBF through the artery supplying the gravid uterine 
horn by experimental group, from baseline values (92±0.2 days gestation; post-operative day 
3) until final determinations on the day prior to necropsy (130±0.2 days gestation; post-
operative day 41). Significant differences between groups were observed at 94±0.1 and 96±0.1 
days gestation only (overall ANOVA: p=0.045 and p=0.047, respectively). Subsequently there 
were no significant differences between any of the four groups. At 94±0.1 days gestation,
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Table 4.3 – Maternal live weight gain following embryo transfer and baseline ultrasound 
measurements in mid-gestation prior to gene therapy administration 
 C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline  
(n=13) 
H+Ad.LacZ 
 (n=14) 
P 
value 
Live weight gain 
(g/day) 
184 ± 24.3a 297 ± 17.8b 286 ± 26.5b 278 ± 11.7b <0.001 
BPD (mm) 35.3 ± 0.29 35.4 ± 0.30 34.8 ± 0.28 35.6 ± 0.29 0.299 
OSL (mm) 71.0 ± 0.92 70.5 ± 0.85 70.8 ± 0.73 71.3 ± 0.56 0.898 
TD (mm) 53.0 ± 1.21 51.2 ± 0.98 50.3 ± 1.47 51.2 ± 1.00 0.462 
AC (mm) 171 ± 3.4 166 ± 3.2 161 ± 4.0 167 ± 3.1 0.251 
FL (mm) 22.2 ± 0.79 21.7 ± 0.38 21.0 ± 0.36 21.4 ± 0.33 0.375 
TL (mm) 29.2 ± 0.79 29.7 ± 0.45 28.3 ± 0.42 29.4 ± 0.43 0.277 
RV (cm3) 2.38 ± 0.120 2.23 ± 0.129 2.10 ± 0.174 2.36 ± 0.124 0.499 
UA PI 1.32 ± 0.072a 1.43 ± 0.032ab 1.40 ± 0.048ab 1.52 ± 0.059b 0.074 
UA RI 0.74 ± 0.025a 0.78 ± 0.008b 0.79 ± 0.012b 0.78 ± 0.011b 0.014 
UA SDR 3.75 ± 0.312a 4.64 ± 0.189ab 4.92 ± 0.274b 4.70 ± 0.513b 0.014 
BPD:AC ratio 0.21 ± 0.003 0.22 ± 0.004 0.22 ± 0.004 0.21 ± 0.002 0.341 
DVP (cm) 4.61 ± 0.332 4.71 ± 0.256 4.88 ± 0.250 4.55 ± 0.294 0.866 
UCD (mm) 12.7 ± 0.24 12.9 ± 0.25 12.2 ± 0.33 12.7 ± 0.36 0.312 
Plac. index (cm2) 5.43 ± 0.256a 4.24 ± 0.233b 4.14 ± 0.246b 3.75 ± 0.229b <0.001 
 
Maternal live weight gain (g/day) between embryo transfer and 83±0.2 days gestation and 
baseline ultrasound measurements prior to gene therapy administration. P values shown in the 
table are for overall ANOVA. Mean values within a row with unlike superscripts are significantly 
different (p=<0.05 for individual comparisons, see text for details). 
  
relative to the C+Saline group, UBF was significantly reduced in the H+Ad.LacZ group (401±27.9 
vs. 291±16.3 ml/min, p=0.006) and tended to be reduced in the H+Saline group (401±27.9 vs. 
324±32.9 ml/min, p=0.053). UBF was reduced in both H+Saline and H+Ad.LacZ versus C+Saline 
groups at 96±0.1 days gestation (339±30.8 and 310±19.7 vs. 426±29.5 ml/min, p=0.042 and 
p=0.007, respectively).  
As there were no significant differences between the H+Ad.Saline and H+Ad.LacZ groups at any
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Figure 4.13 – Uterine blood flow 
 
 
Serial measurements of uterine blood flow from 92±0.2 days until 130±0.2 days gestation in 
singleton-bearing adolescent dams offered a control-intake (C) or high-intake (H) diet and 
receiving bilateral uterine artery injections of Ad.VEGF, Ad.LacZ or saline. * p<0.05. P values 
shown are for overall ANOVA - see text for significance levels of individual comparisons.  
A 
B
B 
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stage, these were combined into one group (H+Saline/Ad.LacZ) for comparison with C+Saline 
and H+Ad.VEGF groups (Figure 4.13B). This approach revealed a tendency towards an 
additional difference at 92±0.2 days gestation (overall ANOVA: p=0.081) and post-hoc testing 
demonstrated a significant reduction in UBF in the H+Saline/Ad.LacZ group relative to the 
C+Saline group at this stage (306±18.9 vs. 384±29.4 ml/min, p=0.032). UBF was also reduced in 
H+Saline/Ad.LacZ versus C+Saline groups at 94±0.1 and 96±0.1 days gestation (p=0.007 each). 
UBF in the H+Ad.VEGF group was not significantly different to any other group at any stage of 
gestation (using either approach). 
UBF at all time points was weakly correlated with eventual fetal and placental weight at late-
gestation necropsy (r=0.358–0.526, n=56, p<0.001–0.007; and r=0.321–0.526, n=56, p<0.001–
0.009, respectively). Average UBF from 92±0.2 to 130±0.2 days gestation was not significantly 
different between C+Saline, H+Ad.VEGF, H+Saline and H+Ad.LacZ groups (456±27.4, 434±34.1, 
435±41.1 and 389±22.4 ml/min, respectively) and was also correlated with fetal and placental 
weight (r=0.453, n=56, p=0.001; and r=0.438, n=56, p=0.001, respectively). Mean change in 
UBF from 92 to 130 days gestation was not different between C+Saline, H+Ad.VEGF, H+Saline 
and H+Ad.LacZ groups (134±96.3, 188±100.6, 201±115.1 and 176±78.6 ml/min, representing 
fold changes of 0.35, 0.61, 0.63 and 0.60, respectively) and was not correlated with 
subsequent fetal or placental weight. Neither individual or summary measurements of UBF 
demonstrated any significant correlation with umbilical arterial Doppler indices (reported in 
Sections 4.3.3.6 and 4.3.3.7) or measures of vascular reactivity from the organ bath analysis of 
harvested uterine arteries (see Section 4.3.5.4). 
4.3.3 Ultrasound parameters 
The following sections report the serial changes in the various ultrasound markers throughout 
the second half of gestation.  
4.3.3.1 Abdominal circumference 
Figure 4.14 shows serial measurements of abdominal circumference by experimental group. 
AC measurements were reduced in all three overnourished groups (H+Ad.VEGF, H+Saline and 
H+Ad.LacZ) relative to the C+Saline group at 105±0.1 days (223±2.9, 217±2.7 and 219±2.9 vs. 
235±2.3 mm, p=0.003, p<0.001 and p<0.001, respectively), 112±0.1 days (241±2.8, 233±2.3 
and 233±2.5 vs. 257±3.9 mm; p<0.001), 119±0.1 days (258±3.1, 249±2.3 and 248±2.8 vs. 
274±3.3 mm; p<0.001) and 126±0.3 days gestation (272±4.3, 262±1.8 and 264±4.5 vs. 286±2.4 
mm, p=0.011, p<0.001 and p<0.001, respectively). AC measurements were increased in 
H+Ad.VEGF relative to H+Saline and H+Ad.LacZ groups at 112 (p=0.031 and p=0.047,
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Figure 4.14 – Fetal abdominal circumference 
 
Serial ultrasound measurements of fetal abdominal circumference at weekly intervals between 
83±0.1 days and 126±0.3 days gestation in singleton-bearing adolescent dams offered a 
control-intake (C) or high-intake (H) diet and receiving bilateral uterine artery injections of 
Ad.VEGF, Ad.LacZ or saline. *** p<0.001. P values shown are for overall ANOVA - see text for 
significance levels of individual comparisons. Letters A and B indicate time points at which 
measurements in H+Ad.VEGF group > H+Saline / H+Ad.LacZ groups (p=<0.05) 
  
respectively) and 119 days gestation (p=0.032 and p=0.016, respectively), which corresponds 
to 22±0.2 and 29±0.2 days post therapy, respectively. 
4.3.3.2 Biparietal diameter 
Serial measurements of biparietal diameter by experimental group are detailed in Figure 
4.15A. There were increasing tendencies towards overall differences between groups at 112, 
119and 126 days gestation (overall ANOVA: p=0.081, p=0.071 and p=0.051, respectively) and 
post-hoc testing revealed a number of significant differences between overnourished and
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Figure 4.15 – Fetal biparietal diameter and BPD:AC ratios 
 
 
Serial ultrasound measurements of biparietal diameter [A] and BPD:AC ratios [B] at weekly 
intervals between 83±0.1 days and 126±0.3 days gestation in singleton-bearing adolescent 
dams offered a control-intake (C) or high-intake (H) diet and receiving bilateral uterine artery 
injections of Ad.VEGF, Ad.LacZ or saline. † p=0.05-0.1, *** p<0.001. P values shown are for 
overall ANOVA - see text for significance levels of individual comparisons. Letters A, B and C 
indicate points at which measurements in H+Ad.VEGF > H+Saline / H+Ad.LacZ groups (p=<0.05) 
B
B 
A 
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control-intake fetuses at these time points. At 112 days gestation, BPD was reduced in 
H+Ad.VEGF and H+Saline groups versus the C+Saline group (47.9±0.61 and 47.8±0.27 vs. 
49.5±0.22 mm; p=0.021 and p=0.025, respectively). At 119 days gestation, BPD was reduced in 
all three overnourished groups (H+Ad.VEGF, H+Saline and H+Ad.LacZ) relative to the C+Saline 
group (50.2±0.76, 50.3±0.29 and 50.3±0.44 vs. 52.2±0.33 mm; p=0.016, p=0.037 and p=0.034, 
respectively). At 126 days gestation, BPD was reduced only in H+Ad.VEGF relative to C+Saline 
groups (52.2±0.81 vs. 54.7±0.29 mm, p=0.006). BPD measurements in the H+Ad.VEGF group 
were not significantly different to the H+Saline or H+Ad.LacZ groups at any stage. 
4.3.3.3 BPD : AC ratio 
From the above measurements, the BPD to AC ratio was calculated at each gestational time 
point (Figure 4.15B). BPD:AC ratios were increased in H+Ad.VEGF, H+Saline and H+Ad.LacZ 
groups relative to C+Saline groups at 105 days gestation (0.20±0.002, 0.21±0.002 and 
0.21±0.003 vs. 0.19±0.002; p=0.012, p<0.001 and p<0.001, respectively). Subsequently only 
H+Saline and H+Ad.LacZ groups differed from the C+Saline group and were increased at 112 
(0.21±0.002 and 0.21±0.001 vs. 0.19±0.003; p<0.001), 119 (0.20±0.002 and 0.21±0.003 vs. 
0.19±0.001; p=0.002 and p<0.001, respectively) and at 126 days gestation (0.20±0.002 and 
0.20±0.002 vs. 0.19±0.001; p<0.001). BPD:AC ratios were attenuated in H+Ad.VEGF relative to 
H+Saline and H+Ad.LacZ groups at 112 (p=0.007 and p=0.016, respectively), 119 (p=0.016 and 
p<0.001, respectively) and 126 days gestation (p<0.001). 
4.3.3.4 Renal volume 
Figure 4.16 depicts serial measurements of renal volume by experimental group. At 105 days 
gestation there was a tendency towards an overall difference between groups (p=0.076) and 
post-hoc testing revealed a significant difference between H+Saline and C+Saline groups only 
(4.3±0.24 vs. 5.2±0.19 cm3, p=0.012). Subsequently RV measurements were reduced in all 
three overnourished groups (H+Ad.VEGF, H+Saline and H+Ad.LacZ) relative to the C+Saline 
group at 112 (5.9±0.28, 5.4±0.22 and 5.3±0.21 vs. 6.6±0.16 cm3; p=0.038, p=0.002 and 
p=0.001, respectively), 119 (7.0±0.33, 6.3±0.24 and 6.4±0.24 vs. 8.3±0.39 cm3; p=0.003, 
p<0.001 and p<0.001, respectively) and at 126 days gestation (8.7±0.47, 8.2±0.24 and 8.1±0.42 
vs. 10.0±0.35 cm3; p=0.027, p=0.004 and p=0.002, respectively). RV values in the H+Ad.VEGF 
group were not significantly different to the H+Saline or H+Ad.LacZ groups at any stage. 
4.3.3.5 Femur length and tibia length 
Serial ultrasound measurements of femur length by experimental group are shown in Figure
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Figure 4.16 – Fetal renal volume 
 
Serial ultrasound measurements of renal volume at weekly intervals between 83±0.1 days and 
126±0.3 days gestation in singleton-bearing adolescent dams offered a control-intake (C) or 
high-intake (H) diet and receiving bilateral uterine artery injections of Ad.VEGF, Ad.LacZ or 
saline. † p=0.05-0.1, ** p<0.01, *** p<0.001. P values shown are for overall ANOVA - see text 
for significance levels of individual comparisons. 
  
4.17A. At 98 days gestation there was a tendency towards a difference between groups 
(overall ANOVA p=0.07). Post-hoc testing revealed a significant difference between H+Saline 
and C+Saline groups (29.5±0.54 vs. 31.6±0.62 mm, p=0.017). FL measurements also tended to 
be reduced in H+Ad.VEGF versus C+Saline groups (30.0±0.55 vs. 31.6±0.62 mm, p=0.056). 
Subsequently FL measurements were reduced in all overnourished (H+Ad.VEGF, H+Saline and 
H+Ad.LacZ) groups relative to C+Saline groups at 105 (36.2±0.73, 36.1±0.55 and 36.8±0.50 vs. 
39.0±0.46 mm; p=0.002, p=0.003 and p=0.019, respectively) and 119 days (49.3±0.68, 
47.8±0.75 and 49.0±0.79 vs. 53.6±0.69 mm; p<0.001) but not at 112 or 126 days gestation. FL 
measurements in the H+Ad.VEGF group were not significantly different to the H+Saline or 
H+Ad.LacZ groups at any stage. 
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Figure 4.17 – Fetal femur and tibia lengths 
 
 
Serial ultrasound measurements of femur length [A] and tibia length [B] at weekly intervals 
between 83±0.1 days and 126±0.3 days gestation in singleton-bearing adolescent dams offered 
a control-intake (C) or high-intake (H) diet and receiving bilateral uterine artery injections of 
Ad.VEGF, Ad.LacZ or saline. * p<0.05, ** p<0.01, *** p<0.001. P values shown are for overall 
ANOVA - see text for significance levels of individual comparisons. 
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Figure 4.17B details serial ultrasound measurements of tibia length by experimental group. TL 
measurements were reduced in H+Ad.VEGF, H+Saline and H+Ad.LacZ groups relative to 
C+Saline groups at 119±0.1 days gestation only (65.9±1.00, 65.2±0.63 and 65.3±1.08 vs. 
69.9±1.23 mm; p=0.009, p=0.005 and p=0.004, respectively). TL values in the H+Ad.VEGF group 
were not significantly different to the H+Saline or H+Ad.LacZ groups at any stage. 
4.3.3.6 Umbilical artery Doppler indices 
Values of all umbilical artery Doppler indices decreased progressively with advancing 
gestation. Variability within groups was greater for Doppler indices than for fetal biometry.  
Figure 4.18A shows serial ultrasound measurements of umbilical artery pulsatility index by 
experimental group. UA PI was higher in H+Ad.VEGF, H+Ad.Saline and H+Ad.LacZ groups 
relative to C+Saline groups at 98 (1.26±0.029, 1.25±0.048 and 1.26±0.034 vs. 1.03±0.039; 
p<0.001), 119 (1.07±0.046, 1.03±0.038 and 1.08±0.033 vs. 0.90±0.033; p=0.003, p=0.033 and 
p=0.002, respectively) and 126days gestation (1.07±0.045, 1.10±0.038 and 1.06±0.033 vs. 
0.89±0.037; p=0.002, p=0.001 and p=0.006, respectively). At 105 days gestation there was a 
tendency towards a difference between groups (overall ANOVA p=0.068) and post-hoc testing 
revealed significant differences in H+Ad.VEGF and H+Ad.LacZ versus C+Saline groups 
(1.17±0.081 and 1.15±0.038 vs. 0.96±0.026; p=0.012 and p=0.031). UA PI measurements also 
tended to be increased in H+Saline versus C+Saline groups (1.11±0.040 vs. 0.96±0.026; 
p=0.098). UA PI measurements in the H+Ad.VEGF group were not different to the H+Saline or 
H+Ad.LacZ groups at any stage. 
Serial ultrasound measurements of umbilical artery resistance index by experimental group are 
illustrated in Figure 4.18B. UA RI was increased in H+Ad.VEGF, H+Ad.Saline and H+Ad.LacZ 
groups relative to C+Saline groups at 98 (0.72±0.008, 0.73±0.013 and 0.73±0.011 vs. 
0.66±0.014; p<0.001), 105 (0.70±0.018, 0.68±0.016 and 0.70±0.013 vs. 0.63±0.011; p=0.003, 
p=0.039 and p=0.004, respectively) and 126 days gestation (0.65±0.014, 0.66±0.013 and 
0.65±0.012 vs. 0.59±0.015; p=0.003, p=0.001 and p=0.006, respectively). At 112 days gestation, 
UA RI was increased in H+Ad.VEGF and H+Ad.LacZ groups only relative to the C+Saline groups 
(0.69±0.020 and 0.67±0.012 vs. 0.61±0.016; p=0.002 and p=0.016, respectively). At 119 days 
gestation, UA RI was significantly higher in H+Ad.VEGF and H+Ad.LacZ relative to C+Saline 
groups (0.65±0.015 and 0.67±0.012 vs. 0.60±0.015; p=0.009 and p=0.002) and there was a 
tendency towards increased UA PI in H+Saline versus C+Saline groups (0.64±0.015 and vs. 
0.60±0.015; p=0.081). UA RI measurements in the H+Ad.VEGF group were not different to the 
H+Saline or H+Ad.LacZ groups at any stage. 
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Figure 4.18 – Umbilical artery pulsatility index and resistance index 
 
 
Serial ultrasound measurements of umbilical arterial pulsatility index [A] and resistance index 
[B] at weekly intervals between 83±0.1 days and 126±0.3 days gestation in 57 singleton-
bearing adolescent dams offered a control-intake (C) or high-intake (H) diet and receiving 
bilateral uterine artery injections of Ad.VEGF, Ad.LacZ or saline. * p<0.05, ** p<0.01, *** 
p<0.001. P values shown are for overall ANOVA - see text for significance levels of individual 
comparisons. 
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Figure 4.19A shows serial ultrasound derived measurements of umbilical arterial systolic to 
diastolic ratio by experimental group. UA SDR was increased in H+Ad.VEGF, H+Saline and 
H+Ad.LacZ groups relative to C+Saline groups at 98 (3.66±0.117, 4.28±0.526 and 3.73±0.143 vs. 
2.74±0.202; p=0.021, p<0.001 and p=0.018, respectively) and 126 days (2.92±0.122, 
3.00±0.117 and 2.78±0.106 vs. 2.28±0.161; p=0.001, p<0.001 and p=0.011, respectively). At 
119 days gestation, UA SDR was increased in H+Ad.VEGF and H+Ad.LacZ versus C+Saline 
groups (3.01±0.189 and 3.05±0.111 vs. 2.35±0.129; p=0.003) and there was a tendency 
towards increased UA PI in H+Saline versus C+Saline groups (2.81±0.121 and vs. 2.35±0.129; 
p=0.055). UA SDR measurements in the H+Ad.VEGF group were not different to the H+Saline 
or H+Ad.LacZ groups at any stage. 
4.3.3.7 Umbilical cord diameter 
Serial ultrasound measurements of umbilical cord diameter by experimental group are shown 
in Figure 4.19B. UCD was reduced in H+Saline and H+Ad.LacZ groups relative to the C+Saline 
group at 98 (14.3±0.32 and 14.8±0.24 vs. 15.8±0.33 mm, p=0.002 and p=0.031, respectively), 
105 (15.7±0.25 and 16.3±0.25 vs. 17.6±0.39 mm, p<0.001 and p=0.01, respectively) and 112 
days gestation (17.2±0.28 and 17.7±0.33 vs. 19.1±0.47 mm, p=0.001 and p=0.012, 
respectively). At these time points, UCD measurements also tended to be reduced in 
H+Ad.VEGF versus C+Saline groups (p=0.064, p=0.097 and p=0.05, respectively). Subsequently 
UCD was decreased in all overnourished (H+Ad.VEGF, H+Saline and H+Ad.LacZ) groups relative 
to the C+Saline group, at 119 (19.8±0.42, 18.7±0.34 and 19.5±0.30 vs. 21.2±0.39 mm; p=0.012, 
p<0.001 and p=0.007, respectively) and at 126 days gestation (21.2±0.51, 20.2±0.29 and 
20.6±0.46 vs. 22.9±0.42 mm; p=0.009, p<0.001 and p=0.001, respectively). UCD was increased 
in the H+Ad.VEGF group relative to the H+Saline (but not H+Ad.LacZ) group at 105 and 119 
days gestation (p=0.02 and p=0.049). 
4.3.3.8 Placentome index 
Figure 4.20A shows serial ultrasound measurements of placentome index by group. Mean 
placentome index progressively decreased with advancing gestation between mid and late 
pregnancy and was reduced in all overnourished (H+Ad.VEGF, H+Saline and H+Ad.LacZ) groups 
relative to the C+Saline group at 98 (3.85±0.230, 3.54±0.231 and 3.58±0.201 vs. 4.71±0.243 
cm2; p=0.011, p=0.001 and p=0.002, respectively), 105 (3.23±0.200, 3.01±0.225 and 
3.04±0.161 vs. 4.25±0.230 cm2; p=0.001, p<0.001 and p<0.001, respectively), 112 (3.00±0.181, 
2.81±0.235 and 2.74±0.123 vs. 3.86±0.218 cm2; p=0.002, p=0.001 and p<0.001, respectively), 
119 (2.86±0.180, 2.66±0.209 and 2.53±0.087 vs. 3.82±0.204 cm2, all p<0.001) and 126 days
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Figure 4.19 – Umbilical artery systolic to diastolic ratio and umbilical cord diameter 
 
 
Serial ultrasound measurements of umbilical artery systolic to diastolic ratios [A] and umbilical 
cord diameter [B] at weekly intervals between 83±0.1 days and 126±0.3 days gestation in 57 
singleton-bearing adolescent dams offered a control-intake (C) or high-intake (H) diet and 
receiving bilateral uterine artery injections of Ad.VEGF, Ad.LacZ or saline. * p<0.05, ** p<0.01, 
*** p<0.001. P values shown are for overall ANOVA - see text for significance levels of 
individual comparisons. 
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Figure 4.20 – Placentome index and deepest vertical pool of amniotic fluid 
 
 
Serial ultrasound measurements of placentome index [A] and deepest vertical pool of liquor [B] 
at weekly intervals between 83±0.1 days and 126±0.3 days gestation in singleton-bearing 
adolescent dams offered a control-intake (C) or high-intake (H) diet and receiving bilateral 
uterine artery injections of Ad.VEGF, Ad.LacZ or saline. ** p<0.01, *** p<0.001. P values shown 
are for overall ANOVA - see text for significance levels of individual comparisons. 
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gestation (2.76±0.163, 2.75±0.219 and 2.66±0.200 vs. 3.67±0.181 cm2; p=0.001, p=0.002 and 
p=0.001, respectively). Measurements of placentome index in the H+Ad.VEGF group were not 
significantly different to the H+Saline or H+Ad.LacZ groups at any stage. Placentome index at 
the final time point (126 days gestation) correlated with total placental weight at necropsy 
irrespective of treatment group (r=0.672, n=57, p<0.001), and in H+Ad.VEGF (r=0.681, n=18, 
p=0.002), H+Saline (r=0.708, n=13, p=0.007) and H+Ad.LacZ (r=0.698, n=18, p=0.006) but not 
C+Saline groups (r=–0.175, n=12, p=0.587). 
4.3.3.9 Deepest vertical pool of liquor 
Serial ultrasound measurements of DVP by experimental group are illustrated in Figure 4.20B. 
DVP progressively decreased with advancing gestation. There were no differences between 
any of the four groups at any stage. 
4.3.4 Necropsy parameters 
4.3.4.1 Maternal characteristics 
Table 4.4 summarises maternal parameters at the time of necropsy. Maternal weight, BCS and 
weight of the liver, perirenal fat depots and residual carcass were all significantly increased in 
H+Ad.VEGF, H+Saline and H+Ad.LacZ groups relative to the C+Saline group (p<0.001 for all 
individual comparisons). There were no differences in the absolute weight of maternal blood 
(an index of maternal blood volume) or uterine weight (either before or after removal of the 
fetus and placenta). However, the relative weight of maternal blood (expressed per kg live 
weight) was significantly lower in all three overnourished groups compared to the control-
intake group. There were no differences in any maternal parameters between the H+Ad.VEGF, 
H+Saline and H+Ad.LacZ groups. 
4.3.4.2 Fetal and placental weight 
Fetal weight at necropsy (131±0.2 days gestation) was reduced in all overnourished groups 
relative to the C+Saline group (Figure 4.21). Total placental weight was also reduced in 
H+Ad.VEGF, H+Saline and H+Ad.LacZ (see Table 4.5) compared to C+Saline groups (p<0.001, 
p=0.001 and p<0.001, respectively). There were no significant differences in fetal or placental 
weight between H+Ad.VEGF, H+Saline and H+Ad.LacZ groups. Fetal to placental weight ratio 
was highest in the H+Ad.VEGF group and was increased relative to the C+Saline group 
(p=0.009). Fetal to placental weight ratios were intermediate in H+Saline and H+Ad.LacZ 
groups (i.e. not significantly different to either H+Ad.VEGF or C+Saline groups).  
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Table 4.4 – Maternal live weight, body condition score and internal organ weights at point of 
necropsy in late gestation 
 C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P  
Value 
Live weight (kg) 65.74 ± 0.58a 81.36 ± 1.11b 80.54 ± 1.33b 81.17 ± 1.19b <0.001 
BCS (units) 2.35 ± 0.037a 2.93 ± 0.027b 2.90 ± 0.035b 2.95 ± 0.028b <0.001 
Perirenal fat 
weight (kg) 
543 ± 51.9a 1407 ± 83.7b 1308 ± 105.1b 1286 ± 78.0b <0.001 
Liver weight (kg) 854 ± 21.6a 1183 ± 34.1b 1183 ± 36.5b 1177 ± 46.7b <0.001 
Gravid tract 
weight (g) 
8404 ± 332.9 7670 ± 247.2 7452 ± 396.7 7114 ± 428.2 0.098 
Residual uterus 
weight (g) 
686.2 ± 29.95 624.7 ± 25.84 603.7 ± 23.02 604.6 ± 33.92 0.193 
Blood weight (g) 1984 ± 72.9 2175 ± 78.5 2028 ± 120.2 2082 ± 123.8 0.540 
Carcass (kg) 39.09 ± 0.74a 51.19 ± 0.58b 51.25 ± 0.76b 50.5 ± 0.76b <0.001 
Fat / live weight 
(g/kg) 
8.3 ± 0.78a 17.3 ± 1.10b 16.2 ± 1.19b 15.8 ± 0.91b <0.001 
Liver / live weight 
(g/kg) 
13.0 ± 0.32a 14.5 ± 0.35b 14.7 ± 0.37b 14.5 ± 0.45b 0.016 
Blood / live weight 
(g/kg) 
30.1 ± 0.97a 26.7 ± 0.79b 25.3 ± 1.43b 25.6 ± 1.50b 0.033 
 
P values shown in the table are for overall ANOVA. Mean values within a row with unlike 
superscripts are significantly different (p=<0.05 for individual comparisons, see text for details). 
  
For the three overnourished groups, the number of fetuses falling more than two standard 
deviations below the control-intake group mean was determined as an indicator of the 
incidence of "marked" FGR. In the present study, the mean weight in the C+Saline group was 
5084g and the standard deviation was 431g, therefore the threshold for diagnosis of marked 
FGR was <4222g. Proportions of fetuses above and below this cut-off in the H+Ad.VEGF, 
H+Saline and H+Ad.LacZ groups are presented in Figure 4.22. For the purpose of statistical 
analysis, in view of the presence of frequency < 5 in one of the cells in the 2 x 3 contingency 
table and the fact that there were no statistically significant difference between H+Saline and 
H+Ad.LacZ groups, these two groups were combined as one group (H+Saline/Ad.LacZ) to 
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Figure 4.21 – Fetal weight at necropsy 
 
Fetal weight at late gestation necropsy (131±0.2 days gestation) in singleton pregnancies in  
adolescent dams offered a control-intake (C) or high-intake (H) diet and receiving bilateral 
uterine artery injections of Ad.VEGF, Ad.LacZ or saline. P values shown are for individual post-
hoc comparisons using the test of least significant difference (overall ANOVA p<0.001). 
  
Table 4.5 – Fetal and placental weights and weight ratio (placental efficiency) at necropsy 
 C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P 
Value 
Fetal weight (g) 5084 ± 124
a
 4395 ± 188
b
 4153 ± 202
b
 4008 ± 234
b
 0.003 
Placental weight (g) 802 ± 36.1
a
 594 ± 33.5
b
 595 ± 42.4
b
 570 ± 37.2
b
 <0.001 
Fetal : placental wt ratio 6.45 ± 0.27
a
 7.52 ± 0.25
b
 7.16 ± 0.25
ab
 7.21 ± 0.34
ab
 0.018 
 
P values shown in the table are for overall ANOVA. Mean values within a row with unlike 
superscripts are significantly different (p=<0.05 for individual comparisons, see text for details).  
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Figure 4.22 – Proportions of fetuses categorised as markedly growth-restricted 
 
Numbers of fetuses from overnourished singleton-bearing adolescent dams categorised as 
markedly FGR at late gestation necropsy (131±0.2 days gestation). Marked FGR was defined as 
a fetal weight more than 2 standard deviations below the mean fetal weight of the normally 
grown fetuses of 12 contemporaneous control-intake ewes (<4222g). Fetuses with weights 
>4222g were of similar weight to normally grown controls and therefore termed "non-FGR". In 
mid-gestation ewes received bilateral uterine artery injections of Ad.VEGF or inactive control 
treatment (Ad.LacZ/Saline).  
  
produce a 2 x 2 contingency table. The proportion of fetuses demonstrating marked FGR was 
significantly reduced in H+Ad.VEGF vs. H+Saline/Ad.LacZ groups (p=0.033; Fisher’s exact test). 
Table 4.6 shows the breakdown of total placental weight into its component parts (placentome 
and membrane weight) as well as the total placentome number and its breakdown into 
categories by morphological type and size. Total placentome weight and membrane weight 
were reduced in all overnourished (H+Ad.VEGF, H+Saline and H+Ad.LacZ) groups relative to the 
C+Saline group (all p<0.001; and p=0.01, p=0.009 and p=0.11, respectively). Placentome 
number and mean placentome weight were also reduced in H+Ad.VEGF, H+Saline and 
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Table 4.6 – Indices of placental weight, size and morphology at late gestation necropsy 
 C+Saline 
(n=12) 
H+Ad.VEG
F (n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P  
Value 
Total placental weight (g) 802 ± 36.1
a
 594 ± 33.5
b
 595 ± 42.4
b
 570 ± 37.2
b
 <0.001 
Membrane weight (g) 280 ± 15.9
a
 228 ± 12.9
b
 223 ± 14.0
b
 225 ± 13.9
b
 0.024 
Placentome weight (g) 521 ± 23.8
a
 367 ± 22.8
b
 372 ± 29.6
b
 345 ± 25.0
b
 <0.001 
Placentome number 113 ± 5.2
a
 99 ± 3.6
b
 99 ± 3.2
b
 97 ± 5.4
b
 0.078 
Mean placentome weight (g) 4.7 ± 0.21
a
 3.7 ± 0.22
b
 3.8 ± 0.27
b
 3.6 ± 0.16
b
 0.005 
Type A (%) 41.6 ± 11.46 51.2 ± 8.89 50.9 ± 9.23 50.7 ± 8.10 0.612 
Type B (%) 34.8 ± 6.18 35.4 ± 6.21 39.6 ± 7.69 29.7 ± 7.17 0.803 
Type C (%) 7.4 ± 2.79 4.5 ± 1.82 1.1 ± 0.45 2.2 ± 1.04 0.119 
Type D (%) 16.2 ± 3.86 8.9 ± 2.32 8.5 ± 4.08 17.3 ± 9.35 0.532 
Size > 5cm (%) 2.0 ± 3.51 1.0 ±2.21 0.9 ± 3.79 1.4 ± 9.01 0.234 
Size 2-5cm  (%) 63.8 ± 0.49 62.5 ± 0.43 63.4 ± 0.48 63.3 ± 0.45 0.459 
Size 1-2cm  (%) 15.6 ± 4.25 23.5 ± 4.60 20.7 ± 4.54 20.6 ± 4.41 0.477 
Size < 1cm  (%) 18.6 ±2.15 13.0 ± 3.29 15.0 ± 2.41 14.7 ± 1.98 0.470 
 
P values shown in the table are for overall ANOVA. Mean values within a row with unlike 
superscripts are significantly different (p=<0.05 for individual comparisons, see text for details). 
  
H+Ad.LacZ versus C+Saline groups (p=0.032, p=0.043 and p=0.02; and p=0.003, p=0.006 and 
p=0.001, respectively). There were no significant differences between the three overnourished 
groups for any placental parameters. There were no significant differences between any of the 
four groups with respect to the proportions (% by number) of placentomes of each 
morphological type or in each category of size. Irrespective of treatment group, fetal weight 
was strongly correlated with total placental weight (r=0.776, n=57, p<0.001), placentome 
weight (r=0.735, n=57, p<0.001) and membrane weight (r=0.753, n=57, p<0.001). 
4.3.4.3 Fetal anthropometric measurements and gender distribution 
There were no significant differences in the male to female fetal sex ratio between the four 
experimental groups (see Table 4.7). Post-mortem measurements of biparietal diameter and 
girth at the level of the lowermost rib (ultrasound plane) were reduced in both H+Ad.Saline
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Table 4.7 – Fetal gender distribution and post-mortem physical measurements following late 
gestation necropsy 
 C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
Total 
(n=57) 
Male 7 8 4 7 26 
Female 5 10 9 7 31 
 
 C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P 
Value 
Biparietal head diameter 71.0 ± 0.78a 68.6 ± 1.28ab 66.6 ± 1.12b 66.8 ± 1.00b 0.043 
Girth (level of umbilicus) 363 ± 4.9a 340 ± 6.2b 336 ± 7.2b 328 ± 7.0b 0.006 
Girth (ultrasound plane) 340 ± 5.6a 327 ± 6.4ab 320 ± 5.6b 314 ± 5.9b 0.038 
Length of femoral bone 89.8 ± 1.00a 85.9 ± 1.42b 84.4 ± 1.11b 83.9 ± 1.56b 0.024 
Length of tibial bone 107 ± 1.2a 102 ± 1.9ab 101 ± 1.4b 100 ± 1.9b 0.070 
 
P values shown in the table are for overall ANOVA. Mean values within a row with unlike 
superscripts are significantly different (p=<0.05 for individual comparisons, see text for details). 
  
and H+Ad.LacZ (but not H+Ad.VEGF) relative to C+Saline groups (p=0.013 and p=0.015; p=0.04 
and p=0.006, respectively). There was a tendency towards an overall difference in post-
mortem measurements of tibia length, with post-hoc testing demonstrating a significant 
reduction in H+Saline and H+Ad.LacZ relative to C+Saline groups (p=0.026 and p=0.016) and a 
tendency towards a reduction in the H+Ad.VEGF group (p=0.087). Post-mortem measurements 
of femur length and umbilical girth were reduced in all three overnourished (H+Ad.VEGF, 
H+Saline and H+Ad.LacZ) groups relative to C+Saline groups (p=0.044, p=0.01 and p=0.005; and 
p=0.015, p=0.009 and p=0.001, respectively). There were no statistically significant differences 
for any measurements in the H+Ad.VEGF group relative to the H+Saline or H+Ad.LacZ groups. 
4.3.4.4 Absolute fetal organ weights 
Absolute weights of the fetal internal organs and the weight of the residual carcass, as 
determined at late gestation necropsy are presented in Table 4.8. Weights of the fetal kidneys,
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Table 4.8 – Weights of the major internal organs of the fetus in absolute terms at late gestation 
necropsy 
 C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P 
 Value 
Brain 47.0 ± 0.95 44.1 ± 1.58 44.8 ± 0.79 44.5 ± 1.10 0.431 
Pituitary 0.16 ± 0.014 0.14 ± 0.009 0.14 ± 0.007 0.12 ± 0.006 0.133 
Adrenals 0.50 ± 0.023 0.46 ± 0.022 0.47 ± 0.027 0.50 ± 0.032 0.666 
Pancreas 3.93 ± 0.134 3.75 ± 0.197 3.63 ± 0.287 3.51 ± 0.182 0.582 
Gut (full) 302.5 ± 17.20 271.3 ± 16.44 267.3 ± 15.77 248.4 ± 19.43 0.230 
Stomach 32.64 ± 1.460 30.16 ± 1.207 30.55 ± 0.846 28.52 ± 1.264 0.171 
Small intestine 50.85 ± 2.741 44.59 ± 2.327 48.12 ± 2.450 42.68 ± 2.117 0.109 
Large intestine 14.50 ± 1.084 12.93 ± 0.485 13.31 ± 0.592 12.43 ± 0.754 0.261 
Liver 161.3 ± 6.99
a
 134.1 ± 6.31
b
 131.6 ± 7.80
b
 120.8 ± 9.32
b
 0.007 
Spleen 9.03 ± 0.415 8.10 ± 0.444 8.16 ± 0.736 7.57 ± 0.598 0.374 
Perirenal fat 21.11 ± 0.575
a
 18.23 ± 0.925
b
 18.86 ± 1.047
ab
 17.20 ± 1.088
b
 0.055 
Kidneys 27.49 ± 0.766
a
 25.11 ± 1.171
ab
 23.37 ± 1.136
b
 21.99 ± 1.429
b
 0.019 
Heart 36.71 ± 1.199
a
 33.55 ± 1.475
ab
 30.89 ± 1.289
b
 29.57 ± 1.454
b
 0.007 
Lungs 171.6 ± 10.85
a
 157.9 ± 8.47
ab
 142.3 ± 8.67
b
 128.4 ± 10.78
b
 0.021 
Thymus 7.15 ± 0.447 6.72 ± 0.489 5.95 ± 0.581 6.10 ± 0.661 0.472 
Thyroid 0.97 ± 0.021
a
 0.77 ± 0.069
b
 0.80 ± 0.044
b
 0.74 ± 0.048
b
 0.025 
Testes* 1.84 ± 0.074 1.69 ± 0.121 2.03 ± 0.092 1.98 ± 1.402 0.855 
Ovaries* 0.11 ± 0.014 0.09 ± 0.008 0.12 ± 0.022 0.10 ± 0.012 0.373 
Carcass 3289 ± 92.2
a
 2847 ± 134.7
b
 2779 ± 132.6
b
 2669 ± 157.7
b
 <0.001 
 
P values shown in the table are for overall ANOVA. Mean values within a row with unlike 
superscripts are significantly different (p=<0.05 for individual comparisons, see text for details). 
* Gender distribution between groups = C+Saline: 7 male, 5 female. H+Ad.VEGF: 8 male, 10 
female. H+Saline: 4 male, 9 female. H+Ad.LacZ: 7 male, 7 female. 
  
heart and lungs were reduced in H+Saline and H+Ad.LacZ (but not H+Ad.VEGF) versus C+Saline 
groups (p=0.026 and p=0.003; p=0.008 and p=0.001; p=0.049 and p=0.004, respectively). 
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Weights of the fetal liver, thyroid and carcass were reduced in all three overnourished 
(H+Ad.VEGF, H+Saline and H+Ad.LacZ) groups compared to the C+Saline group (p=0.014, 
p=0.013 and p=0.001 for liver; p=0.01, p=0.044 and p=0.005 for thyroid and p=0.025, p=0.016 
and p=0.003 for carcass, respectively). The weight of the perirenal fat depot was significantly 
reduced in H+Ad.VEGF and H+Ad.LacZ (but not H+Saline) relative to C+Saline groups (p=0.037 
and p=0.008, respectively). Irrespective of treatment group all fetal organ weights (except 
gonads) correlated with fetal body weight. The weakest correlation was demonstrated for the 
adrenals (r=0.449, n=57 p<0.001) and the strongest for the kidneys (r=0.902, n=57 p<0.001).  
4.3.4.5 Relative fetal organ weights 
Table 4.9 summarises the relative weights of the fetal internal organs, expressed per kg fetus 
together with the liver to brain weight ratio. Relative brain weight was increased in H+Saline 
and H+Ad.LacZ relative to C+Saline groups (p=0.002 and p=<0.0001, respectively) with a 
tendency towards an increase in the H+Ad.VEGF group (p=0.079).  Relative brain weight was 
lower in the H+Ad.VEGF group compared with the H+Ad.LacZ group (p=0.008) and also tended 
to be lower in H+Ad.VEGF versus H+Saline groups (p=0.077). Relative adrenal weight was 
increased in H+Ad.LacZ versus C+Saline groups (p=0.005) with tended to be higher in H+Saline 
versus C+Saline groups (p=0.053). Relative adrenal weight was lower in H+Ad.VEGF compared 
to H+Ad.LacZ groups (p=0.038) but was not significantly different to the C+Saline or H+Saline 
group. Relative stomach weight was increased in H+Saline versus C+Saline groups (p=0.006) 
but was not significantly different to H+Ad.VEGF or H+Ad.LacZ groups. Relative small intestine 
weight was increased in H+Saline versus both C+Saline and H+Ad.VEGF groups (p=0.003 and 
p=0.002, respectively) but was not significantly different to the H+Ad.LacZ group. Liver to brain 
weight ratios were significantly increased in H+Saline and H+Ad.LacZ relative to C+Saline 
groups (p=0.018 and p<0.001, respectively) and tended to be increased in H+Ad.VEGF versus 
C+Saline groups (p=0.093). Liver to brain weight ratios were also significantly lower in 
H+Ad.VEGF versus H+Ad.LacZ (but not H+Ad.Saline) groups (p=0.015). 
As there were no significant differences in fetal weight specific organ weights between the 
H+Saline and H+Ad.LacZ groups for any organ, these two groups were once again combined 
(H+Saline/Ad.LacZ) to facilitate further comparisons with the H+Ad.VEGF and C+Saline groups. 
This approach revealed significant differences between the H+Ad.VEGF and H+Saline/Ad.LacZ 
groups in relative brain weight (see Figure 4.23A), brain to liver weight ratio (see Figure 4.23B) 
and relative small intestine weight (see Figure 4.24A), as well as a tendency towards a 
difference in relative adrenal weight (see Figure 4.24B). Significance levels for individual group 
comparisons are indicated in the figures. 
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Table 4.9 – Relative weights of the major internal organs (expressed in g per kg fetus) at late 
gestation necropsy, and brain to liver weight ratios 
 C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P 
Value 
Brain 9.27 ± 0.239
a
 10.15 ± 0.259
ab
 11.00 ± 0.400
bc
 11.43 ± 0.451
c
 <0.001 
Pituitary 0.03 ± 0.002 0.03 ± 0.002 0.03 ± 0.002 0.03 ± 0.002 0.817 
Adrenals 0.10 ± 0.004
a
 0.11 ± 0.004
a
 0.12 ± 0.008
ab
 0.12 ± 0.007
b
 0.029 
Pancreas 0.78 ± 0.027 0.85 ± 0.018 0.87 ± 0.051 0.87 ± 0.051 0.285 
Gut (full) 59.50 ± 3.042 61.59 ± 2.769 64.67 ± 3.227 60.84 ± 3.882 0.748 
Stomach 6.41 ± 0.208
a
 6.93 ± 0.618
ab
 7.47 ± 0.252
b
 7.09 ± 0.337
ab
 0.047 
Small intestine 9.95 ± 0.345
a
 10.13 ± 0.313
a
 11.65 ± 0.457
b
 10.71 ± 0.400
ab
 0.011 
Large intestine 2.84 ± 0.175 2.99 ± 0.100 3.22 ± 0.091 3.06 ± 0.138 0.238 
Liver 31.70 ± 1.089 30.53 ± 0.707 31.79 ± 1.490 29.30 ± 1.266 0.388 
Spleen 1.77 ± 0.053 1.84 ± 0.059 1.94 ± 0.122 1.84 ± 0.092 0.594 
Perirenal fat 4.18 ± 0.144 4.15 ± 0.152 4.54 ± 0.126 4.24 ± 0.216 0.363 
Kidneys 5.42 ± 0.118 5.70 ± 0.079 5.64 ± 0.140 5.37 ± 0.170 0.164 
Heart 7.24 ± 0.230 7.68 ± 0.187 7.50 ± 0.214 7.27 ± 0.241 0.426 
Lungs 33.60 ± 1.607 35.95 ± 1.473 34.19 ± 1.254 31.09 ± 1.895 0.169 
Thymus 1.41 ± 0.084 1.52 ± 0.070 1.41 ± 0.105 1.46 ± 0.111 0.810 
Thyroid 0.19 ± 0.005 0.17 ± 0.012 0.20 ± 0.009 0.18 ± 0.013 0.364 
Testes* 0.35 ± 0.015 0.36 ± 0.016 0.44 ± 0.039 0.55 ± 0.026 0.488 
Ovaries* 0.02 ± 0.003 0.02 ± 0.002 0.03 ± 0.005 0.03 ± 0.004 0.094 
Brain: liver 
weight ratio 
0.29 ± 0.042
a
 0.33 ± 0.038
ab
 0.35 ± 0.074
bc
 0.39 ± 0.077
c
 0.003 
 
P values shown in the table are for overall ANOVA. Mean values within a row with unlike 
superscripts are significantly different (p=<0.05 for individual comparisons, see text for details). 
* Gender distribution between groups = C+Saline: 7 male, 5 female. H+Ad.VEGF: 8 male, 10 
female. H+Saline: 4 male, 9 female. H+Ad.LacZ: 7 male, 7 female. 
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Figure 4.23 – Indices of fetal brain sparing at necropsy 
 
 
Relative fetal brain weights [A] and brain to liver weight ratios [B] at late gestation necropsy 
(131±0.2 days gestation) in singleton pregnancies in adolescent ewes offered a control-intake 
(C) or high-intake (H) diet and receiving bilateral uterine artery injections of Ad.VEGF, Ad.LacZ 
or saline. P values shown are for individual post-hoc comparisons using the test of least 
significant difference (overall ANOVA p<0.001 and p=0.002 for figures A and B, respectively). 
A 
B 
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Figure 4.24 – Small intestine and adrenal weights per kg fetus 
 
 
Relative fetal small intestine weights [A] and adrenal weights [B] at late gestation necropsy 
(131±0.2 days gestation) in singleton pregnancies in adolescent ewes offered a control-intake 
(C) or high-intake (H) diet and receiving bilateral uterine artery injections of Ad.VEGF, Ad.LacZ 
or saline. P values shown are for individual post-hoc comparisons using the test of least 
significant difference (overall ANOVA p<0.013 and p=0.016 for figures A and B, respectively). 
B 
A 
189 
 
4.3.4.6 Gross abnormalities 
A number of anomalies were found during the course of the fetal dissections. One fetus in the 
H+Ad.LacZ group had an undescended right testicle and a hydrocoele of the left testicle. One 
fetus in the H+Saline group was found to have a mass arising from the right atrium of the heart 
(see Figure 4.25A). Histology revealed this to be an extension of the myocardial tissue of 
generally normal appearances, but with several small foci of myofibre hypereosinophilia and 
nuclear pyknosis. One fetus in the H+Ad.VEGF group had discordant kidneys, the right one 
weighing 50% more than the left. A second fetus in the H+Ad.VEGF group was found to have a 
mass adjacent to the small bowel mesentery (see Figure 4.25B). Histology revealed this to be a 
lymph node with normal internal architecture and no evidence of hyperplasia or abnormal 
cellular infiltrates. A third fetus in the H+Ad.VEGF group had a similar finding of a discrete mass 
arising from the lymphoid tissue of the gut. Only one abnormality of note was found during the 
course of the maternal dissections. The ewe in question (allocated to the H+Saline group) did 
not have a flow probe fitted and received only a unilateral UtA injection due to major difficulty 
in locating and hence visualising  the uterine horn and vessels on the left side at the time of 
surgery. On the right the main UtA was noted to be tortuous and enlarged. The impression at 
the time was that there was a possible partial uterine torsion or adhesion due to the prior 
embryo transfer surgery compromising access to the left hand side. While enlarging the mid-
line incision would have been possible it was considered that the ewe would be vulnerable to 
subsequent herniation. As she was allocated to receive saline only the decision was taken to 
inject on one side only. The ewe was observed closely during the post-op period but recovered 
normally and fetal growth and wellbeing at weekly ultrasound examination were 
unremarkable thereafter.  At necropsy, the ewe was discovered to have uterus didelphys, a 
rare congenital abnormality of the reproductive tract. The gravid (right) horn was completed 
separated from the non-gravid (left) horn, and each horn had its own cervix (see Figure 4.25C). 
The pregnancy was located in the right uterine horn, the site of the original embryo transfer. 
Placentome number in this gravid horn was 54 compared to an average of 98 amongst the 
overnourished pregnancies of the present study, in which both horns were utilised 
(representing a 45% reduction in caruncle occupancy). There was evidence of compensatory 
placentome growth in the gravid horn (mean placentome weight was 7.2g compared with an 
average of 3.8g for the other animals in the H+Saline group). The left uterine horn was filled 
with clear fluid only (hydrometra). There had still been considerable development of the 
uterine arterial vasculature, presumably an effect of the circulating reproductive steroids. In 
view of this significant abnormality, data from this ewe was excluded from further analysis. 
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Figure 4.25 – Fetal and maternal abnormalities encountered at necropsy 
  
  
Fetal abnormalities included a right atrial appendage, composed of normal myocardial tissue 
[A] and a mass arising from small bowel mesentery [B], histology of which demonstrated a 
normal lymph node. One ewe was found to have uterus didelphys [C] with two cervices 
(indicated by white arrows) and completely separate uterine horns: gravid (right, with fetus 
removed) and non-gravid (left) containing only fluid and completely devoid of placentomes. 
  
4.3.5 Laboratory analyses 
4.3.5.1 Nutrients and metabolic hormones 
Table 4.10 shows the concentration of nutrients and metabolic hormones in maternal and fetal 
plasma on the day before and on the day of necropsy, respectively. Concentrations of glucose, 
insulin and IGF-1 in the maternal circulation were all increased in overnourished (H+Ad.VEGF, 
H+Saline and H+Ad.LacZ) versus the C+Saline group (p=0.012, p=0.002 and p=0.004; p<0.001, 
p=0.001 and p<0.001; p<0.001, p=0.005 and p=0.002, respectively). There were no significant 
C 
A B 
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Table 4.10 – Concentrations of selected nutrients and metabolic hormones in maternal and 
fetal plasma and in the amniotic fluid 
 C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P  
Value 
Maternal glucose 
(mg/dl) 
62.3 ± 1.44a 67.8 ± 1.44b 69.6 ± 1.21b 67.4 ± 2.08b 0.009 
Maternal insulin 
(ng/ml) 
1.13 ± 0.157a 2.17 ± 0.185b 2.08 ± 0.164b 1.97 ± 0.208b <0.001 
Maternal IGF-1 
(ng/ml) 
0.36 ± 0.022a 0.49 ± 0.019b 0.46 ± 0.028b 0.47 ± 0.024b 0.001 
Fetal glucose 
(mg/dl) 
19.8 ± 2.54 19.4 ± 2.25 24.1 ± 4.12 22.7 ± 3.98 0.992 
Fetal insulin 
(ng/ml) 
0.55 ± 0.038 0.53 ± 0.050 0.39 ± 0.029 0.52 ± 0.043 0.060 
Fetal IGF-1 
(ng/ml) 
0.21 ± 0.018 0.18 ± 0.014 0.19 ± 0.014 0.18 ± 0.014 0.423 
Fetal lactate 
(mmol/l) 
8.8 ± 0.40 8.1 ± 0.29 8.4 ± 0.36 8.5 ± 0.41 0.370 
Amniotic fluid 
glucose (mg/dl) 
19.8 ± 2.54 19.4 ± 2.25 24.1 ± 4.12 21.4 ± 3.98 0.700 
 
Concentrations of glucose, insulin and IGF-1 in late-gestation maternal and fetal plasma, fetal 
lactate and amniotic fluid glucose concentrations. P values shown in the table are for overall 
ANOVA. Mean values within a row with unlike superscripts are significantly different (p=<0.05 
for individual comparisons, see text for details). 
  
differences between the three overnourished groups for any of the above parameters. With 
respect to the fetal blood results, there were no significant differences between any of the 
four groups in glucose, insulin, IGF-1 or lactate. There were also no differences between 
groups in amniotic fluid glucose concentrations. Fetal IGF-1 (but not insulin, glucose or lactate) 
concentrations were correlated with fetal weight (r=0.528, n=57, p<0.001).  
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4.3.5.2 Small intestinal crypt cell proliferation 
Figure 4.26 illustrates the absolute numbers of proliferating cells within the crypts of the small 
intestine as well as the labelling index (proportion of proliferating cells per unit tissue area) by 
study group. There were no differences between groups for either parameter (p=0.716 and 
p=0.915, respectively). Despite the significant effects of FGR and Ad.VEGF gene therapy on the 
relative small intestinal weights (see Figure 4.24A), there were no differences in the total cell 
number between C+Saline, H+Ad.VEGF, H+Saline and H+Ad.LacZ groups (1158±288, 1176±571, 
1284±663 and 1054±250, respectively, overall ANOVA p=0.680). No significant correlalations 
were seen between these parameters and fetoplacental weight or absolute/relative weights of 
the various components of the gastrointestinal tract, including the small intestine. 
4.3.5.3 Body composition analysis 
The results of the fetal carcass analysis are shown in Table 4.11. Prior to mincing, the weight of 
the thawed-out carcasses was significantly reduced in all three overnourished groups 
(H+Ad.VEGF, H+Saline and H+Ad.LacZ) relative to the C+Saline group (p=0.045, p=0.046 and 
p=0.12, respectively) in keeping with the group differences previously observed at necropsy, 
prior to freezing (see Table 4.8). Absolute carcass dry matter weight (in grams) was lower in 
H+Ad.LacZ versus C+Saline groups (p=0.013) and carcass ash content (in grams) was lower in 
both H+Ad.LacZ and H+Ad.VEGF relative to C+Saline groups (p=0.049 and p=0.015, 
respectively). However percentage dry matter was equivalent between groups and similarly 
the ash, protein and fat contents of the fetal carcass were equivalent between groups when 
expressed as a percentage of dry matter and per kg “wet” carcass. Thus no alteration in 
chemical carcass composition was demonstrated. 
4.3.5.4 Vascular reactivity 
Figure 4.27A shows the vasoconstriction response of UtA2/UtA3 vessel segments to increasing 
concentrations of phenylephrine in the organ bath when examined on the day after necropsy. 
Satisfactory dose response curves were achieved in 76 of 78 vessels examined from a subset of 
22 animals. For these vessels the degree of contraction was greater in H+Ad.VEGF relative to 
H+Ad.LacZ/Saline groups at phenylephrine concentrations of -6.0 logM (87±7.2% vs. 71±3.6%, 
p=0.043), -5.5 logM (140±13.1% vs. 112±2.8%, p=0.007), -5.0 logM (168±15.7% vs. 133±3.1%, 
p=0.005) and -4.5 logM (174±16.7% vs. 136±3.2%, p=0.004). Contraction of Ad.VEGF tranduced 
vessels was not significantly different to the C+Saline group at any point. Maximum contractile 
response (Emax) was also increased in H+Ad.VEGF versus H+Saline/Ad.LacZ groups (190±18.5 vs. 
148±3.2%, p=0.04) and was not significantly different to the C+Saline group (p=0.718). 
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Figure 4.26 – Fetal small intestinal crypt cell proliferation 
 
 
Crypt cell proliferation assessed by anti-Ki-67 immunohistochemistry and image analysis of 
fetal jejunum perfuse-fixed at 131±0.2 days gestation in singleton pregnancies in adolescent 
ewes offered a control-intake (C) or high-intake (H) diet and receiving bilateral uterine artery 
injections of Ad.VEGF, Ad.LacZ or saline. There were no differences between groups (p>0.05).  
194 
 
Table 4.11 – Fetal body composition analysis by chemical determination of the dry matter, ash, 
protein and fat contents of the fetal carcass 
 C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P 
Value 
Pre-mince weight (g) 3591 ± 101a 3159 ± 147b 3129 ± 156b 3010 ± 169b 0.067 
Wet weight (g) 272 ± 12.8 267 ± 10.3 272 ± 12.2 269 ± 11.5 0.992 
Dry weight (g) 66.6 ± 3.65 65.7 ± 2.74 67.9 ± 3.32 66.3 ± 3.17 0.966 
Dry matter (g) 878 ± 28.7a 776 ± 36.8ab 780 ± 38.3ab 737 ± 38.2b 0.080 
Dry matter (%) 24.4 ± 0.22 24.5 ± 0.16 25.0 ± 0.18 24.6 ± 0.21 0.247 
Ash (g) 145 ± 5.8a 125 ± 6.5b 134 ± 7.9ab 119 ± 7.4b 0.076 
Ash (%) 16.6 ± 0.43 16.1 ± 0.34 17.1 ± 0.41 16.1 ± 0.49 0.318 
Ash (g/kg) 40.4 ± 1.21 39.6 ± 0.95 42.7 ± 1.17 39.6 ± 1.31 0.209 
Protein (g) 588 ± 21.0 518 ± 25.2 519 ± 25.9 495 ± 28.0 0.102 
Nitrogen (%) 10.7 ± 0.08 10.7 ± 0.07 10.6 ± 0.08 10.7 ± 0.09 0.870 
Protein (g/kg) 164 ± 2.1 163 ± 1.6 166 ± 1.7 164 ± 1.0 0.670 
Fat (g) 103 ± 3.8 95 ± 4.4 95 ± 5.4 91 ± 4.5 0.400 
Fat (%) 11.8 ± 0.30 12.3 ± 0.24 12.2 ± 0.34 12.5 ± 0.47 0.509 
Fat (g/kg) 28.7 ± 0.77 30.2 ± 0.64 30.5 ± 0.75 30.8 ± 1.38 0.445 
Post-mortem fetal carcass analysis, detailing body composition in absolute terms (in grams) 
and relative terms as follows. Fat percentage was expressed relative to dry matter content and 
relative fat weight (g/kg) was expressed as a proportion of wet weight. All other parameters 
were expressed relative to the pre-mince weight. P values shown in the table are for overall 
ANOVA. Mean values within a row with unlike superscripts are significantly different (p=<0.05 
for individual comparisons, see text for details). 
  
Figure 4.27B illustrates the relaxation response of the same set of vessels to increasing doses 
of bradykinin within the organ bath. The relaxation response to bradykinin was insufficient for 
analysis in 3 out of 14 vessel segments (27.3%) in C+Saline, 7 of 24 (29.2%) in H+Ad.VEGF, and 
13 of 38 (34.2%) in H+Saline/Ad.LacZ groups, respectively. Consequently no data was available 
from these particular vessels. For the remaining vessels, vasorelaxation was markedly greater 
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Figure 4.27 – Vascular reactivity of uterine artery segments examined in the organ bath 
 
 
Dose response curves to phenylephrine [A] and bradykinin [B] assessing vascular contraction 
and relaxation, respectively, of uterine artery (UtA) segments examined in an organ bath the 
day after late gestation necropsy (131±.0.2 days gestation). Uterine arteries were injected mid-
pregnancy with Ad.VEGF, Ad.LacZ or saline in 22 singleton-bearing adolescent dams receiving a 
control-intake (C) or high-intake (H) of a complete diet. * p<0.05, ** p<0.01, *** p<0.001. P 
values shown are for overall ANOVA - see text for significance levels of individual comparisons.  
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in H+Ad.VEGF relative to H+Saline/Ad.LacZ and C+Saline groups at bradykinin concentrations 
of -8.5 logM (46±6.1 vs. 30±4.3% and 25±5.4%, p=0.021 and p=0.015, respectively), -8.0 logM 
(58±6.0 vs. 33±4.9% and 29±5.7%, p=0.001 and p=0.002, respectively), -7.5 logM (65±5.7 vs. 
34±5.4% and 29±5.7%, p<0.001 each), -7.0 logM (70±5.9 vs. 37±5.8% and 29±5.7%, p<0.001 
each) and -6.5 logM (74±6.3 vs. 40±6.2% and 29±5.7%, p<0.001 each). Relaxation of UtA from 
control-intake pregnancies were noted to plateau at concentrations of -8.0 logM upwards. The 
maximum relaxation (Emax) was higher in H+Ad.VEGF (75±6.2%) versus both H+Saline/Ad.LacZ 
(41±6.1%, p<0.001) and C+Saline (30±6.0%, p<0.001) groups. There were no significant 
differences in the half maximal effective concentration (EC50) of bradykinin between C+Saline, 
H+Ad.VEGF and H+Saline/Ad.LacZ groups (9.3±3.68 x 10-10, 6.4±2.72 x 10-9 and 4.0±4.02 x 10-9, 
respectively, p=0.483). 
There were no significant differences in any indices of vascular contractility or relaxation 
between branches UtA2 and UtA3 (p=0.984 and p=0.655, respectively) or between those from 
the gravid versus non-gravid horns (p=0.156; p=0.562). There were also no interactions 
between these factors and treatment group (p=0.386–0.855; p=0.129–0.778).  
4.3.5.5 Intima to media ratios 
Table 4.12 shows the intimal and medial thicknesses and IMR for each UtA branch. Significant 
differences were observed between the three different levels of branching (UtA1, 2 and 3) for 
all of these parameters. Whilst, unsurprisingly, the absolute vessel dimensions decreased with 
successive branching, values of IMR increased significantly with progression from UtA1 to UtA3 
(p<0.001). The dimensions of the vessels supplying the gravid and non-gravid horn were 
equivalent. Although there were no differences between study groups when analysing each 
branch separately, comparisons across all vessel segments showed that the intima was thicker 
in C+Saline compared with H+Ad.VEGF and H+Ad.LacZ/Saline groups (96±4.4 vs. 86±3.4 and 
80±2.6  p=0.001 and p=0.038, respectively) and that the media was thicker in C+Saline versus 
H+Saline/LacZ groups only (500±20.6 versus 417±30.9μm, p=0.024). There were no differences 
in IMR between any of the groups, neither was there any demonstrable effect of Ad.VEGF on 
any of these vessel parameters. 
4.3.5.6 Neovascularisation in perivascular adventitia 
Table 4.13 shows absolute numbers of blood vessels in the perivascular adventitia, adventitial 
area and vessel density (number of vessels per unit adventitial area) stratified by UtA branch. 
There were no differences between vessels harvested from the gravid and non-gravid horns 
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Table 4.12 – Intima to media ratios in the uterine arteries at three different levels of branching 
Parameter UtA 
Branch 
C+Saline          
(n=24) 
H+Ad.VEGF 
(n=36) 
H+Saline/Ad.LacZ 
(n=54) 
P      
Value 
Intimal thickness (μm) UtA1 108 ± 9.4 99 ± 7.3 90 ± 4.7 0.191 
UtA2 95 ± 6.3 82 ± 4.9 78 ± 4.5 0.103 
UtA3 88 ± 6.5  75 ± 4.1 74 ± 4.2 0.151 
Medial thickness (μm) UtA1 658 ± 56.7 562 ± 47.1 563 ± 40.4 0.366 
UtA2 496 ± 46.7 411 ± 39.6 396 ± 30.8 0.200 
UtA3 347 ± 36.4 344 ± 31.2 293 ± 24.3 0.319 
Intima to media ratio UtA1 0.083 ± 0.0037 0.097 ± 0.0065 0.088 ± 0.0038 0.172 
UtA2 0.104 ± 0.0059 0.116 ± 0.0073 0.109 ± 0.0045 0.408 
UtA3 0.144 ± 0.0009 0.128 ± 0.0010 0.145 ± 0.0067 0.295 
P values shown in the table are for overall ANOVA. As there were no significant differences 
between groups, no post-hoc tests were performed. 
  
therefore data were combined. Although there were no significant differences in the absolute 
vessel numbers between study groups when looking at individual levels of branching, overall 
there were more vessels per section in H+Ad.VEGF and H+Ad.LacZ/Saline versus C+Saline 
groups (142±7.2 and 138±11.0 vs. 105±7.0, p=0.006 and p=0.024, respectively). As there were 
no significant differences between groups in adventitial area (p=0.846), this translated into a 
significant increase in vessel density in high-intake relative to control-intake pregnancies, both 
overall and at each individual level of branching (p<0.001). There was no correlation between 
these the degree of neovascularisation and fetal to placental weight ratio. Notably both vessel 
number and adventitial area decreased with successive branching (p<0.001) and consequently 
there were no differences in vessel density between branches UtA1, 2 and 3 (p=0.113). There 
was no demonstrable effect of Ad.VEGF on any of these parameters. 
In UtA2 branches, lumen area was increased in H+Ad.VEGF relative to both H+Saline/Ad.LacZ  
and C+Saline groups (p=0.023 and p=0.046, respectively). Intima+media area was also greater 
198 
 
Table 4.13 – Neovascularisation within the perivascular adventitia of the uterine arteries at 
three different levels of branching 
Parameter UtA 
Branch 
C+Saline 
(n=24) 
H+Ad.VEGF 
(n=36) 
H+Saline/Ad.LacZ 
(n=54) 
P 
 Value 
Total vesssel area 
(mm
2
) 
 
UtA1 15.7 ± 1.42 15.7 ± 1.36 16.0 ± 1.25 0.762 
UtA2 9.4 ± 0.81 11.3 ± 1.23 10.4 ± 0.86 0.493 
UtA3 7.0 ± 0.94 7.1 ± 0.95 5.7 ± 0.46 0.243 
Intima+media+lumen 
area (mm
2
) 
 
UtA1 5.2 ± 0.47 5.2 ± 0.38 5.4 ± 0.30 0.884 
UtA2 3.0 ± 0.31 3.6 ± 0.37 3.0 ± 0.27 0.323 
UtA3 1.5 ± 0.23 2.0 ± 0.26 1.4 ± 0.14 0.134 
Lumen area (mm
2
) 
 
UtA1 2.0 ± 0.26 2.3 ± 0.31 1.9 ± 0.16 0.495 
UtA2 1.0 ± 0.14
a
 1.7 ± 0.30
b 
 1.1 ± 0.14
a
 0.049 
UtA3 0.4 ± 0.08
a
 0.9 ± 0.21
b
 0.4 ± 0.05
a
 0.019 
Intima+media area 
(mm
2
) 
 
UtA1 3.2 ± 0.25 3.4 ± 0.24 3.6 ± 0.19 0.431 
UtA2 1.9 ± 0.20
a
 2.8 ± 0.36
b
 2.0 ± 0.16
a
 0.021 
UtA3 1.0 ± 0.17
ab
 1.5 ± 0.26
b
 1.0 ± 0.09
a
 0.058 
Adventitial area (mm
2
) 
 
UtA1 10.5 ± 1.09 10.5 ± 1.05 11.7 ± 1.03 0.621 
UtA2 6.5 ± 0.62 7.7 ± 0.92 7.6 ± 0.69 0.539 
UtA3 5.5 ± 0.77 5.1 ± 0.71 4.2 ± 0.36 0.224 
No. of blood vessels in 
perivascular adventitia 
UtA1 144 ± 13.2 190 ± 26.5 190 ± 14.0 0.256 
UtA2 105 ± 10.2
a
 137 ± 12.1
ab
 150 ± 11.4
b
 0.058 
UtA3 67 ± 6.9   85 ± 9.4 85 ± 6.1 0.257 
Blood vessels per unit 
adventitial area (mm
-2
) 
 
UtA1 13.1 ± 1.73
a
 21.0 ± 2.62
b
 19.7 ± 1.21
b
 0.026 
UtA2 17.1 ± 2.13
a
 24.2 ± 2.46
b
 23.8 ± 1.48
b
 0.049 
UtA3 15.6 ± 2.40
a
 20.5 ± 2.93
ab
 24.5 ± 1.83
b
 0.044 
 
  
(p=0.012 and p=0.02, respectively). In UtA2 vessel number was significantly greater in 
H+Saline/Ad.LacZ versus C+Saline (p=0.017), Ad.VEGF being intermediate. In UtA3 branches, 
lumen area was increased in H+Ad.VEGF relative to both H+Saline/Ad.LacZ and C+Saline 
groups (p=0.008 and p=0.03, respectively). Intima+media area was also greater relative to 
H+Saline/Ad.LacZ (p= 0.021) and tended to be greater versus C+Saline (p=0.084). 
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4.3.5.7 Expression of placental angiogenic factors and receptors 
Table 4.14 details the placental mRNA expression of nine different angiogenic factors and their 
receptors, quantified separately in caruncular and cotyledonary tissues. In the carcuncle, 
mRNA expression of endogenous VEGFA as well as its two main receptors (FLT1 and KDR) was  
reduced in H+Ad.LacZ/Saline relative to C+Saline groups (p=0.012, p=0.031 and p=0.039, 
respectively). Although endogenous ovine VEGFA expression was not significantly influenced 
by Ad.VEGF treatment, expression of both FLT1 and KDR was increased in H+Ad.VEGF versus 
H+Ad.LacZ/Saline groups (p=0.028 and p=0.034, respectively) and was similar in magnitude to 
control-intake pregnancies. In fetal cotyledonary tissues, mRNA expression of ANGPT2 and TEK 
were significantly increased in both H+Ad.VEGF and H+Ad.LacZ/Saline compared with C+Saline 
groups (ANGPT2: p=0.032 and p=0.003; and TEK: p=0.018 and p=0.045, respectively), 
commensurate with an effect of maternal nutrition per se. There was no significant effect of 
Ad.VEGF on expression of any angiogenic factors or receptors measured in the fetal placental 
compartment.   
Unsurprising there were also some clear correlations between the various angiogenic factors 
and receptors, both within and across groups. The correlations between VEGFA, FLT1, KDR and 
NOS3 were particularly reproducible and are detailed in Table 4.15 (n=57, p<0.001–0.037).  In 
the fetal cotyledon, these four parameters were correlated irrespective of treatment group. 
The equivalent correlations for the maternal caruncle were consistently weaker and, with the 
exception of KDR's relationship with VEGFA and FLT1, were restricted to one or more groups.  
4.3.5.8 Expression of placental glucose transporters 
Placental mRNA expression of GLUT1 and GLUT3, measured separately in maternal caruncular 
and fetal cotyledonary tissues, is illustrated in Figure 4.28. Caruncular GLUT3 expression was 
reduced in both H+Ad.VEGF and H+Saline/Ad.LacZ relative to C+Saline groups (p=0.011 and 
p<0.001, respectively, see Figure 4.28A). Caruncular GLUT1 expression tended to be greater in 
both H+Ad.VEGF and C+Saline compared with H+Saline/Ad.LacZ groups (p=0.065 and p=0.085, 
respectively, see Figure 4.28B). Irrespective of treatment group, GLUT1 correlated with GLUT3 
(r=0.735, n=57, p<0.001) within the fetal cotyledon (Figure 4.29A), however a corresponding 
correlation between GLUT1 and GLUT3 in the caruncle was observed for high-intake (r=0.699, 
n=45, p<0.001) but not for control-intake (r=0.211, n=12, p=0.511) pregnancies (Figure 4.29B). 
In the H+Saline/Ad.LacZ group, fetal plasma glucose concentrations at the time of necropsy 
demonstrated a weak negative correlation with cotyledonary GLUT1 and GLUT3 expression 
(r=-0.386, p=0.047; and r=-0.428, p=0.026, respectively; n=27 each).  Similarly maternal plasma 
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glucose concentrations correlated inversely with caruncular GLUT1 (but not GLUT3) expression 
only in the H+Saline/Ad.LacZ group (r=-0.400, n=27, p=0.039). Of the four variables measured, 
only caruncular GLUT1 correlated significantly with fetal and placental weights, once again 
only in high-intake pregnancies treated with saline or Ad.LacZ (r=0.479, p=0.011; and r=0.462, 
p=0.015, respectively; n=27 each). 
  
Table 4.14 – Placental mRNA expression of various important angiogenic factors and receptors 
measured separately in maternal caruncular and fetal cotyledonary tissues 
Placental Compartment and 
Gene of Interest 
 
C+Saline          
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline/Ad.LacZ 
(n=27) 
P   
Value 
 
 
 
MATERNAL          
CARUNCLE 
(GOI: 18S) 
 
VEGFA 27.3 ± 3.04a 23.7 ± 1.75ab 20.3 ± 1.26b 0.036 
FLT1 18.8 ± 2.26a 18.1 ± 2.36a 12.5 ± 1.36b 0.031 
KDR 23.8 ± 2.40a 23.2 ± 2.52a 17.4 ± 1.43b 0.040 
NOS3 28.6 ± 2.82 37.6 ± 3.25 33.5 ± 2.65 0.185 
FGF2 15.7 ± 1.54 13.8 ± 1.28 12.5 ± 1.15 0.280 
ANGPT1 24.0 ± 1.62 
2 
21.1 ± 1.65 20.1 ± 1.48 0.291 
ANGPT2 14.0 ± 1.17 14.7 ± 0.85 12.4 ± 0.69 0.110 
TEK 21.6 ± 2.63 22.9 ± 1.51 19.8 ± 1.33 0.370 
GUCY1B3 16.5 ± 1.52 16.2 ± 1.15 13.6 ± 0.96 0.138 
 
 
 
FETAL                    
COTYLEDON 
(GOI: 18S) 
 
VEGFA 26.5 ± 3.53 30.6 ± 2.67 30.9 ± 2.59 0.579 
FLT1 15.1 ± 2.42 13.0 ± 1.50 14.6 ± 1.44 0.699 
KDR 17.0 ± 2.44 17.6 ± 1.59 18.4 ± 1.80 0.877 
NOS3 16.1 ± 2.17 21.5 ± 3.01 19.6 ± 1.87 0.383 
FGF2 9.9 ± 1.07 10.6 ± 0.58 11.3 ± 0.69 0.430 
ANGPT1 21.9 ± 1.64 20.9 ± 0.94 23.1 ± 0.90 0.312 
ANGPT2 13.0 ± 0.79a 16.0 ± 0.73b 16.9 ± 0.80b 0.010 
TEK 14.0 ± 0.79a 16.8 ± 0.71b 16.2 ± 0.61b 0.049 
GUCY1B3 8.9 ± 0.90 9.3 ± 0.81 8.3 ± 0.40 0.517 
  
Abbreviations: GOI = gene of interest 
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Figure 4.28 – Placental expression of glucose transporters 
 
 
mRNA expression of GLUT3 [A] and GLUT1 [B], measured by qRT-PCR and quantified relative to 
18s content, in maternal caruncular and fetal cotyledonary tissues from late gestation necropsy 
(131±0.2 days gestation) in singleton pregnancies in adolescent ewes offered a control-intake 
(C) or high-intake (H) diet and receiving bilateral uterine artery injections of Ad.VEGF, Ad.LacZ 
or saline. P values shown are for individual post-hoc comparisons using the test of least 
significant difference (overall ANOVA p=0.002 and p=0.095 for figures A and B, respectively). 
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Figure 4.29 – Correlations between placental mRNA expression of GLUT1 and GLUT3 
 
 
Correlations between mRNA expression of GLUT1 and GLUT3, measured by qRT-PCR and 
quantified relative to 18s content, in maternal caruncular [A] and fetal cotyledonary [B] tissues 
from late gestation necropsy (131±0.2 days gestation) in singleton pregnancies in adolescent 
ewes offered a control-intake (C) or high-intake (H) diet and receiving bilateral uterine artery 
injections of Ad.VEGF, Ad.LacZ or saline. Within the caruncle, the correlation was significant in 
high-intake (long regression line) but not control-intake (short regression line) pregnancies. 
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Table 4.15 – Correlations between four key placental angiogenic factors and receptors in the 
maternal caruncule and fetal cotyledon 
 FETAL COTYLEDON              MATERNAL CARUNCLE 
 VEGFA FLT1 KDR     VEGFA FLT1 KDR 
VEGFA      VEGFA      
FLT1 0.839a       FLT1 0.722b       
KDR 0.933a 0.915a      KDR 0.822a 0.803a      
NOS3 0.660a 0.461a 0.558a NOS3 0.494c 0.402c 0.452c 
 
Co-efficients of correlation (r values) between mRNA expression of VEGFA, FLT1, KDR and NOS3 
genes measured by qRT-PCR and quantified relative to 18s content in maternal caruncular and 
fetal cotyledonary tissues at late gestation necropsy (131±0.2 days gestation) of 57 adolescent 
ewes offered a control-intake (C) or high-intake (H) diet and receiving bilateral uterine artery 
injections of Ad.VEGF, Ad.LacZ or saline in mid-pregnancy. a = correlated in every group (n=57); 
b = only correlated within H+Ad.VEGF and H+Saline/Ad.LacZ groups (n=45); c = only correlated 
in the H+Saline/Ad.LacZ group (n=27). R values for latter two are n=45 and n=27, respectively. 
  
4.4 Discussion 
4.4.1 Ad.VEGF increased fetal growth velocity 
The most important finding of this study was that Ad.VEGF treatment mid-pregnancy improves 
fetal growth velocity in this well-characterised ovine paradigm of FGR. This was apparent from 
the greater AC measurements at 3 and 4 weeks following Ad.VEGF treatment compared with 
inactive treatments controlling for surgical intervention ± adenoviral infection in the putatively 
FGR pregnancies. As explained in Chapter 3, the AC is the most sensitive ultrasound marker of 
longitudinal fetal growth in human and sheep pregnancies. Fetal growth was not completely 
normalised, given that the growth trajectories of Ad.VEGF- treated growth-restricted fetuses 
remained significantly below those of the normally-growing fetuses of the contemporaneous 
control-intake ewes. However complete normalisation of growth is: (a) likely to be unrealistic; 
and (b) unlikely to be necessary to achieve a significant clinical benefit (discussed in Chapter 7). 
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4.4.2 Ad.VEGF mitigated fetal brain sparing 
As discussed in Section 1.1.3.4, uteroplacental insufficiency tends to produce an asymmetrical  
pattern of FGR (Cox & Marton 2009). Faced with a reduced substrate supply, the compromised 
fetus adapts to its poor uterine environment using a wide range of compensatory mechanisms 
(Peebles 2004) that serve to prioritise growth and development of important organ systems, 
such as the heart and brain. This so-called brain sparing effect results in a higher ultrasound 
BPD:AC ratio, a higher brain to liver weight ratio and a progressive redistribution of blood flow 
to the cerebral circulation (Mari & Deter 1992; Mari 2009). Brain sparing has generally been 
regarded as a benign, beneficial adaptive response mounted by the fetus to ensure adequate 
cerebral perfusion (Scherjon et al. 1993; Scherjon et al. 1998). However there is now a growing 
body of evidence that this phenomenon may actually confer an increased risk of brain injury 
since it is an imperfect compensation. Children born following brain sparing, reflected by an 
increased ratio of UA to middle cerebral artery PI, have recently been shown to have poorer 
neurobehavioural outcomes at 40 weeks corrected gestational age (Figueras et al. 2011) and 
18 months of age (Roza et al. 2008), as well as poorer cognitive outcomes at 5 years of age 
(Scherjon et al. 2000). Recent studies also show that FGR fetuses with normal blood flow in the 
umbilical artery may have cerebral vasodilatation, and these fetuses are also at increased risk 
of abnormal neurodevelopment after birth (Benavides-Serralde et al. 2011). Even in mild FGR 
there is increased perfusion of all cerebral regions with a preferential flow to the frontal lobe, 
which is associated with altered neurodevelopment after birth (Cruz-Martinez et al. 2009). 
In the present study, the degree of fetal brain sparing was attenuated in H+Ad.VEGF compared 
with H+Saline/Ad.LacZ groups, indicated by both ultrasonographic (BPD to AC ratios) and post-
mortem findings. Importantly BPD measurements were not reduced, rather it was the AC that 
caught up to produce the fall in BPD to AC ratio. These findings suggest that the need for fetal 
adaptation to poor nutrient supply was reduced following Ad.VEGF treatment. Although fetal 
oxygenation was not measured in these sheep studies (other than venous oxygen content at 
birth), it might be hypothesised that oxygen delivery was improved following Ad.VEGF therapy, 
as hypoxia is predominantly responsible for the cardiovascular changes resulting in fetal brain 
sparing (Giussani et al. 2012). Accordingly, attenuated brain sparing may imply less hypoxia. 
4.4.3 Ad.VEGF reduced the incidence of marked FGR 
Despite the improvements in fetal growth velocity, fetal weight per se on a group basis was not 
significantly increased in Ad.VEGF-treated compared with Ad.Saline/LacZ-treated high-intake 
pregnancies. This likely reflects the heterogeneous response to nutritional manipulation that 
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occurs in this and many other sheep models of FGR. Consistently in the overnourished 
adolescent paradigm approximately 52% of high-intake pregnancies result in marked FGR, an 
accepted definition of which is a birthweight more than two standard deviations (SD) below 
the genetic potential (Robinson et al. 1979), which can be estimated from the 
contemporaneous control-intake group on a study-by-study basis. In these pregnancies fetal 
and placental weights are reduced by approximately 48%, whilst the remaining high-intake 
pregnancies (48%) produce fetuses that may be considered "non-FGR" (Wallace et al. 2004b). 
In the present study significantly fewer fetuses were categorised as markedly growth-
restricted at necropsy following Ad.VEGF treatment (p=0.033) and the incidence of marked 
FGR in this group (28%) was considerably lower than the historical average for overnourished 
adolescents delivering near to term (52%). 
4.4.4 Ad.VEGF attenuated disproportionate organ growth 
In the present study, the restriction of fetal size induced by overnourishment of the adolescent 
mother was largely proportionate, as evidenced by the lack of significant differences in the 
relative weights of most fetal organs as well as the fetal carcass composition analysis. There 
were however two exceptions to this observation, namely relative fetal small intestine weight 
and relative fetal adrenal weight, which were both significantly increased in Saline/Ad.LacZ 
treated high-intake pregnancies relative to control-intake pregnancies. These findings are not 
new as relative weights of the adrenal glands and the empty gut have previously been shown 
to be higher at 134 and 128 days gestation, respectively, in fetuses of overnourished versus 
control-fed dams (Wallace et al. 2000; Wallace et al. 2002).  
The biological significance of increased relative adrenal weight unfortunately remains unclear. 
Theoretically accelerated adrenal maturation in growth-restricted fetuses might be expected 
to result in higher levels of adrenal hormones, which help promote maturation of the fetal 
lung, liver and gut, and might also play a role in the initiation of parturition. However the 
literature in this area is conflicting and in this particular model no significant differences in 
fetal plasma cortisol have been measured at ~130 days gestation between high- and control-
intake pregnancies (Wallace et al. 2005a) in spite of a robust reduction in gestation length in all 
overnourished pregnancies allowed to proceed to delivery (Wallace et al. 2006a). Furthermore 
when function of the hypothalamic-pituitary-adrenal axis was examined in vivo at various 
stages during postnatal life (in lambs at 9, 18 and 24 months of age) there was no obvious 
relationship with prenatal growth (Wallace et al. 2011). A similar increase in relative adrenal 
weight is observed in ovine FGR induced by single umbilical artery ligation (Supramaniam et al. 
2006), uteroplacental embolisation (Murotsuki et al. 1996) and pre-mating carunclectomy 
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(Phillips 1996). The latter is also associated with reduced adrenal expression of 
phenylethanolamine N-methyltransferase (Adams et al. 1998) and steroidogenic acute 
regulatory protein (Coulter et al. 2002). With respect to the small intestine, it is well 
documented that relative immaturity of the gut in growth-restricted neonates places them at 
increased risk of necrotising enterocolitis (Halliday 2009), however it is not immediately clear 
what the relationship between higher relative gut weight and gut function might be in the  
paradigm used herein. This was the rationale behind examining for putative differences in 
small intestinal crypt cell proliferation in the small intestine in the present study. Notably there 
were no differences between control- and high-intake pregnancies in these parameters. Future 
work will include examination of the tissues sampled in this study for evidence of any 
differences in indices of mesenteric vascularity. 
The novel finding herein was that Ad.VEGF treatment resulted in a significant attenuation of 
the disproportionate small intestine growth and tended also to mitigate the disproportionate 
adrenal growth seen in this model, indicated by the reduction in relative small intestine and 
adrenal weights in H+Ad.VEGF- versus Ad.Saline/LacZ-treated fetuses (p=0.016 and p=0.058, 
respectively). As these pregnancies were terminated in late gestation it is not known whether 
there would have been any significant correlation between relative adrenal weights and 
gestation length. It is also not known whether there were associated changes in the adrenal 
hormone levels, however given the lack of any baseline differences in cortisol by nutritional 
group measured previously, this appears unlikely. There was also no effect of Ad.VEGF on crypt 
cell proliferation.  
4.4.5 Ad.VEGF increased uterine artery vascular reactivity 
In the subset of animals whose UtA were examined in the organ bath, there was clear evidence 
of effects on in vitro vascular reactivity following Ad.VEGF treatment. Ad.VEGF transduced 
vessels demonstrated an enhanced contractile response to phenylephrine relative to 
Ad.LacZ/Saline treated vessels that was very similar in magnitude to vessels harvested from 
control-intake pregnancies. There was also a strikingly enhanced relaxation response to 
bradykinin relative to all other groups (David et al. 2008; Mehta et al. 2011). These results 
contrast with the previous work in normal sheep pregnancy in which Ad.VEGF UtA segments 
from normal sheep pregnancies were examined at short and long term time points: 4–7 days 
and 30–45 days post injection, respectively. Previously a reduced contractile response was 
observed in Ad.VEGF- versus Ad.LacZ-transduced vessels at both stages, whilst enhanced 
relaxation was apparent only in the short term. Although the interval between vector injection 
and analysis was similar in the long term cohort to the present study, the studies are otherwise 
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not directly comparable with respect to maternal genotype, age or nutritional treatment. An 
additional problem here was the unavoidable delay between harvesting and analysing the 
vessels, as the tissues had to be couriered overnight from Aberdeen, where the FGR model 
was based, to London, where the organ bath equipment was available. Unfortunately no 
suitable equipment of sufficient quality or channel size could be found in Aberdeen in order to 
perform the analyses locally. Samples were shipped in chilled Krebs buffer and the viability of 
the endothelium was checked prior to analysis in the organ bath. Nevertheless, more subtle 
changes in the condition of the vessel may have occurred and might have impacted the results.  
The observation herein that Ad.VEGF enhanced both vasoconstriction and vasorelaxation in 
the organ bath would initially appear difficult to explain, and there is to my knowledge no 
published evidence that an intervention can have apparently opposite effects on vascular 
reactivity. However the fact that VEGF is believed to have a vascular protective effect and can 
induce prolonged endothelial cell survival (Zachary et al. 2000) may help to explain these 
apparently contradictory findings. The observation that Ad.VEGF-transduced vessels were 
significantly more contractile than Saline/Ad.LacZ-treated vessels may appear to contradict the 
initial hypothesis, however it is possible that this merely reflects an improvement in overall 
vascular function as a hangover effect of VEGF-A165 over-expression. The dramatically 
enhanced vasorelaxation that was observed is on the face of it more in keeping with the 
original hypothesis. The fact that no significant differences were seen between C+Saline and 
H+Saline/Ad.LacZ groups in relaxation may again reflect relative degradation of the vessels, 
particularly the endothelium, in the absence of Ad.VEGF transduction. This could have further 
magnified the differences seen in the H+Ad.VEGF relative to all other study groups in terms of 
vascular relaxation responses. 
4.4.6 Ad.VEGF increased caruncular expression of VEGF receptors 
At necropsy in late gestation, placental nutrient transport efficiency, as inferred from the fetal 
: placental weight ratio, was noted to be highest in the H+Ad.VEGF group, and was significantly 
greater than in the C+Saline group. There was also a significant upregulation of both VEGF 
receptors (FLT1 and KDR) in caruncular but not cotyledonary tissues in Ad.VEGF- versus 
Saline/Ad.LacZ-treated high-intake pregnancies. FLT1 and KDR are both important for 
vasculogenesis and angiogenesis throughout pregnancy. mRNA expression of FLT1 and KDR 
increases dramatically in the maternal caruncle during early sheep pregnancy (up to 30 days 
gestation) without any concurrent increase in VEGF expression (Grazul-Bilska et al. 2010).  
Endogenous VEGF expression steadily increases from 50 to 110 days gestation, after which it 
remains fairly static (Borowicz et al. 2007). KDR expression also peaks at 110 days gestation 
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but declines thereafter, whilst FLT1 expression increases progressively to 140 days gestation.  
The upregulation of FLT1 and KDR expression seen here was not associated with any significant 
change in VEGFA expression, however this is relatively unsurprising as the RT-PCR was specific 
for endogenous (ovine) VEGF and would not have detected any transcripts from the transgenic 
(human) VEGF gene. Consequently over-expression of human VEGF-A165 might well have led to 
an upregulation of FLT1 and KDR without any shift in endogenous VEGF-A. It did not seem that 
human VEGF down-regulated ovine VEGF however, as mean mRNA levels were intermediate in 
the H+Ad.VEGF group. The lack of significant changes in placental angiogenic factor/receptor 
expression on the fetal side of the placenta is in keeping with the absence of any effect on UA 
Doppler indices, which reflect fetoplacental vascular resistance. Furthermore, previous work in 
normal adult sheep pregnancies showed that expression of transgenic VEGF (measured using 
RT-PCR with primers spanning the vector-transgene boundary) was not detectable in any fetal 
tissues, suggesting that the adenovirus vector does not traverse the ovine placental barrier. In 
addition VEGF itself (the transgenic protein) is relatively large and therefore unlikely to cross 
the epitheliochorial placenta (Vonnahme et al. 2005). 
In the present study, mRNA expression of VEGF-A, FLT1 and KDR were all reduced in untreated 
high- versus control-intake pregnancies. VEGF-A and FLT1 have previously been shown to be 
attenuated in overnourished adolescent pregnancies when measured in whole placentomes at 
81 days gestation, along with ANGPT1, ANGPT2 and NOS3. The finding of reduced expression 
of KDR herein is novel but perhaps unsurprising given that VEGF-A, FLT1 and KDR correlated 
strongly with each other, irrespective of treatment group. A reduction in KDR expression may 
be a relatively late feature of placental vascular compromise in this paradigm. No significant 
differences in caruncular ANGPT1, ANGPT2 and NOS3 expression were seen herein. The lack of 
a persistent reduction in NOS3 expression between nutritional groups might reflect adaptative 
changes occurring in late pregnancy. eNOS protein expression is actually increased relative to 
normal controls in the near term placentae of growth-restricted sheep pregnancies induced by 
maternal hyperthermic exposure (Arroyo et al. 2006). Increased eNOS protein expression is 
also detected in the trophoblast cells of human placentae from term pregnancies complicated 
by FGR and pre-eclampsia (Barut et al. 2010a; Barut et al. 2010b). In addition, in the previous 
work in normal adult sheep pregnancies it was not considered possible to demonstrate any 
additional effect of Ad.VEGF on term eNOS protein levels (measured by Western blot) as 
expression already appeared to be maximal by this stage (Mehta et al. 2011). 
In the fetal cotyledon there was an upregulation of ANGPT2 and its receptor TEK in late 
gestation. In a previous late gestation study using the overnourished adolescent model, there 
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were no significant differences between high- and control-intake pregnancies in cotyledonary 
mRNA expression of any angiogenic factors or receptors, although switching from a high- to a 
low-intake diet from 90 days gestation to induce a severe catabolic state was associated with 
an upregulation of cotyledonary ANGPT1, TEK, VEGFA, neuropilin 1 and hypoxia inducible 
factor 1 alpha subunit expression. In both situations upregulation of ANGPT and TEK probably 
reflects fetoplacental adaptation to an adverse intrauterine environment i.e. uteroplacental 
insufficiency ± metabolic stress. Like VEGF, the angiopoietins are important growth factors for 
physiological vasculogenesis and angiogenesis in pregnancy and are similarly upregulated 
during the first 28 days of ovine pregnancy (Grazul-Bilska et al. 2010; Grazul-Bilska et al. 2011). 
Thereafter ANGPT1 and ANGPT2 increase approximately five-fold and ten-fold, respectively, 
from 50 to 140 days gestation (Borowicz et al. 2007). ANGPT1 mRNA expression is consistently 
higher in cotyledonary compared with caruncular tissues, but the opposite is true for ANGPT2.  
During the course of primate pregnancy, ANGPT2 levels increase whilst ANGPT1 remain static 
or decrease, resulting in a lower ANGPT1:2 ratio (Babischkin et al. 2007; Hurliman et al. 2010). 
ANGPT2 expression appears to be sensitive to various gestational insults but the direction of 
shift is variable. For example, ANGPT2 expression has been shown to be increased by hypoxia 
in human placental explants (Zhang et al. 2001) but is decreased in the fetal cotyledon at 135 
days gestation following hyperthermia-induced ovine FGR (Hagen et al. 2005). Similarly serum 
levels of angiopoietin-2 protein during the first trimester have been shown to be increased in 
pregnancies later developing pre-eclampsia (Leinonen et al. 2010) and yet decreased in those 
subsequently complicated by severe FGR (Wang et al. 2007). TEK expression is reduced at 135 
days gestation following hyperthermic exposure in ewes (Regnault et al. 2002) and soluble TEK 
protein levels are reduced in human pregnancies affected by pre-eclampsia (Sung et al. 2011). 
4.4.7 Ad.VEGF tended to increase caruncular expression of GLUT1 
In view of the significant effect of Ad.VEGF therapy on placental FLT1/KDR mRNA expression 
and evidence of increased placental efficiency, expression of the glucose transporters GLUT1 
and GLUT3 was evaluated separately in the maternal caruncle and fetal cotyledon to examine 
whether there might have been an increase in placental glucose transport capacity secondary 
to prenatal Ad.VEGF treatment. Caruncular GLUT1 (but not GLUT3) expression tended to be 
increased in Ad.VEGF- versus Ad.Lacz/Saline-treated high-intake pregnancies and was similar in 
magnitude to control-intake pregnancies with normally grown placentae. As for the angiogenic 
factors and receptors detailed above, the absence of an effect of Ad.VEGF in the fetal placental 
compartment is in keeping with the lack of evidence that Ad.VEGF crosses the ovine placenta. 
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The fact that the effects are limited to the maternal caruncle suggests downstream effects of 
UtA transduction on placental function with a potential increase in placental glucose transfer. 
Previously no significant differences in GLUT1/GLUT3 expression were seen in high- versus 
control-intake pregnancies at 81 or 133 days gestation (Wallace et al. 2004a; Wallace et al. 
2004b). Expression of both these transporters increases several fold between mid- and late- 
gestation, and is associated with a five-fold increase in placental glucose transport capacity 
(Molina et al. 1991). The results of the present study differed in that there was a reduction in 
caruncular GLUT3 expression in the overnourished dams with growth-restricted placentae and 
a tendency towards a similar reduction in GLUT1 in late gestation. Notably the previous 
experiment at 133 days gestation in this FGR model measured GLUT1/GLUT3 in whole rather 
than in separated placentomes, which might explain this apparent discrepancy. Currie et al. 
(1997) also measured these transporters in whole placentomes from normal ovine pregnancies 
and found that GLUT1 expression peaked around 120 days gestation, whilst GLUT3 continued 
to increase significantly until term. By contrast, in human pregnancy, GLUT1 expression rises 
steadily throughout gestation (Sakata et al. 1995) whilst GLUT3 appears to be maximal in the 
first trimester and declines thereafter (Brown et al. 2011). GLUT1 is reduced in high altitude 
pregnancies (Zamudio et al. 2006) and GLUT3 mutations are associated with FGR (Ganguly et 
al. 2007). Both glucose transporters are down-regulated by glucocorticoid exposure (Hahn et 
al. 1999), which may partially explain the detrimental effect of repeated antenatal steroids on 
fetal growth. GLUT1 and GLUT3 are also upregulated by moderate maternal undernutrition in 
ewes (Bell et al. 1999; Ma et al. 2011). This presumably represents a form of compensation for 
reduced maternal substrate concentrations in the maternal blood.    
4.4.8 Ad.VEGF had no measurable effect on uterine blood flow 
The original hypothesis for this programme of work was that increased fetal growth would 
occur secondary to a therapeutic increase in UBF. Surprisingly, however, in this study no 
impact of Ad.VEGF on UBF was detectable in the growth-restricted pregnancies despite quite 
obvious effects on fetal growth velocity, incidence of marked FGR and vascular reactivity, as 
detailed above. There are broadly speaking two possible explanations for this lack of a 
measurable effect on UBF. On one hand, it may be that Ad.VEGF treatment was unable to 
restore the putative reduction in UBF characteristic of this model and that other effects of the 
therapy, possibly mediated downstream at the level of the placenta, were actually responsible 
for the beneficial impact on fetal growth. The upregulation of VEGF receptors on the maternal 
side of the placenta (as discussed above) lends further credibility to this particular hypothesis. 
On the other hand, it may be that there was a genuine increase in UBF following Ad.VEGF 
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treatment but that for one or more reasons this was not detected by the telemetric 
monitoring system used herein. Personally I would speculate that both factors may have 
contributed, but on balance the telemetric flow probe system was probably not functioning 
optimally for a number of reasons, as detailed below.  
Firstly, the fact that Ad.VEGF-transduced vessels demonstrated strikingly enhanced relaxation 
responses to bradykinin relative to all other groups and increased contraction relative to the 
H+Saline/Ad.LacZ group, perhaps due to the vasoprotective effects of VEGF, suggests that 
Ad.VEGF did indeed exert some effects on the function of the uterine artery, as anticipated. 
Secondly, the apparent variability in baseline UBF amongst the high-intake ewes in this study 
was 98ml/min, which is well below the 212ml/min derived from our original study and used for 
the power calculation. Thirdly, and most importantly, it is perhaps quite telling that, other than 
for a transient reduction between 94 and 96 days gestation, there were no significant 
differences in UBF between high- and control-intake pregnancies. This is particularly surprising 
given the fact that all other parameters, including fetal and placental weights, were reduced to 
the degree that one would expect from historical observations in this ovine paradigm of FGR. 
In this study we also demonstrated highly significant differences between overnourished and 
control-intake pregnancies in UA Doppler indices, which can be considered a reflection of 
resistance to umbilical blood flow. Although for technical reasons umbilical blood flow has not 
been directly measured at mid-gestation in this paradigm, one would expect it to be strongly 
correlated with UBF, as is the case in late gestation (Wallace et al. 2002). Previous studies in 
the overnourished adolescent paradigm have shown highly significant reductions in UBF 
relative to control-intake pregnancies using two different methods of measurement. When 
quantified using flow probes linked directly (i.e. non-telemetrically) to a flow meter, UBF was 
found to be reduced by 42% as early as 88 days gestation and remained reduced by 30% on 
average during the subsequent 50 day period (Wallace et al. 2008b). When determined using 
the Fick principle in chronically instrumented pregnancies at 130 days gestation (via fetal 
infusion of blood flow indicators and simultaneous blood sampling under steady state 
conditions), UBF and umbilical blood flow were attenuated by 36 and 37%, respectively, in 
high-intake versus control-intake pregnancies (Wallace et al. 2002). The reason for the 
apparent discrepancy in a key feature of this experimental paradigm is therefore unclear. 
Notably, the increase in flow from mid to late gestation within the normally developing  
control- intake pregnancies (41%) in the present study was markedly lower than the 2-fold 
increase reported previously in this genotype (Wallace et al. 2008b) and the 2.5- to 4.5-fold 
increase found by other studies in sheep (Meschia 1983), other mammals (Reynolds et al. 
1986; Reynolds & Redmer 1995) and indeed in human pregnancies (Konje et al. 2003). 
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Taken overall, these observations imply that the telemetric system used for the present study 
might have lacked the required sensitivity to detect both the expected differences between 
nutritional groups and the impact of Ad.VEGF treatment. It was with good intention that a 
telemetric system was chosen for this study. Indwelling transit time flow probes are widely 
considered to be the gold standard for blood flow determination and have been successfully 
used to quantify differences between nutritional treatments in this paradigm (Wallace et al. 
2008b) and to measure changes in UBF acutely following sildenafil citrate (Miller et al. 2009) 
and long term following Ad.VEGF administration in sheep (Mehta et al. 2011). The previous 
experiments assessing the short term effects of Ad.VEGF used Doppler ultrasonography to 
measure UBF (David et al. 2008). However, although Doppler and flow probe measurements 
do correlate with one another in mid-gestation sheep pregnancies (Acharya et al. 2007), this 
method lacks precision and can also be technically challenging (Abi-Nader et al. 2010). The use 
of a telemetric system was considered an advantage as it allows the ewe to behave normally 
during monitoring, rather than being restrained. This also constituted a refinement under the 
principle of the three "R"s, as promoted by the UK Home Office (Robinson 2005). However, 
retrospectively, this may have introduced an additional level of complexity that could have 
contributed to the lack of precision, although it remains unclear at which point any technical 
error might have been introduced. In addition to potential problems with the wireless transfer 
data, other possibilities include problems with data acquisition at the level of the flow probe 
within the animal or with the analysis. With respect to the latter, in the present study a 
mathematical adjustment had to be made to the raw UBF values for the majority of the 
animals as the equipment was not completely fit for purpose. The flow probe system used was 
designed to monitor up to two animals at once and each flow probe had its own 3-pin erasable 
programmable read only memory (EPROM) key, which was housed within the Physiogear unit. 
Consequently to gain accurate flow readings the unit would have had to be have been opened 
up and the EPROM key changed prior to each monitoring episode i.e. around 10 times per day.  
As the pins were extremely fragile this was not done in view of the risk of irreparably damaging 
the equipment. Consequently a single EPROM key was used and a mathematical conversion 
factor was calculated based on the calibration information for each individual flow probe 
following discussion with the manufacturer. 
It also possible that this study lacked power, although it would not explain the lack of control- 
versus high-intake pregnancy differences. The assumption of a 50% increase in UBF following 
Ad.VEGF treatment for the purpose of sample size calculation (Section 4.2.1) was based on a 
previous study with a distinctly different experimental design, having compared the effects of 
Ad.VEGF injection into one UtA with Ad.LacZ injection into the opposite UtA of the same 
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animal (Mehta et al. 2011). Moreover, changes in UBF were also expressed as a percentage 
change from baseline values measured within the same animal using flow probes, which had 
been determined over 4-7 days prior to gene therapy administration. Comparing UBF with a 
pre-intervention baseline in this way controls for some of the inter-animal variability seen in 
uterine blood flow (which is known to be high) and this has been done previously (Miller et al. 
1999; Miller et al. 2009). By contrast, the present study compared UBF between animals and in 
absolute terms. UBF was not measured in the first few days after probe placement because of 
the need to recover the ewes from surgery and the fact that these animals had already gone a 
laparotomy for embryo transfer. Adding in a third laparotomy to fit the flow probes earlier in 
order to measure baseline blood flow was considered excessive by the investigators and the 
Home Office. In addition the 50% estimation was derived from injection of both gravid and 
non-gravid UtA, and it has been reported that Ad.VEGF-induced increases in UBF are more 
dramatic within the non-gravid UtA (Mehta et al. 2011), possibly because it has undergone less 
vascular remodeling (Osol & Mandala 2009). In the present study flow probes were only placed 
around the gravid UtA in view of the cost implications of monitoring large numbers of animals 
concurrently, hence a potentially larger effect on the contralateral side may have been missed. 
Unfortunately it was not possible to perform a retrospective power calculation based on the 
primary outcome measure of UBF because the baseline values and gestational increase were 
not believable compared with previous investigations. As detailed above the variability in UBF 
seen in the present study was in keeping with the assumptions of the initial power calculation, 
suggesting the study was not underpowered (assuming a 50% increase following UBF), hence it 
appears more likely that the telemetric equipment used was not working correctly. However it 
could also be argued that only a ~20% increase in UBF could be directly attributed to Ad.VEGF 
treatment in the previous experiments in normal sheep pregnancy, as the apparent doubling 
was relative to baseline values and not absolute blood flow (Mehta et al. 2011). In this case, 
based on the inter-animal variability in the present study of 98ml/min, 45 or 60 pregnancies 
per group would have been required to detect a 20% increase in UBF (61.2ml/min) with 80% or 
90% power, respectively. With respect to the effects of Ad.VEGF on fetal growth, the sample 
size for the present study appears to have been sufficient when a retrospective power 
calculation is performed based on the secondary outcome measure of fetal weight. Based on 
the inter-animal variability seen in the present study of 728g, 12 to 16 animals per group were  
required to show a 20% increase in fetal weight (831g) with 80% or 90% power, respectively. 
4.4.9 Ad.VEGF had no measurable effect on intima-to-media ratios 
In the present study there was also no detectable effect of Ad.VEGF on intima-to media ratios.
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This contrasted with the previous studies in normal adult sheep pregnancy, which 
demonstrated a reduction in IMR in Ad.VEGF- versus Ad.LacZ-transduced vessels at 30 days 
post-injection. This previous work differed somewhat, in that it involved comparison of one 
UtA with the other within the same animal, and in twin pregnancies only. Consequently the 
degree of variability was markedly less. 
Interest in the IMR and a related parameter, intima-media thickness (IMT), largely comes from 
the field of cardiovascular biology and medicine. Increases in IMT occur in vasoproliferative 
disorders characterised by neointima formation, such as atherosclerosis. IMT can be easily 
measured in the carotid artery by ultrasound, in which it helps to stratify cardiovascular risk 
(Simon et al. 2002), although recent meta-analyses have challenged its use as a surrogate 
endpoint in randomised clinical trials (Goldberger et al. 2010) in favour of direct ultrasound 
evaluation of carotid plaque (Simon et al. 2010; Inaba et al. 2012). Atherosclerosis also occurs 
in the UtA and appears to reflect the degree of atherosclerosis in other critical vascular beds 
such as the coronary and carotid arteries. UtA IMR increases with advancing age and is 
associated with electrocardiographic abnormalities and elevated markers of cardiovascular risk 
including hypercholesterolaemia (Crawford et al. 1997). Various studies have associated 
intimal hyperplasia and/or increased IMR with reduced NO action via different mechanisms. 
Premenopausal women with intimal hyperplasia and increased IMR have been shown to have 
impaired cGMP production and increased arginase activity, which reduces the availability of L-
arginine to NOS (Marinova et al. 2008). Increased IMR has also been linked to increased levels 
of endothelin-1, a potent vasoconstrictor, to higher levels of endogenous NOS inhibitors in 
endothelial cells (Beppu et al. 2002; Loyaga-Rendon et al. 2005), and to impaired synergism 
between prostaglandin I2 and NO (Obayashi et al. 1996). One study of UtA vascular reactivity 
in perimenopausal women found that an abnormally high IMR was associated with the failure 
of 17β-estradiol to augment endothelium-dependent relaxation and cAMP/cGMP production 
in the UtA, an effect that did occur in vessels with a normal IMR (Obayashi et al. 2001). Overall 
the literature would suggest that a high IMR is associated with endothelial dysfunction and an 
adverse cardiovascular profile. It is however unclear whether any putative arterioprotective 
reduction in IMR secondary to Ad.VEGF gene therapy would have any impact on long-term 
cardiovascular risk. It is well known that there is an association between FGR and maternal 
cardiovascular disease (Smith et al. 2001; Manten et al. 2007), although to what degree this 
represents cause and effect still remains unclear. In the present study, control-fed ewes had 
significantly greater intimal and medial thicknesses (with no significant change in IMR) and 
increased intima+media areas on image analysis when compared to overnourished animals.
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This likely reflects a lack of appropriate vascular development during pregnancy in the latter 
group, commensurate with reduced UBF and levels of circulating sex steroids, resulting in 
(proportionately) smaller vessels. It seems particularly unlikely that a thicker intima in this 
scenario reflects any pathological process, particularly as these were adolescent ewes in good 
cardiovascular health prior to pregnancy. 
4.4.10 Ad.VEGF had no measurable effect on adventitial neovascularisation 
Previous work in normal sheep pregnancy suggested that the increase in UBF was likely to be 
mediated in the longer term through neovascularisation within the perivascular adventitia, as 
there was a significant increase in the number of positively-stained peripheral small vessels in 
Ad.VEGF- versus Ad.LacZ-transduced vessels (Mehta et al. 2011). This was believed to reflect a 
proliferation of the vasa vasorum, a network of small blood vessels that supplies oxygen and 
nutrients to the tunica adventitia and peripheral tunica media of larger blood vessels (Heistad 
et al. 1981), such as the uterine or ovarian arteries. It has been suggested that the vasa vasora 
might play a role in mediating increases in ovarian and uterine blood flows during the oestrus 
cycle and pregnancy, respectively (Zezula-Szpyra et al. 1997). The neovascularisation observed 
following Ad.VEGF treatment may represent a migration and reorganisation of endothelial 
cells into new blood vessels, as previous work using the VEGF-D isoform in normal pregnancy 
demonstrated a significant increase in adventitial endothelial cell proliferation at 4–7 days but 
not at 30 days post-injection (Mehta et al. 2013), i.e. preceding the increase in vessel numbers.  
In the present study there was no significant effect of Ad.VEGF on neovascularisation within 
the perivascular adventitia, expressed either in absolute numbers or per unit adventitial area. 
Notably however there was increased neovascularisation in all three high-intake groups versus 
the control-intake pregnancies. This might represent an adaptive response aimed at optimising 
blood flow in these compromised pregnancies. This would be in keeping with the greater fetal 
to placental weight ratios and increased expression of TEK and ANGPT2 in the fetal 
compartment of the placenta (see Section 4.4.6 above) in the overnourished pregnancies. 
Further evidence of adaptation is provided by the previous observation that capillary number 
within the fetal cotyledon was increased in high- versus control-intake pregnancies when 
examined at 90 days (but not at 130 days) gestation (Redmer et al. 2009). Irrespective, on a 
background of enhanced neovascularisation secondary to a high nutritional intake it would 
seem intuitive that any additional effect owing to Ad.VEGF delivery might be more difficult to 
detect. Alternatively other mechanisms may be more important in mediating the effects of 
Ad.VEGF on fetal growth, such as downstream effects at the level of the placenta, possibly 
affecting placental vascularity or nutrient transport capacity. 
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4.5 Conclusions 
Mid-gestation delivery of Ad.VEGF gene therapy in FGR pregnancies induced by overnourishing 
adolescent sheep dams resulted in a significant increase in fetal growth velocity at 3 and 4 
weeks post-treatment. Despite no significant differences in overall final fetal weight, fewer 
fetuses exhibited marked FGR in late gestation following Ad.VEGF treatment. Moreover fetal 
brain sparing and disproportionate growth of the fetal adrenal and small intestine were 
mitigated. Ad.VEGF-transduced UtA demonstrated both increased vasoconstriction and 
strikingly enhanced vasorelaxation, however there was no measurable effect of Ad.VEGF on 
UBF, IMR or neovascularisation in the perivascular adventitia. There was however an 
upregulation of both VEGF receptors (FLT1 and KDR) in the maternal placental compartment, 
suggesting downstream effects on placental function. 
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Chapter 5                                                                                                               
Term and Postnatal Consequences of Ad.VEGF Gene Therapy for Ovine FGR 
5.1 Introduction 
This chapter details the second of two studies aimed at evaluating the efficacy, safety and 
mechanism of action of Ad.VEGF gene therapy treatment in an ovine paradigm of FGR. 
5.1.1 Background 
During the course of the previous study a beneficial effect of Ad.VEGF on fetal growth velocity 
had been observed and a number of different mechanisms of action were explored. However 
as the pregnancies had been terminated in late gestation it was not possible to say what 
impact Ad.VEGF might have had on neonatal mortality and morbidity had they continued until 
delivery. As discussed in Section 1.1.3.6, growth-restricted neonates are at risk of a wide range 
of medical complications as a result of a combination of prenatal starvation, hypoxia and 
acidaemia, small size at birth, prematurity and the negative consequences of adaptations 
designed to maximise in utero survival at the potential expense of ex utero wellbeing (Halliday 
2009). Consequently it was important to investigate whether prenatal Ad.VEGF treatment 
could mitigate such effects. 
In the overnourished adolescent paradigm, lambs can be born alive from as early as 135 days 
gestation. Accordingly, as sheep tolerate premature delivery poorly, a significant amount of 
neonatal care is required to ensure survival. While the mean gestation length in the 52% of 
pregnancies that historically result in marked FGR is significantly shorter than the remaining 
48% of overnourished pregnancies: 141.2 ±0.44 vs. 142.7±0.30 days gestation, p<0.01, 
respectively, both groups are delivered prematurely as term = 145 days gestation (Wallace et 
al. 2006a). In addition to the problems of prematurity, overnourishment of the adolescent ewe 
is associated with a ~62% reduction in colostrum yield and total immunoglobulin G (IgG) supply 
(Wallace et al. 2001), which is the main determinant of neonatal immunity (Hunter et al. 
1977). Unlike in the human, IgG does not cross the placenta in ruminants and therefore lambs 
must acquire all their passive immunity via the maternal colostrum (Larson et al. 1980). It has 
been established that newborn lambs require 50ml good quality colostrum per kg of their body 
weight at birth (Logan et al. 1978), and this requirement is not met by many overnourished 
adolescent dams due to suboptimal mammary development. This in turn is probably related to 
reduced circulating oestradiol-17β levels as well as attenuated secretion of other lactogenic 
hormones such as placental lactogen, growth hormone and progesterone (Wallace et al. 
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1997a; Wallace et al. 1997b; Lea et al. 2007; Wallace et al. 2008a). Consequently, without 
colostrum supplementation and other supportive care measures, neonatal mortality is high. In 
the earliest study using this paradigm of FGR, the neonatal mortality rate was 62% (Wallace et 
al. 1996). In addition to assessing the impact of Ad.VEGF on the delivery process per se and 
neonatal outcomes, a second reason for including a term study with early post-natal follow-up 
was that, although there had been no obvious maternal or fetal adverse effects of gene 
therapy treatment between mid and late gestation in the previous study (see Chapter 4), it 
was considered necessary to follow up both mother and offspring for an extended period to 
exclude any indications of longer term problems. In particular it was considered that putative 
effects of Ad.VEGF on uterine blood flow and angiogenesis within the uteroplacental bed 
might confer an increased risk of post-partum haemorrhage. Consequently assessment of 
safety was a key aspect of this study. 
As discussed in Section 1.1.3.8, there is a growing body of epidemiological and experimental 
evidence that FGR predisposes to a number of different metabolic diseases in later life. It is 
likely that this results from a combination of changes occurring in utero as a consequence of 
FGR (intrauterine programming effects) and a mismatch between the prenatal and postnatal 
environments (Godfrey et al. 2007), as there is considerable developmental plasticity in both 
fetal and neonatal life. Various factors may contribute to mismatch including the release of the 
fetus from the constraint of poor nutrient supply secondary to uteroplacental insufficiency at 
birth, programmed hyperphagia (Vickers et al. 2000) and relative calorie excess secondary to 
maternal lifestyle factors and/or formula feeding, which is more prevalent in growth-restricted 
and premature babies. Irrespective, a mismatch between the prenatal and postnatal nutrient 
environment is an important risk factor for metabolic disease in the human, in that catch-up 
growth in early postnatal life is associated with adiposity (Ibanez et al. 2008), insulin resistance 
(Jaquet et al. 2000) and an increased risk of cardiovascular disease (Barker et al. 2005) in later 
life. The early postnatal period presents an opportunity for interventions aimed at preventing 
the long-term morbidity associated with FGR (Hanson & Gluckman 2011).  
In the overnourished adolescent sheep paradigm, the impact of the resultant FGR on postnatal 
growth and metabolism has been studied in young lambs up to three months of age, relative 
to the normally grown lambs of control-intake ewes. Following prenatal growth restriction 
lambs exhibit rapid catch-up growth with increased fractional growth rates to weaning, at 
which stage there is evidence of increased adiposity and reduced bone mineral density (BMD) 
measured using dual energy X-ray absorptiometry (DEXA) (Wallace et al. 2010a; Wallace et al. 
2010b). At 6 weeks of age, there is an exaggerated immune response to routine vaccination, as 
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indicated by higher levels of the acute phase reactant serum amyloid A 24 and 48 hours later 
(Carr et al. 2012). At 7 weeks of age, fasting plasma levels of glucose, insulin, non-esterified 
fatty acids (NEFA) and glycerol are increased and plasma urea levels are decreased (Wallace et 
al. 2010b). For glucose, insulin and urea these represent reversals of the patterns observed in 
late gestation, when growth-restricted fetuses are hypoglycaemic, hypoinsulinaemic and 
hyperuraemic relative to normally growing fetuses (Wallace et al. 2000). Glucose-stimulated 
insulin secretion, given by the area under the curve (AUC) of plasma insulin over time following 
an intravenous glucose bolus, is increased at 7 weeks postnatal age in the prenatally growth-
restricted lambs and accompanied by alterations in protein and fat metabolism, specifically 
increased NEFA AUC and glycerol AUC, and decreased urea AUC, respectively (Wallace et al. 
2010b). Insulin AUC : glucose AUC ratios and fasting insulin : glucose ratios are both increased, 
suggesting relative insulin resistance (Wallace et al. 2010a). Aspects of altered metabolism and 
body composition, including relative obesity, persist into adulthood (JM Wallace, unpublished 
data) in keeping with the developmental origins of adult disease concept. It was hypothesised 
that prenatal Ad.VEGF gene therapy, by mitigating the degree of FGR, would reduce neonatal 
catch-up growth and thereby improve the metabolic profile and body composition of lambs in 
early postnatal life.  
5.1.2 Aims 
The aims of this second study were to assess the effect of prenatal Ad.VEGF gene therapy on:   
 Fetal growth velocity (measured by ultrasound) 
 Gestation length and the delivery process 
 Lamb birth weight 
 Neonatal mortality and morbidity 
 Postnatal growth rates to weaning 
 Inflammatory response to routine vaccination 
 Metabolic responses to a standardised glucose tolerance test 
 Body composition (in vivo using DEXA and subsequently at necropsy) 
5.2 Materials and Methods 
5.2.1 Experimental design 
This study was predominantly designed to provide information about the efficacy and safety of 
Ad.VEGF as a therapy for FGR. The main outcome measure was lamb birth weight following 
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spontaneous delivery at term and important secondary outcome measures included 
assessments of fetal growth velocity (determined by serial ultrasound examination) and 
neonatal growth and development. A sample size calculation was performed based on a target 
increase in lamb birth weight of 20% following Ad.VEGF delivery in the putatively growth-
restricted sheep. Assuming inter-animal variability of 607g, it was estimated that 16 animals 
per group would be required to detect a 20% increase in birth weight (719g) with 90% power. 
Given that patterns of fetal growth following Ad.VEGF treatment relative to normally growing 
fetuses of control-intake ewes had been investigated in the previous study terminated in late 
gestation (see Chapter 4), a contemporaneous group of control-intake ewes was not included 
in the present experiment. A second reason for not including a non-FGR control group was that 
previous studies have shown that their lambs do not suffer any significant neonatal morbidity 
(Wallace et al. 2010). Thus in order to investigate the rate of neonatal complications or need 
for intervention, a direct comparison between treated and untreated FGR lambs was 
prioritised. As there had been no significant differences between saline- and Ad.LacZ-treated 
fetuses in the previous study, a single FGR control group was chosen for the present 
experiment (receiving saline only) to control for the effects of the laparotomy and injection 
procedure. Hence all ewes herein were overnourished and were allocated in mid-gestation to 
one of two study groups: Ad.VEGF or Saline. 
5.2.2 Establishment of singleton pregnancies and nutritional management 
Oestrus cycles were synchronised in 69 potential adolescent recipients and 13 potential adult 
donor ewes in the lead up to four separate embryo recovery and transfer days in the mid 
breeding season (Section 2.1.1.1). Adolescent recipients weighed 44.1±0.32 kg (mean ± SEM) 
and had an initial body condition score (BCS) of 2.3±0.01. Donor ewes weighed 67.7±2.20 kg 
with a BCS of 2.4±0.04 and were superovulated prior to undergoing laparoscopic intrauterine 
insemination (Section 2.1.1.2) and embryo recovery (see Section 2.1.1.3). Seven donors in total 
required to be flushed to provide sufficient embryos for singleton transfer into 56 recipient 
ewes (see Section 2.1.1.4). 
Immediately following embryo transfer and throughout gestation, all adolescent ewes were 
overnourished (see Section 2.1.2) as per the study design. Pregnancy diagnosis was carried out 
by ultrasound at 45 days gestation (Section 2.1.1.5) and initially confirmed viable pregnancies 
in 42 of 56 ewes (overall pregnancy rate 75.0%). Two ewes subsequently reabsorbed their 
fetuses between day 45 and mid-gestation. The 40 ewes with ongoing pregnancies had serial 
venous blood samples taken at 55, 70, 85, 100, 114, 128 and 136 days gestation for 
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subsequent placental hormone analyses. Blood samples were taken into 10ml lithium-heparin 
tubes and processed as described in Section 2.2.1. 
5.2.3 Ultrasound examination and gene therapy administration 
At 79±0.1 days gestation all ewes underwent a baseline ultrasound examination, as described 
in Section 2.1.3. For the present study the following ultrasound parameters were measured: 
abdominal circumference (AC), renal volume (RV), deepest vertical pool (DVP) of amniotic 
fluid, umbilical cord diameter (UCD), placentome index and umbilical arterial (UA) Doppler 
indices. Head and long bone measurements (biparietal diameter (BPD), occipito-snout length 
(OSL), femur length (FL) and tibia length (TL)) were omitted in this cohort due to the large 
number of animals being scanned on any given day. Interim analysis of ultrasound data had 
indicated that AC and RV were the strongest markers of fetal growth (see Chapter 3 for a 
detailed discussion) and therefore these parameters were prioritised. 
At 88±0.7 days gestation, 33 ewes underwent a midline laparotomy (as described in Section 
2.1.4.2) and received bilateral uterine artery (UtA) injections of 1x1012 particles Ad.VEGF (n=17) 
or 10ml saline only (n=16) over 1 minute, following which each UtA was occluded for a further 
4 minutes. Ewes were evenly allocated to Ad.VEGF and Saline groups on the basis of estimated 
fetal and placental size (values of AC, RV and placentome index) and the maternal live weight 
gain between embryo transfer and surgery. After allowing a full week’s postoperative recovery 
for all ewes, serial scans were performed at approximately weekly intervals from 101±0.1 until 
133±0.1 days gestation. Wounds were inspected for signs of infection or dehiscence prior to 
each scan and care was taken to minimise pressure from the transducer. All examinations 
were carried out by a single operator (David Carr), who was kept blind to the treatment 
administered in order to avoid any bias in the ultrasound evaluation of fetal growth. 
5.2.4 Lambing 
Ewes were supervised 24 hours a day 7 days a week from 135 days gestation (the earliest 
gestational age commensurate with live births in this FGR model) until 72 hours after the birth 
of the final lamb (17 days in total). Lambing was managed as per local husbandry procedures. 
All the lambs were delivered by one of three experienced lambers: Jacqueline Wallace, 
Raymond Aitken or John Milne and the rota was organised in the form of three overlapping 
shifts (7am to 5pm, 4pm to midnight and 10pm to 8am). David Carr assisted in a variety of 
roles, predominantly in the provision of neonatal care and monitoring, and assumed overall 
responsibility for data collection. All the team members except Jacqueline Wallace were blind 
to the treatment allocated at the time of surgery in order to minimise any bias in the provision 
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of perinatal care. An extensive protocol to maximise neonatal survival was used (see below) in 
view of the fact that neonatal morbidity and mortality is otherwise very high amongst lambs 
born to overnourished adolescent dams, particularly in relation to inadequate colostrum 
production, as discussed above (Wallace et al. 1996). The protocol was further developed to 
capture information on the interventions performed so as to provide an assessment of the 
degree of neonatal care needed. 
5.2.4.1 Management of delivery 
Ewes were regularly observed for signs of labour, which usually presented as a slowing of 
voluntary feed intake on the day of parturition, followed by signs of discomfort (raising of 
head, bleating, pawing ground etc.) with or without a show (mucus) or small vaginal bleed. 
Once labour was established and the cervix dilated, a digital vaginal examination was usually 
performed to establish fetal presentation, exclude obstruction and assess the need for assisted 
delivery (which is very common in primigravid and obese adolescent ewes that have been 
housed indoors throughout pregnancy). Malpresentation was corrected if present and 
appropriate traction was applied to facilitate safe delivery of the lamb. If assisted vaginal 
delivery was necessary, the degree of intervention was detailed in narrative form and the 
overall delivery was categorised as easy, average or difficult. Persistent failure of cervical 
dilatation or severe dystocia incompatible with vaginal delivery prompted review by a licensed 
veterinary surgeon, with recourse to caesarean section. Following completion of the third 
stage (typically 2–12 hours following birth of lamb), the placenta was carefully examined to 
ensure that it was complete and to identify any abnormalities such as stigmata of intrauterine 
infection, abnormal cotyledonary tissue or abnormal vasculature. All fetal cotyledons were 
dissected off the membranes, counted and weighed. The residual membrane weight was then 
determined and added to the cotyledon weight to give the total fetal placental weight. The 
degree of blood loss at delivery was assessed and categorised as average or excessive. In the 
event of a post-partum haemorrhage, the suspected cause (e.g. uterine atony, vaginal trauma) 
and any measures required to control it (e.g. use of oxytocin) were recorded. Following a 
difficult assisted vaginal delivery or caesarean section, maternal antibiotics (i.m. 
Duphapen®+Strep for at least 3 days) and analgesia in the form of flunixin (Finadyne®, 
Schering-Plough Animal Health) were provided. 
5.2.4.2 Neonatal resuscitation 
Initial condition at birth was assessed using an ABC (airway, breathing, circulation) approach. 
Firstly, any requirement for suctioning in order to establish a functional airway was recorded. 
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In particular a distinction was made between “routine” suctioning to clear maternal secretions 
in an otherwise potentially vigorous lamb and “extensive” suctioning to stimulate respiration 
and/or clear a non-patent airway in a compromised lamb. Secondly, a subjective assessment 
was made of breathing, which was categorised as normal or abnormally fast, slow or laboured. 
Thirdly, the circulation was assessed by observing the colour of the mucous membranes and 
palpating the anterior chest for the cardiac impulse, which was documented either as normal 
or obviously slow. In addition, an initial assessment of tone was made. Tone was categorised 
as normal, decreased (floppy) or increased (stiff, extended neck). Any additional resuscitation 
measures required were detailed in narrative form, e.g. mouth-to-mouth ventilation, cardiac 
compressions, supplementary oxygen therapy or use of respiratory stimulants such as 
doxapram (Dopram-V® Drops, Fort Dodge Animal Health) or etamiphylline (Millophylline-V®, 
Dechra Veterinary Products, Shrewsbury, Shropshire, UK). 
5.2.4.3 Routine neonatal care 
Once stabilised, each lamb was dried thoroughly with a warm cotton towel before being 
placed onto a set of scales (D-7470, Sauter, Ebingen, Germany) to measure birth weight (see 
Figure 5.1A). Sex and gestational age at delivery were recorded. The biparietal head diameter 
and abdominal girth at the level of the umbilicus were measured as described in Section 
4.2.5.2. Within 10 minutes of delivery and with the lamb remaining in its mother's pen, the 
wool on the lamb’s neck was shaved to expose the jugular vein, from which a sample of 
venous blood was taken into a 2.5ml heparinised syringe using a 21 gauge needle. Fetal 
haemoglobin and venous blood gas parameters were determined immediately using an OSM™ 
3 Hemoximeter™ (Radiometer Medical A/S, Copenhagen, Denmark). A small amount of blood 
was transferred into a pair of glass capillary tubes, which were subsequently sealed with non-
dry putty (Brand GMBH, Wertheim, Germany) before being spun at 12000 rpm for 3 minutes in 
a haematocrit centrifuge (Micro Haematocrit MK-IV, Hawksley and Sons Ltd, Lancing, Sussex, 
UK). The haematocrit was then determined in duplicate using a tube reader. The remaining 
blood sample was transferred into a 5ml glass tube and processed as described in Section 
2.2.1. The resultant plasma was analysed immediately for glucose and lactate (as described in 
Section 2.2.4.1) and then stored at –20oC pending further analyses. Lambs routinely received 
i.m. vitamin E and selenium supplementation (0.5ml Vitesel® (Norbrook Laboratories, Newry, 
Co. Down, Northern Ireland, UK) and prophylactic antibiotics in the form of 0.1mg/kg s.c. 
enrofloxacin (Baytril®, Bayer Ltd, Newbury, Berks, UK) for a total of 5 days. The lamb’s navel 
was dipped in iodine to reduce the risk of infection (at birth and repeated within 12 hours). 
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Figure 5.1 – Routine neonatal care measures 
  
[A] Young lamb being weighed on a set of scales - this was done at regular intervals to ensure 
appropriate weight gain and to identify lambs requiring supplementary feeding. [B] A lamb 
suckling spontaneously from its mother. 
  
Shortly after delivery 10 IU oxytocin i.v. or i.m. (Oxytocin-S®, Intervet UK Ltd) was administered 
to the ewe to induce milk let-down, following which the udder was completely stripped of all 
colostrum by hand. Colostrum was collected in a measuring jug and weighed to determine the 
total colostrum yield. After freezing a 40ml sample for subsequent IgG and nutrient 
composition analyses (see Sections 5.2.7.2 to 5.2.7.5), the remaining colostrum was filtered 
through a gauze to remove any obvious dirt and then fed back to the lamb at a dose of 
50ml/kg using a sterilised baby bottle. A lamb feeding tube (William Daniels UK Ltd, 
Withernsea, East Yorkshire, UK) was used if the bottle was not tolerated (rare). Lambs born to 
ewes producing insufficient colostrum to meet this basic requirement were supplemented 
with donor colostrum, which had been collected previously and stored frozen. Donor 
colostrum was sourced from healthy multiparous adult ewes and pooled ahead of this study in 
order to standardize its nutrient and IgG content (105mg/ml). Following this initial feed, lambs 
were encouraged to suckle their mothers (see Figure 5.1B) and to establish demand feeding. 
At one hour of age, once vital signs had stabilised following birth, a set of routine observations 
was performed on all lambs. The respiratory rate per minute was determined by counting the 
number of outward chest movements in a 15 second period and multiplying by four. The heart 
A B 
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rate per minute was determined by palpation of the left anterior chest over a 15 second period 
and multiplying by four. Core temperature was measured using a rectal thermometer (Becton 
Dickinson) and prior to the use of a heating lamp if this was deemed necessary (see Section 
5.2.4.4). Lambs were observed at frequent intervals until they were seen to be standing 
independently on all four legs, at which point time to standing was documented.  
Routine reviews of wellbeing for uncomplicated neonates were performed every 4 hours until 
48 hours of age, and subsequently every 6 hours until 72 hours of age. Lambs were weighed at 
each review to confirm weight gain, an (indirect) indicator of appropriate lactation and 
suckling technique. If sleeping or lying down prior to being weighed, lambs were gently 
stimulated, encouraged to stand and observed for a stretch response, which is a reassuring 
sign of wellbeing. On returning to their mothers, lambs’ suckling behaviour was observed as a 
further sign of appropriate establishment and functioning of the ewe lamb bond. At 24 hours 
of age, shoulder height was measured using a horse height measuring stick with an extending 
stem, folding arm and spirit level. Lambs were encouraged to stand still and in a neutral 
position without excessive extension or flexion of the back. Measurements were taken at the 
anterior shoulder and were repeated several times for accuracy. A proforma for routine lamb 
data collection is shown in Appendix 6. At the same time, paired maternal and lamb venous 
blood samples were taken into heparinised tubes and processed as described in Section 2.2.1. 
The resultant plasma was subsequently analysed for IgG, as described in Section 5.2.7.2.   
5.2.4.4 Additional neonatal care 
Any deviation from the routine schedule of care was documented in detail in narrative form, 
with particular care taken to document specific concerns and justification for any 
interventions. Lamb weight was used as the primary surveillance tool for neonatal wellbeing. 
Weight loss or failure of the lamb to gain weight over an 8 hour period prompted a careful 
review of feeding as well as consideration of other complications such as hypothermia or 
infection. Lambs with inadequate suckling technique, or for whom maternal milk production 
was insufficient, had supplementary feeding. If this was required during the first 24 hours of 
life, further colostrum was provided. Thereafter milk was used for all supplementary feeds and 
was ideally sourced by hand milking the lamb’s own mother, provided lactation was adequate. 
Further doses of oxytocin were given if necessary to enhance milk let down and supply. If 
insufficient, donor milk was obtained from neighbouring ewes with milk supply in excess of 
their own lambs’ requirements or from a commercial flock of adult ewes. As a last resort, lamb 
milk replacer was occasionally used to supplement feeds (SCA Shepherdess®, SCA NuTec, 
Dalton, North Yorkshire, UK). This formula milk consisted of 23% protein, 23% oil, 7% ash and 
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0.05% fibre, and provided 45000 IU vitamin A, 4000 IU vitamin D3 and 150 IU vitamin E (alpha-
tocopherol) per kg. Supplementary feeds were continued for as long as necessary until the 
ewe lamb bond and appropriate lactation and suckling technique had been established. The 
number and frequency of supplementary feeds per lamb were recorded. All feeds were given 
by bottle unless this was not tolerated, in which case a nasogastric route was used (rare). For 
lambs with specific concerns, such as prematurity or poor urine output, supplementary 
colostrum or milk was mixed 50:50 with Energaid® (Elanco Animal Health, Basingstoke, 
Hampshire, UK) in order to provide energy without overloading the neonatal gut (and 
ultimately also the kidneys) with relatively high concentrations of fat and protein. 
The most common intervention was the use of heating lamps, which were set up for a wide 
range of indications including concerns prior to delivery (e.g. initiation of labour at an early 
gestational age, very low estimated fetal weight by ultrasound) as well as neonatal concerns 
(e.g. poor condition at birth or evidence of hypothermia). In addition lamps were often put up 
in response to boisterous maternal behaviour, when the lamb was considered to be at risk of 
crush injury. In this specific context warmth from the heat lamp encouraged the lamb to lie in 
the corner of the pen, which was then wired off (see Figure 5.2A) to provide an area of relative 
safety. Cotton towels were provided where necessary for comfort and to confirm meconium 
throughput and urine output. Lambs with respiratory difficulty requiring supplementary 
oxygen were transferred to an intensive care area in a heated surgery, where ambient oxygen 
was provided from a cylinder via a face mask (see Figure 5.2B) and oxygen saturations were 
monitored using a portable hemoximeter unit, with the probe attached to the lamb’s ear. 
Rectal temperature was regularly checked in any unwell lambs. Further medications were 
given as necessary, as dictated by the clinical condition e.g. further antibiotics 
(Duphapen®+Strep and/or marbofloxacin (Marbocyl®, Vetoquinol UK Ltd, Buckingham, UK)), 
analgesia (meloxicam or buprenorphine) and dexamethasone (Dexadreson®, Intervet UK Ltd). 
In the event of any persistent concerns about neonatal health, individualised advice was 
sought from the named veterinary surgeon. 
5.2.5  Postnatal investigations 
At the end of the intensive neonatal monitoring period (minimum 72 hours per lamb), lambs 
were weighed using CW-11 scales (Ohaus Corporation, Pine Brook, NJ, USA) initially at daily 
and then at weekly intervals to determine absolute and fractional postnatal growth velocity. 
Fractional growth velocity to weaning (%/day) were calculated by expressing the live weight 
gain between birth and necropsy as a proportion of lamb birth weight and dividing by the 
interval between birth and necropsy. Measurements of umbilical girth and shoulder height 
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Figure 5.2 – Additional neonatal care measures 
  
[A] Wired off pen corner beneath a heat lamp, providing a safe area for the lamb. [B] Provision 
of supplementary oxygen to a lamb experiencing respiratory difficulties following a protracted 
labour which eventually necessitated a caesarean  section. 
  
were also repeated weekly. Serial blood samples were taken by jugular venepuncture into 5ml 
heparinised assay tubes at 7, 14, 21, 28, 35, 42, 49, 56, 63, 70 and 77 days of age for 
subsequent insulin and IGF1 analyses (see Section 2.2.4). An additional venous blood sample 
was taken into a plain (serum) tube on day 8. All samples were processed as described in 
Section 2.2.1. Day 8 serum samples were sent to the laboratories at the Royal Veterinary 
College, North Mimms, Hertfordshire, where they were analysed for serum biochemistry and 
liver function. The parameters reported included sodium, potassium, chloride, urea, 
creatinine, albumin, alanine transaminase (ALT), aspartate aminotransferase (AST), gamma-
glutamyl transferase (GGT), glutamate dehydrogenase (GLDH) and alkaline phosphatase (ALP).  
5.2.5.1 Immune challenge 
At 58±0.4 days postnatal age, all lambs underwent routine vaccination with 2ml i.m. Heptavac 
P Plus® 8 in 1 Clostridial and pasteurella vaccine for sheep (Intervet UK Ltd). Venous blood was 
sampled into K2-EDTA (plasma) tubes immediately prior to vaccination (day 0) and at exactly 
24 hours (day 1) and 48 hours (day 2) post-vaccination by jugular venepuncture and processed 
as described in Section 2.2.1. Individual immune responses to vaccination were investigated by 
measurement of the concentrations of serum amyloid A (San acute phase reactant) in these 
samples (see Section 5.2.7.6). 
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5.2.5.2 Metabolic challenge 
At 68±0.5 days postnatal age, metabolic function was assessed by the measurement of various 
metabolite responses to a body weight specific glucose bolus, as described (Wallace et al. 
2010a). By this age lambs had been handled frequently and hence were exceptionally docile. 
They remained with their mothers during the glucose challenge, were observed throughout 
and did not display any overt signs of stress or discomfort. 
Glucose tolerance tests were performed in groups of three lambs per day across a seven day 
period. Maternal udder covers (custom-made cloth slings) were applied three hours before 
glucose infusion in order to prevent suckling and thereby fast the lambs. Lambs were weighed 
at the time of application of the udder covers. After shaving the neck fleece on both sides and 
cleaning the skin thoroughly with a mixture of HibiTANE® and ethanol, a 16-gauge short 
intravenous cannulae (Vygon, Ecouen, France) was inserted into the jugular vein on each side 
of the neck and secured using nonabsorbable braided silk (2.0 Mersilk®, W327H, Ethicon). 
Patency of the cannulae was checked bilaterally during the withdrawal of baseline blood 
samples at –20 and –10 minutes relative to glucose administration. Thereafter one side was 
designated for sampling and the other for infusion. At 0 minutes a third and final baseline 
sample was taken from the sampling cannula, immediately prior to the administration of 
0.25mg/kg (=0.5ml/kg) sterile 50% glucose solution (Baxter Healthcare Corporation, Deerfield, 
IL, USA). The infusion was given steadily (at a rate of approximately 1ml every 5 seconds) and 
was synchronised between the 3 lambs in each group. The infusion was followed by a 5ml 
sterile normal saline flush. Thereafter further venous blood samples were collected at +5, +10, 
+15, +20, +25, +30, +45, +60, +90 and +120 minutes relative to the glucose bolus. All blood 
samples were taken into heparinised 5ml assay tubes and were kept on ice and processed as 
quickly as possible, as described in Section 2.2.1. The resultant plasma was stored at –20°C for 
subsequent measurement of serial concentrations of glucose (see Section 2.2.4.1), insulin (see 
Section 2.2.4.2), non-esterified fatty acids, glycerol and urea (Section 5.2.7.8). Udder covers 
were removed after the final sample was collected and a post-fasting weight was taken 15 
minutes later to give an index of appetite following a total fasting period of around 5 hours. 
5.2.5.3 Body composition analysis 
At 74±0.4 days postnatal age, all lambs underwent a non-invasive assessment of body 
composition using dual-energy X-ray absorptiometry (DEXA). Lambs (and their cohabiting 
mothers) had their feed withheld on the morning of DEXA examination. General anaesthesia 
was induced and maintained using isoflurane in a mixture of oxygen and nitrous oxide. Lambs 
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were temporarily removed from their mothers and transported a short distance to the 
scanning facility on site. Lambs were then positioned prone (see Figure 5.3A) in a Norland XR-
26 Mark II analyser (Norland Corporation, Fort Atkinson, WI, USA). DEXA images (see Figure 
5.3B) were analysed by computer to determine bone mineral density, bone mineral content, 
lean mass, fat mass and percentage body fat. Three replicate scan analyses were averaged for 
the final results. Coefficients of variation for DEXA measurements of total body fat, lean mass 
and bone mineral content were 3.6%, 3.2% and 1.5%, respectively. 
  
Figure 5.3  –  Dual energy X-ray absorptiometry 
 
[B] Lamb anaesthetised and undergoing DEXA analysis at 11 weeks of age. [B] Representative 
DEXA scan image. 
  
5.2.6 Necropsy procedures 
At 83±0.2 days postnatal age, lambs were sacrificed for post-mortem analysis. On the day prior 
to necropsy final measurements of live weight, shoulder height and umbilical girth were made 
and a venous blood sample was taken for measurement of leptin (described in Section 5.2.7.7), 
haematocrit and haemoglobin (see Section 5.2.4.3). The following day, lambs were humanely 
killed using an overdose of 20ml pentobarbital sodium administered by i.v. injection into the 
jugular vein. Death was confirmed by the absence of corneal reflexes. Thereafter lambs were 
suspended by the back legs using a ceiling mounted electric hoist and exsanguinated by 
severing the main vessels of the neck. Blood was collected into a bucket and subsequently 
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weighed. Each lamb underwent a systematic post-mortem examination with careful 
documentation of any gross abnormalities. Samples for freezing were placed into liquid 
nitrogen chilled isopentane until frozen through and then stored on dry ice until the end of 
each necropsy, when they were transferred to –80oC storage. Samples for fixing were 
immersed in approximately 10 times their volume of NBF or Carnoy's solution, prepared as 
described in Section 2.2.2. Fixed tissues were subsequently processed to the wax block stage 
as detailed in Section 2.2.3. A sample lamb necropsy record sheet is shown in Appendix 7. 
Widespread tissue sampling was carried out as described below, mainly as a precautionary 
measure. If Ad.VEGF treatment were to have any unexpected effects on gross organ 
morphology then a large tissue bank would be available for histopathological examination and 
additional analyses. 
Firstly, the lamb’s head was removed and placed into a vice by one member of the team. The 
skull was opened up using a saw and chisel and the brain was removed and snap-frozen whole. 
The underlying pituitary gland was dissected from the sella turcica and frozen in Tissue-Tek®, 
following which the residual head was weighed. In parallel another team member sampled the 
longissimus dorsi muscle for fixing and freezing. At the same time the abdomen was opened by 
a third team member and the pancreas was dissected out as swiftly as possible. It was weighed 
before being separately sampled at its hepatic and splenic ends for freezing and fixing, 
respectively. Next, the gastrointestinal tract was dissected out whole and laid out so that the 
vascular mesenteric arcade was clearly visible. The intersection of the mesenteric and 
ileocaecal veins was identified. From this landmark, moving in a direction away from the liver, 
the third mesenteric branch up the arcade was located and followed down to the intestinal 
wall. At this site, multiple “rings” of jejunum were excised and snap frozen. Further jejunal 
samples in the form of rings and rolls (rings cut along the mesenteric seem and opened up) 
were obtained for fixing. Half of these were immersed in NBF and half in Carnoy’s solution. 
Next the liver was removed and weighed. A sample was taken from the right lobe for fixing, 
followed by generous samples from both lobes for freezing. The spleen was removed, weighed 
and sampled for fixing and freezing. Both kidneys were removed together with all perirenal fat, 
which was subsequently stripped off, weighed and sampled for fixing and freezing. The kidneys 
were then cut transversely and mid-section slices were fixed and frozen. The adrenal glands 
were removed and cut in half, one transversely and one longitudinally. Half of each adrenal 
was fixed and the other half frozen.  
Next the fetal chest was opened and the heart was removed and weighed. The lungs were 
disconnected from the trachea, removed and weighed. The right lower lobe was sampled for 
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fixing and freezing by cutting perpendicularly to the main bronchus approximately 3cm above 
the inferior border of the lobe. The thymus and gonads were also removed and weighed. 
Finally, all four hocks were removed and weighed together. The tibia was dissected out from 
the front left hock and cleared of connective tissue. The length of the bone was measured 
using callipers and its weight determined. The residual carcass was then weighed and the 
weight of the lamb’s blood collected in a bucket following exsanguination was recorded as an 
index of blood volume.  
5.2.7 Laboratory measurements 
5.2.7.1 Oestradiol-17β 
Oestradiol-17β was extracted in duplicate from serial maternal plasma samples and measured 
using a double antibody radioimmunoassay technique, as described by Johnson et al. (1997). 
Assay buffer solutions were first made up as follows and stored at 4°C. Phosphate buffered 
saline (PBS) was prepared by stirring 1.55g Na2HPO4, 0.224g Na2H2PO4, 8.183g NaCl and 1.0g 
NaN3 into 900ml d.H2O, adjusting the pH to 7.3 and making up to 1 litre with d.H20. PBS/Gel 
was prepared by adding 0.1g gelatin to 100ml PBS, warming and stirring until dissolved. 
Dextran-coated charcoal solution was prepared by adding 0.625g charcoal (Ref. C-526, Sigma 
Aldrich) and 0.0625g dextran (Ref. 31390, Fluka Biochemica, Buchs, Switzerland) to 100ml PBS 
and stirring for 2 hours. 1ml of each plasma sample was placed in a Soveril screw cap 
extraction tube, to which 4ml benzene (Ref. 12549, Fluka Biochemika) was added. Each tube 
was capped and vigorously shaken for 4 minutes before being centrifuged for 2 minutes at 
1000rpm (225g) at 4°C. Under an extractor hood, the top layer of benzene (containing the 
extracted oestrogens) was aspirated from each tube and placed into 12x75mm borosilicate 
glass assay tubes (Fisherbrand®, Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK). 
Tubes were then placed in an evaporating block (Techne DB-3), gently warmed and the solvent 
evaporated under a stream of air. Thereafter 100μl of PBS/Gel was added to each tube. A set 
of 10 standards (ranging from 0.585 to 300pg 17β-oestradiol per tube) was prepared by serial 
dilution of a stock solution of 17β-oestradiol (Ref. E-8875, Sigma Aldrich) using ethanol. The 
standard tubes were dried down and reconstituted with PBS/Gel as described above.  
To begin the assay, 100μl of diluted antiserum (E2-6 #3 2-19-73, Eli Lilly & Co., Lilly Corporate 
Center, Indianapolis, IN, USA) at a dilution of 1:20,000 was added to each tube and to two 
tubes containing 100μl PBS/Gel only (for total binding). Tubes were vortexed before being 
incubated at 4°C for 30 minutes. Next, 100μl of a tritiated oestradiol tracer solution (NEN 
2,4,6,7 3 H(N) Estradiol, Ref. NET317250UC, PerkinElmer Inc), diluted with PBS/Gel to give 
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12000cpm/100μl, was added to all tubes as well as to 4 additional tubes containing 200μl 
PBS/Gel only (2 for total counts and 2 for non-specific binding). Tubes were then incubated 
overnight at 4°C. The following morning 500μl cold PBS with sodium azide was added to the 
total count tubes, which were then capped. To all remaining tubes was added 500μl cold 
Dextran-coated charcoal solution, as quickly as possible. The mixture was then incubated for 
10 minutes on ice before being centrifuged at 3300rpm (2250g) at 4°C for 15 minutes. The 
supernatant was decanted into mini scintillation vials, to which 3ml Ultima Gold™ scintillation 
fluid (PerkinElmer) was added. Vials were capped, shaken well to mix and then left for 3 to 4 
hours. Thereafter vials were counted for 5 minutes each on a Tri-Carb 2900TR liquid 
scintillation analyser (Packard BioScience, Meriden, CT, USA). A calibration curve for the assay 
was produced following logistic transformation. The limit of sensitivity of the assay was 
1pg/ml. Serial maternal plasma samples were analysed during 9 consecutive assays, each 
comprising samples from four animals matched according to treatment group (i.e. two from 
Ad.VEGF and two from Saline groups). The inter-assay coefficient of variation was 7.1% and 
was calculated using QC plasma samples (known concentrations of oestradiol ranging from 
high to low values) at the start of each assay. 
5.2.7.2 Immunoglobulin G 
Levels of IgG were determined in triplicate in colostrum and in paired maternal and lamb 
plasma samples (taken at 24 hours of life) by competitive ELISA, as previously described 
(Wallace et al. 2006b). A 96-well polysterene microtitre high-protein binding assay plate 
(Immunolon 4 HBX, Dynex Technologies, Chantilly, VA, USA) was firstly coated with purified 
stock ovine IgG (0.5µg/ml in a 0.05M bicarbonate buffer, Ref. I-5131, Sigma Chemical Co, St. 
Louis, MO, USA) and stored at 4°C for 24 hours before being washed 3 times at 2 minute 
intervals with a 0.05% solution of PBS/Tween (Ref. P1379, Sigma Aldrich) to remove any 
unbound antibody. 500µl of each colostrum sample was then transferred into an eppendorf 
tube and centrifuged at 12000rpm (12000g) for 5 minutes at 4°C. Test samples were pipetted 
from below the fat layer and diluted 1:100000 with PBS/Tween. Maternal and lamb plasma 
samples were diluted 1:30,000 with PBS/Tween. A set of 10 standard solutions (ranging from 
0.025 to 12.5µg IgG/ml) was prepared by serial dilution of a stock solution of IgG (Ref. E-8875, 
Sigma Aldrich) using PBS/Tween. In a separate 96-well round-bottomed microtitre assay plate, 
to 120µl of each sample and 120µl of each standard solution was added 120µl of first 
antibody, raised in rabbit to purified sheep IgG (Ref. S-1265, Sigma Aldrich). At the same time, 
240µl of PBS/Tween was added to two blank wells (for zero binding). Plates were incubated 
overnight at room temperature. The following day, the IgG coated assay plate was washed 
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three times with PBS before 200µl from each well in the round-bottomed plate was 
transferred to its corresponding well on the high-protein binding plate. After incubating at 
room temperature for 2 hours, the assay plate was once again washed three times with fresh 
PBS. Next 200µl of second antibody (anti-rabbit peroxidase conjugate, Ref. A-0545, Sigma 
Aldrich) was added to each sample and standard well, whilst 200µl of PBS/Tween was added to 
the two blank wells. After incubating at room temperature for a further 1 hour, the plate was 
washed for a final time. Next 200µl of enzyme substrate (2,2’-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid) (ABTS, Ref. A-1888, Sigma Aldrich)–hydrogen peroxide (Ref. H-6520, Sigma 
Aldrich)) was added to each well and incubated for 30 minutes, following which 100µl 0.4M 
sodium fluoride (stop solution) was added. At 30 minutes optical density at 405nm was read by 
a multichannel spectrometer. A calibration curve for the assay was produced following logistic 
transformation. Intra- and inter-assay coefficients of variation (calculated from two colostrum 
QC samples included in each plate) were 8.2 and 13.4%, respectively. 
5.2.7.3 Fat 
Concentrations of butterfat were measured in duplicate in colostrum using the Soxhlet 
procedure after initial acid hydrolysis. In a conical flask, 2.5 to 5.0g of well-mixed colostrum 
was accurately weighed before being dissolved in 100ml 4M hydrochloric acid. The flask was 
placed onto a refluxing hotplate attached to a cold finger condenser and boiled gently for 60 
minutes. Thereafter the solution was allowed to cool down to below 40°C beneath an 
extractor hood. A 22µm ashless filter paper (Whatman® grade 541) was folded and placed into 
a funnel, to which was added 1g Celite® Hyflo Super-Cel filter aid (Shengzhou Huali Diatomite 
Products Co. Ltd, Zhejiang, China). The contents of the flask were slowly filtered through and 
the flask was repeatedly washed to ensure that no residue was left behind. The filter paper 
was subsequently washed continuously until no acidity was detectable in the washings (using 
litmus paper). The above steps were repeated for each colostrum sample. Funnels and filter 
papers were then dried overnight at 50°C in an oven. The following day, filter papers were 
removed and placed into extraction thimbles. The surface of each funnel was wiped with a 
piece of petroleum spirit-soaked cotton wool, which was then added to the thimble, to ensure 
all the fat was transferred. Soxtec™ extraction cups were preheated to 50°C prior to the 
addition of anti-bumping granules. Thereafter cups were cooled to room temperature in a 
dessicator and their initial weight was determined. The thimbles (containing sample) were 
attached to the condensers in a Soxtec™ extraction system (Foss Analytical, Hilleroed, 
Denmark) and the extraction cups were inserted after addition of 40–45ml fresh petroleum 
spirit to each. Thimbles were extracted by boiling for 30 minutes and subsequently rinsed for 
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35 minutes. Thereafter condenser valves were closed to recover the solvent. Air pressure was 
used to remove the final traces. Extraction cups were dried at 100–103°C in an oven for 30 
minutes and then placed into a dessicator to cool. Finally cups were reweighed and the 
butterfat concentration was calculated as the difference in weight multiplied by 100 and 
divided by the precise sample weight in grams. Variation between duplicates was less than 5%. 
5.2.7.4 Protein 
Concentrations of crude protein were measured in duplicate in colostrum using a Vario Max 
CN analyser. To begin, 0.7 to 0.8g of colostrum was accurately weighed out and placed into 
nickel crucibles. A sample of lentil peas was used as a standard/quality control. Samples were 
combusted at high temperatures in an oxygen-rich environment and the liberated gases 
passed through a series of reduction and absorption tubes by way of a helium-gas carrier. The 
resultant mixture of helium and nitrogen was channelled through a thermal conductivity 
detector to determine the volume of nitrogen present in the sample. Crude protein was then 
calculated by multiplying the volume of nitrogen by 6.38, which is a previously validated 
constant for ovine colostrum. 
5.2.7.5 Lactose 
Concentrations of lactose were measured in duplicate in colostrum. Samples of approximately 
0.1g were accurately weighed and then made up to a total of 30g with 0.02% Brij® 
(polyoxyethylene (20) cetyl ether) solution (G Biosciences®, Maryland Heights, MO, USA). To 
2.5ml of the diluted sample in a test tube was added 0.2ml 5% zinc sulphate and 0.2ml barium 
hydroxide. Tubes were centrifuged at 3000rpm for 30 seconds, following which 1ml of each 
supernatant was transferred to a new test tube. A set of 5 standard solutions was prepared, 
ranging from 10% to 80% pure lactose. To 1ml of each standard, 1ml of each sample and to 
1ml water (blank) was added 2.5ml Teles’ reagent (made up of 1 part phenol, 2 parts sodium 
hydroxide, 2 parts picric acid and 1 part sodium bisulphate). Tubes were capped and placed 
into a bath of boiling water for 6 minutes, following which they transferred into cold water. A 
further 9ml Brij® solution was added to each tube before absorbance was read at 520nm using 
a spectrophotometer. Lactose concentrations were calculated from absorbance readings and 
sample weights. 
5.2.7.6 Serum amyloid A 
Serum amyloid A (SAA) levels were determined in three plasma samples per lamb taken prior 
to and 24 and 48 hours following routine vaccination (Section 5.2.5.1) using a commercial solid 
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phase sandwich ELISA kit (Phase™ Range Multispecies SAA, Tridelta Development Ltd, Bray, Co. 
Wicklow, Ireland). 96-well microtitre assay plates coated with monoclonal antibody specific for 
SAA were used. To begin, 50µl of biotinylated anti-SAA antibody conjugate was added to each 
well. Plasma samples were diluted 1:5 (baseline samples) or 1:100–2000 (post-vaccination 
samples) with diluent buffer and a set of 6 standard solutions was prepared by serial dilution 
of SAA calibrator using diluent buffer. In duplicate, 50µl of each diluted sample or standard 
was added to each well and the sides of each plate were tapped gently to mix. Plates were 
covered with a dust cover and incubated for 1 hour at 37°C, following which the reagents were 
aspirated out of each well. Plates were washed 4 times with a minimum of 400µl diluted wash 
buffer per well. After the last aspiration, plates were tapped dry on absorbent paper. 
Subsequently 100µl of streptavidin horse radish peroxidise (HRP) conjugate at 1:4000 dilution 
was added to each well. Plates were covered again and incubated at room temperature and in 
the dark for 30 minutes, following which reagents were decanted. Plates were once again 
washed 4 times with a minimum of 400µl diluted wash buffer per well. After drying, 100µl of 
tetramethylbenzidine (TMB) substrate was added to each well, plates were covered again and 
incubated for a further 30 minutes at room temperature in the dark. Finally 50µl of stop 
solution was added and the absorbance in each well was read at 450nm. A calibration curve 
for the assay was produced following logistic transformation. Samples were analysed across 4 
consecutive plates. The intra- and inter-assay coefficients of variation were both <10%. 
5.2.7.7 Leptin 
Leptin concentrations were determined in duplicate in pre-necropsy lamb plasma samples 
using a double antibody radioimmunoassay technique, as described by Marie et al. (2001). 
Assay buffer was first prepared by adding 0.5% bovine serum albumin to 0.05M phosphate 
buffer, adjusting the pH to 7.4 and storing at 4°C. Eight standard solutions (ranging from 0.195 
to 25.0ng/ml) were prepared from a stock solution of recombinant ovine leptin, produced by 
the method of Gertler et al. (1998). On day 1 of the assay, 500μl of whole anti-serum (chicken 
Igγ anti-recombinant ovine leptin, Ref. C35, Genosys, Cambridge, UK) at 1:2000 dilution was 
added to 100μl of each standard solution or plasma sample, as well as to two tubes containing 
100μl assay buffer only (for total binding). Tubes were vortexed before being incubated at 
room temperature for 48 hours. On day 3, 100μl of 125I-Leptin tracer (prepared in house by 
chloramine-T iodination of leptin standard followed by purification on a Sephadex G25 
column) at 12000 cpm/100μl ml was added to each tube as well as 2 empty tubes (for total 
counts) and 2 tubes containing 600μl assay buffer only (for non-specific binding). Tubes were 
vortexed before being incubated overnight at 4°C. On day 4, 500μl of the second antibody 
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mixture, containing goat anti-chicken whole serum antibody (Ref. A30-109, Bethyl 
Laboratories, Montgomery, Texas, USA) at 1:50 dilution and chicken Ig-γ, prepared in house 
using an EGGstract® Ig-γ  purification system (Promega), at 1:300 dilution, was added to each 
tube. Tubes were vortexed again before being incubated for 3 days at 4°C. On day 7, 1ml cold 
polyethylene glycol solution was added to all tubes except the total counts. Tubes were then 
centrifuged at 3300 rpm (2250g) for 30 minutes at 4°C. The supernatant from each tube was 
decanted off and the residual pellets were counted on an automatic gamma counter (Wallac 
Wizard™ 1470) for 1 minute. A calibration curve for the assay was produced following logistic 
transformation. All the lamb samples were analysed in a single assay, for which the intra-assay 
coefficient of variation was 6.2%. The limit of sensitivity of the assay was 0.05ng leptin/ml. 
5.2.7.8 Glycerol, urea and non-esterified fatty acids  
Concentrations of glycerol, urea and non-esterified fatty acids (NEFA) were measured in 13 
serial plasma samples per lamb, collected relative to a glucose bolus (see Section 5.2.5.2). 
Samples were processed through an automated clinical analyser (KONELAB30) using kits 
supplied by the manufacturer (LabMedics, Manchester, UK), which were capable of measuring 
plasma glycerol and NEFA levels in the ranges of 0.1–1.0 mmol/l, 2–20 mmol/l and 0–100 
mmol/l, respectively.  
Glycerol was first converted by glycerol kinase into glycerol-3-phosphate, which was in turn 
converted into dihydroxyacetone-phosphate and H2O2 by glycerol phosphate oxidase. H2O2 
subsequently reacted in the presence of 3,5-dichloro-2-hydroxybenzene sulphonic acid and 
aminophenazone to produce n-(4-antipyrl)-3-chloro-5-sulphonate-p-benzoquinoneimine. A 
direct colorimetric procedure was used to determine glycerol concentrations. Urea was first 
hydrolysed to produce ammonia, which reacted with 2-oxyglutarate (catalysed by glutamate 
dehydrogenase) to form L-glutamate with oxidation of NADH to NAD. Absorbance was read at 
340nm to determine urea concentrations. Free NEFA were first converted into coenzyme A 
(CoA) esters by CoA synthetase. Acyl-CoA was oxidised by acyl-CoA oxidase to produce 
hydrogen peroxide (H2O2), which was subsequently converted by peroxidase (POD) in the 
presence of 3-methyl-N-ethyl-N-beta-hydroxyethyl-aniline and 4-aminoantipyrine into a purple 
quinone product. Absorbance was read at 540nm to determine NEFA concentrations.  
5.2.8 Statistical analyses 
After checking for normality using Q-Q plots and for equality of variance using Levene's test, 
comparisons between the Ad.VEGF and Saline groups were made using Student’s t test. 
Correlations were assessed using Pearson’s product moment test. In postnatal life it is well 
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known that strong male versus female differences rapidly become apparent in a number of 
different biological parameters. In view of this, the General Linear Model was used in order to 
examine for the effect of prenatal Ad.VEGF treatment, gender and their potential interactions 
for all variables from birth onwards. Where significant gender differences or interactions were 
detected, results are presented as four groups (Ad.VEGF-M, Ad.VEGF-F, Saline-M and Saline-F) 
Categorical data were compared between groups using Chi squared tests.  
5.3 Results 
Serial ultrasound data was collected in 30 of 33 pregnancies following administration of gene 
therapy or saline. Three ewes (two in the Saline group and one in the Ad.VEGF group) 
developed hernias of their midline surgical wounds in the first post-operative week and 
ultrasound examinations were omitted in order to avoid placing pressure on the bowel. They 
otherwise remained well throughout the study and parturition was unremarkable. There was 
one intra-uterine death in the study (in the Saline group) which occurred at 132 days gestation 
in a fetus which had tracked extremely small on serial ultrasound assessment with persistently 
high UA Doppler indices (>2SD above mean values from 87 days to 116 days gestation). A 
stillborn lamb was subsequently delivered, weighing only 1496g. Full pregnancy outcome data 
(including blood parameters) was collected in the remaining 32 ewes, which went on to deliver 
live lambs between 136 and 145 days gestation. One lamb in the Ad.VEGF group was crushed 
by its mother and sustained 16 fractured ribs necessitating euthanasia at 27 hours of age. Full 
postnatal datasets (including growth, immune challenge, glucose tolerance test, DEXA and 
necropsy data) were collected for the surviving 31 lambs. One lamb in the Ad.VEGF group 
developed severe pneumonia in the eleventh week of life which required aggressive medical 
treatment and resulted in an acute and dramatic weight loss (5kg over a three day period). For 
this reason final live weight and body composition data for this particular lamb were excluded 
from the relevant analyses. All data are presented as mean ± SEM unless otherwise specified. 
5.3.1 Baseline characteristics prior to gene therapy administration 
5.3.1.1  Maternal weight and adiposity 
Table 5.1 shows baseline characteristics of the two study groups at the time of embryo 
transfer, summarised retrospectively. There were no significant differences between groups in 
initial maternal live weight, adiposity score or recipient ovulation rate at the time of embryo 
transfer. With respect to maternal genetics, embryos derived from 5 of 7 adult donor ewes 
were represented in both study groups, across which there was a reasonably even spread in 
embryo source. Figure 5.4 illustrates the serial changes throughout gestation in maternal live 
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Table 5.1 – Baseline maternal characteristics at the time of embryo transfer 
 Saline 
(n=16) 
Ad.VEGF 
(n=17) 
P  
Value 
Live weight (kg) 43.1 ± 0.55 43.9 ± 0.42 0.239 
BCS 2.3 ± 0.02 2.3 ± 0.02 0.331 
Ovulation rate 2 ± 0.25 2 ± 0.35 0.330 
 
  
weight and body condition score, by study group. There were no significant differences 
between groups in maternal weight or adiposity at any stage.  
5.3.1.2 Maternal live weight gain and baseline ultrasound parameters 
Table 5.2 shows the maternal live weight gain (in g/day) between embryo transfer and gene 
therapy administration and baseline ultrasound measurements (taken at 79±0.1 days 
gestation) by study group. Following even allocation of ewes to Ad.VEGF and Saline groups on 
the basis of TD, AC, RV, placentome index and maternal live weight gain, there were 
unsurprisingly no significant differences between groups in any of these parameters. In spite of 
randomisation for this large number of ultrasound parameters, baseline measurements of UCD 
and UA PI, but not RI or SDR, were retrospectively found to be significantly higher in Ad.VEGF 
relative to Saline groups.  
5.3.2 Ultrasound parameters 
5.3.2.1 Abdominal circumference 
Figure 5.5A shows serial changes in fetal AC from mid to late gestation by study group. 
Abdominal circumference measurements were higher in Ad.VEGF relative to Saline groups at 
108±0.1 days and 116±0.1 days gestation (221±2.7 vs. 211±3.5 mm, p=0.021; and 239±2.6 vs. 
226±3.9 mm, p=0.013, respectively), corresponding to 21±0.8 and 28±0.7 days post treatment, 
respectively.  
5.3.2.2 Renal volume 
Figure 5.5B depicts serial measurements of fetal RV by group. Renal volume was greater in
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Figure 5.4 – Changes in maternal live weight and adiposity throughout gestation 
 
 
Changes in maternal live weight [A] and body condition score [B] between embryo transfer and 
mid-gestation in singleton-bearing adolescent dams overnourished to induce fetal growth 
restriction and subsequently receiving bilateral uterine artery injections of Ad.VEGF or saline. 
240 
 
Table 5.2 – Maternal live weight gain following embryo transfer and baseline ultrasound 
measurements in mid-gestation prior to gene therapy administration 
 Saline 
 (n=16) 
Ad.VEGF  
(n=17) 
P 
Value 
Live weight gain (g/day) 317 ± 11.1 308 ± 9.1 0.495 
AC (mm) 145 ± 1.4 145 ± 1.6 0.992 
TD (mm) 44.4 ± 0.49 44.4 ± 0.66 0.924 
RV (cm3) 1.29 ± 0.038 1.32 ± 0.035 0.643 
UA PI 1.54 ± 0.030 1.45 ± 0.028 0.032 
UA RI 0.81 ± 0.005 0.79 ± 0.009 0.293 
UA SDR 5.21 ± 0.142 4.83 ± 0.293 0.262 
DVP (cm) 3.88 ± 0.106 4.23 ± 0.210 0.154 
UCD (mm) 11.3 ± 0.15 11.7 ± 0.16 0.046 
Placentome index (cm2) 3.70 ± 0.248 3.69 ± 0.217 0.967 
 
  
Ad.VEGF compared with Saline groups at 108 days and 116 days gestation (5.14±0.193 vs. 
4.37±0.165 cm3, p=0.006; and 6.38±0.224 vs. 5.60±0.280 cm3, p=0.037, respectively). 
Furthermore, there remained a tendency towards higher RV in Ad.VEGF versus Saline groups 
at 133±0.1 days gestation (8.63±0.416 vs. 7.51±0.381 cm3, p=0.061). 
5.3.2.3 Umbilical artery Doppler indices 
Figure 5.6A shows serial measurements of UA PI by study group. Values of UA PI progressively 
fell with advancing gestation and were attenuated in Ad.VEGF versus Saline groups at 79±0.1 
days gestation, prior to gene therapy administration (see Table 5.2). Subsequently there were 
no significant differences except for a tendency towards decreased UA PI in Ad.VEGF relative 
to Saline groups at 108 days gestation (1.00±0.031 vs. 1.16±0.079, p=0.066). Figure 5.6B 
illustrates serial measurements of UA RI by study group. UA RI decreased with advancing
241 
 
Figure 5.5 – Fetal abdominal circumference and renal volume 
 
 
Serial ultrasound measurements of fetal abdominal circumference [A] and renal volume [B]  at 
regular intervals between 76±0.1 days and 133±0.3 days gestation in singleton-bearing 
adolescent dams overnourished to induce fetal growth restriction and receiving mid-gestation 
bilateral uterine artery injections of Ad.VEGF or saline. * p<0.05, ** p<0.01. 
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Figure 5.6 – Umbilical artery pulsatility index and resistance index 
 
 
Serial ultrasound measurements of umbilical arterial pulsatility index [A] and resistance index 
[B] at regular intervals between 76±0.1 days and 133±0.3 days gestation in  singleton-bearing 
adolescent dams overnourished to induce fetal growth restriction and receiving mid-gestation 
bilateral uterine artery injections of Ad.VEGF or saline. † p=0.05-0.1 * p<0.05. 
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gestation and there were no significant differences between groups at any stage examined. 
Figure 5.7A shows serial measurements of UA SDR by study group. UA SDR decreased with 
advancing gestation, as per other UA Doppler indices. There were no significant differences 
between groups at any stage of gestation. There was a tendency towards decreased UA SDR in 
Ad.VEGF relative to Saline groups at 108 and 116 days gestation (2.73±0.143 vs. 3.35±0.287, 
p=0.054; and 2.58±0.135 vs. 3.01±0.202, p=0.078, respectively). 
5.3.2.4 Umbilical cord diameter 
Figure 5.7B shows serial measurements of UCD by study group. The diameter of the umbilical 
cord was  significantly higher in Ad.VEGF relative to Saline groups at baseline in mid-gestation 
(see Table 5.2) and at 116 days gestation (18.5±0.35 vs. 17.5±0.33 mm, p=0.042). There was a 
similar tendency towards an increase in Ad.VEGF versus Saline groups at all other time points, 
namely 101, 108 and 133 days gestation (16.0±0.33 vs. 15.0±0.33 mm, p=0.052; 17.1±0.37 vs. 
16.1±0.34 mm, p=0.08; and 20.1±0.40 vs. 19.2±0.30 mm, p=0.091, respectively). 
5.3.2.5 Placentome index 
Figure 5.8A shows serial ultrasound assessments of placentome index by study group. Values 
progressively decreased in both groups with advancing gestation. Variability between animals 
was greater for measurements of placentome index than for fetal biometric parameters. There 
were no significant differences between Ad.VEGF and Saline groups at any stage of gestation. 
Irrespective of treatment, final time point measurements of placentome index correlated with 
lamb birth weight (r=0.647, n=29, p=<0.001). By contrast, placentome index correlated with 
total fetal placental weight in Ad.VEGF (r=0.634, n=16, p=0.008) but not Saline groups (0.264, 
n=11, p=0.433).  
5.3.2.6 Deepest vertical pool of liquor 
Figure 5.8B depicts serial measurements of DVP by group. The DVP was significantly lower in 
Saline compared with Ad.VEGF groups at 108 days gestation (3.61±0.226 vs. 4.25±0.185, 
p=0.036) and also tended to be lower at 133 days gestation in Saline versus Ad.VEGF groups 
(2.64±0.189 vs. 3.00±0.102, p=0.09). 
5.3.3 Maternal oestradiol-17β 
Figure 5.9 shows maternal plasma oestradiol-17β concentrations from early to late pregnancy. 
Peripheral oestradiol-17β concentrations increased with advancing gestation and were not 
affected by Ad.VEGF treatment. Oestradiol-17β levels tended to correlate with eventual total
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Figure 5.7 – Umbilical artery systolic to diastolic ratio and umbilical cord diameter 
 
 
Serial ultrasound measurements of umbilical arterial systolic to diastolic ratio [A) and umbilical 
cord diameter [B] at regular intervals from 76±0.1 days to 133±0.3 days gestation in  singleton-
bearing adolescent dams overnourished to induce fetal growth restriction and receiving mid-
gestation bilateral uterine artery injections of Ad.VEGF or saline. † p=0.05-0.1 * p<0.05. 
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Figure 5.8 – Placentome index and deepest vertical pool of amniotic fluid 
 
 
Serial ultrasound measurements of placentome index [A] and deepest vertical pool of liquor [B] 
at regular intervals between 76±0.1 days and 133±0.3 days gestation in singleton-bearing 
adolescent dams overnourished to induce fetal growth restriction and receiving mid-gestation 
bilateral uterine artery injections of Ad.VEGF or saline. † p=0.05-0.1 * p<0.05 
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Figure 5.9 – Oestradiol-17β in maternal plasma 
 
Serial concentrations of oestradiol-17β, measured in maternal plasma by radioimmunoassay, 
at regular intervals between 55 and 136 days gestation in singleton-bearing adolescent dams 
overnourished to induce fetal growth restriction and receiving mid-gestation bilateral uterine 
artery injections of Ad.VEGF or saline. 
  
fetal placental weight at delivery from 85 days gestation onwards in the Saline group (r=0.535–
0.697, n=16, p=0.012–0.073) however there appeared to be a disassociation of this 
relationship in the Ad.VEGF group with no significant correlations observed between these 
parameters. Similarly oestradiol-17β levels at 114 days gestation onwards were strongly 
correlated with lamb birth weight from 114, 128 and 135 days gestation, once again only in the 
Saline group (r=0.716-0.770, n=16, p<0.001). Gestation length and colostrum yield did not 
correlate significantly with oestradiol-17β levels at any stage of gestation. 
5.3.4 Pregnancy outcome and early neonatal care 
One ewe (in the Ad.VEGF group) had a spontaneous vaginal delivery and 2 ewes (both in the 
Saline group) required caesarean sections because of failure of cervical dilatation. Interestingly 
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the two ewes born by caesarean were the two smallest lambs in the study overall, suggesting a 
functional rather than a mechanical cause for dystocia. Notably the mother of the smallest 
lamb had a particularly low maternal plasma oestradiol level of 1.41 pg/ml (mean ± SEM = 6.09 
± 1.2 pg/ml) at 135 days gestation. The only ewe to have a lower value than this (0.29 pgl/ml at 
128 days gestation) was the one who experienced a stillbirth All the other ewes had assisted 
vaginal deliveries and there were no differences between groups with respect to the level of 
difficulty (4 vs. 8 births were categorised as “easy”, 12 vs. 3 “average” and 0 vs. 2 “difficult” in 
Ad.VEGF and Saline groups, respectively). This high frequency of intervention is not unusual 
when delivering obese primigravid adolescents. Estimated blood loss at all deliveries was 
categorised as average, with the exception of one ewe (in the Saline group) which sustained 
excessive blood loss secondary to a vaginal tear. There were no significant differences in the 
requirement for airway suctioning at delivery between Ad.VEGF and Saline groups (with 7 
versus 5 lambs requiring “routine” and 1 versus 3 “extensive” suctioning, respectively). Two 
lambs (both in the Saline group) were noted to have abnormally slow breathing at birth, one of 
which also had an initially slow heart rate and poor tone. All other lambs were born in good 
condition. 
5.3.4.1 Birth weight, gestation length and placental weight 
Lamb birth weight, gestational age at delivery and placental data are presented in Table 5.3. 
There was a tendency towards increased birth weight and length of gestation in Ad.VEGF 
versus Saline groups. The number of lambs delivering on each day of gestation is illustrated as 
a histogram in Figure 5.10. Individual birth weights were adjusted to term gestation (145 days) 
using the following formula (as previously described by (Wallace et al. 2008b)): adjusted birth 
weight = birth weight x 1.01305 per day of gestation. Birth weights were also adjusted to the 
mean gestational age at delivery for the cohort as a whole, namely 142 days. The tendency 
towards a difference in birth weight between groups remained following correction for 
gestation length using either approach and birth weight was on average 18% higher in the 
Ad.VEGF group. There was virtually an even gender distribution within groups and for the 
study as a whole (17 males and 16 females in total).  
Figure 5.11 shows the individual birth weight values by study group in the form of a dot plot 
[A] and for all lambs (irrespective of group) as a Q-Q plot [B]. These illustrate clearly that the 
range of birth weights in the Saline group (1496–6050g) was wider than in the Ad.VEGF group 
(2620–5540g) but that a normal distribution was maintained across groups. The largest lamb in 
this study was born to a Saline-treated ewe. It was evident that this lamb had a major impact 
on the statistical analysis of the birth weight data as its exclusion greatly altered the
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Table 5.3 – Lamb birth weight, gestation length, gender distribution and placental weight 
following spontaneous delivery near term 
 Saline 
(n=16) 
Ad.VEGF 
(n=17) 
P 
Value 
Birth weight (g) 
(range) 
3433 ± 303.3 
(1496–6050) 
4114 ± 230.4 
(2620–5540) 
0.081 
 
Gestation length (days) 
(range) 
140 ± 0.8 
(132–144) 
142 ± 0.4 
(138–145) 
0.072 
Total fetal placental weight** (g) 
(range) 
298 ± 20.2 
(186–438) 
289 ± 19.2 
(164–416) 
0.776 
Male to female sex ratio 8 : 8 9 : 8 0.866 
Membrane weight** (g) 216 ± 13.0 214 ± 13.5 0.919 
Cotyledon weight* (g) 78 ± 8.7 76 ± 6.34 0.849 
Cotyledon number* 81 ± 4.8 89 ± 3.4 0.203 
Mean cotyledon weight (g) 0.86 ± 0.066 0.96 ± 0.100 0.372 
Birth weight to placental weight ratio 13.10 ± 0.640 14.46 ± 0.419 0.074 
Birth weight adjusted to 142 days (g) 3449 ± 283.6 4083 ± 226.1 0.089 
Birth weight adjusted to 145 days (g) 3634 ± 298.1 4300 ± 238.1 0.089 
* Total cotyledon weight and number were unavailable for 3 lambs (individual birth weights 
1720, 2090 and 3080g) ** Membrane weight and therefore total placental weight were unable 
for a fourth fetus (1496g) – see text for explanation of missing data 
  
significance level of the birth weight difference between groups from p=0.081 to p=0.02. 
However, it was not valid to exclude this animal as it did not meet criteria to be an outlier and 
simply lay at one extreme of the normal distribution in birth weight. 
In the late gestation study, the number of fetuses of overnourished mothers whose weight fell 
more than two standard deviations below their genetic potential was calculated on the basis
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Figure 5.10 – Gestation length of pregnancies treated with Ad.VEGF or saline 
 
Histogram showing the number of lambs delivering per day of gestation between 132 and 145 
days gestation (full term) to singleton-bearing adolescent dams overnourished to induce fetal 
growth restriction and receiving mid-gestation bilateral uterine artery injections of Ad.VEGF or 
saline. The single lamb born at 132 days gestation was stillborn and the other 32 were liveborn. 
  
of the contemporaneous control-intake group mean, to give an indicator of the incidence of 
marked FGR. In the present study, no such control group was included. In order to estimate 
the effect of Ad.VEGF on rates of marked FGR a comparison was made with historical control 
data. The mean birthweight of 77 normally grown lambs born near term between 2005 and 
2009 was 5453g, with a standard deviation of 798g, which gave a -2SD cut-off of 3857g. The 
proportions of fetuses weighing above and below 3857g within each group are presented in 
Figure 5.12. Although fewer fetuses were markedly growth-restricted in Ad.VEGF versus Saline 
groups (35% versus 63%, compared with historical average of 52% (Wallace et al. 2004b), this 
difference did not reach statistical significance (p=0.118). It is noteworthy that markedly FGR 
lambs had a significantly shorter gestation length than non-FGR lambs within the Saline group
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Figure 5.11 – Lamb birth weight distribution 
 
 
Dot plot showing individual birth weights by group [A] and Q-Q plot for all birth weights 
demonstrating normality of data [B] in lambs born to singleton-bearing adolescent dams 
overnourished to induce fetal growth restriction and receiving mid-gestation bilateral uterine 
artery injections of Ad.VEGF or saline. ‡ indicates a particularly large lamb with a major impact 
on the statistical analysis - see text for full discussion. 
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Figure 5.12 – Incidence of marked FGR relative to historical controls 
 
Numbers of lambs from overnourished singleton-bearing adolescent dams categorised as 
markedly FGR following spontaneous delivery near to term (~141 days gestation). Marked FGR 
was defined as a birth weight more than 2 standard deviations below the historical mean birth 
weight of 77 normally grown lambs of control-intake ewes (<3857g). Lambs weighing  >3857g 
were of similar weight to normally grown controls and therefore termed "non-FGR".  
  
(139±0.9 versus 142±0.7 days, p=0.022) but not in the Ad.VEGF group (141±0.9 versus 142±0.4 
days, p=0.470) suggesting a dissociation of the usual relationship following Ad.VEGF treatment. 
Placental data was unavailable from two ewes in the Saline group which underwent caesarean 
section (section of placenta retained) and from a third ewe (in the Ad.VEGF group) which had 
partially eaten her placenta before it was retrieved. Fetal cotyledon weight only was obtained 
for the stillborn fetus. Total fetal placental weight, its component parts (membrane and 
cotyledon weights), cotyledon number and mean cotyledon weight were not significantly 
different between groups. There was a tendency towards increased birth weight to placental 
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weight ratio in Ad.VEGF versus Saline groups. Irrespective of treatment group, birth weight 
was strongly correlated with total fetal placental weight (r=0.839, n=30, p=<0.001), membrane 
weight (r=0.810, n=30, p=<0.001) and cotyledon weight (r=0.812, n=30, p=<0.001). Birth 
weight was correlated with gestation length in the Saline group (r=0.742, n=16, p=0.001) but 
not in the Ad.VEGF group (r=0.212, n=17, p=0.413). The relationship between birth weight and 
total fetal placental weight is illustrated in Figure 5.13A. These two parameters correlated  
strongly in both Ad.VEGF (r=0.907, n=17, p<0.001) and Saline groups (r=0.780, n=12, p=0.003). 
5.3.4.2 Lamb measurements and blood parameters at birth 
Table 5.4 summarises physical measurements taken from all lambs and the results of various 
analyses performed on blood samples taken at birth, by study group. There was a tendency 
towards increased biparietal head diameter, girth at the level of the umbilicus and glucose 
concentrations in Ad.VEGF versus Saline groups. There were no significant differences between 
groups in any hormonal or haematological parameters. Birth weight was positively correlated 
with biparietal head diameter (r=0.845, n=33, p=<0.001), abdominal girth (r=0.954, n=33, 
p=<0.001) and plasma IGF-1 at birth (r=0.682, n=32, p=<0.001), irrespective of treatment 
group. Birth weight was strongly correlated with plasma insulin levels at birth in the Saline 
group (r=0.828, n=15, p=<0.001) but not in the Ad.VEGF group (r=0.008, n=17, p=0.976). Lamb 
birth weight and abdominal girth correlated strongly in both Ad.VEGF (r=0.941, n=17, p<0.001) 
and Saline groups (r=0.960, n=16, p<0.001), as illustrated in Figure 5.13B. 
5.3.4.3 Routine observations within the first 24 hours of life 
Table 5.5 shows the routine observations made on all lambs at one hour of age as well as time 
to standing, lamb shoulder height at 24 hours and the concentration of IgG in maternal and 
lamb blood at 24 hours of age. There were no significant differences between groups in any of 
these parameters.  
5.3.4.4 Colostrum yield, nutrient composition and immunoglobulin G content 
The total volume, nutrient and IgG content of colostrum sampled at the time of birth is shown 
in Table 5.6. There were no differences in colostrum yield, IgG, butterfat, lactose or protein 
between Ad.VEGF and Saline groups when expressed either as concentration or total content. 
Energy concentration per ml colostrum was determined from the concentration of butterfat 
using the equation [E = 32.80 F + 2.5 D + 2303.3] as previously described by Brett et al. (1972) 
where E = energy concentration (kJ/kg), F = butterfat concentration (g/kg) and D = day of 
lactation (=1 for all colostrum samples). Total energy concentration and total energy content
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Figure 5.13 – Birth weight versus placental weight and abdominal girth 
 
 
Scattergrams of total fetal placental weight and lamb birth weight [A] and birth weight versus 
girth at the level of the umbilicus [B], respectively. Placental data was unavailable for 4 lambs 
(birth weights 1496, 1720, 2090 and 3080g). Correlations coefficients are detailed in the text. 
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Table 5.4 – Metabolic, haematological and venous blood gas parameters in birth plasma 
samples and physical measurements of lambs taken immediately after birth 
 Saline 
(n=15) 
Ad.VEGF 
(n=17) 
P  
Value 
Biparietal head diameter (mm) 63.6 ± 1.72 67.4 ± 1.17 0.072 
Abdominal girth (mm) 341 ± 15.3 376 ± 9.6 0.059 
Glucose (mg/dl) 38.04 ± 4.125 51.44 ± 6.020 0.089 
Lactate (mmol/l) 6.49 ± 0.528 7.82 ± 0.607 0.116 
Insulin (ng/ml) 0.461 ± 0.0667 0.440 ± 0.0472 0.788 
IGF-1 (ng/ml) 0.122 ± 0.0151 0.147 ± 0.0171 0.287 
Haematocrit (%) 44.96 ± 1.249 44.09 ± 1.609 0.681 
Haemoglobin (g/dl) 13.53 ± 0.383 13.32 ± 0.438 0.733 
Methaemoglobin (g/dl) 1.83 ± 0.056 1.84 ± 0.043 0.857 
Carboxyhaemoglobin (g/dl) 3.56 ± 0.106 3.49 ± 0.113 0.632 
Venous oxygen saturation (%) 48.89 ± 3.400 47.37 ± 2.712 0.726 
Venous oxygen content (mmol/l) 8.81 ± 2.700 8.39 ± 0.639 0.661 
 
  
were not significantly different between groups. Four ewes in the Ad.VEGF group and five in 
the Saline group produced insufficient colostrum to meet initial requirements of 50ml/kg and 
hence their lambs were supplemented using the donor colostrum pool. Irrespective of 
treatment group, the colostrum yield was correlated with total fetal placental weight (r=0.430, 
n=32, p=0.008).  Although colostrum IgG concentrations were unrelated to lamb birth weight 
(r=-0.069, n=32, p=0.708), the large differences seen in colostrum yield translated into large 
differences in total colostrum content, which also correlated positively with birth weight 
(r=0.667, n=32, p<0.001). 
5.3.4.5 Additional neonatal care 
Figure 5.14 summarises the additional neonatal care measures required to ensure lamb
255 
 
Table 5.5 – Routine vital signs (cardiorespiratory and temperature) taken on all lambs in the 
first 24 hours of life and immunoglobulin G levels in lamb / maternal plasma at 24 hours of age 
 Saline 
(n=15) 
Ad.VEGF 
(n=17) 
P 
Value 
Heart rate (min-1) at 1 hour 232 ± 13.3 246 ± 6.24 0.342 
Respiratory rate (min-1) at 1 hour 71 ± 3.10 72 ± 2.71 0.960 
Rectal temperature (oC) at 1 hour 39.8 ± 0.20 39.9 ± 0.14 0.757 
Time to standing (min) 107.5 ± 28.19 96.8 ± 19.80 0.752 
Shoulder height (cm) at 24 hours 33 ± 1.0 35 ± 0.7 0.237 
Lamb IgG (mg/ml) at 24 hours 22.9 ± 1.85 23.1 ± 4.06 0.975 
Maternal IgG (mg/ml) at 24 hours 12.3 ± 0.79 12.0 ± 1.81 0.882 
 
  
Table 5.6 – Colostrum yield, nutrient composition and immunoglobulin G content at birth 
 Saline 
(n=15) 
Ad.VEGF 
(n=17) 
P  
Value 
Colostrum yield (ml) 266 ± 39.1 314 ± 48.5 0.452 
IgG concentration (mg/ml) 50.8 ± 3.48 56.8 ± 5.74 0.396 
Total IgG content (g) 12.7 ± 1.84 15.9 ± 2.20 0.278 
Butterfat concentration (g/100g) 7.74 ± 1.274 7.43 ± 0.958 0.845 
Total butterfat (g) 23.0 ± 4.42 23.0 ± 3.74 0.997 
Lactose (g/100g) 1.54 ± 0.15 1.72 ± 0.12 0.398 
Total lactose (g) 5.03 ± 0.92 4.46 ± 0.79 0.631 
Crude protein (g/100g) 18.5 ± 1.11 19.3 ± 1.06 0.572 
Total crude protein (g) 46.4 ± 6.75 56.6 ± 8.17 0.352 
Total energy concentration (kJ/kg) 2459 ± 41.8 2449 ± 32.4 0.838 
Total energy content (kJ) 662 ± 95.9 769 ± 117.5 0.495 
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Figure 5.14 – Additional neonatal care measures required to ensure lamb survival 
 
* All these interventions were required in one particular lamb, born by caesarean section 
weighing 2090g. Number of lambs studied throughout the neonatal period was 31 of 33, 
excluding one stillbirth and one accidental neonatal death (due to maternal crushing) in the 
Saline and Ad.VEGF groups, respectively. 
  
survival, by study group. For the 10 and 7 lambs in the Ad.VEGF and Saline groups, 
respectively, requiring supplementary feeding in the neonatal period, there were no significant 
group differences in the number of additional feeds (6±3.0 vs. 13±5.4) or in the duration of 
supplementary feeding (64±24.0 vs. 70±24.2 hours) required to ensure appropriate weight 
gain. Those lambs requiring supplementary feeding for longer than 48 hours (n=7) were of 
lower birth weight than spontaneously suckling lambs (n=25) (2931±467.3 vs. 4114±173.9, 
p=0.007). Only four lambs (two Ad.VEGF and two Saline) required supplementary feeding 
beyond 72 hours of age and these comprised the first, second, fourth and seventh smallest
257 
 
Table 5.7 – Serum urea and electrolytes and liver enzymes at 8 days of postnatal age 
 Saline 
(n=15) 
Ad.VEGF 
(n=16) 
P  
Value 
Sodium (mmol/l) 149.2 ± 0.34 149.2 ± 0.46 0.983 
Potassium (mmol/l) 6.15 ± 0.118 5.98 ± 0.130 0.339 
Urea (mmol/l) 7.43 ± 0.663 7.86 ± 0.563 0.624 
Creatinine (μmol/l) 50.9 ± 1.29 50.3 ± 1.08 0.714 
Chloride (mmol/l) 106.1 ± 0.42 105.6 ± 0.50 0.506 
Albumin (g/l) 27.6 ± 0.45 27.7 ± 0.25 0.847 
Alanine transaminase (IU/l) 3.93 ± 0.248 4.19 ± 0.344 0.558 
Aspartate aminotransferase (IU/l) 51.6 ± 1.10 53.3 ± 3.34 0.644 
Gamma-glutamyl transferase (IU/l) 289 ± 34.9 306 ± 30.2 0.715 
Alkaline phosphatase (IU/l) 1034 ± 81.4 1011 ± 86.1 0.849 
Glutamate dehydrogenase (IU/l) 27.4 ± 12.40 15.0 ± 3.09 0.346 
Serum urea, creatinine, electrolytes and liver enzymes at 8 days of postnatal age in 31 surviving 
prenatally growth-restricted lambs whose overnourished adolescent mothers received mid-
gestation bilateral uterine artery injections of Ad.VEGF or saline. There were no significant 
differences between levels in male versus female lambs and no gender x treatment interaction. 
  
lambs by initial birth weight, indicating that small size at birth was a strong predictor of the 
need for prolonged supplementary feeding. 
5.3.4.6 Serum biochemistry and liver function 
Table 5.7 shows values of serum biochemistry and liver function at 8 days of postnatal age, by 
study group and gender. There were no differences between Ad.VEGF and Saline groups in any 
parameters. Irrespective of treatment group, lamb birth weight was positively correlated with 
sodium (r=0.562, n=15, p=0.029) and negatively correlated with potassium (r=–0.542, n=15, 
p=0.037), ALP (r=–0.563, n=15, p=0.029) and GLDH (r=–0.609, n=15, p=0.016) in Saline but not
258 
 
Ad.VEGF groups. By contrast, birth weight was positively correlated with chloride (r=0.554,  
n=16, p=0.026) and albumin (r=0.555, n=16, p=0.026) and negatively correlated with ALT (r=     
-0.536, n=16, p=0.032) and albumin (r=–0.516, n=16, p=0.041) only within the Ad.VEGF group. 
5.3.5 Postnatal growth and anabolic hormones 
5.3.5.1 Live weight 
Figure 5.15A shows serial measurements of lamb body weight from birth until necropsy at 12 
weeks of age. There was a tendency towards increased live weight in Ad.VEGF relative to 
Saline groups at 14 days (9.4±0.43 vs. 8.1±0.53 kg, p=0.066), 21 days (11.6±0.50 vs. 10.1±0.62 
kg, p=0.071), 28 days (14.0±0.58 vs. 12.3±0.69 kg, p=0.07) and 35 days of age (16.9±0.72 vs. 
14.8±0.81 kg, p=0.061). Subsequently live weight was significantly increased in Ad.VEGF versus 
Saline groups at 42 days (20.0±0.70 vs. 17.5±0.91 kg, p=0.041), 49 days (23.0±0.72 vs. 
20.4±1.00 kg, p=0.037), 56 days (26.5±0.73 vs. 23.2±1.05 kg, p=0.015), 63 days (29.5±0.77 vs. 
26.1±1.11 kg, p=0.016), 70 days (31.8±0.81 vs. 28.5±1.15 kg, p=0.024), 77 days (35.2±0.91 vs. 
31.6±1.18 kg, p=0.021) and 82±0.3 days of age (37.1±0.89 vs. 33.5±1.17 kg, p=0.019). 
Correspondingly overall absolute postnatal growth velocity from birth until necropsy was 
increased in Ad.VEGF relative to Saline groups (397±8.7 vs. 362±11.7 g/day, p=0.023). In 
contrast, fractional growth velocity was not significantly different (10.0±0.61 vs. 10.7±0.76 % 
per day, respectively, from birth until 82±0.3 days of age). Fractional growth velocity 
demonstrated a strong and inverse relationship with birth weight, irrespective of treatment 
group (r=–0.910, n=31, p=<0.001), as illustrated in Figure 5.15B. 
5.3.5.2 Abdominal girth 
Figure 5.16A depicts serial upward changes in abdominal girth at the umbilicus from birth until 
necropsy. Girth was increased in Ad.VEGF relative to Saline groups at 56 days (88±1.2 vs. 
84±1.5 cm, p=0.019), 77 days (104±1.3 vs. 99±1.5 cm, p=0.026) and 82 days of age (108±1.4 vs. 
104±1.1 cm, p=0.032). In addition, there was a tendency towards higher abdominal girth in 
Ad.VEGF compared to Saline groups at 7 days (48±1.0 vs. 45±1.4 cm, p=0.063), 14 days (54±0.9 
vs. 51±1.4 cm, p=0.061), 42 days (75±1.2 vs. 71±1.8 cm, p=0.07), 63 days (92±1.3 vs. 89±1.4 
cm, p=0.1) and 70 days of age (96±1.2 vs. 93±1.7 cm, p=0.092). 
5.3.5.3 Shoulder height 
Figure 5.16B shows serial increases in shoulder height from birth until necropsy. Lambs in the 
Ad.VEGF group were taller at 28 days (44±0.5 vs. 42±0.7 cm, p=0.036), 35 days (46±0.5 vs. 
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Figure 5.15 – Absolute and fractional postnatal growth 
 
 
[A] Serial measurements of live weight made at weekly intervals from birth until 83±0.2 days of 
postnatal age in 31 surviving prenatally growth-restricted lambs whose overnourished 
adolescent mothers received mid-gestation bilateral uterine artery injections of Ad.VEGF or 
saline. † p=0.05-0.1 * p<0.05. [B] Scattergram of lamb birth weight versus fractional growth 
velocity for weight to weaning (= final live weight - birth weight, expressed as a percentage of 
lamb birth weight and per day of postnatal age. Correlation coefficients are detailed in the text. 
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Figure 5.16 – Lamb abdominal girth and shoulder height measurements 
 
 
Serial measurements of abdominal girth at the level of the umbilicus [A] and height at the 
anterior shoulder [B] at weekly intervals from birth until 83±0.2 days of postnatal age in 31 
surviving prenatally growth-restricted lambs whose overnourished adolescent mothers received 
mid-gestation bilateral uterine artery injections of Ad.VEGF or saline. † p=0.05-0.1 * p<0.05. 
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44±0.8 cm, p=0.013), 49 days (49±0.5 vs. 47±0.7 cm, p=0.018) and 56 days of age (51±0.5 vs. 
49±0.8 cm, p=0.031). There was also a tendency towards increased shoulder height in Ad.VEGF 
versus Saline groups at 42 days of age (47±0.6 vs. 45±0.7 cm, p=0.087). 
Lamb birth weight and all three measures of offspring size (live weight, shoulder height and 
umbilical girth) were independent of gender throughout the postnatal period up to weaning.  
5.3.5.4 Insulin 
Figure 5.17A shows serial measurements of plasma insulin from birth until necropsy. Insulin 
concentrations were relatively low at birth, increased 5 fold by the end of the first week of life 
and thereafter stabilised for the rest of the suckling period. There was a tendency towards 
higher insulin levels in Ad.VEGF compared with Saline groups at 7 days of age (71.6±7.21 vs. 
55.1±6.23 µU/ml, p=0.097) but subseqeuntly no other significant differences between groups 
at any point up to 12 weeks postnatal age. Insulin concentrations were independent of gender.  
5.3.5.5 IGF-1 
Figure 5.17B illustrates serial measurements of plasma IGF-1 from birth until necropsy. IGF-1 
concentrations were relatively low at birth, increased ~3 fold by the end of the first week of 
life and thereafter largely plateaued for the rest of the suckling period. There were no 
significant differences in IGF-1 between Ad.VEGF and Saline groups at any stage but males 
tended to have greater IGF-1 concentrations than females at 7 days (p=0.056) and levels were 
significantly higher in males versus females from 14 days of age onwards (p<0.001-0.043). 
5.3.6 Immune challenge 
Figure 5.18 illustrates the mean levels of SAA prior to and 24 and 48 hours following routine 
vaccination at 58±0.4 days of age, by study group. There were no significant differences 
between Ad.VEGF and Saline groups at baseline or after challenge. Levels at each stage were 
compared by one-way ANOVA and post-hoc LSD tests. SAA levels were increased >500-fold at 
24 and 48 hours relative to baseline levels in all lambs, commensurate with an acute phase 
response and overall were not significantly different between 24 and 48 hours (29.5±5.10 
versus 29.2±4.93, respectively, p=0.966). Similarly there was no detectable difference when 
the individual post-challenge data were combined. There were no significant correlations 
between SAA levels and lamb birth weight and placental weight, however peak/mean SAA 
levels correlated with neonatal plasma IgG concentrations for the Saline group (r=0.636/0.609, 
n=15, p=0.011/0.016) but not within the Ad.VEGF group (r=0.187/0.200, n=16, p=0.487/0.458). 
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Figure 5.17 – Lamb plasma insulin and insulin-like growth factor 1 levels from birth to weaning 
 
 
Serial measurements of plasma insulin [A] and IGF-1 [B], measured by radioimmunoassay, at 
weekly intervals from birth until 83±0.2 days of postnatal age in 31 surviving prenatally 
growth-restricted lambs whose overnourished adolescent mothers received mid-gestation 
bilateral uterine artery injections of Ad.VEGF or saline. † p=0.05-0.1 * p<0.05, ** p<0.01, *** 
p<0.001, as indicated. IGF-1 levels did not differ between Ad.VEGF and saline groups but were 
signficantly higher in male (squares) vs. females (diamonds), thus IGF-1 is presented by gender. 
A 
B 
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Figure 5.18 – Lamb serum amyloid A concentration before and after routine vaccination 
 
Serial levels of the acute phase reactant serum amyloid A (measured by ELISA) at baseline and 
24/48 hours following routine vaccination with Heptatvac P Plus® at 58±0.4 days postnatal age 
in 31 surviving prenatally growth-restricted lambs whose overnourished adolescent mothers 
received mid-gestation bilateral uterine artery injections of Ad.VEGF or saline. There were no 
significant differences between Ad.VEGF or saline groups, or between males and females. 
Levels were increased (p<0.001) at 24 and 48 hours relative to baseline (0.049±0.0447 and 
0.058±0.0255 mg/l in Ad.VEGF saline groups, respectively). 
  
5.3.7   Metabolic challenge 
Measurements of insulin and various metabolite responses to an intravenous 0.25mg/kg 
glucose bolus at 68±0.5 days of age are shown below. For each metabolite, the three baseline 
values (–20, –10 and 0 minutes relative to the glucose infusion) were averaged to find the 
baseline fasting mean. Fasting baseline values for each metabolite are shown in Table 5.8, by 
study group and gender. There were no significant differences in fasting metabolite levels 
between Ad.VEGF and Saline groups, however urea levels were higher (p=0.004) and non-
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Table 5.8 – Fasting plasma metabolite levels and area under the curve for glucose, insulin and NEFA following an intravenous glucose bolus at 7 weeks of age 
 Saline-F 
(n=8) 
Saline-M    
(n=7) 
Ad.VEGF-F  
(n=8) 
Ad.VEGF-M 
(n=8) 
P Values 
Treatment Gender Interaction 
Fasting glucose (mg/dl) 85.3 ± 1.15 82.9 ± 1.96 85.1 ± 3.90 82.9 ± 1.32 0.946 0.822 0.990 
Fasting insulin (ng/ml) 1.24 ± 0.089 1.38 ± 0.179 1.60 ± 0.211 1.24 ± 0.135 0.499 0.350 0.131 
Fasting NEFA (mmol/l min) 0.47 ± 0.045 0.41 ± 0.024 0.56 ± 0.055 0.46 ± 0.042 0.111 0.085 0.585 
Fasting glycerol (mmol/l) 93.9 ± 1.67 86.0 ± 6.81 111.9 ± 14.58 92.1 ± 10.62 0.232 0.304 0.551 
Fasting urea (mmol/l) 7.97 ± 0.416 7.19 ± 0.352 8.25 ± 0.337 6.71 ± 0.336 0.783 0.004 0.302 
Fasting glucose : insulin ratio 1.38 ± 0.264 1.58 ± 0.564 1.07 ± 0.170 1.12 ± 0.139 0.222 0.692 0.821 
Fasting insulin : glucose ratio 0.91 ± 0.160 1.19 ± 0.373 1.12 ± 0.200 1.05 ± 0.199 0.890 0.660 0.469 
HOMA index 113 ± 13.3 123 ± 16.5 150 ± 29.0 110 ± 7.7 0.522 0.417 0.187 
Glucose AUC (mg/min/dl) 2050 ± 360 2216 ± 324 2570 ± 425 2720 ± 281 0.430 0.659 0.983 
Insulin AUC (ng/ml min) 71.0 ± 11.53 88.4 ± 18.86 104.7 ± 7.65 117.4 ± 19.88 0.040 0.876 0.329 
NEFA AUC (mmol/min/l) 12.21 ± 5.535 6.58 ± 3.427 20.09 ± 3.20 16.12 ± 3.20 0.038 0.236 0.585 
Fasting plasma metabolite levels and indices of insulin resistance before and area under the curve (AUC) following an intravenous glucose bolus (metabolic 
challenge) at 68±0.5 days postnatal age in 31 surviving prenatally growth-restricted lambs whose overnourished adolescent mothers received mid-gestation 
bilateral uterine artery injections of Ad.VEGF or saline. Abbreviations: HOMA index = homeostatic model assessment index; NEFA = non-esterified fatty acids.
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esterified fatty acid levels tended also to be higher (p=0.085) in female lambs compared to 
males. The area under the curve (AUC) for each metabolite was calculated minus this baseline 
i.e. the increase or decrease in a given metabolite relative to baseline values across the 2 hour 
test period. AUC are summarised in Table 5.8 and discussed individually by metabolite below. 
There were no significant gender differences in AUC for any parameter. Moreover there were 
no differences in any indices of insulin resistance (homeostatic model assessment (HOMA) 
index, or fasting glucose to insulin or insulin to glucose ratios) by treatment or gender. There 
were no differences between Ad.VEGF and Saline groups in appetite index, taken as the acute 
live weight gain in the first 15 minutes after feeding was resumed following a five hour fast for 
metabolic challenge (191±78g versus 233±78g, respectively, p=0.714). 
5.3.7.1 Glucose response 
Figure 5.19A shows serial measurements of plasma glucose by study group. Glucose 
concentrations were significantly higher in Ad.VEGF compared to Saline groups at 15 minutes 
post glucose infusion (156.81±4.379 vs. 146.51±4.604 mg/dl, p=0.023) and there was a 
tendency towards higher concentrations in Ad.VEGF versus Saline groups at 20, 25 and 45 
minutes (146.23±4.769 vs. 134.51±4.036 mg/dl, p=0.073; 134.83±4.519 vs. 123.60±3.805 
mg/dl, p=0.069; and 105.66±4.067 vs. 96.45±2.992 mg/dl, p=0.082, respectively).  
Despite the significant differences at these individual time points, overall glucose AUC was not 
significantly different between groups (see Table 5.8). Interim AUC values were also calculated 
at each consecutive time point and similarly did not differ between groups (data not shown). 
Irrespective of treatment group, baseline fasting glucose demonstrated a weak negative 
correlation with birth weight (r=-0.407, n=31, p=0.023) but not with lamb body weight or 
dimensions at the time of glucose challenge. 
5.3.7.2 Insulin response 
Figure 5.19B illustrates serial measurements of plasma insulin by study group. There was a 
tendency towards higher insulin concentrations in Ad.VEGF compared to Saline groups at 25 
and 30 minutes post glucose infusion (89.54±5.823 vs. 72.97±5.591 μU/ml, p=0.05; and 
85.80±5.736 vs. 69.00±6.266 μU/ml, p=0.057, respectively) and insulin concentrations were 
significantly higher in Ad.VEGF versus Saline groups at 45 and 60 minutes (64.94±6.143 vs. 
43.30±5.046 μU/ml, p=0.011; and 45.06±4.763 vs. 31.69±3.431 μU/ml, p=0.032, respectively). 
Overall, insulin AUC was significantly increased in Ad.VEGF relative to Saline groups (see Table 
5.8). Fasting insulin : glucose and insulin AUC : glucose AUC ratios were not significantly 
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Figure 5.19 – Glucose and insulin responses to glucose challenge 
 
 
Serial measurements of plasma glucose [A] and insulin [B] at regular intervals up to 120 
minutes following a standardised intravenous glucose infusion administered at 68±0.5 days  
postnatal age in 31 surviving prenatally growth-restricted lambs whose overnourished 
adolescent mothers received mid-gestation bilateral uterine artery injections of Ad.VEGF or 
saline. † p=0.05-0.1, * p<0.05. 
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Figure 5.20 – Non-esterified fatty acid response to glucose challenge 
 
Serial measurements of plasma non-esterified fatty acid (NEFA) at regular intervals up to 120 
minutes following a standardised intravenous glucose infusion administered at 68±0.5 days 
postnatal age in 31 surviving prenatally growth-restricted lambs whose overnourished 
adolescent mothers received mid-gestation bilateral uterine artery injections of Ad.VEGF or 
saline. † p=0.05-0.1, * p<0.05. 
  
different between treatment groups. Insulin parameters were not significantly correlated with 
birth weight, fetal : placental weight ratios or weight / girth at the time of metabolic challenge.  
5.3.7.3 NEFA response 
Figure 5.20 details serial measurements of plasma NEFA by study group. Although baseline 
values tended to be higher in Ad.VEGF relative to Saline groups at 10 minutes prior to glucose 
infusion (p=0.073), mean baseline NEFA levels did not differ between groups (see Table 5.8).  
There was a tendency towards higher NEFA concentrations in Ad.VEGF versus Saline groups at 
10 minutes post glucose infusion (0.45±0.045 vs. 0.35±0.026 mmol/l, p=0.069) and NEFA 
concentrations were significantly higher in Ad.VEGF compared with Saline groups at 15, 20 and 
268 
 
25 minutes (0.31±0.040 vs. 0.20±0.016 mmol/l, p=0.015; 0.20±0.028 vs. 0.13±0.013 mmol/l, 
p=0.026; and 0.16±0.018 vs. 0.12±0.009 mmol/l, p=0.048, respectively). By contrast, NEFA 
concentrations were lower in Ad.VEGF versus Saline groups at 60 minutes (0.22±0.021 vs. 
0.29±0.022 mmol/l, p=0.031). Overall, NEFA AUC was significantly increased in Ad.VEGF 
relative to Saline groups (see Table 5.8). There appeared to be an upward shift of the curve in 
Ad.VEGF relative to Saline groups. Despite a tendency towards higher baseline levels in 
females versus males, NEFA AUC did not differ by gender. 
5.3.8 Body composition analysis 
Table 5.9 summarises body composition as measured by DEXA at 74±0.4 days gestation. At this 
point, lambs prenatally treated with Ad.VEGF were larger than those treated with saline 
(32.6±0.86 vs. 29.8±1.01kg, respectively, p=0.047) but there were no significant differences 
between males and females (p=0.280) and no treatment x gender interaction (p=0.244). There 
was a tendency towards higher bone mineral density, total bone mineral content and lean 
tissue mass in Ad.VEGF relative to Saline groups. There were no significant differences 
between groups in body fat, either in absolute or relative terms, neither were there any 
significant differences between males and females in the degree of adiposity as assessed by 
DEXA.  Bone mineral content and lean tissue mass were positively correlated with birth weight 
(r=0.570, n=30, p=0.001 and r=0.813, n=30, p=<0.001) and current live weight (r=0.802, n=30, 
p=<0.001 and r=0.887, n=30, p=<0.001), abdominal girth (r=0.687, n=30, p=<0.001 and 
r=0.852, n=30, p=<0.001) and shoulder height (r=0.636, n=30, p=<0.001 and r=0.855, n=30, 
p=<0.001) at the time of examination. Lean tissue mass was also inversely correlated with 
fractional growth velocity to weaning (r=–0.610, n=30, p=0.001).  
  
Table 5.9 – Body composition analysis by dual energy X-ray absorptiometry 
 Saline 
(n=15) 
Ad.VEGF 
(n=16) 
P 
 Value 
Bone Mineral Density (g/cm) 0.482 ± 0.0099 0.510 ± 0.0096 0.057 
Bone Mineral Content (g) 783.1 ± 27.80 856.7 ± 27.19 0.069 
Lean Tissue Mass (kg) 26.32 ± 0.943 28.65 ± 0.772 0.066 
Fat Mass (kg) 2.43 ± 0.350 3.02 ± 0.339 0.222 
% Body Fat  8.03 ± 1.14 9.26 ± 1.01 0.383 
 
There were no significant differences between males and females for any parameters. 
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5.3.9 Necropsy parameters 
5.3.9.1 Blood results 
Table 5.10 shows the concentrations of various metabolic hormones and haematological 
parameters in lamb blood sampled on the day prior to necropsy. There were no significant 
differences between Ad.VEGF and Saline groups. Peripheral plasma IGF-1 concentrations were 
higher in male compared with female lambs (51.48±4.295 vs. 40.86±2.457 pmol/ml, p=0.015) 
whilst leptin concentrations were lower in males versus females (2.53±0.467 vs. 4.49±0.591 
ng/ml, p=0.043). Irrespective of treatment group and gender, leptin correlated strongly with 
perirenal fat weight (both absolute and relative) at subsequent necropsy (r=0.744 and r=0.756, 
respectively, p=<0.001). Haemoglobin levels tended to be higher in female versus male lambs 
(p=0.05), in keeping with a lower relative blood volume (p<0.001) in female compared to male 
lambs (see Section 5.3.9.3 below), suggesting relative haemoconcentration. 
5.3.9.2 Absolute organ weights and measurements 
Table 5.11 shows major lamb organ weights and additional post mortem measurements taken 
at necropsy at 82±0.2 days postnatal age, by study group and gender. Lambs in the Ad.VEGF 
group were heavier (live weight and carcass weight) with greater abdominal girth than those in 
the Saline group. Male lambs did not weigh more than female lambs at this stage. Liver and 
perirenal fat weights were also significantly greater and there was a tendency towards 
decreased adrenal weight in Ad.VEGF versus Saline groups. Blood, hock and tibial bone weights 
were greater in male versus female lambs (1369±58.9 vs. 1188±40.8 g, p=0.016; 1116±35.2 vs. 
1013±25.9 g, p=0.022; and 59.2±1.73 vs. 52.5±1.70 g, p=0.012; respectively) whilst perirenal 
fat weight was lower in males versus females (229.4±20.50 vs. 416.8±42.48 g, p=<0.001). There 
was also a significant interaction between study group and gender with respect to perirenal fat 
weight, such that this was highest in the Ad.VEGF-treated female lambs (p=0.034). All 
remaining absolute organ weights were unaffected by treatment or gender. 
5.3.9.3 Relative organ weights 
Table 5.12 details the major lamb internal organ weights, expressed relative to residual lamb 
carcass weight, by treatment group and gender. The relative adrenal weight was significantly 
lower in Ad.VEGF versus Saline groups. Relative brain weight and brain to liver ratios (shown in 
Figure 5.21A), two different indices of fetal brain sparing, also tended to be lower in Ad.VEGF 
relative to Saline groups. There was also a lower relative heart weight and tendency towards 
lower relative lung weight in Ad.VEGF compared with Saline groups. Relative perirenal fat
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Table 5.10 – Measurement of metabolic hormones and haematological parameters at 82 days of postnatal age 
 Saline-F 
(n=8) 
Saline-M    
(n=7) 
Ad.VEGF-F  
(n=8) 
Ad.VEGF-M 
(n=8) 
P Values 
Treatment Gender Interaction 
Leptin (ng/ml) 4.07 ± 0.921 2.43 ± 0.589 4.91 ± 0.987 2.62 ± 0.744 0.519 0.018 0.683 
IGF-1 (ng/ml) 0.32 ± 0.020 0.39 ± 0.037 0.29 ± 0.014 0.39 ± 0.054 0.626 0.043 0.738 
Insulin (ng/ml) 1.66 ± 0.338 1.79 ± 0.202 1.31 ± 0.085 1.69 ± 0.174 0.342 0.292 0.593 
Haematocrit (%) 39.1 ± 0.92 36.4 ± 2.08 40.9 ± 0.52 39.2 ± 0.97 0.092 0.124 0.715 
Haemoglobin (g/dl) 12.9 ± 0.32 12.1 ± 0.44 12.8 ± 0.15 12.8 ± 0.37 0.097 0.050 0.740 
Plasma measurements of leptin, IGF-1, insulin, haematocrit and haemoglobin at 82±0.2 days postnatal age in 31 surviving prenatally growth-restricted                       
lambs whose overnourished adolescent mothers received mid-gestation bilateral uterine artery injections of Ad.VEGF or saline. Comparisons were made              
using the General Linear Model. Abbreviations: IGF-1 = insulin-like growth factor 1.
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Table 5.11 – Weights of major lamb organs, hock, blood and residual carcass, and weight and length of the tibial bone 
 Saline-F 
(n=8) 
Saline-M    
(n=7) 
Ad.VEGF-F  
(n=8) 
Ad.VEGF-M 
(n=8) 
P Values 
Treatment Gender Interaction 
Live weight (kg) 31.9 ± 1.43 35.3 ± 1.76 36.9 ± 1.10 37.4 ± 1.53 0.019 0.195 0.322 
Abdominal girth (cm) 103.1 ± 1.56 105.9 ± 1.28 108.9 ± 1.47 107.9 ± 2.47 0.032 0.632 0.306 
Brain weight (g) 69.6 ± 1.11 71.2 ± 2.95 72.5 ± 0.91 72.5 ± 2.17 0.294 0.690 0.709 
Pituitary weight (g) 0.53 ± 0.046 0.50 ± 0.054 0.61 ± 0.046 0.54 ± 0.028 0.210 0.292 0.650 
Weight of both adrenals (g) 1.78 ± 0.050 1.84 ± 0.051 1.61 ± 0.069 1.76 ± 0.085 0.081 0.144 0.571 
Pancreas weight (g) 33.8 ± 2.34 38.9 ± 2.26 39.3 ± 1.13 39.5 ± 2.06 0.163 0.186 0.225 
Liver weight (g) 560 ± 24.4 630 ± 24.7 651 ± 20.2 659 ± 22.9 0.016 0.104 0.188 
Spleen weight (g) 135 ± 11.8 155 ± 20.2 149 ± 12.2 149 ± 6.7 0.811 0.420 0.456 
Perirenal fat weight (g) 308 ± 36.4 226 ± 33.7 498 ± 53.7 233 ± 26.1 0.024 <0.001 0.034 
Weight of both kidneys (g) 106 ± 5.2 124 ± 7.3 124 ± 5.4 122 ± 6.1 0.249 0.202 0.116 
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Heart weight (g) 186 ± 14.0 178 ± 18.3 183 ± 10.4 170 ± 8.8 0.691 0.439 0.892 
Weight of both lungs (g) 470 ± 43.4 504 ± 16.3 485 ± 17.0 507 ± 31.1 0.798 0.324 0.826 
Thymus weight (g) 46.5 ± 4.05 40.1 ± 3.05 48.9 ± 3.56 45.7 ± 3.15 0.202 0.178 0.657 
Weight of both testes (g)  39.8 ± 6.38  50.8 ± 8.57 0.322   
Weight of both ovaries (g) 1.49 ± 0.128  1.24 ± 0.155  0.267   
Hock weight (g) 965 ± 40.4 1112 ± 51.2 1050 ± 29.3 1120 ± 51.6 0.400 0.022 0.399 
Blood weight (g) 1122 ± 68.2 1385 ± 100 1237 ± 46.0 1355 ± 73.7 0.691 0.016 0.344 
Tibia weight (g) 50.8 ± 3.43 58.0 ± 1.63 53.9 ± 1.57 60.2 ± 2.99 0.388 0.012 0.868 
Tibia length (cm) 96.7 ± 2.23 98.9 ± 2.14 98.4 ± 1.32 100.1 ± 1.50 0.429 0.294 0.875 
Residual carcass weight (kg) 19.3 ± 1.04 20.5 ± 1.05 25.7 ± 0.91 25.4 ± 1.00 0.038 0.868 0.334 
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Table 5.12 – Relative weights of major lamb organs (in g per kg empty carcass weight) plus relative carcass weight (per kg live weight at necropsy) 
 Saline-F     
(n=7) 
Saline-M 
(n=7) 
Ad.VEGF-F 
(n=8) 
Ad.VEGF-M  
(n=8) 
P Values 
Treatment Gender Interaction 
Brain 3.66 ± 0.232 3.49 ± 0.078 3.43 ± 0.143 3.37 ± 0.146 0.112 0.812 0.387 
Pituitary 0.028 ± 0.003 0.024 ± 0.002 0.027 ± 0.002 0.025 ± 0.001 0.891 0.225 0.756 
Adrenals 0.094 ± 0.006 0.091 ± 0.005 0.072 ± 0.002 0.083 ± 0.005 0.004 0.369 0.133 
Pancreas 1.75 ± 0.093 1.90 ± 0.058 1.78 ± 0.099 1.87 ± 0.050 0.971 0.144 0.719 
Liver 29.2 ± 1.22 30.9 ± 0.77 29.2 ± 0.79 30.8 ± 1.61 0.974 0.150 0.967 
Spleen 7.06 ± 0.739 7.48 ± 0.723 6.56 ± 0.348 6.68 ± 0.257 0.238 0.626 0.786 
Perirenal fat 15.8 ± 1.30 10.9 ± 1.42 21.8 ± 1.71 10.7 ± 1.01 0.055 <0.001 0.037 
Kidneys 5.53 ± 0.269 6.06 ± 0.173 5.54 ± 0.121 5.67 ± 0.332 0.433 0.165 0.391 
Heart 9.68 ± 0.654 8.61 ± 0.571  8.18 ± 0.483 7.89 ± 0.241 0.044 0.200 0.460 
Lungs 24.3 ± 1.67 24.7 ± 0.65 21.7 ± 0.62 23.5 ± 1.10 0.072 0.295 0.529 
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Thymus 0.0025 ± 0.0004 0.0020 ± 0.0002 0.0022 ± 0.0002 0.0022 ± 0.0002 0.928 0.310 0.373 
Testes        1.88 ± 0.210    2.54 ± 0.319 0.106   
Ovaries 0.080 ± 0.012     0.057 ± 0.008      0.130   
Hock 50.1 ± 1.20 54.5 ± 1.68 47.0 ± 0.90 53.1 ± 1.11 0.084 <0.001 0.500 
Tibia 2.64 ± 0.155 2.86 ± 0.113 2.42 ± 0.107 2.85 ± 0.140 0.384 0.020 0.430 
Blood 57.9 ± 1.17 67.2 ± 2.06 55.4 ± 1.91 63.5 ± 2.04 0.113 <0.001 0.757 
Carcass 1.75 ± 0.093 1.90 ± 0.058 1.78 ± 0.099 1.87 ± 0.050 0.624 0.003 0.434 
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Figure 5.21 – Indices of asymmetrical growth and relative perirenal fat depot by group/gender  
 
 
Relative lamb brain weight, brain to liver weight ratios [A] and relative perirenal fat weight [B] 
at necropsy at 83±0.2 days postnatal age in 31 surviving prenatally growth-restricted lambs 
whose overnourished adolescent mothers received mid-gestation bilateral uterine artery 
injections of Ad.VEGF or saline. Relative perirenal fat data is presented separately by gender as 
it was greater in females versus males (p<0.001) with a significant treatment/sex interaction.  
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weights were significantly higher in female versus male lambs (11.68±0.908 vs. 6.29±0.514 
g/kg, p=<0.001) and tended also to be higher in Ad.VEGF versus Saline groups (p=0.055). In 
keeping with the pattern seen for absolute perirenal fat weight, there was a significant 
interaction between treatment group and gender, such that relative perirenal fat weight was 
highest in the Ad.VEGF-treated female lambs (p=0.042), illustrated in Figure 5.21B.  By 
contrast, there were no significant treatment group or gender differences in relative liver 
weight when these were expressed per kg of lamb body weight, indicating proportionate shifts 
in hepatic growth. Weight of the blood following exsanguination (an index of circulating blood 
volume and/or density of its cellular components) was lower in females than males (p<0.001) 
and tended also to be lower in Ad.VEGF versus Saline groups, with no significant interaction 
between treatment and gender. Relative hock weight tended to be higher in Ad.VEGF versus 
saline-treated lambs (p=0.084), providing further evidence of increased musculoskeletal mass. 
5.3.9.4 Gross abnormalities 
Several anomalies were found during the course of the lamb dissections. The lamb in the 
Ad.VEGF group which contracted pneumonia in the eleventh week of life was noted to have 
macroscopically abnormal lungs weighing 810g (which was more than 2 standard deviations 
above the 610g mean). Histological examination revealed diffuse collapse with eosinophil 
infiltrate around the airways and blood vessels. A second lamb in the Ad.VEGF group, which 
had followed an uneventful postnatal course, was found to have an enlarged heart at 
necropsy, weighing 530g (greater than 7 standard deviations above the 282g mean). When 
examined histologically the myocardium appeared hyperplastic but otherwise normal and this 
was presumed to have been secondary to a congenital abnormality e.g. valvular stenosis or 
septal defect. A third lamb in the Ad.VEGF group was found to have a hydrocoele of the right 
testicle and one lamb in the Saline group had discordantly sized testes. Both these gonadal 
defects have been observed on multiple occasions in lambs during the course of previous 
research studies and consequently were not unexpected. 
5.4 Discussion 
5.4.1 Ad.VEGF increased fetal growth velocity 
The most important finding of this study was that the positive effect of Ad.VEGF therapy on 
fetal growth velocity observed in the late gestation study (see Section 4.4.1) was reproduced. 
Measurements of the fetal AC were once again noted to be greater at 3 and 4 weeks following 
Ad.VEGF treatment compared with inactive treatment (saline), using an experimental design 
featuring randomisation and a blind assessor. The change in AC relative to baseline following 
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Ad.VEGF treatment at these two time points was remarkably similar in this study compared to 
the late gestation study (75.8±2.16 vs. 75.6±3.62mm, and  93.1±2.57 vs. 92.1±4.31mm, at 3 
and 4 weeks, respectively), which adds precision to the estimate of the effect size of Ad.VEGF 
treatment. In addition to the impact on fetal AC measurements, a simultaneous shift in renal 
growth was also observed here, which was not seen in the previous study. Measurements of 
RV were also significantly greater at 3 and 4 weeks in Ad.VEGF compared with Saline groups. 
Furthermore RV measurements tended to be higher in Ad.VEGF versus Saline groups at >6 
weeks post-treatment (p=0.061) at a time when AC measurements were no longer different. 
This thesis has introduced RV as a novel marker of ovine fetal growth (discussed extensively in 
Chapter 3). RV correlates well with fetal weight in late gestation irrespective of the degree of 
FGR and is technically easier to measure than the AC, which becomes increasingly variable 
towards term. This may explain the tendency towards higher RV in Ad.VEGF versus Saline 
groups at 133 days gestation. Comparison of the change in AC and RV measurements relative 
to baseline between Ad.VEGF and Saline groups indicated that Ad.VEGF treatment increased 
renal growth by 23.2% and 17.1% and abdominal growth by 16.4% and 14.8%, at 3 and 4 
weeks post-treatment, respectively. The potential clinical significance of an ~18% increase in 
fetal growth (on average) over a 3 to 4 week period is discussed in Chapter 7. Notably, despite 
randomisation, fetuses allocated to the Ad.VEGF group had lower initial mean umbilical artery 
pulsatility indices than those allocated to the Saline group. As mid-gestation UA PI values are 
negatively correlated with term birth weight (see Section 3.3.6) this suggests that these 
pregnancies were more compromised at baseline and the fetuses were tracking to be smaller, 
which is consequently biased against the hypothesis that Ad.VEGF would improve fetal growth.  
5.4.2 Ad.VEGF tended to increase birth weight and gestation length 
As stated above, when fetal growth was reassessed using ultrasound at 133 days gestation 
there were no significant differences between study groups in fetal AC measurements but 
there remained a tendency towards higher RV measurements in fetuses of Ad.VEGF- relative 
to saline-treated ewes (p=0.061). After spontaneous delivery near to term, lamb birth weight 
and abdominal girth (which directly reflects the ultrasonograhic AC measurement) also tended 
to be higher in Ad.VEGF versus Saline groups (p=0.081), in keeping with the late gestation 
ultrasound findings. RV measurements at 133 days gestation correlated strongly with lamb 
birth weight at ~141 days gestation, irrespective of study group (r=0.825, n=29, p<0.001), 
reinforcing the strength of the RV ultrasound parameter as a predictor of lamb birth weight. 
The mean increase in lamb birth weight in the Ad.VEGF relative to the Saline group was 681g 
(approximately 20%) which was in agreement with the 18% shift in fetal growth by ultrasound. 
278 
 
It is interesting that the significance level of the group comparison was so strongly affected by 
the presence of a particularly large lamb in the Saline group (see Section 5.3.4.1). This 
highlights the challenges of working with a paradigm in which only 52% of pregnancies are 
expected to exhibit a major degree of FGR (Wallace et al. 2004b), wherein Ad.VEGF would only 
be expected to exert a therapeutic effect in one half of all cases treated. The combination of 
maternal overnutrition and the failure to induce placental insufficiency can on occasion 
produce a fetus or lamb of even greater size than in moderate (control) intake pregnancies, 
which introduces a large degree of variability in the overnourished group. This could 
potentially have masked the true effect of treatment in the smallest fetuses. In the late 
gestation study the inclusion of a contemporaneous group of control-intake ewes meant that 
the proportions of markedly growth-restricted fetuses could be determined with a reasonable 
degree of certainty and compared between Ad.VEGF and Saline/Ad.LacZ-treated groups. The 
lack of genetically matched control-intake ewes in the present study meant it was not possible 
to do this and an attempt to use historical control data for lambs born near term did not reveal 
any significant differences in the proportions of marked growth-restricted versus non-FGR 
lambs. Physical measurements at the time of birth (abdominal girth and biparietal head 
diameter) also tended to be greater in Ad.VEGF versus Saline groups, suggesting proportionate 
increases in brain and somatic growth. This would seem to imply that Ad.VEGF had no effect of 
fetal brain sparing herein, however at 3 months of age there was evidence at post-mortem 
examination to the contrary (see Section 5.4.6). 
There was a tendency towards increased placental efficiency following Ad.VEGF treatment in 
agreement with the findings of the late gestation study, in which fetal to placental weight ratio 
was found to be significantly greater in Ad.VEGF-treated overnourished versus control-intake 
pregnancies (see Section 4.3.4.2) accompanied by an upregulation in the caruncular expression 
of VEGF receptors FLT1 and KDR relative to Saline/Ad.LacZ-treated overnourished pregnancies 
(see Section 4.3.5.7). However, in the present study, maternal plasma oestradiol-17β levels 
were equivalent in both groups throughout gestation, suggesting that Ad.VEGF did not impact 
placental secretory function. Other possible mechanisms behind increased placental efficiency 
include increased placental vascularity or transport capacity, as discussed in Chapters 4 and 7.  
There was also a tendency towards increased gestation length in Ad.VEGF versus Saline groups 
(p=0.074). During lambing, considerable neonatal complications are associated with as little as 
two to three days' prematurity (Wallace JM, personal communication). However with regards 
to human pregnancy it could be argued that, even if this represents a true effect of prenatal 
Ad.VEGF gene therapy, a mean difference of two days (0.01 gestation, equivalent to four days 
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in the human) is unlikely to be of major clinical significance. Importantly, the tendency towards 
increased birth weight in the Ad.VEGF group was not explained only by this slight prolongation 
of pregnancy, as the significance levels for the birth weight differences did not change greatly 
after correcting mathematically for gestation length (p=0.084 versus p=0.081). 
5.4.3 Ad.VEGF increased absolute postnatal growth rates to weaning 
The original hypothesis was that the potential mitigation of FGR by Ad.VEGF treatment would 
result in an attenuation of the catch-up growth that is characteristic of this ovine paradigm. 
Consequently it was a relatively surprising observation that lambs born following Ad.VEGF 
continued to grow at a faster rate during the first 12 weeks and hence were significantly larger 
than their saline-treated counterparts from 6 weeks of age onwards. Interestingly this increase 
in postnatal growth was apparent when expressed in absolute terms, but not when expressed 
as a fraction of lamb birthweight. This suggests that there was no disassociation of the normal 
positive relationship seen between initial weight and fractional growth velocity. Previously, 
when the postnatal growth trajectories of small lambs born to overnourished mothers were 
compared with those of normally grown offspring from control-intake pregnancies, absolute 
growth rates to weaning were not significantly different (368±13.4 vs. 359±10.9 g/day, 
p>0.05), indicating that lambs born following FGR were indeed catching up in early postnatal 
life (Wallace et al. 2010a). As a result fractional growth rates were higher in prenatally growth-
restricted lambs (p<0.001) and these differences were more pronounced in male lambs 
compared to females: 11.2 vs. 6.6 and 9.1 vs. 6.8%/day, n=9 and 16, respectively (Wallace et 
al. 2010b). In the present study mean fractional growth rates in the Ad.VEGF group (10.0%) 
were similar in magnitude to that previously observed in lambs born to (untreated) 
overnourished mothers (10.1%), suggesting that the increased absolute postnatal growth rates 
following Ad.VEGF treatment herein were not excessive relative to baseline and probably just 
reflected the relative size advantage of these lambs at birth (p=0.081), magnified as the weeks 
went on. Measurements of abdominal girth and shoulder height followed a similar pattern to 
lamb body weight, with significant differences between Ad.VEGF and Saline groups at various 
time points between birth and necropsy at 12 weeks. Measurements of shoulder height began 
to plateau after ~7 weeks, following which there were no further significant differences 
between groups. Relative to lambs of control-intake dams, prenatally growth-restricted lambs 
have been shown to have significantly reduced girth and shoulder height up to 68 days of age, 
with gender differences beginning to emerge from 58 days postnatal age (Wallace et al. 2013). 
In the present study no significant male/female differences were evident for these parameters. 
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5.4.4 Ad.VEGF increased glucose-stimulated insulin secretion / NEFA suppression 
A further hypothesis was that mitigation of FGR by Ad.VEGF treatment would result in an 
attenuation of the increased glucose-stimulated insulin secretion that is characteristic of this 
ovine paradigm. However, surprisingly, in the present study there was a significant increase in 
insulin secretion, reflected by a greater insulin AUC following an intravenous glucose tolerance 
test in Ad.VEGF versus Saline groups. This appeared to relate to a greater second phase insulin 
response, as significant differences at individual time points did not become apparent until 25 
minutes following glucose administration. Insulin secretion has been shown to be biphasic in 
rats and humans with a brief spike lasting approximately 10 minutes, followed by a more 
sustained response, although the usefulness of distinguishing between them is questionable, 
given that both phases appear to be impaired in diabetes (Gerich 2002). With respect to the 
glucose curves, although there were some differences in plasma levels at individual time 
points, overall glucose AUC did not differ between groups. NEFA AUC was also increased 
following glucose infusion, although this most likely represents a response to enhanced insulin 
secretion rather than altered fat metabolism per se. Perhaps most reassuringly, there were no 
significant differences between Ad.VEGF and Saline in any indices of insulin sensitivity, namely 
insulin AUC : glucose AUC ratio, fasting plasma insulin : glucose ratio or the HOMA index. This 
suggests that the enhanced insulin secretion seen following Ad.VEGF did not reflect relative 
insulin resistance, and therefore does not suggest any detriment to the metabolic phenotype, 
rather an increased capacity to secrete insulin without any alteration in insulin action per se. 
There were also no significant differences in the fasting levels of glucose, insulin, NEFA, 
glycerol or urea, suggesting that Ad.VEGF had no impact (positive or negative) on basal 
metabolic function. Interestingly plasma glucose tended to be higher at birth in Ad.VEGF 
versus Saline groups (p=0.089), which was in the expected direction in keeping with improved 
fetal growth and implies higher transplacental glucose transfer pre-delivery. This finding is also 
in keeping with the tendency towards increased caruncular GLUT1 expression following 
Ad.VEGF treatment in the late gestation study (see Section 4.4.7). 
5.4.5 Ad.VEGF tended to increase lean tissue mass and bone mineral density 
Given the increased absolute growth rates, as discussed above, it became especially important 
to assess whether this might be a reflection of an associated increase in adiposity, as this might 
have a bearing on the risk of metabolic syndrome. It has previously been shown that, relative 
to the normally grown lambs of control-intake ewes, prenatally growth-restricted lambs have 
reduced BMD (p<0.02) and higher percentage total body fat (p<0.001) on DEXA examination at 
11 weeks of age (Wallace et al. 2010b). It was initially reassuring that despite the increased 
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growth rates following Ad.VEGF, there were no differences in fat mass or percentage body fat 
between Ad.VEGF and Saline groups when examined at 11 weeks of age. Rather there was a 
tendency towards increased BMD, bone mineral content and lean tissue mass in Ad.VEGF 
versus Saline groups, all of which are in the direction of normal. However, at the point of 
necropsy at 12 weeks of age there some notable differences in the weight of the perirenal fat 
depot between groups. As expected, perirenal fat stores were greater in females than males 
(p<0.001) however there were also a tendency towards increased relative perirenal fat weight 
(g/kg fetus) in Ad.VEGF versus Saline groups and a significant interaction between gender and 
treatment group. Consequently relative perirenal fat weight was highest in female lambs 
treated prenatally with Ad.VEGF (p<0.001). This appears to indicate that females may be more 
sensitive to putatively enhanced nutrient supply in utero, although there were no gender 
differences in fetal growth velocity or lamb birth weight in the present study. No significant 
gender differences in fat deposition have previously been observed in response to increasing 
fetal nutrient supply in late gestation sheep pregnancy, which is largely under the regulation of 
insulin and leptin (Muhlhausler et al. 2002; Muhlhausler et al. 2003), neither of which were 
influenced by Ad.VEGF treatment in the present study. However it seems more likely that this 
relative increase in perinatal fat mass was established during fetal rather than neonatal life as 
the perirenal fat depot is largely laid down in late pregnancy. Irrespective, there was no 
evidence that female and/or Ad.VEGF-treated lambs had a worse metabolic profile than male 
and/or saline-treated lambs. Furthermore the perirenal fat is but one of several major fat 
depots in the body and it is a potential limitation of this study that the effect of Ad.VEGF on 
overall adiposity was not assessed beyond this individual proxy measure. It is interesting that 
the DEXA assessment of body fat did not reveal any differences between Ad.VEGF and Saline 
groups, although notably it also failed to detect gender differences, which have previously 
been shown at this stage of life (Carr et al. 2012). Furthermore, DEXA is less sensitive than 
measurement of the dissected fat depot at necropsy.   
Ultimately it would be necessary to follow-up the offspring for a longer period to see whether 
any changes in relative adiposity persisted into adulthood and/or were associated with an 
adverse phenotype. Perhaps reassuringly, it has recently been shown that feeding an optimum 
diet (as opposed to ad libitum feeding) in the postnatal period can reverse the adverse 
metabolic phenotype in female but not male lambs following FGR induced by overnourishment 
of adolescent dams (Wallace et al. 2012). Consequently if Ad.VEGF does increase relative 
adiposity in females, it may be easier to ameliorate through dietary modification than in males. 
More positively, Ad.VEGF therapy tended to increase lean tissue mass and BMD. The latter has 
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been shown to be reduced both in human FGR (Verkauskiene et al. 2007) and in this particular 
animal model (Wallace et al. 2010b). In the late gestation study, Ad.VEGF had no demonstrable 
effect on skeletal growth as assessed by serial ultrasound measurement of the femur and tibia, 
and by direct measurement of the same bones at necropsy. In the present study, there was no 
effect of Ad.VEGF on length or weight of the tibial bone at 12 weeks of postnatal age. Together 
these findings imply that although skeletal size is not affected, there may be an improvement 
in the quality of the skeleton, perhaps through increased bone mineralisation. The timing of 
this potential improvement in BMD (e.g. prenatal versus postnatal) is however not known. 
There was also a tendency towards higher lean tissue mass by DEXA in Ad.VEGF versus Saline 
groups, irrespective of gender. This was in keeping with significantly increased residual carcass 
weights at postnatal necropsy, reflecting musculoskeletal mass. Despite the female-specific 
effects on relative perirenal fat weight discussed above, this suggested that increased absolute 
postnatal growth rates of the Ad.VEGF-treated lambs reflected enhanced lean tissue accretion. 
5.4.6 Ad.VEGF tended to mitigate brain sparing / disproportionate adrenal growth 
In this study no data was available on serial ultrasound fetal BPD:AC ratios as head 
measurements were not included in the set of measurements taken at ultrasound 
examination. Furthermore there were no significant differences between groups in the ratio of 
biparietal head diameter (measuring using calipers) to abdominal girth at the time of birth. 
However, despite this lack of early evidence of a mitigating effect of Ad.VEGF on fetal brain 
sparing, at the point of necropsy at 12 weeks gestation there were some clues that this had 
taken place, presumably during prenatal life. There was a tendency towards reduced relative 
fetal brain weights and brain to liver weight ratios in Ad.VEGF versus Saline groups, which 
mirrored what had been observed at necropsy in late gestation (see Section 4.3.4.5). Although 
there were no control-intake pregnancies here to directly compare with, this is in keeping with 
an attenuation of the fetal brain sparing effect, which likely reflects a reduced need for fetal 
adaptation and is therefore an encouraging finding (Section 4.4.2). Furthermore at postnatal 
necropsy there was also a reduction in the relative adrenal weight in Ad.VEGF relative to Saline 
groups. This was once again in keeping with what had been observed at fetal necropsy in the 
late gestation study and may represent an attenuation of the accelerated maturation of the 
adrenal gland that is characteristic of this and many other animal models of FGR. Interesting 
there was a negative correlation between relative adrenal weight and gestation length in the 
Saline group (r=-0.658, n=15, p=0.020), suggesting that the greater the relative size of the 
adrenal, the earlier spontaneous delivery occurred. In spite of the lack of any measurable 
differences in plasma cortisol between control- and high-intake ewes when previously 
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measured at ~128 days gestation (Wallace et al. 2000), this supports the concept of a 
functional relationship between premature activation of the hypothalamic-pituitary-adrenal 
axis and the initiation of labour in this paradigm. Interestingly there appeared to be a 
dissociation of this relationship following Ad.VEGF treatment (r=-0.246, n=16, p=0.376), which 
is in keeping with the slightly increased gestation length seen in this group. Incidentally it is 
currently not known whether an increase in plasma cortisol occurs between 128 and 145 days 
gestation, in overnourished pregnancies as the associated prematurity precludes a 
comprehensive assessment  nearer to term. 
5.4.7 Ad.VEGF was not associated with any complications in the perinatal period 
As in the previous study there were no adverse responses of the mother or fetus to the 
injection or occlusion procedure and all Ad.VEGF-treated pregnancies continued until term, 
following an uncomplicated course. At delivery particular attention was paid to blood loss at 
delivery as a theoretical association between enhanced uterine blood flow and postpartum 
haemorrhage was anticipated. No such complications were encountered. Furthermore there 
were no unexpected problems in the neonatal period and no significant differences in the level 
of neonatal care required to ensure lamb survival. Fetal serum biochemistry and liver function 
were not altered. The latter observation was particularly reassuring as there is a particular 
concern that adenovirus vectors can induce liver inflammation (Worgall et al. 1997), although 
it does not appear that any fetal transfer of the vector occurs following administration during 
sheep pregnancy (David et al. 2008). Furthermore, as the hepatic transaminases are acute 
phase reactants and are often raised non-specifically in illness, low levels are suggestive of an 
absence of systemic inflammation. Collectively the above observations support the safety of 
Ad.VEGF as a prenatal therapy.  
5.4.8 Ad.VEGF did not impact upon colostrum quantity, quality or antibody levels 
In the sheep, the functional development of the mammary gland is virtually complete by the 
end of gestation, with negligible growth observed postnatally (Anderson 1975). Gestational 
mammary development is nutritionally sensitive, since maternal undernutrition results in a 
reduction in mammary weight at term (Swanson et al. 2008) and vascularity within the gland is 
also influenced by maternal diet, and in particular its selenium content (Vonnahme et al. 2011; 
Neville et al. 2013). It was considered that Ad.VEGF therapy might potentially have an effect on 
mammary gland development via two different mechanisms: (1) directly by systemic spread of 
the vector or raised plasma VEGF levels secondary to over-expression; or (2) indirectly through 
enhanced placental secretory function. However in this study it did not appear that Ad.VEGF 
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had any effect on the growth, development or function of the mammary gland as there were 
no significant differences in the colostrum yield, nutrition composition, IgG concentration or 
IgG content. This in agreement with the lack of any measurable change in circulating levels of 
oestradiol-17β levels throughout the second half of pregnancy following Ad.VEGF treatment, 
as mammary development is principally driven by oestrogen (Flint & Knight 1997). The positive 
correlation between placental size and colostrum yield seen herein illustrates the importance 
of placental secretory function for physiological mammary development. Although colostrum  
IgG and nutrient concentrations are unperturbed in this paradigm, the reduction in placental 
size and overall colostrum yield translates into large differences in IgG and nutrient content. 
This is important because it is the total volume of colostrum available to the lamb that matters 
with respect to the provision of passive immunity. In the present study 9 of 32 (28%) live born 
lambs required the use of donor colostrum to meet the minimum requirement of 50ml/kg 
body weight. The outlook for these lambs without supplementation would probably have been 
poor. However the provision of pooled donor colostrum appeared to be effective, given that 
plasma IgG levels were unrelated to birth weight by 24 hours of age (r=0.094, n=32, p=0.615). 
Moreover this suggests that early function of the neonatal gut is relatively unimpaired in these 
prenatally growth-restricted lambs and that the absorptive capacity was sufficient to normalise 
circulating IgG levels within 24 hours. This is in keeping with the lack of any differences in fetal 
small intestinal crypt cell proliferation and an increase in relative small intestinal weight in 
overnourished versus control-intake pregnancies within the late gestation study (see Sections 
4.3.5.2 and 4.3.4.5, respectively), which suggests that there is a relative preservation of gut 
development (similar to that seen in the brain) in the face of a reduced fetal nutrient supply. 
5.4.9 Ad.VEGF did not influence the inflammatory response to routine vaccination 
In the present study there were no significant differences between groups in the levels of 
serum amyloid A, an acute phase reactant that is released in response to infection and 
inflammation, at baseline or at 24 or 48 hours following routine vaccination with a combined 
Clostridium and Pasteurella vaccine. Interest in serum amyloid A levels in relation to postnatal 
growth and metabolism has been stimulated by previous observations of an association with 
both obesity (Zhao et al. 2010) and insulin resistance (Leinonen et al. 2003). The lack of any 
effect of Ad.VEGF on serum amyloid A levels is therefore in keeping with the absence of any 
excessive adiposity or insulin resistance, both of which are reassuring, along with the adequate 
serum IgG levels at 24 hours and absence of any evidence of hepatic inflammation at 7 days of 
age (Sections 5.3.4.3 and 5.3.4.6). When previously measured in this FGR paradigm in lambs of 
the same age, peak serum amyloid A levels were increased in prenatally growth-restricted 
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relative to normally grown lambs  (357±42.4 vs. 219±49.0mg/l, p=0.005) and were also greater 
in males than females (356±53.3 vs. 233±41.1mg/l, p=0.014) (Carr et al. 2012). By contrast, in 
the present study no gender differences were present. Interestingly, when immune response 
to vaccination was previously re-tested at 13 weeks postnatal age, differences by prenatal 
nutrition tended to be in the opposite direction (69±13.4 vs. 141±34.9mg/l, p=0.051) and 
serum amyloid A levels were independent of gender (Carr et al. 2012). This appears to suggest 
an alteration in the ontogeny of the immune system following prenatal growth restriction. It is 
unknown whether Ad.VEGF might have impacted immune responses at a later gestation as no 
comparable data at 13 weeks was available for the present study. However it would seem 
unlikely given the lack of any clear difference when examined at 6 weeks.  
5.5 Conclusions 
Mid-gestation delivery of Ad.VEGF gene therapy in FGR pregnancies induced by overnourishing 
adolescent sheep dams resulted in a significant increase in fetal growth velocity at 3 and 4 
weeks post-treatment and tended to increase gestation length by approximately two days. 
Pregnancies following Ad.VEGF tended to have increased placental efficiency, and lambs 
tended to be heavier at birth with greater abdominal girth and higher plasma glucose. Ad.VEGF 
had no effect on colostrum quantity or quality and there were no differences in the level of 
neonatal care required to ensure lamb survival between groups. Absolute postnatal growth 
rates were increased following Ad.VEGF but fractional growth velocity was unaltered. There 
was no effect on the immune response to routine vaccination. Ad.VEGF-treated lambs 
demonstrated increased insulin secretion and NEFA suppression following an intravenous 
glucose challenge. However fasting levels of glucose, insulin, urea, NEFA and glycerol were 
unchanged, as were the insulin to glucose ratios and HOMA indices, suggesting that this 
observation was not due to insulin resistance. On DEXA analysis lean tissue mass and bone 
mineral density/content tended to be increased. At necropsy at ~12 weeks postnatal age, 
relative perirenal fat stores were increased in Ad.VEGF-treated female but not male lambs. 
Otherwise there appeared to be enhanced lean tissue accretion which, along with the 
increased glucose-stimulated insulin secretion, likely represents a greater anabolic drive in the 
Ad.VEGF-treated animals. Whether this simply reflects their relative size advantage at birth or 
some form of intratuerine programming effect remains unclear, and this is investigated and 
discussed further in Chapter 6. 
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Chapter 6                                                                                                               
Epigenetic Status of Growth Related Genes in Hepatic Tissues of Fetuses and 
Lambs Following Fetal Growth Restriction & Prenatal Ad.VEGF Gene Therapy 
6.1    Introduction 
This chapter describes a programme of work to evaluate the impact of FGR and Ad.VEGF gene 
therapy upon the epigenetic status of key genes related to postnatal growth and metabolism. 
6.1.1    Background 
As discussed in Section 1.1.3.8, FGR and its proxy measures small-for-gestational age (SGA) and 
low birth weight (LBW) are associated with an increased risk of adult cardiovascular, renal and 
metabolic diseases. Several different mechanisms for this "intrauterine programming" effect 
have been proposed, which can broadly be considered as structural, functional or epigenetic in 
nature - currently much attention is focused on the latter because of the implications for the 
long term health of the affected individual (Santos & Joles 2012).  
Epigenetic modifications result in changes in gene expression in the absence of any alteration 
in the actual DNA sequence. There are three main processes involved in epigenetics, namely 
DNA methylation, histone modification and microRNAs. These mechanisms appear to work in 
concert with one another and have been comprehensively reviewed by (Chen & Zhang 2011). 
It has been demonstrated that changes in the intrauterine environment can influence the fetal 
epigenome resulting in an altered phenotype for a given genotype. This is perhaps best 
illustrated by the seminal experiments using the agouti mouse, in which variable dietary 
methyl supplementation of the mother resulted in a range of different offspring phenotypes 
(coat colours) secondary to variable DNA methylation (Wolff et al. 1998; Cooney et al. 2002). 
DNA methylation is by far the best characterised epigenetic mechanism. It occurs at specific 
palindromic sequences in which a cystosine (C) residue is directly followed by a guanine (G). 
These pairings are termed CpG dinucleotides -  the intervening "p" is used to distinguish this 
pairing from the complementary CG pairing between the sense and anti-sense strands of DNA. 
CpG dinucleotides occur non-randomly throughout the genome, usually within short stretches 
of G:C-rich and CpG dense DNA, which are termed CpG islands. CpG islands often occur close 
to or within the promoter regions of genes. The cytosine residue within CpG dinucleotides will 
occasionally covalently acquire a methyl group at its 5-carbon position.  The overall degree of 
methylation at the C residues within CpG islands is highly variable between different genomic 
regions and between different cell and tissue types. By contrast, cytosines outwith CpG islands 
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are usually unmethylated throughout most of the genome. This is partly due to the fact that 
there is a high rate of spontaneous decay of methylated cytosines to uracil, following which 
the DNA repair process consistently replaces them with a unmethylated cytosine such that the 
natural tendency overall is towards a state of demethylation. Consequently it is believed that 
maintenance of DNA methylation at certain sites is an active process mediated by the DNA 
methyltransferases (Delcuve et al. 2009). Methylated cytosines inhibit the attachment of 
various transcription factors, both directly and indirectly through forming bonds with methyl-
CpG-binding domain (MBD) proteins (Kass et al. 1997) - illustrated in Figure 6.1. Consequently 
hypermethylation is associated with reduced gene expression or gene silencing, whilst relative 
hypomethylation is associated with enhanced gene expression. In addition to its putative role 
in intrauterine programming, DNA methylation is the mechanism behind genetic imprinting, 
whereby one parental allele is silenced by hypermethylation. Imprinting may be physiological, 
as occurs in the fetal H19 and IGF-2 genes, or pathological, for example as seen in Silver-Russell 
syndrome (Rossignol et al. 2008). There is also recent evidence that exposure to environmental 
toxins in utero such as nicotine (Wang et al. 2011b) and alcohol (Resendiz et al. 2013) can have 
directly harmful effects on CpG methylation. Aberrant DNA methylation is also seen in some 
other disease states and is especially important in cancer biology (Dawson & Kouzarides 2012). 
Histone modification and miRNAs contribute an additional layer of epigenetic control. Histones 
are octameric globular protein structures around which DNA is coiled to form nucleosomes, 
which are packaged together as chromatin, a relatively dense aggregation of DNA and protein. 
The accessibility of transcription factors, DNA helicase, RNA polymerase and other proteins 
involved in the regulation of gene expression can be facilitated or impeded by the modification 
of the histones on their tail ends, which protrude out of the nucleosomes. Such modifications 
can occur biochemically by way of methylation, acetylation, phosphorylation, biotinylation, 
ubiquitination and ADP-ribosylation (Munshi et al. 2009). MicroRNAs (miRNAs) are relatively 
short non-coding sequences of single-stranded RNA that combine with mRNAs in a specific 
fashion, resulting in their degradation or inhibition of their translation into proteins (Chuang & 
Jones 2007). Unlike the other two mechanisms, the miRNAs act at a post-transcriptional level. 
The work detailed in this chapter focused on assessment of DNA methylation in various genes 
of interest. There are currently numerous different approaches that can be used to assess DNA 
methylation. At the most basic level, global DNA methylation can be determined in any tissue 
by quantification of mRNA expression of DNA methyltransferases using qRT-PCR or detection 
of 5-methyl-cytosine residues by means of immunohistochemistry or DNA dot blot analysis 
(Grazul-Bilska et al. 2011). Unfortunately these methods do not give any information about 
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Figure 6.1 – Putative effect of DNA methylation on gene expression  
 
Diagram illustrating unmethylated DNA, which allows transcription factors (TF) to bind freely, 
compared with methylated DNA following the action of DNA methyltransferases (Dnmt). 
Methylated DNA allows methyl binding domain (MBD) proteins to bind, which obstruct the 
access of transcription factors resulting and thereby inhibit gene expression. Figure reproduced 
with permission from a presentation by Dr Mandy Drake, Scottish Senior Clinical Fellow and 
Honorary Consultant in Paediatric Endocrinology, University of Edinburgh. 
  
which individual genes might be differentially methylated. More specific information can be 
gained by interrogating individual CpG sites. Broadly speaking this can either be achieved by 
methyl-specific PCR or by a bisulphite sequencing method. Methyl-specific PCR necessitates 
two reactions using different sets of primers, one which amplifies methylated DNA at the site 
of interest and one which amplifies unmethylated DNA. The ratio between the amount of PCR 
product from the two reactions can then be calculated, however as they are run separately 
there may be amplification bias or other inequalities. An extension of this technique called 
Methylight uses an additional oligonucleotide probe to increase the sensitivity and specificity 
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(Trinh et al. 2001). However both these approaches are limited by the fact they quantify the 
amount of fully methylated relative to fully unmethylated DNA, and are unable to distinguish 
variable degrees of methylation between these two states. The ability to detect more subtle 
shifts in methylation is particularly important within the field of intrauterine programming as 
the somatotrophic axis genes are unlikely to be turned completely on or off (like, for example, 
proto-oncogenes or tumour suppressor genes, respectively (Teodoridis et al. 2005)) but rather 
may be expected to exhibit relative degrees of hyper- or hypomethylation sufficient to 
differentially impact gene expression. Bisulphite sequencing methods have the advantage that 
individual CpG sites can be investigated at high resolution. Sodium bisulphite is a compound 
that actively degrades unmethylated cystosines to uracils (which are then converted to 
thymine during subsequent PCR) whilst leaving methylated cytosines intact (Hayatsu 2008). 
This effectively creates a C / T single nucleotide polymorphism at each CpG site, where 
methylated cytosines are represented by "C"s and unmethylated cytosines by "T"s. This is 
illustrated in Figure 6.2. The C / T ratios can then be examined by one of a number of different 
methodologies including pyrosequencing, Sequenom™ MassArray™, immunoprecipitation or 
cloning followed by direct sequencing.  
Pyrosequencing is a technique in which a sequencing primer is hybridised to the PCR amplicon 
and combined with four enzymes (DNA polymerase, ATP sulphurylase, luciferase and apyrase) 
and two substrates (adenosine 5' phosphosulphate (APS) and luciferin) - see Marsh (2007) for 
an overview. The expected order of bases of the amplicon is inputed into the sequencer to 
calculate the dispensation order of deoxyribonucleotide triphosphates (dNTPs) that are added 
into the reaction sequentially. For example, if an adenosine residue were to be expected next 
then the complementary dNTP, in this case deoxyribothymidine triphosphate (dTTP), would be 
added and would be incorporated into the DNA strand, catalysed by DNA polymerase. This 
reaction is accompanied by the release of an equimolar amount of pyrophosphate (PPi), which 
is then converted to ATP by ATP sulphurylase in the presence of APS. The resultant ATP 
triggers the conversion of luciferin to oxyluciferin by luciferase, which emits a quantity of 
visible light that is proportional to the amount of ATP/dNTP/nucleotide present. The amount 
of light detected is illustrated as a "pyrogram", on which the height of each peak indicates the 
number of nucleotides incorporated. Meanwhile the apyrase mops up any unincorporated 
nucleotides and ATP ready for the addition of the next dNTP according to the predetermined 
dispensation order. The general pyrosequencing reaction is illustrated in Figure 6.3. With 
respect to CpG dinucleotides, these can be specifically highlighted where these occur within 
the dispensation order as a "Y", indicating that a mixture of C and T nucleotides (representing 
methylated and unmethylated cytosines, respectively) of unknown proportions is expected.
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Figure 6.2 – Effects of sodium bisulphite conversion on CpG dinucleotides 
 
Illustration of the differential effects of sodium bisulphite on methylated (red) and 
unmethylated (pink) cytosine (C) residues within CpG dinucleotides. Unmethylated cytosines 
are degraded to uracil (U) whilst methylated cytosines are preserved. During subsequent 
polymerase chain reaction (PCR), uracil is converted to thiamine (T) whilst cystosine remains 
unchanged. Primers (black arrows) specifically designed to avoid CpG sites amplify all template 
DNA resulting in a mixture of Cs and Ts at the CpG sites of interest within the amplicon. The 
ratio of C : T is proportional to the amount of methylated and unmethylated sites, respectively, 
and can be quantified by pyrosequencing and measurement of the relative height of the two 
peaks. Figure adapted with permission from a presentation by Dr Mandy Drake, Scottish Senior 
Clinical Fellow and Honorary Consultant in Paediatric Endocrinology, University of Edinburgh. 
  
The pyrosequencer will release the complementary dNTPs into the reaction in close 
succession. The proportion of C to T present can be determined by the measuring the ratio of 
the two peaks on the pyrogram and reflects percentage DNA methylation at that locus.  
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Figure 6.3 – Pyrosequencing 
 
Diagram illustrating the various chemical reactions involved in the pyrosequencing process - 
please see text for full explanation. Abbreviations: DNA = deoxyribonucleic acid; dNTP = 
deoxyribonucleotide triphosphate; PPi = pyrophosphate; APS = adenosine 5' phosphosulphate; 
ATP = adenosine triphosphate; dNDP = deoxyribonucleotide diphosphate; dNMP = 
deoxyribonucleotide monophosphate; ADP = adenosine diphosphate; AMP = adenosine 
monophosphate; G = guanine; C = cytosine; A = adenosine; T = thymine. Figure reproduced with 
permission from Marsh (2007). 
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Assessment of gene-specific, as opposed to global, DNA methylation during sheep pregnancy is 
limited to only a few reports to date, with most epigenetic studies using other species such as 
rodents. Reports relating to sheep models of FGR are detailed in the Discussion (Section.6.4).  
However, it is clear that maternal nutrition in general can impact fetal DNA methylation. For 
example, DNA methylation of IGF2R and H19 is increased in sheep dams fed a diet comprised 
of alfalfa haylage compared with corn (Lan et al. 2013) and moderate maternal undernutrition 
reduces DNA methlyation of the proopimelacanocortin and glucocorticoid receptor genes in 
the fetal hypothalamus (Begum et al. 2012). 
6.1.2    Aims 
The aims of this work were to: 
 To identify ovine genes related to postnatal growth and metabolism that contain one or 
more CpG islands according to conventional definitions 
 To work up functioning assays to quantify the degree of methylation at specific CpG sites 
within these CpG islands using bisulphite conversion, PCR and pyrosequencing 
 To determine if DNA methylation patterns in growth related genes differ between growth-
restricted and normally grown fetuses of overnourished and control-fed adolescent ewes 
 To examine for any changes in methylation status of growth related genes associated with 
maternal Ad.VEGF gene therapy in late gestation fetuses and in postnatal lamb tissues 
 To evaluate whether there are any differences in DNA methylation patterns in growth 
related genes between male and female fetuses and lambs 
6.2    Methods 
DNA extraction and sodium bisulphite conversion was performed at University College London. 
PCR and pyrosequencing were performed in collaboration with The Genome Centre at Barts 
and the London School of Medicine and Dentistry, Queen Mary University London.  
6.2.1    Identification of CpG islands 
Genomic DNA sequences for various ovine genes relevant to postnatal growth and metabolism 
were searched for in the US National Center for Biotechnology Information (NCBI) Nucleotide 
database. All available sequences were imported into Methyl Primer Express® software version 
1.0 (Applied Biosystems, Foster City, CA, USA) to determine the presence or absence of CpG 
islands according to the following criteria: 
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 Length >200bp 
 GC content >55% 
 Observed : expected CpG ratio (= no. of CpG / no. of C x no. of G) >0.65 
The original criteria for GC content and observed : expected CpG ratios were >50% and >0.60 
(Gardiner-Garden & Frommer 1987) however it has been proposed that increasing the cut-offs 
to those detailed above makes identification of CpG islands more specific as it is more likely to 
exclude other GC-rich genomic sequences such as Alu repeats, which are repetitive elements 
that occur in non-coding regions (Takai & Jones 2002). It has also been recommended that the 
minimum length be increased to >500bp, however this was not done here due to the relatively 
short length of the published sheep genomic DNA sequences, and particularly a lack of 
extensive non-coding sequences in which CpG islands are likely to lie. Nevertheless a total of 
24 CpG islands were identified in ten different genes relating to the somatotrophic axis. These 
are detailed in Table 6.1 and gene structures are described below. 
6.2.1.1    Insulin and insulin-like growth factor 2 
The insulin and insulin-like growth factor (IGF)-2 genes are contiguous and are similar in their 
structural arrangement and expression profile in sheep and humans (Ohlsen et al. 1994). The 
human IGF-2 gene contains ten exons. The first seven are non-coding and are alternatively 
spliced to exons 8, 9 and 10, which together encode the IGF-2 precursor protein. The ovine 
IGF-2 gene has a similar exonic arrangement, although no equivalent of non-coding exon 2 has 
been identified. It also appears to lack the proposed CCAAT/enhancer binding protein (C/EBP) 
site that is located upstream of human exon 1 (van Dijk et al. 1992). The intergenic region 
between insulin and IGF-2 is approximately 750 nucleotides shorter than in the human and 
contains a stretch of 85 nucleotides with a particularly high C:G density (96%). There are four 
putative promotors (P1 to P4), which precede exons 1, 4, 6 and 7, respectively. Of these P3 and 
P4 are considered to be the major promoters utilised in fetal and non-hepatic adult tissue, 
whilst P1 is only active in adult liver. The linked insulin gene is comprised of three exons, which 
lie proximal to IGF-2 exon 1. CpG islands were identified proximal to insulin exon 1 and IGF-2 
exons 1, 4, 5, 6, 7, 8, 9 and 10. 
6.2.1.2    Insulin-like growth factor 1 
The ovine IGF-1 is highly homologous with the human IGF-1 gene, with the exception of a 
single nucleotide substitution (alanine in place of proline at position 66) and the presence of 
an additional glutamine residue at the boundary between exons 1 and 2 (Wong et al. 1989). 
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Table 6.1 – Details of 24 CpG islands identified within the genes of the ovine somatotrophic axis 
CpG 
Island 
No. 
Gene Accession 
No. 
Length of 
Gene 
(bases) 
Length of 
CpG Island 
(bases) 
%CG 
1 Insulin Exons 1 to 3 U00659 1520 980 71.4 
2 IGF-2 Exon 1 U00659 873 180 71.4 
3 IGF-2 Exon 4 U00664 1760 1323 68.8 
4 IGF-2 Exon 5 U00664 800 800 68.8 
5 IGF-2 Exon 6 U00664 1932 1520 68.8 
6 IGF-2 Exon 7 U00665 547 262 68.3 
7 IGF-2 Exon 8 U00666 889 440 61.6 
8 IGF-2 Exon 9 U00667 611 496 69.0 
9 IGF-2 Exon 10 U00668 720 622 59.8 
10 IGF-1 Exon 2 X51357 1808 515 55.7 
11 IGF-1 Exon 3 X51358 560 496 55.4 
12 IGF-1 Exon 3  X69473 573 379 56.2 
13 IGF-1 Exon 4 X69474 526 469 55.7 
14 H19 AJ566210 8767 1160 64.0 
15 H19 AJ566210 8767 818 64.9 
16 H19 AJ566210 8767 1502 67.8 
17 H19 AJ566210 8767 1939 67.2 
18 H19 AJ566210 8767 628 69.4 
19 GH X12546.1 2162 320 55.9 
20 GH Receptor Exon 1B S78252 1379 215 55.8 
21 Insulin Receptor ‡ 264 226 56.2 
22 NRC31 HM204706 4791 2984 65.6 
23 IGF1R Exon 3 EF669473 346 343 69.4 
24 IGF2R Intron 2 DMR AY182033 3048 2619 72.3 
‡  No accession number available - sequence published by McGrattan et al. (1998)  
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The IGF-1 gene has five exons. In the sheep there are two known variants of exon 1 (1W and 
1A), whilst exon 4 has not been shown to be expressed at all (Dickson et al. 1991). Accordingly 
ovine IGF-1 mRNA is comprised of exons 1,2,3 and 5, with alternative splicing of the first exon 
(1/1A/1W). The putative promoter site for IGF-1 is located proximal to exon 1 but is reportedly 
not GC-rich (Ohlsen et al. 1993) therefore unsurprisingly no conventional CpG island was found 
at this location in the ovine sequence. However three separate downstream CpG islands were 
identified preceding exons 2, 3 and 4, respectively. 
6.2.1.3    H19 
H19 is composed of five exons, separated by four very short intronic sequences. Unlike insulin, 
IGF-1 and IGF-2, there is little homology with the human gene with respect to its nucleotide 
sequence, with the exception of specific regions (particularly exon 1), although the overall size 
and structure of the gene is relatively well conserved (Lee et al. 2002). The H19 gene has a very 
high GC content, which is characteristic of imprinted genes. There is a differentially methylated 
region (DMR) upstream of the H19 gene that tends to be predominantly methylated in one of 
the two parental alleles (Young et al. 2003). Studies in parthenogenetic pregnancies suggest 
that H19 is paternally imprinted in the sheep (Feil et al. 1998; Hagemann et al. 1998) whilst, 
conversely, IGF-2 is maternally imprinted (McLaren & Montgomery 1999). Five different CpG 
islands of reasonable size were identified across the H19 gene, ranging from 620 to 1939 bases 
in length (see Table 6.1). 
6.2.1.4    Growth hormone 
The ovine GH gene contains five exons interspersed by four introns and shows 97.5% sequence 
homology with the bovine form (Orian et al. 1988). It has also been shown that sheep may be 
homozygous or heterozygous for two different alleles (GH1 and GH2) although the latter is 
more commonly seen in domesticated breeds (Ofir & Gootwine 1997). Here a single CpG island 
was identified within the GH gene, preceding and extending into exon 5.  
6.2.1.5    Growth hormone receptor 
The ovine growth hormone receptor gene is known to contain seven different alternatively 
spliced untranslated regions. Exon 1A is only expressed in liver and contains a developmentally 
regulated liver-specific promoter (P1) which lies upstream of the transcription initiation site 
(Adams et al. 1990). Exon 1B maps upstream of exon 1A and coding exon 2, which contains the 
translation initiation site. It is differentially expressed across a range of different tissues, 
predominates in skeletal muscle, and contains a putative second promoter, P2 (Adams 1995). 
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A single CpG island was identified within the ovine GHR gene, preceding and extending into the 
non-coding sequence of exon 1B. 
6.2.1.6    Insulin receptor 
For the insulin receptor gene, a relatively short partial ovine sequence that demonstrates 84% 
nucleotide homology with human exons 11, 12 and 13 (McGrattan et al. 1998) was examined 
and a single CpG island identified within the intronic region. This gene also features alternative 
splicing resulting in two different isoforms with differing specificity for insulin. 
6.2.1.7    Glucocorticoid receptor 
The glucocorticoid receptor is also known as the nuclear receptor subfamily 3, group C, 
member 1 (NRC31). An as-of-yet unpublished sequence listed in NCBI Nucleotide database 
(accession number HM204706.1) which spans both the promoter region and partial coding 
sequence was examined and a single large CpG island (2984bp) identified within the promoter.  
6.2.1.8    Insulin-like growth factor 1 receptor 
The human IGF1R gene contains a CG-rich promoter region that lacks conventional TATA and 
CCAAT elements. The transcription start site is approximately 1000 base pairs proximal to the 
translation start site (Sepp-Lorenzino 1998). The ovine IGF1R gene is highly homologous with 
that of other mammalian species and three different allelic sequences have been characterised 
(Byun et al. 2008). Although the published ovine sequence is relatively short and lacks the long 
5' untranslated region of the human gene, nevertheless a single CpG island was identified that 
precedes and extends into exon 3. 
6.2.1.9    Insulin-like growth factor 2 receptor 
IGF2R, like H19 and IGF-2, is an imprinted gene that is known to contain an important CpG 
island located within the second intron, which is known as region 2 in the mouse (Wutz & 
Barlow 1998) and differentially methylated region (DMR) 2 in the sheep (Young et al. 2001; 
Young et al. 2003). The CpG island at this location was more GC rich than any of the islands 
identified within the other nine genes (72.3% - see Table 6.1), which is in keeping with its 
putative role as a key regulator of IGF2R gene expression via uniparental imprinting. 
6.2.2    Primer design 
In order to design primers for bisulphite-converted DNA, the genomic DNA sequences first 
needed to be modified to take into account the genome-wide degradation of unmethylated 
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cytosine to thymine that is anticipated following bisulphite treatment and PCR. To achieve this 
DNA sequences were first imported into Microsoft Word (Microsoft Corporation, Redmond, 
WA, USA). Using the "find and replace" function, all instances of "CG" in the sequence were 
converted to "X" in order to preserve these particular cytosines, which may or may not be 
methylated and therefore vulnerable to sodium bisulphite. Next all the remaining "C"s were 
converted to "T"s in line with the expected effects of sodium bisulphite on unmethylated 
cystosines. Finally "X"s were converted back into "CG"s and highlighted as regions of interest. 
Forward/reverse and sequencing primers, for the PCR and pyrosequencing steps, respectively, 
were designed within the modified DNA sequences using the PyroMark Assay Design software 
version 2.0.1.15 (Qiagen, Uppsala, Sweden) and are shown in Tables 6.2 and 6.3. Although PCR 
and pyrosequencing are completely separate reactions, the software designs all primers 
together as even a strong PCR product is redundant if no appropriate sequencing primer is 
able to bind to it during the subsequent step. Potential primer sets generated by the software 
were ranked according to a scoring system (maximum = 100) taking into account various 
factors including primer melting and annealing temperatures, risk of hairpin (or other 
secondary structure) formation and % GC. The ideal length of a PCR product for subsequent 
pyrosequencing is approximately 100 base pairs. Amplicon length is somewhat of a 
compromise. On the one hand, shorter amplicons are likely to contain fewer CpG sites for 
interrogation, limiting the amount of methylation information gained. On the other hand, 
longer amplicons are more likely to fail the pyrosequencing step. Wherever possible forward 
and reverse primers that did not include any CpG sites within their sequences were chosen to 
minimise the chance of any methylation-specific amplification bias.  
Primer sets were successfully designed for 21 out of 24 CpG island sequences. Design is more 
challenging when dealing with bisulphite-converted DNA as the majority of the genetic code is 
effectively simplified from four to three bases. This means that the risks of primers binding 
non-specifically to other parts of the genome as well as to the region of interest is increased. 
Nevertheless primer specificity can be checked at the sequencing stage to ensure an amplicon 
of the expected size has been produced. As the sense and anti-sense DNA strands are no 
longer complementary post sodium bisulphite conversion, primer sets for the remaining 3 of 
24 CpG islands were designed using the modified reverse DNA sequence as an alternative. 
6.2.3    DNA extraction 
DNA was extracted from snap-frozen liver samples obtained from necropsy of fetuses at ~131 
days gestation and lambs at ~83 days postnatal age (see Sections 4.2.5.2 and 5.2.6).
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Table 6.2 – PCR primers for 14 functioning assays interrogating CpG sites in 10 genes of interest 
Assay Target Primer Sequence 
1 Insulin Forward 5'-[Biotin]AGTTATGAAGATTTTTAAGGGGGTTTTAT-3' 
 
Reverse 5'-AAACCCTCCACCCCTAAATTAACCT-3' 
 
2 IGF-2 Exon 1 Forward 5'-[Biotin]ACCTTAATACAACCAAATCACC-3' 
 
Reverse 5'-ATAGGTATTTGTTTAGGTTATTAT-3' 
 
3 IGF-2 Exon 4 Forward 5'-TTTGGAATTTTTTAAGTTTTATATTGAGGA-3' 
 
Reverse 5'- [Biotin]ACCCAAACATATAAATCAACAAACTC-3' 
 
4 IGF-2 Exon 6 Forward 5'-GGGTTTTTAAATATTTTAGAATAGTGATT-3' 
 
Reverse 5'-[Biotin]AACTCCAACCAAAAAAAAACCAAACTTA-3' 
 
5 IGF-1 Exon 2 Forward 5'-GGGAGTGTGTGAAGAGTTGAAT-3' 
 
Reverse 5'-[Biotin]ACTAAAAAAAAAAATCCATCCAAAATCTAC-3' 
 
6 IGF-1 Exon 3 Forward 5'-TGAATGATAGTTTGTGGTTGGTAGTTA-3' 
 
Reverse 5'-[Biotin]AAAAAAAACTCCATCCAAAATCTACA-3' 
 
7 IGF-1 Exon 4 Forward 5'-GATATGTTTAAGGTTTAGAAGGTAAGTT-3' 
 
Reverse 5'-[Biotin]TACTACTAAATTACTACAACCACATAACTC-3' 
 
8 H19 Forward 5'-ATTAGTTTTGGAAGGTGTTGG-3' 
 
Reverse 5'-[Biotin]ATAAATCTTCCCTTCCTTTAAATCAACCT-3' 
 
9 GH Forward 5'-GGGAGGTTAGTTGAGTTTTTTAGTTGTTAG-3' 
 
Reverse 5'-[Biotin]TACCTAACCCCACCCCCTAA-3' 
 
10 IGF1R Forward 5'-GTGTTGGGAGGGTAGTTGG-3' 
 
Reverse 5'-[Biotin]CACCCCCAATACCTAAACAACTACAAC-3' 
 
11 IGF2R Forward 5'-AGAGTAGAAATTTTTTTTGGAGTGTT-3' 
 
Reverse 5'-[Biotin] AACACCTTACTCAAAACCTACCA-3' 
 
12 GHR Forward 5'-GTTTTGTTTTTTTTTTGGGAATAGG-3' 
 
Reverse 5'-[Biotin]CCTCCTAAAAAAAAATATTAATAATTACAA-3' 
 
13 NRC31 Forward 5'-GAGTTATATAAATGGTAGTATGTGT-3' 
 
Reverse 5'-[Biotin]CAACCCCCTTCCCAAACT-3' 
 
14 Insulin Receptor Forward 5'-GTTTTTTAGAAGGTTTGGGGATGAAAATT-3' 
 
 
Reverse 5'-[Biotin]-AACCCACTCTCAAATCCTCAAAAAACTAA-3' 
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Table 6.3 – Sequencing primers for 14 functioning assays covering CpG sites in genes of interest 
Assay Target PCR 
Primer 
Score 
PCR 
Product 
Size 
Sequencing Primer 
1 Insulin 66 132 5'-ACCCCTAAATTAACCTC-3' 
2 IGF-2 Exon 1 95 110 5'-ATAGGTATTTGTTTAGGTTATTAT-3' 
3 IGF-2 Exon 4 82 114 5'-AGTTTTATATTGAGGATTTTGT-3' 
4 IGF-2 Exon 6 65 154 5'-TTTTAGAATAGTGATTTTAGATGTT-3' 
5 IGF-1 Exon 2 80 145 5'-GTGTTGGTAGTTATTTTTAGTT-3' 
6 IGF-1 Exon 3 83 119 5'-AGTTTTAGAGATTTTTTATTTTAAT-3' 
7 IGF-1 Exon 4 93 100 5'-GGGGAGGAGGTGAGGG-3' 
8 H19 88 117 5'-TTGGAAGGTGTTGGT-3' 
9 GH 59 174 5'-TTGTTAGTTATTTGTTGTTATTTTT-3' 
10 IGF1R 70 110 5'-GGGAGGGTAGTTGGG-3' 
11 IGF2R 85 231 5'-AAAGGTGAGGTAGGA-3' 
12 GHR 76 80 5'-TTTTTTTTTGGGAATAGGG-3' 
13 NRC31 70 97 5'-AGTATGTGTAGTTTAAGGTAGG-3' 
14 Insulin Receptor 89 104 5'-GATGAAAATTAAGTTGTGTAGGTA-3' 
 
  
DNA was extracted using the using the DNEasy Blood & Tissue Kit (Qiagen). To start, 
approximately 25mg of liver tissue was thawed, cut into small pieces and placed into a 1.5ml 
centrifuge tube, to which was added 180µl tissue lysis buffer 1 and 20µl proteinase K. After 
mixing thoroughly tubes were incubated at 56°C in a heated block and intermittently vortexed 
until the tissue had been completely lysed. Next 200µl lysis buffer 2 and 200µl 100% ethanol 
were added and tubes were thoroughly mixed to produce a homogeneous solution. The 
mixture was transferred into a DNEasy Mini spin column (Qiagen), which was mounted in a 
2ml collection tube and centrifuged at 8000rpm (6000g) for 1 minute. The flow-through was 
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discarded and the spin column was refilled with 500µl wash buffer 1, remounted in a new 2ml 
collection tube and centrifuged at 8000rpm (6000g) for 1 minute. The flow-through was again 
discarded and the spin column refilled with 500µl wash buffer 2, remounted in a new 2ml 
collection tube and centrifuged at 14000rpm (20000g) for 3 minutes. Membranes were 
checked to ensure that they were dry to avoid any transfer of ethanol into subsequent steps. 
The spin column was then placed into a new 2ml collection tube and 200µl elution buffer was 
pipetted directly onto the membrane, incubated at room temperature for 1 minute and was 
centrifuged at 8000rpm (6000g) for 1 minute. In order to maximise the final DNA yield, the 
flow-through was then pipetted back onto the membrane and the last centrifuge step was 
repeated. The exact concentration of DNA in each sample was determined using a NanoDrop® 
ND-1000 spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE, USA). Samples 
were checked for any RNA contamination by capillary electrophoresis using an Agilent 2100 
Bioanalyser (Agilent Technologies) before being stored at -20°C pending bisulphite conversion. 
6.2.4    Control sample preparation 
In order to ensure the capability of the pyrosequencing assay (see below) to detect absent and 
complete methylation in the genes of interest, it was necessary to generate an unmethylated 
and fully methylated control DNA sample, respectively. Additional hepatic DNA was extracted 
for this purpose from a single normally grown fetus of one of the control-intake ewes in the 
late gestation study (Chapter 4). Both control samples were subsequently bisulphite converted 
alongside all of the test samples and run concurrently on the same PCR/pyrosequencing plates. 
To generate the unmethylated control, genome wide amplification (GWA) was performed on 
the template DNA using the GenomiPhi™ DNA Amplification Kit (GE Healthcare, Little Chalfont, 
Buckinghamshire). During PCR, new DNA synthesised by DNA polymerase does not contain any 
methylated cytosine residues as it is the antisense strand that is read when the new cystosine 
is produced. Therefore regardless of whether the original cytosine happened to be methylated 
or unmethylated it is actually the complementary guanine that is read by the DNA polymerase, 
in response to which a new (unmethylated) cytosine residue is laid down. When a nested GWA 
approach is used, eventually after numerous PCR cycles the proportion of original DNA (and 
any methylation therein) becomes negligible. To further refine the approach, an adaptation of 
the GWA methodology (utilising DNA polymerase derived from the bacteriophage φ29) was 
introduced, as previously described by Umetani et al. (2005). The reason for this modification 
is that conventional GWA using thermal cycling is associated with unequal amplification of 
certain parts of the genome such that CG rich areas such as CpG islands, which are obviously 
very important regions for DNA methylation studies, are not efficiently amplified (McDowell et 
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al. 1998). By contrast, continuous amplification method using φ29 DNA transferase at a 
constant temperature (30°C) results in more homogeneous amplification and greater accuracy.  
To generate the fully methylated control, the template DNA was treated with the enzyme CpG 
methylase, M.SssI (EC.2.1.1.37, Zymo Research Corporation), which acts to rapidly, completely 
and reproducibly methylate all the cytosine residues in double-stranded DNA, including those 
within the CpG dinucleotides (Nur et al. 1985; Renbaum et al. 1990). M.SssI is a recombinant 
enzyme that is isolated from a strain of E.Coli that expresses the methyltransferase gene from 
Spiroplasma sp. strain MQ1. To prepare the control, 4µl of genomic DNA at a concentration of 
200ng/µl was added to 2µl of CpG reaction buffer, 1µl of 20X SAM (s-adenosylmethionine, 
12mM in a low pH buffer), 1µl of CpG methylase (at a concentration of 4 units/µl) and 12µl 
nuclease-free water (P1195, Promega UK Ltd, Southampton). The mixture was then incubated 
overnight at 30°C in a heated block to maximise completeness of the hypermethylation. An 
additional 1µl CpG methylase was added to the reaction two hours into the incubation period 
to further drive methylation to completion. 
6.2.5    Bisulphite conversion 
From each sample 400ng of genomic DNA was modified with sodium bisulphite (optimal range 
200-500ng) using the EZ DNA Methylation-Gold™ Kit (D5005, Zymo Research Corporation, 
Irvine, CA, USA). Based on the initial DNA concentration, each sample was individually diluted 
with nuclease-free water (Promega) in order to achieve a volume of 20µl at a concentration of 
20ng/µl in a PCR tube. To this was added 130µl of CT conversion reagent. Tubes were placed 
into a PTC-100 Thermocycler (MJ Research, Inc., Watertown, MA, USA) at 98°C for 10 minutes 
followed by 64°C for 2.5 hours. Thereafter tubes were incubated for 20 hours (overnight) at 
4°C. The next morning, each sample was transferred into 600µl binding buffer in a Zymo-Spin™ 
IC column, which was then capped and inverted repeatedly to mix. Spin columns were 
centrifuged at maximum speed (10000g) for 30 seconds and the flow-through was discarded. 
Next 100µl of wash buffer was added to each spin column and the centrifugation step was 
repeated. After discarding the flow-through, 200µl desulphonation buffer was added to each 
column, which were then incubated at room temperature for 20 minutes before being spun 
again at 10000g for 30 seconds. This was followed by two wash steps, wherein 200µl wash 
buffer was added and the centrifugation step was repeated each time. Finally the column was 
placed into a fresh 1.5ml microcentrifuge tube to which was added 10µl elution buffer. After 
centrifugation again at 10000g for 30 minutes, the resultant eluted DNA (flow-through) was 
stored at -20°C pending the PCR step. All samples for each study were bisulphite-converted in 
a single batch to avoid the introduction of any conversion bias. 
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6.2.6    Polymerase chain reaction 
PCR was performed on the bisulphite-converted DNA samples using the forward and reverse 
primers designed as detailed in Section 6.2.2 and synthesised by Metabion International AG 
(Martinsried, Germany). All other reagents were provided as part of the AmpliTaq Gold® DNA 
Polymerase, LD (low DNA) kit using a Hot Start, Strong Finish™ protocol (Applied Biosystems). 
The LD DNA polymerase is encoded by a modified form of the Thermus aquaticus polymerase 
gene and further purified in order to reduce bacterial DNA contamination from incorporation 
into an Escherichia coli host (Lawyer et al. 1989). The "hot start" technique features initiation 
of the amplification reaction at a temperature higher than that of optimal primer annealing in 
order to minimise unwanted priming and non-specific product formation (Chou et al. 1992). 
PCR reactions were set up in 96-well plates. All samples for each study were processed across 
a single plate, negating any inter-assay variation. In each well, 4µl of bisulphite-converted DNA 
at 5ng/µl concentration was added to 50µl PCR MasterMix, which was made up as follows to 
give a final concentration of magnesium chloride (MgCl2) of 2mM: 
 Nuclease free water (Promega UK Ltd)  30.8µl 
 GeneAmp 10X PCR Gold Buffer   5.0µl 
 25mM MgCl2 solution    4.0µl 
 Deoxyadenosine triphosphate (dATP)  1.0µl 
 Deoxycytidine triphosphate (dCTP)   1.0µl 
 Deoxyguanosine triphosphate (dGTP)  1.0µl 
 Deoxythymidine triphosphate (dTTP)  1.0µl 
 Forward primer     1.0µl 
 Reverse primer     1.0µl 
 AmpliTaq Gold® DNA polymerase LD (5 units/µl) 0.2µl 
Plates were processed through a PTC-225 Peltier Thermal Cycler (MJ Research). Samples were 
initially incubated at 95°C for 5 minutes, following which the following cycle was initiated and 
repeated a total of 45 times: 
 95°C for 15 seconds  
 57°C for 30 seconds  (annealing temperature) 
 72°C for 15 seconds 
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To finish, plates were incubated at 72°C for a further 5 minutes and then 4°C for 10 minutes. 
Subsequently the resultant PCR products were subjected to gel electrophoresis to check that 
an amplicon of the expected size had been generated by the assay. Of the 24 initially designed 
primer sets, 21 were tested at the PCR stage - the remaining three were not needed as others 
had worked well for the same gene. Of these 21 assays, 19 generated appropriate products,   
which were then taken forward to pyrosequencing. The reaction conditions were satisfactory 
for all these assays bar one, which was the insulin receptor. An incremental adjustment of 
MgCl2 concentration from 2mM to 3mM (by increasing the volume of MgCl2 in the MasterMix 
from 4.0µl to 6.0µl and reducing the volume of water from 30.8µl to 28.8µl) and a reduction in 
annealing temperature from 57°C to 54°C solved this problem and produced a working assay.  
6.2.7    Pyrosequencing 
Pyrosequencing was performed on PCR products from the above reaction, using sequencing 
primers designed as described in Section 6.2.2 and synthesised by Metabion International AG. 
To begin, 20μl of PCR product from each sample was added to 37μl Pyromark binding buffer 
(Ref. 979006, Qiagen) and 3μl streptavidin sepharose beads (Ref. 17-5113-01, GE Healthcare) 
in an Abgene-skirted 96-well plate (Ref. 732-4888, Merk Ltd, Feltham, Middlesex). A PCR plate 
seal was applied and the plate was continuously shaken on a high-speed microplate shaker 
(Illumina, San Diego, Ca, USA) at 1600rpm for 20 minutes to allow the biotinylated product to 
bind to the streptavidin, without allowing sedimentation to the bottom of the well resulting in 
inability to retrieve it. Subsequently a vacuum Prep workstation (Pyrosequencing®, Qiagen) 
was used to wash and denature the beads and transfer them to a new plate. The patency of all 
pins on the vacuum Prep tool was first checked by aspirating MilliQ water (Millipore, Billerica, 
MA, USA). Any pins with delayed aspiration rates were immediately replaced with new filter 
probes (Ref. 979010, Qiagen). Thereafter the plate was removed from the shaker and 
immediately transferred to the vacuum prep station. Water was aspirated for 10 seconds then 
the vacuum tool was held in the air and shaken lightly to ensure that all water had drained 
away. Thereafter samples were aspirated from the Abgene PCR plate. The tool was immersed 
in 70% ethanol (Ref. 104766P, Merk Ltd) for 5 seconds, and then transferred into 0.2M sodium 
hydroxide (Ref. 102524X, AnalaR NORMAPUR®, VWR) for 5 seconds to denature the DNA and 
to render it single-stranded in order to allow the sequencing primer to bind. Next it was 
immersed  in PyroMark wash buffer (Ref. 979008, Qiagen), leaving only the beads on the tips 
of the pins. The beads were then transferred into a PSQ low plate (Ref. 979002, Qiagen) 
containing 43.5μl annealing buffer and 1.5μl sequencing primer at 10μM (diluted in annealing 
buffer) and briefly agitated. The last three steps were repeated in order to increase the yield. 
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Plates were then incubated at 80°C for 2 minutes (PTC-225) to destroy the streptavidin beads 
and release the PCR product, and allowed to cool to room temperature before being placed 
into a PSQ 96MA pyrosequencer (Qiagen). PSQ 96MA software version 2.1 (Qiagen) was used 
to calculate the required amounts of the PyroMark Gold Q96 reagents (Ref. 972804, Qiagen). 
The substrate mix and enzyme mix were each resuspended in 620μl MilliQ water prior to being 
loaded into a PyroMark Q96 cartridge (Ref. 979004, Qiagen) together with the required 
volumes of dATP, dGTP, dTTP and dCTP. The pyrosequencing process itself is illustrated by the 
example pyrogram in Figure 6.4. First the enzyme mixture was added to each well containing 
PCR product (indicated by the letter E), shortly followed by substrate mixture (S). Thereafter 
the complementary dNTP for each nucleotide in the dispensation order (expected sequence) 
was added in turn until the reaction was completed. Pyro-Q-CpG software version 1.0.9 
(Biotage) was used to analyse the pyrograms in order to determine the percentage DNA 
methylation at each individual CpG site by measuring the ratio of the C/T peaks. Satisfactory 
pyrosequencing assays were established for 16 of the 19 acceptable PCR products. For the H19 
gene there was a choice of three different assays that had been developed within the same 
sequence (albeit in three different CpG islands) therefore the assay with the strongest PCR 
product was chosen to take forward for sample analysis. Consequently a total of 14 assays 
were run on each fetal and lamb DNA sample, covering a total of 10 genes of interest and 
providing a quantification of the degree of methylation at 57 individual CpG sites. The forward 
and reverse PCR primers and pyrosequencing primers for these 14 assays are detailed in Tables 
6.2 and 6.3, respectively. 
6.2.8    Data analysis 
Percentage DNA methylation was compared between groups at each individual CpG site and 
also as an average according to individual assays and genes of interest. Data was tested for 
normality and equality of variance using Q-Q plots and Levene's test, respectively. For the fetal 
study, the four groups were compared by one-way ANOVA. For the postnatal study, in view of 
anticipated gender differences, the General Linear Model was used in order to examine for the 
effect of prenatal Ad.VEGF treatment, gender and their potential interaction and therefore the 
results are presented as four groups (Ad.VEGF-M, Ad.VEGF-F, Saline-M and Saline-F). For both 
studies, DNA methylation was correlated with a number of relevant in vivo parameters using 
Pearson's product moment test. All data are presented as mean ± standard error of the mean 
(SEM) unless otherwise stated. Formal statistical significance was considered to have been 
reached where p<0.05 and a tendency towards significance was defined as p<0.1. 
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Figure 6.4 – Example pyrogram illustrating use of C/T ratios to quantify methylation status 
 
Abbreviations: E = enzyme mix; S = substrate mix; Y = CpG site; A = adenosine; T = thymine; C = 
cytosine; G = guanine. Example shown is IGF1R - the sequencing primer contains three CpG 
dinucleotides. In this animal these cytosines were 59%, 70% and 63% methylated, respectively. 
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6.3    Results  
Although results were obtained from all 14 assays that were developed, the DNA methylation 
information generated for NRC31 was very limited as there was zero detectable methylation at 
the majority of the 7 individual CpG sites investigated for most of the samples. In the instances 
where DNA methylation was quantified, the amount present was minimal for both cohorts. In 
the postnatal samples, which were analysed first, there was zero detectable methylation in 26 
(90%), 20 (69%), 22 (81%), 27 (93%), 29 (100%) and 29 (100%) of 29 animals at positions 1, 2, 
3, 5, 6 and 7 respectively. Consequently no meaningful comparisons between the study groups 
were possible at these loci. DNA methylation information at position 4 was obtained in 19 of 
29 animals (66%) and was minimal (mean ~2%). There were no significant differences between 
H+Ad.VEGF and H+Saline groups (2.14±0.34 versus 1.85±0.14, p=0.483) or male and female 
lambs (1.84±0.10 versus 2.22±0.43, p=0.295). In the fetal cohort there was no detectable DNA 
methylation in 52 (91%), 50 (88%), 54 (95%), 57 (100%), 46 (81%), 55 (96%) and 55 (96%) of 57 
animals at positions 1 to 7, respectively. Unfortunately no results were available from the fully 
methylated and unmethylated control samples for NRC31 (see below), which meant that it was 
not possible to say whether this lack of detectable methylation was due to a genuine absence 
of methylcytosine at these CpG sites, or whether this assay was lacking the required sensitivity. 
6.3.1    Overview 
Mean DNA methylation for each gene of interest is shown in Figure 6.5, presented separately 
for the fetal and postnatal studies. Due to the (probably technical) problems with NRC31 as 
discussed above, meaningful comparisons were only possible for the remaining nine genes of 
interest. Overall DNA methylation status varied greatly between different genes. The degree of 
methylation ranged from as low as 1.49±0.05% for the GH receptor gene up to 87.9±0.26% for 
the insulin gene. In general, mean levels of methylation were similar in magnitude across the 
two studies and were marginally higher (4–14%, p<0.001) in the lamb study relative to the 
fetal study. Interestingly however, IGF-2 and IGF1R both showed the opposite trend, with DNA 
methylation that was 41–45% lower in lambs versus fetuses (p<0.001). It should be noted that 
the two cohorts are not directly comparable as the hepatic DNA for each batch was bisulphite 
converted separately and also the fetal cohort included both control-intake and overnourished 
ewes whilst the postnatal cohort comprised overnourished ewes only. However as there were 
no significant differences between control-intake and high-intake pregnancies with respect to  
fetal DNA methylation (see Section 6.3.2) it did not seem unreasonable to make a tentative 
general  comparison, whilst keeping these issues in mind. 
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Figure 6.5 – Comparison of overall DNA methylation of nine genes between fetuses and lambs 
 
Mean DNA methylation was calculated by averaging the mean measurements at all individual 
CpG dinucleotides examined within each gene (ranging from 1 to 14). Abbreviations: IGF = 
insulin-like growth factor; GH = growth hormone; R = receptor.  
  
Figure 6.6 shows the degree of methylation in the fully methylated and unmethylated control 
DNA samples. Unfortunately results were only obtained for eight out of ten genes of interest. 
This is because the IGF2R and NRC31 assays required a considerable amount of optimisation 
and needed to be repeated several times, during which both control samples were used up. 
For the remaining eight genes a high degree of methylation was seen in the sample treated 
with M.SssI (81.6–95.1%) and was highest in the insulin gene, in keeping with the results from 
the analysed samples. Most strikingly, despite very low levels of methylation in the GHR gene 
across the cohort, there is clearly the potential for this gene to become heavily methylated, as 
indicated by the 94% methylation status of the GHR in the control sample treated with M.SssI. 
Conversely, treatment of hepatic DNA using a nested GWA resulted in low levels of detectable 
methylation for 7 of 8 genes (0.1–9.3%) with the notable exception of the insulin gene (39.7%). 
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Figure 6.6 – DNA methylation profiles of eight genes in fully methylated/unmethylated controls 
 
Mean DNA methylation was calculated by averaging the mean measurements at all individual 
CpG dinucleotides examined within each gene (ranging from 1 to 14). Abbreviations: IGF = 
insulin-like growth factor; GH = growth hormone; R = receptor. Control samples were derived 
from a single normally growth fetus whose mother was fed a control intake during pregnancy. 
The fully methylated control was prepared by treatment with the methylating enzyme M.SssI. 
The unmethylated control sample was prepared using a nested genome wide amplification kit.  
  
6.3.2    Fetal study 
Table 6.4 presents the DNA methylation at each individual CpG dinucleotide across nine genes 
of interest in the 57 fetal samples taken from the late gestation study (Chapter 4). There were 
no significant differences between the four study groups at any of the 50 loci. Similarly when 
these were averaged by sequence and by gene, there were no differences between C+Saline, 
H+Ad.VEGF, H+Ad.LacZ or H+Saline groups (Table 6.5). Furthermore there were no significant
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Table 6.4 – DNA methylation at 50 individual CpG sites in nine genes in late gestation fetal liver 
 
 
Gene / CpG Position 
C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P 
Value 
1 Insulin Position 1 72.5 ± 1.63 73.9 ± 1.38 73.3 ± 1.46 71.1 ± 1.40 0.579 
2 Insulin Position 2 84.4 ± 1.50 85.8 ± 1.32 85.1 ± 1.41 84.9 ± 1.22 0.892 
3 Insulin Position 3 80.7 ± 1.22 79.2 ± 4.00 82.2 ± 1.17 83.2 ± 1.09 0.727 
4 Insulin Position 4 86.4 ± 1.36 88.3 ± 1.13 87.4 ± 1.35 87.2 ± 1.07 0.755 
5 Insulin Position 5 84.3 ± 1.47 85.6 ±1.21 85.3 ± 1.64 84.8 ± 1.00 0.910 
6 IGF-2 Exon 1 Position 1 69.5 ± 2.21 71.0 ± 1.77 69.8 ± 2.13 68.7 ± 1.52 0.853 
7 IGF-2 Exon 1 Position 2 71.5 ± 1.54 72.7 ± 1.36 72.6 ± 1.50 71.3 ± 1.34 0.857 
8 IGF-2 Exon 1 Position 3 58.4 ± 2.09 60.0 ± 1.69 57.3 ± 1.39 60.7 ± 1.45 0.485 
9 IGF-2 Exon 4 Position 1 17.2 ± 1.12 16.6 ± 1.16 17.8 ± 0.99 16.8 ± 1.62 0.911 
10 IGF-2 Exon 4 Position 2 28.8 ± 0.94 27.7 ± 0.85 28.4 ± 0.74 27.2 ± 1.44 0.704 
11 IGF-2 Exon 6 Position 1 2.83 ± 0.22 2.46 ± 0.13 2.43 ± 0.92 2.87 ± 0.24 0.802 
12 IGF-2 Exon 6 Position 2 3.72 ± 0.24 3.28 ± 0.27 3.08 ± 0.12 3.73 ± 0.20 0.297 
13 IGF-1 Exon 2 Position 1 83.8 ± 1.90 85.0 ± 1.50 86.6 ± 1.82 85.0 ± 1.46 0.728 
14 IGF-1 Exon 2 Position 2 8.8 ± 0.55 8.0 ± 0.40 9.7 ± 0.75 8.6 ± 0.66 0.199 
15 IGF-1 Exon 2 Position 3 83.3 ± 1.40 84.9 ± 1.35 84.5 ± 1.99 84.0 ± 1.60 0.912 
16 IGF-1 Exon 2 Position 4 85.1 ± 1.62 85.9 ± 1.27 86.4 ± 1.76 85.5 ± 1.19 0.938 
17 IGF-1 Exon 2 Position 5 85.3 ± 1.62 86.3 ± 1.30 84.4 ± 1.65 84.9 ± 1.55 0.792 
18 IGF-1 Exon 2 Position 6 78.1 ± 1.47 78.9 ± 1.26 78.8 ± 2.17 79.7 ± 2.30 0.949 
19 IGF-1 Exon 3 Position 1 78.1 ± 1.72 80.5 ± 1.42 78.7 ± 1.73 79.7 ± 1.90 0.847 
20 IGF-1 Exon 3 Position 2 81.6 ± 1.73 82.7 ± 1.48 80.6 ± 1.62 82.2 ± 1.79  0.816 
21 IGF-1 Exon 3 Position 3 80.1 ± 1.94 82.2 ± 1.45 79.8 ± 1.57 81.2 ± 1.90 0.707 
22 IGF-1 Exon 3 Position 4 79.0 ± 1.95 80.4 ± 1.47 77.9 ± 1.67 78.9 ± 2.08 0.776 
23 IGF-1 Exon 4 Position 1 89.1 ± 1.51 91.0 ± 1.21 91.1 ± 1.45 88.4 ± 1.79 0.476 
24 IGF-1 Exon 4 Position 2 89.0 ± 1.39 91.0 ± 1.19 91.6 ± 1.36 88.7 ± 1.47 0.373 
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25 IGF-1 Exon 4 Position 3 75.4 ± 1.76 76.8 ± 1.37 77.2 ± 1.20 74.9 ± 1.34 0.623 
26 H19 Position 1 36.6 ± 0.99 36.9 ± 1.04 35.4 ± 0.92 35.3 ± 1.14 0.567 
27 H19 Position 2 39.4 ± 0.85 38.7 ± 0.89 37.8 ± 0.70 37.4 ± 0.78 0.385 
28 H19 Position 3 35.9 ± 0.98 35.5 ± 1.17 35.1 ± 0.76 35.2 ± 0.87 0.951 
29 H19 Position 4 28.1 ± 0.88 28.2 ± 1.05 26.8 ± 0.87 26.8 ± 1.00 0.615 
30 H19 Position 5 34.8 ± 1.14 34.7 ± 1.18 34.5 ± 0.97 33.9 ± 1.28 0.960 
31 H19 Position 6 42.0 ± 1.88 40.7 ± 1.11 38.4 ± 1.65 39.4 ± 1.24 0.360 
32 GH Position 1 53.8 ± 2.21 57.2 ± 2.38 54.8 ± 2.40 53.1 ± 2.07 0.593 
33 GH Position 2 59.2 ± 1.45 59.7 ± 1.27 59.1 ± 1.20 58.4 ± 1.28 0.899 
34 GH Receptor Position 1 1.64 ± 0.08 1.47 ± 0.09 1.52 ±0.13 1.37 ± 0.11 0.435 
35 Insulin Receptor Position 1 69.5 ± 1.12 69.5 ± 1.25 70.7 ± 1.13 68.0 ± 1.25 0.548 
36 Insulin Receptor Position 2 75.3 ± 1.37 74.9 ± 1.16 74.9 ± 0.95 73.9 ± 1.50 0.896 
37 IGF1R Position 1 67.5 ± 1.58 66.4 ± 1.31 68.7 ± 1.17 67.4 ± 1.60 0.697 
38 IGF1R Position 2 78.6 ± 1.46 77.8 ± 1.26 79.3 ± 1.26 79.0 ± 1.28 0.854 
39 IGF1R Position 3 67.6 ± 1.77 67.0 ± 1.68 67.5 ± 1.21 66.6 ± 1.52 0.968 
40 IGF2R Position 1 49.2 ± 3.47 44.9 ± 1.33 45.3 ± 0.70 44.9 ± 0.75 0.294 
41 IGF2R Position 2 48.3 ± 0.71 45.0 ± 2.31 45.8 ± 0.63 45.3 ± 0.77 0.485 
42 IGF2R Position 3 41.6 ± 3.19 43.6 ± 1.21 43.4 ± 0.85 43.2 ± 0.89 0.844 
43 IGF2R Position 4 49.7 ± 0.70 48.9 ± 1.03 49.5 ± 0.80 46.7 ± 1.16 0.146 
44 IGF2R Position 5 39.4 ± 0.86 38.7 ± 0.64 40.2 ± 2.16 38.8 ± 2.16 0.900 
45 IGF2R Position 6 54.0 ± 2.03 51.5 ± 1.66 49.7 ± 1.97 46.3 ± 1.19 0.101 
46 IGF2R Position 7 41.4 ± 0.60 40.2 ± 1.66 43.2 ± 1.99 39.3 ± 1.36 0.348 
47 IGF2R Position 8 55.4 ± 2.17 56.6 ± 1.97 56.9 ± 3.60 52.3 ± 1.59 0.518 
48 IGF2R Position 9 21.0 ± 1.44 26.0 ± 2.79 22.6 ± 0.96 22.1 ± 1.62 0.319 
49 IGF2R Position 10 78.0 ± 3.63 72.6 ± 5.04 79.2 ± 4.20 73.4 ± 3.87 0.662 
50 IGF2R Position 11 48.6 ± 1.04 44.9 ± 2.72 45.1 ± 2.15 48.1 ± 4.21 0.751 
 
P values shown are for overall ANOVA. There were no significant differences between groups. 
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Table 6.5 – Mean DNA methylation in nine genes of interest in late gestation fetal liver tissue 
 C+Saline 
(n=12) 
H+Ad.VEGF 
(n=18) 
H+Saline 
(n=13) 
H+Ad.LacZ 
(n=14) 
P Value 
Insulin 81.6 ± 1.39 82.6 ± 1.61 82.7 ± 1.36 82.2 ± 0.93 0.963 
IGF-1 Exon 2 70.7 ± 1.32 71.5 ± 1.11 71.7 ± 1.52 71.3 ± 1.19 0.959 
IGF-1 Exon 3 79.9 ± 1.81 81.5 ± 1.44 79.2 ± 1.62 80.5 ± 1.90 0.795 
IGF-1 Exon 4 84.5 ± 1.34 86.3 ± 1.14 86.7 ± 1.18 84.0 ± 1.46 0.398 
IGF-1 78.4 ± 1.46 79.7 ± 1.21 79.2 ± 1.36 79.6 ± 1.47 0.784 
IGF-2 Exon 1 66.5 ± 1.81 67.9 ± 1.51 66.6 ± 1.39 66.9 ± 1.31 0.894 
IGF-2 Exon 4 23.0 ± 0.99 22.1 ± 0.95 23.1 ± 0.79 22.0 ± 1.61 0.849 
IGF-2 Exon 6 3.21 ± 0.21 2.84 ± 0.22 3.69 ± 0.77 3.34 ± 0.20 0.200 
IGF-2 31.0 ± 0.57 31.0 ± 0.45 31.3 ± 0.34 31.3 ± 0.48 0.909 
H19 36.1 ± 0.99 35.8 ± 0.99 34.7 ± 0.79 34.7 ± 1.03 0.630 
GH 56.5 ± 1.39 58.4 ± 1.66 57.0 ± 1.57 55.7 ± 1.34 0.624 
GHR 1.64 ± 0.08 1.47 ± 0.09 1.52 ±0.13 1.37 ± 0.11 0.435 
Insulin Receptor 72.4 ± 1.20 72.2 ± 1.15 72.8 ± 0.96 71.0 ± 1.36 0.763 
IGF1R 71.7 ± 1.46 71.0 ± 1.26 72.4 ± 1.18 71.3 ± 1.31 0.873 
IGF2R 47.9 ± 0.57 46.4 ± 1.04 47.1 ± 0.84 45.3 ±0.74 0.248 
 
  
differences when comparing control-intake versus high-intake, or marked FGR versus non-FGR 
pregnancies. Combining the H+Ad.LacZ and H+Saline groups, as had been done previously (see 
Chapter 4), also had no significant impact on the results. There were no gender differences in 
DNA methylation of eight of nine genes with the single exception of IGF2R, which was higher in 
female compared with male lambs (47.5±0.56 versus 45.4±0.69, respectively, p=0.018). When 
examining the individual CpG sites, % DNA methylation was found to be higher at position 8 
(p=0.039) and tended to be greater at positions 1, 2 and 9 too (p=0.058, p=0.079 and p=0.086). 
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There were no significant correlations between the degree of DNA methylation of these nine 
genes of interest and in vivo parameters such as fetoplacental weights, ultrasonographic fetal 
growth velocity (delta AC and RV), post-mortem physical measurements and internal organ 
weights. Neither insulin nor IGF-1 gene DNA methylation levels correlated with their respective 
determinations in plasma. There were however a number of significant correlations between 
the methylation status of different genes. Irrespective of fetal gender, insulin was correlated 
with IGF-1, H19 and GH (r=0.676–0.929, n=57, p<0.001–0.016), IGF-1 was correlated with H19 
and GH (r=0.589–0.769, n=57, p<0.001–0.003) and H19 with GH (r=0.719, n=57, p<0.008). The 
strength of these correlations were very similar when only control- or high-intake pregnancies 
were included, further implying a lack of any effect of prenatal nutrition. Interestingly neither 
IGF-1 or IGF-2 correlated with either one of their receptors (IGF1R and IGF2R) and GH did not 
correlate with GHR. Meanwhile insulin correlated with its receptor only in the overnourished 
pregnancies (r=0.373, n=45, p=0.014). 
6.3.3    Lamb study 
Mean DNA methylation at 50 individual CpG dinucleotides across nine genes of interest in 31 
lambs surviving at the conclusion of the postnatal study (see Chapter 5) is shown in Table 6.6. 
In keeping with the findings in the fetal cohort (see above), no significant effect of Ad.VEGF on 
DNA methylation was observed at any of these sites. However some gender differences and 
gender X treatment interactions were apparent at this postnatal stage. DNA methylation was 
lower in females versus males at two different CpG sites within the insulin gene. By contrast, 
methylation was greater in females versus males at two CpG dinucleotides preceding IGF-1 
exons 2 and 3, and tended also to be increased at a single position before exon 4. Accordingly 
overall insulin gene methylation was lower (p=0.007) and IGF-1 tended to be higher (p=0.053) 
in female relative to male lambs (see Table 6.7). DNA methylation also tended to be higher in 
female versus male lambs at isolated CpG sites in IGF-2 and GH, but no significant gender 
differences were seen in the average methylation of these genes. Whilst there were some 
minor interactions between gender and treatment group (one significant at p=0.04 and two 
with p=0.05-0.01), notably in all cases it was the saline- and not Ad.VEGF-treated females that 
were the outlying group and no such interactions were evident in the averages by gene.  
6.3.4    Gender effects 
In order to further examine the impact of gender on DNA methylation, additional data was 
incorporated from an additional six lambs from the term/postnatal cohort who had been 
surplus to requirements for the main study, but who had been managed identically both pre- 
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Table 6.6 – DNA methylation at 50 individual CpG sites in nine genes of interest in postnatal lamb liver tissue 
 Gene / CpG Position Saline-F 
(n=8) 
Ad.VEGF-F  
(n=8) 
Saline-M 
(n=7) 
Ad.VEGF-M  
(n=8) 
P Values 
Treatment Gender Interaction 
1 Insulin Position 1 80.1 ± 0.99 78.9 ± 1.80 82.5 ± 0.50 81.2 ± 0.68 0.453 0.145 0.844 
2 Insulin Position 2 90.7 ± 0.44 91.5 ± 0.21 92.1 ± 0.29 92.1 ± 0.31 0.313 0.015 0.238 
3 Insulin Position 3 83.5 ± 1.45 85.0 ± 0.46 86.5 ± 0.77 86.3 ± 0.55 0.128 0.003 0.090 
4 Insulin Position 4 92.1 ± 2.22 91.7 ± 1.27 93.0 ± 1.29 92.2 ± 0.67 0.646 0.853 0.920 
5 Insulin Position 5 90.2 ± 0.49 86.9 ± 2.56 90.6 ± 0.55 90.5 ± 0.70 0.327 0.518 0.353 
6 IGF-2 Exon 1 Position 1 34.2 ± 1.00 32.6 ± 1.06 31.2 ± 0.83 31.6 ± 0.77 0.368 0.058 0.173 
7 IGF-2 Exon 1 Position 2 39.1 ± 1.23 36.9 ± 1.18 36.4 ± 0.80 36.9 ± 0.78 0.155 0.053 0.066 
8 IGF-2 Exon 1 Position 3 25.1 ± 1.73 25.6 ± 1.52 27.4 ± 0.94 25.5 ± 2.17 0.549 0.520 0.618 
9 IGF-2 Exon 4 Position 1 21.3 ± 1.60 19.0 ± 1.13 19.7 ± 1.09 19.1 ± 0.61 0.124 0.433 0.319 
10 IGF-2 Exon 4 Position 2 37.5 ± 2.25 35.0 ± 1.47 35.4 ± 2.19 34.7 ± 0.89 0.353 0.762 0.579 
11 IGF-2 Exon 6 Position 1 4.73 ± 0.26 5.15 ± 0.47 4.96 ± 0.80 4.01 ± 0.29 0.704 0.719 0.182 
12 IGF-2 Exon 6 Position 2 3.89 ± 0.44 5.47 ± 0.69 4.47 ± 0.10 4.11 ± 0.45 0.375 0.569 0.166 
13 IGF-1 Exon 2 Position 1 89.2 ± 1.31 88.6 ± 0.99 86.3 ± 1.05 85.5 ± 1.01 0.603 0.041 0.800 
14 IGF-1 Exon 2 Position 2 4.08 ± 0.82 4.86 ± 0.29 4.74 ± 0.13 4.57 ± 0.33 0.374 0.708 0.205 
15 IGF-1 Exon 2 Position 3 87.5 ± 0.73 88.4 ± 0.30 87.7 ± 0.48 88.3 ± 0.31 0.145 0.913 0.870 
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16 IGF-1 Exon 2 Position 4 91.9 ± 0.82 91.9 ± 0.40 92.3 ± 0.38 92.4 ± 0.41 0.785 0.403 0.862 
17 IGF-1 Exon 2 Position 5 89.7 ± 0.74 90.5 ± 0.59 90.7 ± 0.45 89.8 ± 0.67 0.922 0.901 0.151 
18 IGF-1 Exon 2 Position 6 81.1 ± 0.48 81.9 ± 0.53 81.6 ± 0.78 80.5 ± 0.47 0.656 0.541 0.199 
19 IGF-1 Exon 3 Position 1 87.1 ± 0.55 87.6 ± 0.36 86.2 ± 0.45 86.4 ± 0.23 0.369 0.046 0.698 
20 IGF-1 Exon 3 Position 2 89.8 ± 0.68 89.7 ± 0.24 89.9 ± 0.42 89.6 ± 0.44 0.799 0.734 0.715 
21 IGF-1 Exon 3 Position 3 89.1 ± 0.56 89.7 ± 0.25 88.8 ± 0.71 88.6 ± 0.56 0.830 0.420 0.540 
22 IGF-1 Exon 3 Position 4 85.0 ± 0.34 85.5 ± 0.52 83.9 ± 0.71 84.6 ±0.35 0.242 0.169 0.979 
23 IGF-1 Exon 4 Position 1 95.9 ± 1.42 96.8 ± 0.77 97.0 ± 1.16 96.6 ± 0.82 0.792 0.078 0.850 
24 IGF-1 Exon 4 Position 2 99.9 ± 0.09 99.4 ± 0.34 100 ± 0.02 99.0 ± 0.72 0.155 0.942 0.540 
25 IGF-1 Exon 4 Position 3 82.7 ± 3.54 79.8 ± 0.88 80.0 ± 0.79 79.0 ± 0.73 0.236 0.544 0.515 
26 H19 Position 1 37.6 ± 1.38 38.1 ± 0.51 38.3 ± 0.94 37.5 ± 0.76 0.932 0.990 0.466 
27 H19 Position 2 41.8 ± 1.16 41.1 ± 0.76 42.4 ± 0.61 41.6 ± 1.07 0.419 0.799 0.998 
28 H19 Position 3 42.4 ± 1.00 42.2 ± 0.61 42.9 ± 0.71 42.0 ± 0.96 0.403 0.659 0.807 
29 H19 Position 4 31.0 ± 2.22 30.1 ± 0.56 30.9 ± 0.89 28.6 ± 1.30 0.288 0.828 0.561 
30 H19 Position 5 42.5 ± 2.14 42.9 ± 0.59 40.6 ± 0.90 41.1 ± 0.72 0.777 0.274 0.933 
31 H19 Position 6 45.9 ± 1.51 46.4 ± 0.60 46.3 ± 0.81 45.4 ± 0.78 0.710 0.750 0.560 
32 GH Position 1 71.9 ± 5.69 59.3 ± 3.77 67.2 ± 4.93 66.7 ± 3.55 0.149 0.768 0.186 
33 GH Position 2 60.8 ± 1.10 62.1 ± 0.84 59.6 ± 0.72 59.6 ± 1.05 0.508 0.067 0.496 
34 GH Receptor Position 1 2.53 ± 0.42 2.28 ± 0.21 2.45 ± 0.29 3.41 ± 0.81 0.450 0.271 0.211 
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35 Insulin Receptor Position 1 75.6 ± 1.93 76.0 ± 1.20 76.8 ± 1.12 75.8 ± 0.81 0.453 0.283 0.925 
36 Insulin Receptor Position 2 83.6 ± 0.77 81.9 ± 0.76 81.5 ± 0.57 81.5 ± 0.41 0.164 0.147 0.153 
37 IGF1R Position 1 36.7 ± 1.99 34.5 ± 0.99 36.4 ± 1.28 36.3 ± 0.65 0.258 0.723 0.288 
38 IGF1R Position 2 49.6 ± 2.43 46.6 ± 1.06 48.4 ± 1.52 48.6 ± 1.05 0.245 0.806 0.219 
39 IGF1R Position 3 51.4 ± 7.88 40.4 ± 0.92 41.3 ± 1.40 42.3 ± 1.21 0.152 0.156 0.040 
40 IGF2R Position 1 50.9 ± 0.74 49.1 ± 1.19 49.2 ± 1.39 49.7 ± 1.15 0.793 0.613 0.485 
41 IGF2R Position 2 49.3 ± 1.97 48.1 ± 1.47 46.1 ± 1.24 46.2 ± 0.96 0.793 0.203 0.738 
42 IGF2R Position 3 45.4 ± 0.87 45.0 ± 1.21 45.0 ± 1.10 44.6 ± 0.92 0.814 0.861 0.898 
43 IGF2R Position 4 47.8 ± 1.67 47.2 ± 1.63 47.1 ± 1.63 47.7 ± 1.13 0.954 0.947 0.775 
44 IGF2R Position 5 42.1 ± 1.17 42.1 ± 0.79 43.5 ± 1.38 42.6 ± 0.87 0.756 0.665 0.602 
45 IGF2R Position 6 51.8 ± 1.78 50.3 ± 1.59 49.4 ± 1.81 50.5 ± 0.60 0.939 0.587 0.522 
46 IGF2R Position 7 45.4 ± 1.30 44.6 ± 1.11 43.5 ± 2.20 43.0 ± 1.02 0.924 0.308 0.823 
47 IGF2R Position 8 52.8 ± 1.63 47.4 ± 3.78 52.3 ± 1.49 50.6 ± 0.71 0.258 0.627 0.601 
48 IGF2R Position 9 38.2 ± 1.15 37.9 ± 1.10 36.7 ± 1.93 36.0 ± 2.29 0.957 0.562 0.751 
49 IGF2R Position 10 64.8 ± 3.46 64.7 ± 1.87 65.3 ± 2.44 65.8 ± 2.19 0.973 0.940 0.880 
50 IGF2R Position 11 49.0 ± 1.66 48.6 ± 1.32 46.5 ± 2.81 45.0 ± 1.07 0.810 0.228 0.614 
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Table 6.7 – Mean DNA methylation in nine genes of interest in postnatal lamb liver 
Gene / CpG Position Saline-F 
(n=8) 
Ad.VEGF-F  
(n=8) 
Saline-M 
(n=7) 
Ad.VEGF-M  
(n=8) 
P Values 
Treatment Gender Interaction 
Insulin  87.3 ± 0.84 86.8 ± 0.65 88.9 ± 0.26 88.5 ± 0.36 0.526 0.007 0.868 
IGF-1 Exon 2  73.9 ± 0.26 74.3 ± 0.24 73.9 ± 0.30 73.5 ± 0.21 0.780 0.261 0.870 
IGF-1 Exon 3  87.8 ± 0.47 88.1 ± 0.21 87.2 ± 0.46 87.3 ± 0.30 0.501 0.181 0.659 
IGF-1 Exon 4  92.8 ± 1.35 92.0 ± 0.13 92.3 ± 0.45 91.5 ± 0.29 0.118 0.270 0.731 
IGF-1  84.8 ± 0.51 84.8 ± 0.14 84.5 ± 0.30 84.1 ± 0.15 0.443 0.053 0.639 
IGF-2 Exon 1  32.8 ± 1.20 31.7 ± 1.01 31.7 ± 0.75 31.3 ± 1.12  0.293 0.254 0.472 
IGF-2 Exon 4  29.4 ± 1.71 27.0 ± 1.28 27.6 ± 1.58 26.9 ± 0.59 0.211 0.633 0.436 
IGF-2 Exon 6 4.44 ± 0.33 5.55 ± 0.56 5.06 ± 0.77 4.01 ± 0.27  0.819 0.722 0.460 
IGF-2  22.0 ± 1.05 21.5 ± 0.65 21.2 ± 0.67 20.7 ± 0.56   0.406 0.366 0.835 
H19  40.2 ± 1.41 40.1 ± 0.48 40.2 ± 0.48 39.4 ± 0.67 0.532 0.860 0.661 
GH  66.4 ± 3.29 60.7 ±1.91 63.4 ± 2.26 63.1 ± 1.72 0.257 0.817 0.310 
GHR 2.53 ± 0.42 2.28 ± 0.21 2.45 ± 0.29 3.41 ± 0.81 0.450 0.271 0.211 
Insulin Receptor  79.6 ± 1.28 79.0 ± 0.87 79.2 ± 0.61 78.6 ± 0.43 0.234 0.283 0.573 
IGF1R  43.4 ± 2.30 40.5 ± 0.96 42.0 ± 1.38 42.4 ± 0.94 0.202 0.544 0.132 
IGF2R  47.4 ± 0.47 48.8 ± 1.16 47.7 ± 0.78 48.8 ± 1.16 0.686 0.533 0.867 
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Figure 6.7 – Comparison of insulin and IGF-1 gene methylation between male and female lambs 
 
Mean DNA methylation was calculated by averaging the mean measurements at all individual 
CpG dinucleotides examined in the insulin and insulin-like growth factor (IGF)-1 genes (5 and 
14, respectively) in DNA extracted from liver samples collected at ~12 weeks of age. All lambs 
were born to overnourished adolescent mothers who had received bilateral uterine artery 
injections of Ad.VEGF (n=16), Saline (n=15) or not undergone surgery (n=6). There were no 
significant differences between these three groups and no gender X treatment interaction. 
Comparisons were made using the General Linear Model.  
  
and postnatally. Of the original 40 pregnant ewes in this cohort, only 33 had been randomised 
to Ad.VEGF or Saline groups. The remaining seven had been managed contemporaneously in 
exactly the same way as their operated counterparts up until delivery and the resultant lambs 
received all the same neonatal care measures and postnatal investigations. One of these seven 
was crushed by its mother, leaving six survivors (five male and one female) at 12 weeks of age. 
The lambs were necropsied and underwent liver sampling and DNA extraction with the others. 
Addition of these six lambs further strengthened the gender differences in DNA methylation of 
the insulin and IGF-1 genes, which are depicted in Figure 6.7. Differences were independent of 
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the study group (Ad.VEGF, Saline or unoperated). Insulin gene methylation correlated 
negatively with fasting plasma insulin levels measured prior to glucose challenge at ~7 weeks 
of age (r=-0.422, n=37, p=0.013), illustrated in Figure 6.8, but not with randomly timed insulin 
concentrations measured at weekly intervals between birth and necropsy (p>0.05) during 
which time lambs had free access to their mother's food hopper and were freely suckling. 
Similarly IGF-1 gene methylation did not correlate significantly with in vivo measurements of 
plasma IGF-1 at any stage (p>0.05).  
  
Figure 6.8 – Correlation between methylation of the insulin gene and fasting plasma insulin 
 
Scatterplot between mean insulin gene at 5 CpG dinucleotides examined in liver tissues at ~12 
weeks of age and DNA methylation and fasting plasma insulin measured by radioimmunoassay 
at ~7 weeks of age. All lambs were born to overnourished adolescent mothers who had 
received bilateral uterine artery injections of Ad.VEGF (n=16), Saline (n=15) or had not 
undergone surgery (n=6). Correlation was assessed using Pearson's product moment test. 
  
There were no consistent correlations between the methylation status of the genes examined 
and any other parameters in the postnatal study. However, interestingly GH gene methylation 
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was inversely related to lamb birth weight and necropsy weight in male lambs (r=-0.406, n=37, 
p=0.016; and r=-0.362, n=37, p=0.035, respectively) but not female lambs (p>0.05). Moreover 
the correlations observed between the methylation status of various genes (insulin, H19, GH 
and IGF-1) in the fetal cohort were not replicated in the postnatal study. The only consistent 
and significant correlation in this group was between IGF2 and IGF1R (r=0.476, n=37, p=0.004).  
6.4    Discussion  
6.4.1    Maternal Ad.VEGF therapy had no measurable effect on DNA methylation 
From the results detailed above, there was no evidence that Ad.VEGF impacts the epigenetic 
status of the ten genes studied here in relation to postnatal growth and metabolism. The 
original rationale for performing these studies was the observation of enhanced absolute 
postnatal growth rates (see Section 5.3.5.1) and increased glucose-stimulated insulin secretion 
at 7 weeks postnatal age (see Section 5.3.7.2) following prenatal Ad.VEGF treatment. Although 
methylation status of the GH and insulin genes correlated inversely with lamb body weight 
(males only) and fasting insulin, respectively, no significant differences were seen according to 
treatment group. The lack of any measurable epigenetic effect of prenatal maternal Ad.VEGF 
therapy is reassuring and suggests that no permanent alterations in somatotrophic gene 
function have occurred as a consequence of attempting to therapeutically manipulate fetal 
nutrient supply. Consequently, it seems more likely that the increased postnatal growth and 
insulin secretion observed in Ad.VEGF-treated lambs reflect their relative size advantage at 
birth rather than altered epigenetic status of key genes related to postnatal growth and 
metabolism. However this is a relatively tentative conclusion as it remains possible that 
changes outwith the 57 CpG sites studied could have been missed. The bisulphite sequencing 
methods used herein provide a very high resolution assessment of methylation at specific loci, 
but are limited by the fact that only a small number can be examined in any one reaction. 
Furthermore the specific sites are limited to those around which functional primer sets can be 
designed, which largely depends on the neighbouring genes sequences. It is interesting that 
two of the three genes that showed significant gender differences in DNA methylation (IGF-1 
and IGF2R) were the two genes with the greatest number of CpG dinucleotides assessed (13 
and 11, respectively). It is possible that potential differences may have been missed in some 
other genes simply because too few CpG sites were assessed and/or the available sequences 
were too short. More recently array-based technologies have been developed for the human 
and mouse that can simultaneously examine a vast number of CpG sites (up to 450,000) in a 
single assay (Sandoval et al. 2011). However no such commercial kits were available for the 
sheep at the time of conducting (or writing up) the experiments detailed in this thesis. A 
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further limitation is that, although accepted criteria were used to identify CpG islands within 
published ovine gene sequences, the true biological significance of DNA methylation at these 
specific sites has largely not been assessed. Most of the ovine genes investigated herein were 
originally sequenced with the aim of examining their exonic arrangement rather than focusing 
on the 5' untranslated regions (i.e. the proximal introns) where the majority of CpG islands are 
known to lie (Kass et al. 1997). The methylation assays developed herein are novel and 
therefore direct comparisons with previous studies in the sheep is difficult. For example, 
Sinclair et al. (2007) reported alterations in DNA methylation following manipulation of dietary 
vitamin B and methionine content at 4% of 1400 loci in a gender-specific manner using 
restriction landmark genome scanning, however the identity of these loci was not explicitly dd. 
Wang et al. (2011a) recently examined methylation of the differentially methylated regions of 
IGF-2/H19 and IGF2R in cardiac tissue using combined bisulphite restriction analysis (COBRA) 
but found no significant changes secondary to ovine FGR induced by carunclectomy. 
6.4.2    Fetal DNA methylation of growth related genes was not associated with FGR 
In addition to evaluating the potential epigenetic effects of Ad.VEGF, it was also possible here 
to make comparisons between the normal and growth-restricted fetuses of control-intake and 
untreated high-intake ewes (receiving Ad.LacZ or saline), respectively, at late gestation but not 
postnatal time points. There were no significant differences in the DNA methylation status of 
eight different genes. Unfortunately no information was available for NRC31 and IGF2R genes. 
There were also no differences between marked FGR (fetal weight >2SD below control mean) 
when compared to non-FGR high-intake or control-intake pregnancies in any genes evaluated.  
Albeit subject to the same limitations as discussed above, these findings suggest that the FGR 
induced by overnourishment of the adolescent ewe is not epigenetically mediated at the level 
of the fetal/neonatal tissues, although it remains possible that the epigenetic status of various 
placental genes may be altered by changes in the intrauterine environment (Lee & Ding 2012).  
In the human, genome-wide DNA methylation studies performed in monozygotic and dizygotic 
twins have highlighted the significant contribution that the intrauterine environment makes to 
the neonatal epigenome (Gordon et al. 2012). DNA methylation at LINE-1 repetitive elements, 
which is a surrogate for genome-wide methylation, correlates with birth weight centiles (Fryer 
et al. 2011) and hypo- and hyper-methylation of H19 and IGF2R, respectively, is seen in human  
FGR (Turner et al. 2010). Initial studies on individuals prenatally exposed to the Dutch famine 
(see Section 1.1.3.8) found reduced DNA methylation in the DMR of region of the IGF-2 gene 
(Heijmans et al. 2008) and the INSIGF gene, and increased methylation of the IL10, LEP, ABCA1 
GNASAS and MEG3 genes (Tobi et al. 2009) only when the exposure occurred around the time 
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of conception and not in late gestation. The same group subsequently tested for differences at 
the same loci in adults born SGA following fetal growth restriction and found no differences in 
DNA methylation of IGF-2, GNASAS, INSIGF and LEP relative to appropriate-for-gestational-age 
controls (Tobi et al. 2011). The latter results suggest that not all long-term morbidity of FGR 
that is presumed to result from programming in utero is mediated by epigenetic mechanisms. 
Nevertheless there is a growing body of evidence from different rat models that FGR can result 
in altered DNA methylation patterns in various genes. For example, FGR secondary to dietary 
restriction in the rat is characterised by neonatal catch up growth resulting in adult obesity and 
impaired glucose tolerance that is associated with hypermethylation of the promoter regions 
of the peroxisome proliferator-activated receptor (PPAR)-γ coactivator 1α and the insulin 
receptor genes as well as hypomethylation of the promoter regions of the PPAR-α and 
glucocorticoid receptor genes in the liver (Lillycrop et al. 2008; Burdge et al. 2009; Zeng et al. 
2012). FGR secondary to bilateral uterine artery ligation in the rat results in hypermethylation 
of the IGF-1 gene (Fu et al. 2009) and gender-specific changes in hippocampal dual-specificity 
phosphatase 5 (DUSP5) methylation, which have been implicated in the impaired learning and 
memory seen following FGR (Ke et al. 2011). Genome-wide analysis in FGR rats suggests that 
methylation may be altered at up to 1400 different CpG sites in the pancreatic islet at 7 weeks 
of age (Thompson et al. 2010).  
It is a potential limitation of this study that only effects on DNA methylation were examined, as 
it is feasible that epigenetic changes may alternatively be mediated via histone modification or 
miRNAs. FGR secondary to bilateral uterine artery ligation in the rat has been shown to modify 
histones in the IGF-1 (Fu et al. 2009), PPAR-γ (Joss-Moore et al. 2010) and the glucocorticoid 
receptor (Ke et al. 2010) genes in the liver, lung and hippocampus, respectively. FGR due to 
protein restriction in the rat increases methylation and reduces acetylation of histone H3 in 
the promoter region of the hepatic cholesterol 7α-hydroxyulase gene, which has been 
implicated in the pathogenesis of the hypercholesterolaemia that is observed in the adult 
offspring in this model (Sohi et al. 2011). FGR secondary to maternal undernutrition in the rat 
increases histone acetylation in the promotor region of the endothelin-1 gene in pulmonary 
vascular endothelial cells in an effect which is believed to contribute to the increased risk of 
hypoxia-induced pulmonary arterial hypertension in adult life (Xu et al. 2013). Although 
research into miRNAs in FGR to date is lacking, levels of miR132 are altered in growth-
restricted rat pups after bilateral uterine artery ligation (Joss-Moore et al. 2011). 
A further limitation of the current work is that patterns of methylation were only examined in 
hepatic tissue. Liver was chosen for this study as most of the previous work on the epigenetic 
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impact of FGR had been performed using this tissue type, and because the liver is an important 
metabolic organ. However it is now becoming clearer that the epigenetic changes observed in 
one tissue cannot necessarily be extrapolated to others. Even within a given tissue, there may 
be major differences between different cell types. Umbilical cord blood is often used to study 
neonatal epigenetic changes in the human as it is relatively easy to obtain (Fryer et al. 2009) 
however there are major differences between its constituents, for example the epigenomes of 
lymphocytes and monocytes have distinctly different profiles (Miao et al. 2008). This is 
particularly important when considering studies on the epigenetic status of the placenta, 
which are prevalent (Nelissen et al. 2011). Placental mRNA expression of IGF-2 is reduced in 
placentae from FGR pregnancies and associated with a loss of imprinting at two differentially 
methylated regions in the IGF-2 gene (Koukoura et al. 2011b). There is also hypomethylation of 
the H19 promoter region associated with increased mRNA expression of H19, which is 
consistent with reduced IGF-2 transcription (Koukoura et al. 2011a). Genome-wide placental 
DNA methylation has revealed differential methylation patterns throughout the genome with 
a slight overall tendency towards hypomethylation (Lambertini et al. 2011) and it has been 
suggested that placental methylation might be used as a marker of the intrauterine 
environment (Banister et al. 2011). Placental epigenetics may also give clues about causation 
of FGR, for example aberrant methylation of TBX15 gene is implicated in the pathophysiology 
of uteroplacental insufficiency (Chelbi et al. 2011). However given the high degree of tissue 
specificity, the coexistence of similar changes in fetal or neonatal tissues cannot be assumed. 
6.4.3    Female fetuses had higher IGF2R gene methylation at 0.9 gestation 
Irrespective of study group, the level of DNA methylation in the IGF2R gene was found to be 
significantly greater in female relative to male fetuses when examined in the liver tissue at 131 
days gestation. IGF2R was the only gene to demonstrate any gender differences in the fetal 
cohort. There was no effect of FGR or prenatal Ad.VEGF gene therapy on IGF2R methylation. In 
the aforementioned study on individuals born following the Dutch famine, prenatal exposure 
had no effect on IGF2R methylation, however for the normal (unexposed) controls mean levels 
were 2.6% higher in males versus females in adult life (Tobi et al. 2009), which is the opposite 
pattern to that seen for these young lambs. Notably the epigenetic alterations in various other 
genes following periconceptual famine exposure were gender-specific, with effects on INSIGF 
and LEP restricted to men and GNASAS more pronounced in women. Other work in the human 
has shown that generally CpG sites show more methylation in males, with the exception of the 
DMRs of imprinted genes, in which DNA methylation appears to be more equal between sexes 
(El-Maarri et al. 2007). Unlike IGF1R, which mediates the mitogenic effects of IGF-1 and IGF-2, 
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IGF2R is a clearance receptor that antagonises IGF-2 action, and disruption of the IGF2R gene 
results in increased serum and tissue levels of IGF-2 and fetal overgrowth (Ludwig et al. 1996). 
Relative hypermethylation of the IGF2R gene in females might hypothetically be associated 
with reduced IGF2R gene expression and less IGF-2 clearance, however these potential effects 
have not been assessed here and no conclusions can be made regarding biological significance. 
6.4.4    Female lambs had lower insulin gene methylation at 12 weeks of age 
Irrespective of treatment group, female lambs were found to have less DNA methylation of the 
insulin gene compared with male lambs. Furthermore insulin gene methylation was negatively 
correlated with fasting plasma insulin levels, irrespective of gender. In spite of this however, 
there were no male versus female differences in fasting insulin levels, glucose-stimulated 
insulin secretion or any indices of insulin resistance (see Chapter 5) in this cohort, although 
glucose-stimulated insulin secretion has previously been shown to be lower in females 
compared with male lambs (p<0.003) at 7 weeks of age in the overnourished adolescent 
paradigm (Wallace et al. 2010b). In clinical studies, women have been shown to be less insulin 
resistant (Geer & Shen 2009) and to exhibit lower fasting insulin levels (Ferrara et al. 1995) 
compared with men. These latter changes would initially seem to be in the opposite direction 
to what would be expected from the insulin gene methylation differences seen here in the 
sheep. However the regulation of insulin gene transcription is highly complex (Melloul et al. 
2002) and cleavage of insulin from its precursor protein in vivo is dependent on other factors 
including post-translational modification and diet. It was also interesting that the insulin gene 
demonstrated the highest levels of DNA methylation of all the genes examined in the present 
study (up to ~95%) and that these levels could only be reduced to ~40% by GWA, a technique 
which rendered the methylation status of all other genes <10%. The biological significance of 
these observations is unclear but they imply a high degree of resistant CpG methylation at this 
location in the insulin gene in the sheep fetus and young lamb. Irrespective of gender, insulin 
gene methylation correlated inversely with fasting insulin. This relationship is in the expected 
direction as higher degrees of DNA methylation would hypothetically be associated with less 
transcription and translation of the precursor protein preproinsulin. Insulin gene methylation 
was positively correlated with GH methylation, which did not did not differ by treatment group 
or gender but was inversely related to birth weight and live weight at necropsy in male lambs 
only. Again this relationship is biologically plausible, as increased GH gene methylation would 
hypothetically result in attenuated GH gene expression, GH protein levels and somatic growth. 
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6.4.5    Female lambs had greater IGF-1 gene methylation at 12 weeks of age 
In contrast to the gender pattern for insulin gene methylation, DNA methylation of the IGF-1 
gene was significantly greater in females versus males. Although DNA methylation status did 
not correlate with in vivo plasma measurements of IGF-1, the latter was significantly higher in 
males compared with female lambs throughout the first 12 weeks of life (see Section 5.3.5.5). 
Consequently the relative IGF-1 hypomethylation observed in males is in keeping with the 
greater IGF-1 protein levels, presumably as a result of increased transcription. With respect to 
both IGF-1 and insulin gene DNA methylation, it is interesting that there were no detectable 
differences when examined in late gestation in the fetal study. Obviously the two cohorts are 
not directly comparable, however this does suggest that these epigenetic gender differences 
emerge sometime between 0.9 gestation and 12 weeks of postnatal age, and probably during 
neonatal life. It may be that the changes only become apparent once the gastrointestinal tract 
and appetite axis become fully functional in the early neonatal period. Hence these changes 
may not actually be programmed in utero but represent dissimilarities that emerge alongside 
other sex differences such as fasting metabolite levels and relative adiposity during postnatal 
growth and development. In support of this concept, there is evidence that epigenetic changes 
can occur and can be prevented during postnatal life, for example amelioration of neonatal 
catch-up group by dietary manipulation in rat pups born following prenatal growth restriction 
appears to prevent the changes in IGF-1 methylation that otherwise occur in the first few 
weeks (Tosh et al. 2010) and is associated with an improved metabolic profile (Lim et al. 2011).  
6.4.6    Methylation of IGF-2 and IGF1R was significantly lower in postnatal life 
It was interesting that IGF-2 and IGF1R methylation was 41% lower in postnatal versus fetal 
tissues, whereas the other six comparable genes were very similar and consistently slightly 
higher in their degree of DNA methylation. Functionally IGF-2 is an important mediator of 
constitutive fetal growth but is largely replaced by IGF-1 around the time of birth and into the 
neonatal period (Fowden 2003). Accordingly disruption of the IGF-2 gene causes FGR without 
influencing postnatal growth rates (DeChiara et al. 1990) whilst overexpression causes fetal 
macrosomia (Efstratiadis 1998). IGF-2 also plays a role in the regulation of placental growth 
(Fowden & Forhead 2009), a role which becomes redundant after birth. Consequently it might 
be expected that IGF-2 methylation would be higher (rather than lower) during the postnatal 
period in view of the significant reduction that occurs in IGF-2 mRNA and protein expression. 
Alternatively it might be that non-epigenetic mechanisms (for example transcription factors, 
post-translational modification or antagonists) are responsible for the relative decline in IGF-2 
levels that is observed approaching term (Mesiano et al. 1989). 
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6.5    Conclusions 
There were no differences in DNA methylation of the insulin, IGF-2, IGF-1, H19, GH, GHR, 
insulin receptor or IGF1R genes in either fetal or lamb hepatic tissues following prenatal 
treatment with Ad.VEGF. In addition there were no differences in the IGF2R and glucocorticoid 
receptor genes in the lambs. This suggests that the increased postnatal growth rates and 
glucose-stimulated insulin secretion observed in Ad.VEGF-treated lambs most likely reflected 
their relative size advantage birth rather than an epigenetic effect. IGF-2 and IGF1R 
methylation was noted to be lower in postnatal relative to fetal life. IGF-1 gene methylation 
was higher in female versus male lambs at the postnatal stage, in keeping with the lower 
plasma IGF-1 levels observed in females compared with males. By contrast, insulin gene 
methylation was lower in female relative to male lambs and, irrespective of gender, was 
weakly correlated with fasting plasma insulin levels. 
  
326 
 
Chapter 7                                                                                                               
General Discussion and Conclusions 
7.1 Discussion 
The main aims of the research reported in this thesis were to evaluate the efficacy, safety and 
mechanisms of action of prenatal maternal Ad.VEGF gene therapy in fetal growth restriction 
induced by overnourishment of adolescent ewes. The aims were largely achieved and the 
positive results generated are encouraging, lending support to the notion that prenatal 
maternal Ad.VEGF gene therapy might, in the future, become the first effective treatment for 
severe early-onset FGR. This research has also given rise to several additional programmes of 
work, some ongoing and some scheduled, and together these are supporting the move 
towards clinical translation.  
7.1.1    Effects of Ad.VEGF in ovine FGR 
The following sections briefly summarise and draw together the most important findings from 
the two individual studies of Ad.VEGF in ovine FGR, which are detailed in Chapters 4 and 5. 
7.1.1.1    Fetal growth and gestation length 
In accordance with the original hypothesis, this work has provided first proof of principle that 
maternal uterine artery Ad.VEGF can increase fetal growth in pregnancies complicated by FGR. 
In two separate studies, mid-gestation delivery of Ad.VEGF to the uterine arteries in putatively 
growth-restricted sheep pregnancies produced a significant increase in fetal growth velocity, 
as indicated by increased ultrasonographic fetal abdominal circumference (AC) ± renal volume 
(RV) measurements, relative to fetuses receiving inactive control treatments (Ad.LacZ or 
saline). The precision around the estimate of treatment effect was high, given that the AC shift 
post-Ad.VEGF over this four week period was virtually equal in both studies (93 versus 92mm) 
despite different maternal donor genetics and a mean differential of one day in the timing of 
administration. The additional AC growth observed in Ad.VEGF-treated fetuses indicated a 
~20% increase relative to the Ad.LacZ/saline comparator groups. In both studies these 
differences were significant at 3 and 4 weeks post-injection. The timing of these effects on 
fetal growth are entirely commensurate with the expected duration of adenoviral expression. 
It is important to note here that, with respect to clinical translation, it would not be necessary 
to completely normalise fetal growth. Rather the aim would be to moderately extend time 
spent safely in utero and to achieve a modest increase in weight prior to elective delivery 
because of fetal compromise. Consequently the fact that the effect appeared to tail off after 4 
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weeks is probably not important, given that the fetus would likely be delivered by this stage in 
the clinical situation. For example, hypothetically if we were to replicate these effects in 
treating a human fetus at the very threshold of viability, i.e. at 24 weeks gestation with an 
estimated weight of 500g, and to deliver at the peak of the effect (20% extra growth at 4 
weeks), this might correspond to an additional 100g and delivery at 28 weeks gestation, which 
would be a respectable achievement. It is likely that the indication for delivery, deterioration in 
fetal wellbeing, would be the same in treated fetuses as in untreated fetuses. Clearly this 
extrapolation makes a number of different assumptions, and is rather speculative, particularly 
as this ovine model constitutes a relatively mild and late onset form of FGR (discussed further 
in Section 7.1.1.4 below). Nevertheless the fact remains that very modest increases in fetal 
growth, enough to delay delivery even by a few days or weeks, can translate into major 
improvements in survival and morbidity at this stage of pregnancy (Costeloe et al. 2000). For 
example, in one case series of extremely low birth weight infants born at 26 weeks of 
gestation, one-year survival was 78% with a birth weight of 601-700g versus 51% at 501-600g 
(Morse et al. 2006). In another series of extremely preterm babies, survival free of moderate 
or severe disability at 6 years of age was nearly three times greater (24% vs. 9%) at 25 
compared to 24 weeks gestation (Marlow et al. 2005). As stated previously, gestational age at 
delivery is the single strongest predictor of neonatal outcome following FGR (Baschat et al. 
2007) and thus a therapy capable of producing even a modest improvement in fetal growth or 
time spent in utero could make a significant difference to perinatal outcome in severe FGR. 
Interestingly, in the delivery cohort there was a trend towards a natural increase in gestation 
length in the Ad.VEGF-treated pregnancies of approximately two days, although these lambs 
still delivered slightly prematurely, three days prior to full term. This might possibly have been 
secondary to the attenuation of the increased relative adrenal growth that is seen in the 
model, which theoretically might initiate labour prematurely via increased fetal cortisol 
secretion. However, in clinical cases of severe early-onset FGR it is unlikely that pregnancies 
would be allowed to continue until spontaneous delivery at term, as was the case for these 
sheep experiments.  
In both sheep studies, there was evidence of attenuated fetal brain sparing at post-mortem, in 
addition to the effects on ultrasonographic BPD:AC ratios, which were measured in the fetal 
study only. It is important to reiterate that growth of the fetal head in absolute terms was not 
altered, rather the abdominal (somatic) growth caught up with the preserved head growth. As 
discussed in detail in Section 4.4.2, this is likely to be a positive finding as it suggests that the 
need for the fetus to prioritise its brain growth has been reduced, implying a more favourable 
intrauterine environment and potentially enhanced fetal substrate supply. Although fetal brain 
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sparing is an adapative response (see Section 1.1.3.4), it is a marker of fetal hypoxia (Giussani 
et al. 2012) and appears to confer an increased risk of poorer neurodevelopemental outcomes 
in the longer term. Hence mitigation of the brain sparing effect is likely to be a positive feature. 
7.1.1.2    Fetal weight and birth weight 
Despite the positive effects of Ad.VEGF on ultrasonographic fetal growth velocity, when fetal 
weight at late gestation necropsy and birth weight at term were compared in absolute terms 
between treated and untreated groups, there was no significant difference and a tendency 
(p=0.081) towards a difference, respectively, in Ad.VEGF versus Ad.LacZ/saline-treated groups. 
However it must be borne in mind that in the sheep model of FGR that was used only ~52% of 
pregnancies are expected to demonstrate a marked degree of FGR (Wallace et al. 2004b). The 
proportion of markedly FGR pregnancies in the late gestation study was significantly reduced 
following Ad.VEGF treatment (p=0.033) to just 28%, which is well below the historical average. 
Although the term study lacked contemporaneous controls from which to estimate growth 
potential and determine the proportions of marked FGR, there was a conspicuous lack of very 
low birth weight lambs in the Ad.VEGF treated group: 0 of 17 versus 4 of 16 lambs <2500g in 
the Saline-treated group. Furthermore the mean difference between Ad.VEGF and saline-
treated lambs overall was +681g (19.8%), which was very close to that used for the power 
calculation for this study (+719g; 20%). It was actually the variance introduced by the single 
very large lamb in the Saline group (discussed in Section 5.4.2) that reduced the statistical 
significance to p>0.05. Although no firm conclusions can be drawn from the these 
observations, together they imply that the effects of Ad.VEGF might be confined to, or at least 
greatest in magnitude in, the most compromised pregnancies. Consequently a more accurate 
estimation of effect size might be achieved if the study were to be repeated in only the most 
compromised overnourished adolescent pregnancies. Retrospective analysis of the ultrasound 
data (reported in Chapter 3) suggests that the umbilical artery Doppler indices and placentome 
index in mid-gestation are early predictors of eventual birth weight, and therefore selection of 
fetuses that are destined to become markedly FGR might be feasible using these parameters. 
In the postnatal study, Ad.VEGF-treated lambs demonstrated enhanced absolute postnatal 
growth velocity that was independent of any change in fractional growth rates and epigenetic 
status of key genes of the somatotrophic axis, and increased glucose-stimuated insulin 
secretion that was independent of any changes in markers of insulin resistance. These 
differences likely reflect their relative size advantage at birth rather than any intrauterine 
programming effect (discussed in Chapter 5). 
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7.1.1.3    Putative mechanisms of action 
Prior to these studies in ovine FGR, most attention had been focused on the effects of Ad.VEGF 
at the level of the UtA, in particular the alterations in UBF, vascular reactivity, intima to media 
ratios and angiogenesis in the perivascular adventitia that had been shown following 
administration in normally developing sheep pregnancies (David et al. 2008; Mehta et al. 
2011). These effects were not reproduced in the late gestation study detailed in this thesis, 
with the exception of bradykinin-induced relaxation of the UtA, which was strikingly enhanced 
following Ad.VEGF treatment. Possible reasons for the lack of differences in UBF and the other 
UtA parameters are discussed in detail in Chapter 4. However, an important and novel finding 
of this study was an upregulation of mRNA expression of both VEGF receptors (FLT1 and KDR) 
in the maternal placental compartment, downstream of the site of Ad.VEGF injection. 
Furthermore, placental efficiency (as indicated by the fetal to placental weight ratio) was 
significantly increased in Ad.VEGF-treated overnourished versus control-intake pregnancies in 
late gestation, and tended also to be increased in Ad.VEGF- versus saline-treated 
overnourished pregnancies at term. These observations suggest that effects at the placental 
level might be important in mediating the beneficial impact of Ad.VEGF on fetal growth. FLT1 
and KDR are angiogenic factors and might therefore be expected to produce additional 
vascularisation in the placental bed during the remodelling phase of placental development in 
the final third of gestation (Borowicz et al. 2007). Although there was no evidence of enhanced 
placental secretory function, given that oestradiol levels did not change, there was a tendency 
towards higher GLUT1 mRNA expression in the maternal caruncle. Moreover, plasma glucose 
levels tended to be higher in Ad.VEGF treated lambs at birth, suggesting enhanced placental 
glucose transfer and fetal glucose supply. 
Importantly there was no evidence in either of the studies of any transfer of the vector and/or 
transgene to the fetal placental compartment or fetus, which is in keeping with the findings in 
normal sheep pregnancy after uterine artery delivery of Ad.VEGF. More specifically, the effects 
of Ad.VEGF treatment on the mRNA expression of FLT1, KDR and GLUT1 were all confined to 
the maternal caruncle and there were no effects on the umbilical artery Dopplers, reflecting 
vascular resistance in the fetoplacental circulation. This is reassuring from a safety perspective 
and is a potential benefit of maternal Ad.VEGF therapy over pharmacological agents such as 
sildenafil citrate, which do cross the placenta in significant amounts. These findings may not be 
directly extrapolatable to human pregnancy, and this is discussed further in Section 7.1.3.1 
below. However maternofetal transfer of VEGF-A165 and other isoforms is unlikely to occur as 
hydrophilic molecules usually cross the placenta via water-filled routes of a finite radius, which 
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restrict the passage of larger molecules like VEGF (Stulc 1989). This assumption has been 
supported by ex vivo experiments on human placenta, using VEGF-A165 (Brownbill et al. 2007). 
7.1.1.4    Strengths and limitations of this work 
The main strength of the studies detailed in this thesis lie in the use of a well-characterised 
large animal FGR model with key similarities to human uteroplacental insufficiency. In addition 
the study design incorporated elements that are considered important in human trials testing 
therapeutic interventions, namely randomisation and blinding. The randomisation procedure, 
which was based on the initial measures of the fetal abdominal circumference, renal volume 
and placentome index, did not result in a completely even allocation of all baseline parameters 
in the second study. The Ad.VEGF group demonstrated higher umbilical Doppler indices, which 
were not randomised for and which are associated with poorer placentation and fetal growth, 
however this is unlikely to have affected the interpretation of the results, as it actually biased 
the study against the hypothesis. Unbalanced characteristics at baseline are not uncommon in 
studies with relatively small numbers of animals or participants, and represents a chance 
imbalance rather than bias per se. Given the subjective nature of the ultrasound assessment of 
fetal growth, blinding is highly advantageous to avoid measurement bias. To my knowledge 
this represents the only study to date in which a prenatal intervention has been shown to 
increase fetal growth velocity when quantified by a masked assessor. 
The main limitations of this work are the structural differences in placentation between sheep 
and humans and the relatively late onset of FGR in this particular model. Ultimately no animal 
model can completely represent the human condition and clinical trials in women with severe 
early-onset FGR will ultimately be needed (see Section 7.1.3 below). Placentation in ruminants 
such as the sheep is syndesmochorial. This is a subtype of the epitheliochorial placenta, which 
is the least invasive form (Kaufmann 1981). In ovine pregnancy here are six layers separating 
the maternal and fetal blood. Starting from the maternal side, these constitute: (1) maternal 
endothelium; (2) endometrial connective tissue; (3) endometrial epithelium; (4) trophoblast; 
(5) fetal connective tissue; and (6) fetal endothelium. By contrast, the process of trophoblast 
invasion of the maternal spiral arteries in the human destroys the maternal layers such that 
the maternal blood comes into direct contact with the trophoblast termed haemomonochorial 
placentation). The potential significance of these differences is two-fold. Firstly, it might be 
considered that viral vectors could more easily cross into the fetus in the human compared 
with the sheep, and this is discussed further below in Section 7.1.3.1. Secondly in the context 
of impaired trophoblast invasion, it remains unclear if a putative increase in UBF secondary to 
Ad.VEGF therapy would still be effective if the exchange barrier was greatly impaired, as might 
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be the case in the clinical situation. Furthermore inadequate villous development on the fetal 
side of the placenta (discussed in Section 1.1.2.3) might be a rate-limiting step for gaseous and 
nutrient impaired transfer, in which case theoretically increasing UBF might result in mismatch 
between the umbilical and uterine circulations. Reassuringly, however, the increase in fetal 
growth that was observed in the two sheep studies occurred in the absence of any significant 
change in the umbilical artery Doppler indices, which reflect fetoplacental resistance and blood 
flow, suggesting that a corresponding increase in umbilical blood flow is not actually necessary 
for therapeutic benefit.  
The main rationale for choosing to use the overnourished adolescent sheep paradigm for these 
experiments was the relatively "natural" form of placentally-mediated FGR that is generated. 
However, as illustrated in Figure 3.1, despite the early insult on placental development, growth 
of the fetus is not impacted until the final third of gestation. In considering clinical translation 
it will be important to evaluate this therapy first of all in pregnancies with severe early-onset 
FGR, in which the growth of the fetus has slowed dramatically or completely arrested prior to a 
viable birth weight being achieved. In these pregnancies there is currently no other option for 
parents but to terminate the pregnancy or to await fetal demise in utero, should the fetus not 
reach a viable birthweight (~500g). The model used does not admittedly replicate this extreme 
form of FGR well. However, most of the other available models of FGR would have been 
completely unsuitable for these experiments as they involve surgical procedures that 
permanently compromise uteroplacental perfusion, which could not subsequently be restored 
by gene therapy treatment, e.g. carunclectomy, embolisation and arterial ligation. The single 
exception to this is FGR induced by maternal hyperthermia, which leads to an earlier 
perturbation of fetal growth that better mimics severe early-onset human FGR. However there 
is only a tendency towards a reduction in UBF (p=0.07) in absolute terms in this paradigm and 
UBF is actually increased relative to control (normothermic) pregnancies when expressed on a 
fetal weight specific basis (Regnault et al. 2003). This model features very high perinatal 
mortality rates: historically 29% of heat-stressed ewes will have a miscarriage or stillbirth, and 
45% of live born lambs will die in the neonatal period (Shelton & Huston 1968). Furthermore it 
is relatively expensive to house sheep under constant hyperthermic conditions All these 
factors limited the suitability of the hyperthermia model for the studies detailed here. 
A further potential criticism of the overnourished adolescent model might be the very aspects 
employed to maximise the genetic homogeneity, with the aim of controlling for various factors 
that confound the study of fetal growth. For example it is known that assisted reproduction is 
a risk factor for FGR (Jackson et al. 2004) and embryo transfer from an adult Greyface ewe into 
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a much smaller, peripuberal adolescent recipient is likely to result in an element of maternal 
constraint (see Section 1.1.2.2). For the purposes of the studies detailed in this thesis, all these 
factors were equally represented in groups receiving Ad.VEGF and inactive control treatments 
and the randomisation procedure effectively meant that the groups were similar in all respects 
other than the dietary manipulation and the treatment received. However there may have 
been pertubations of growth attributable to  the  assisted reproductive techniques, adolescent 
uterine environment and/or surgery to administer the vector/saline which were not directly 
measurable given the study design. Hence the additional effect of Ad.VEGF might differ in its 
magnitude if the study were to be repeated in naturally conceiving overnourished adolescent  
ewes or an adult sheep model of FGR. Similarly using a non-invasive means of accessing the 
uterine artery (Section 7.1.3.2.) might avoid the potentially negative effects of open abdominal 
surgery on fetal growth.  
7.1.2    Ongoing work 
7.1.2.1    Assessment of placental vascularity 
Given the observed effects of Ad.VEGF on caruncular mRNA expression of VEGF receptors KDR 
and FLT1, an important question that remains unanswered is whether this had an impact on 
vascularity in the maternal and/or fetal placental compartments. Previously when proliferative 
growth in the maternal caruncle was compared between high- and control-intake adolescent 
sheep pregnancies at 50, 90 and 130 days gestation, various indices of vascularity were 
numerically lower at all stages of gestation in the placentae of overnourished dams, but these 
differences did not reach statistical significance (Redmer et al. 2009). This was in contrast to 
the fetal cotyledon, where vascular indices were actually increased secondary to high intakes 
at 90 days gestation, presumably as a form of compensation (discussed in Section 4.4.10). In 
the fetal study, placental tissues were immersion fixed in Carnoy's solution and embedded in 
paraffin for the subsequent quantification of placental vascularity. In collaboration with 
Professor Dale Redmer at North Dakota State University (NDSU), placental samples will be cut 
into 5μm sections, differentially stained to identify the maternal versus the fetal vessels within 
the placentome and subjected to image analysis to determine capillary area density, capillary 
number density, capillary surface density and area per capillary, as previously described by 
Borowicz et al. (2007). Gestational changes in these indices have been extensively examined in 
both normal and compromised sheep pregnancies and capillary area density is positively 
correlated with VEGF expression in both the carcuncle and cotyledon (Borowicz et al. 2007; 
Reynolds et al. 2010), thus there is a real possibility that adenovirus mediated over-expression 
of VEGF may impact placental vascular development and/or remodelling.   
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7.1.2.2    Expression of genes involved in placental transport 
In both sheep studies there was a suggestion that Ad.VEGF might enhance placental transfer of 
glucose, as indicated by a tendency towards higher GLUT1 mRNA expression in the maternal 
caruncle in late gestation, and a tendency towards higher glucose levels in lamb plasma at 
birth. This effect may have contributed to enhanced fetal growth, either in addition to or 
independently of any (undetected) impact on UBF. Given the encouraging results for the 
glucose transporters, it is of obvious interest to examine for any evidence of altered amino 
acid and/or non-esterified fatty acid (NEFA) transport capacity, both of which are also 
important substrates for normal fetal growth (Hanson et al 1995; Glazier et al. 1997). In sheep, 
transfer of amino acids across the maternal-facing microvillous membrane is dependent on 
accumulative transporters, such as system A, and amino acid exchangers (Cleal & Lewis 2008). 
In addition there are facilitated transporters present in the fetal-facing basal membrane, which 
further promote transfer of amino acids into the fetal circulation, an example of which is T-
type amino acid transporter, TAT-1 (Cleal et al. 2011). By contrast, NEFA are able to cross into 
the fetus by simple diffusion, however they first need to be released from the lipoprotein 
complexes that form in the maternal blood (Gude et al. 2004). Breakdown of these complexes 
is catalysed by lipoprotein lipase (LPL). It has been shown that levels of LPL protein are reduced 
in growth-restricted placentae (Magnusson et al. 2004), although this has not been measured 
to date in the overnourished adolescent paradigm. In collaboration with Drs Lucy Green and 
Jane Cleal, University of Southampton, mRNA expression of TAT-1 and LPL is being examined in 
the maternal and fetal placental tissues from the late gestation study. In addition, mRNA 
expression of the vitamin D and IGF1 receptor will be quantified, as these are considered 
important for the endocrine regulation of placental transport (Murphy et al. 2006). However, it 
must be borne in mind that there are potential limitations with this type of opportunistic in 
vitro analysis, considering that these studies were not specifically powered to detect 
differences in nutrient transporter gene expression. Given that the shift in fetal growth 
attributable to Ad.VEGF was relatively small compared with background differences between 
control- and high- intake pregnancies, greater numbers may be needed to detect a significant 
effect. Furthermore in the absence of reliable assays to quantify protein expression, 
differences in mRNA can be difficult to interpret. An alternative approach would be to study 
placental nutrient transport capacity dynamically by repeating the experiment in chronically 
catheterised animals, which would allow for rates of uptake and utilisation of various 
substrates by the gravid uterus as a whole, as well as the placenta and fetus, to be examined. 
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7.1.2.3    Assessment of small intestinal vascularity 
Maternal nutrient restriction during sheep pregnancy has previously been shown to reduce 
jejunal capillary surface density in the offspring at three weeks of postnatal age (Meyer et al. 
2013). In collaboration with Professor Joel Caton, NDSU, perfusion-fixed sections of fetal small 
intestine, prepared as described in Section 4.2.5.2 and depicted in Figure 4.4, and immersion-
fixed in Carnoy's solution, will be examined to quantify jejunal vascularity. In the late gestation 
study, overnourishment of the adolescent ewe was associated with a significant increase in 
relative small intestinal weight relative to control-fed ewes, and Ad.VEGF therapy attenuated 
this effect. A comparison of fetal small intestinal vascularity between control- and (untreated) 
high-intake pregnancies will assess whether FGR per se has any impact on the number or 
density of mesenteric blood vessels in this paradigm. It will also be assessed whether Ad.VEGF 
attenuates any such effect. In addition, mRNA expression of key angiogenic factors and 
receptors will be examined using RT-PCR in snap-frozen fetal jejunal tissues and correlated 
with these vascular indices. Redistribution of the fetal cardiac output away from the 
developing gut (see Section 1.1.3.4) results in an insult to the mesenteric blood supply, which 
is implicated in the pathogenesis of necrotising enterocolitis (NEC) in the human newborn (Lin 
et al. 2008). Although NEC has not to date been observed as a consequence of FGR in the 
overnourished adolescent paradigm, secondary effects of Ad.VEGF therapy might include a 
reduced risk of this particular neonatal complication if successfully translated into the clinic.  
7.1.2.4    Assessment of somatotrophic gene expression 
In Chapter 6, the DNA methylation status of ten somatotrophic axis genes was quantified to 
examine whether the observed effects of prenatal Ad.VEGF treatment on postnatal growth 
and metabolism were epigenetically mediated. This work is being extended by determination 
of mRNA expression of these same ten genes in hepatic tissues by qRT-PCR. This will facilitate 
correlation between methylation status and gene expression, and also examine for a potential 
upregulation of the somatrophic axis through alternative, non-epigenetic mechanisms. As 
discussed in Section 6.4.2, DNA methylation status varies greatly between different cell and 
tissue types. It would therefore have been interesting to analyse additional tissue sets, such as 
the pancreas and perirenal fat, from these studies for the same 10 genes. However given the 
current lack of evidence of any baseline epigenetic differences in this particular sheep model 
of FGR and the relative expense of pyrosequencing, it was not considered worthwhile pursuing 
in these particular tissues. However, given the potential of Ad.VEGF to mitigate FGR, repeating 
the experiment in an established model of intrauterine programming (ovine or murine) might 
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be informative and would be a better means of investigating whether Ad.VEGF can benefit the 
longer term health of the offspring. This aspect is considered further in Section 7.1.2.6 below. 
7.1.2.5    Evaluation of prenatal Ad.VEGF therapy in a guinea pig FGR model 
At the time of writing, complementary experiments are underway to investigate the effects of 
Ad.VEGF treatment in a guinea pig model of FGR induced by periconceptual maternal 
undernutrition. Restriction of maternal caloric intake by 70% for 4 weeks pre-conception and 
for the first half of pregnancy, followed by 90% for the second half of pregnancy, results in a 
40% reduction of fetal weight with asymmetrical growth restriction and fetal brain sparing. 
Although UBF has not specifically been measured in this model, there is evidence of 
uteroplacental insufficiency in the form of a reduced placental exchange surface area and 
increased thickness of the exchange barrier (Roberts et al. 2001). The guinea pig was chosen 
for additional experiments in view of it similarity to the human with respect to placentation 
and the relatively long length of gestation for a rodent. Guinea pigs have a haemochorial 
placenta and there is trophoblast invasion of the radial arteries (Mess 2007). Treatment of the 
uterine and radial arteries with Ad.VEGF, administered externally using a thermosensitive 
pluronic gel, reduced brain to liver weight ratios and tended to increase fetal weight compared 
to Ad.LacZ treatment (0.45±0.019 vs. 0.53±0.017, p=0.021, and 95±2.0 vs. 85±2.8g, p=0.061; 
respectively) (Mehta et al. 2012), replicating the findings of the sheep studies presented in this 
thesis. Although this data is provisional, it further supports the efficacy of prenatal Ad.VEGF 
gene therapy in FGR and the move towards clinical translation. 
7.1.2.6    Assessment of longer term outcomes  
An important consideration that has not been addressed by this particular programme of work 
is the effect of Ad.VEGF on long term morbidity. As discussed in Sections 4.4.2 and 7.1.1.1, it is 
becoming increasingly recognised that fetal adaptive mechanisms such as the brain sparing 
effect may actually indicate an increased risk of a poorer neurological outcome. In both the 
sheep studies detailed in this thesis, there was evidence that Ad.VEGF attenuated fetal brain 
sparing, which potentially represents an additional benefit of treatment. However it remains 
to be seen whether this translates into a measurable effect on motor or cognitive function. 
Additional funding is currently being sought to examine the impact of Ad.VEGF treatment on 
neurological outcomes using the guinea pig model of FGR described above. In addition, it will 
be important to examine the impact of prenatal Ad.VEGF therapy on health and wellbeing in 
adult life to investigate whether improving the fetal growth trajectory can mitigate the adverse 
metabolic phenotype that is often seen following FGR. However, this is likely to be a secondary 
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consideration for clinical translation as the primary aim will be to reduce: (a) perinatal 
mortality; and (b) neonatal morbidity in severe cases of FGR. However any additional benefit 
on the long term wellness of the individual would be very welcome and could have a 
significant positive impact at a public health level. Currently much attention is focused on the 
role of various preventive nutritional strategies in pregnancy and early childhood to reduce the 
burden of cardiovascular and metabolic disease in adulthood (Barouki et al. 2012; Balbus et al. 
2013), however it remains to be seen whether prenatal treatment of established FGR might 
have a similar impact.  
7.1.3    Moving towards clinical translation 
On the back of the studies detailed in this thesis, funding has now been secured from the 
European Union via a Framework Programme 7 grant for a series of different work packages 
with the overall aim of translating Ad.VEGF therapy into the clinic for the treatment of severe 
early-onset FGR. The EVERREST project (Does vascular endothelial growth factor gene therapy 
safely improve outcome in severe early-onset fetal growth restriction?) includes a full 
reproductive toxicology programme, a bioethical study and a first in-woman phase I/IIa trial to 
be conducted across four European clinical centres of excellence. There are likely to be various 
challenges in the development of the clinical trial protocol for the latter. Patient numbers will 
be limited to 24, and a 3+3 dose escalation dosing regimen in serial patients will be used, with 
an emphasis on safety. Perinatal outcomes will be compared to data from historical controls 
that will be collected prospectively during the course of the study from the four participating 
centres. As the study will be underpowered to look at morbidity and mortality, long-term 
follow up will be essential. 
Very few other therapies are at an equivalent stage of development for FGR or other obstetric 
complications. As discussed in Section 1.1.4.5, a randomised clinical trial of sildenafil for severe 
FGR is underway (STRIDER) despite the various concerns about efficacy and safety of this drug, 
in particular with respect to the risk of placental steal and preventing fetal compensation. Two 
potential advantages of prenatal Ad.VEGF gene therapy over sildenafil are: (a) that the former 
is capable of locally targeting the uteroplacental circulation by transducing only the uterine 
arterial circulation; and (b) that a sustained increase in UBF and/or fetal growth can be 
achieved using only a single dose. Other groups have begun to investigate the potential of 
gene therapy for obstetric conditions, but are not yet ready for clinical studies. Systemic 
delivery of adenoviruses encoding VEGF-A121 in a mouse model of pre-eclampsia reduces 
maternal hypertension and proteinuria (Woods et al. 2011), and placental-specific adenovirus-
mediated over-expression of angiopoietin 2 has been shown to increase fetal weight in normal 
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mouse pregnancy (Katz et al. 2009), although efficacy in an animal model of FGR is yet to be 
reported. Currently the number of new therapies under development in Obstetrics is limited 
when compared to other medical fields, which is likely to be a reflection of the cost of 
reproductive toxicology experiments and long-term follow-up of the offspring, as well as 
specific concerns about teratogenicity and ethics.  
7.1.3.1    Safety aspects of Ad.VEGF in pregnancy 
It is reassuring that there were no obvious signs of toxicity from the adenoviral vector in the 
sheep studies. With respect to maternal wellbeing, ewes receiving Ad.VEGF or Ad.LacZ did not 
show any delay in their post-operative recovery that might have been suggestive of systemic 
infection, and their re-alimentation was equivalent to saline treated ewes. Analysis of neonatal 
blood samples obtained at 1 week of age did not show any detrimental effect on liver function 
or serum biochemistry. This is in agreement with previous investigations on maternal and fetal 
blood at 1 and 6 weeks following vector injection (David et al. 2008; Mehta et al. 2011), which 
also included routine haematological parameters. The lack of evidence of liver dysfunction is 
particularly encouraging. Given the equivalent size of the sheep and the human (both mother 
and her fetus), this suggests that the dose used is unlikely to be harmful and is likely to be 
clinically relevant. Given the differences between human and sheep placentation, there 
remains a possibility that Ad.VEGF may cross into the human fetus. Direct fetal administration 
of adenovirus has been shown to induce an immune response (McCray et al. 1995), which 
becomes more pronounced following repeated exposure (Iwamoto et al. 1999). For long-term 
gene therapy applications, an immune response may be detrimental. However given that 
transgene expression in the fetal tissues is not necessary for the beneficial effects described in 
this thesis, an immune reaction to mop up any spillover into the fetus would not be 
undesirable under the circumstances. This highlights the fact that this is ultimately a maternal 
therapy, albeit one that is indicated on fetal grounds. Moreover, there is some evidence from 
previous experiments that transfer of Ad.VEGF across the human placenta is unlikely to occur 
at all. This may relate to the availability of the Coxsackievirus and adenovirus receptor (CAR), a 
type 1 membrane receptor encoded by the CXADR gene that the adenovirus needs to bind to 
in order to gain access to the cell, via internalisation (Nemerow & Stewart 1999; Carson 2001). 
It has been demonstrated that CAR is continuously expressed on the fetal side of the placenta  
within the invasive cytotrophblast but not the syncytiotrophoblast, which renders the latter 
resistant to adenoviral infection and limits placental transfer (Koi et al. 2001). It appears that 
the ability of the adenovirus to infect the trophoblast is related to its state of differentiation, 
as transduction efficiency is reduced once the mononucleated cytotrophoblast cells terminally 
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differentiates into mulitnucleated syncytiotrophoblast cells (MacCalman et al. 1996; Parry et 
al. 1998). However, although susceptibilty to adenoviral infection is related to the presence or 
absence of CAR, adenoviral infection has been achieved in cell lines and animals that would 
otherwise be considered non-susceptible when modified viruses (e.g. gene therapy vectors) or 
high concentrations of wild-type viruses are delivered (Batra & Sharma 2002; Kim et al. 2002).  
In collaboration with Professor Colin Sibley at the Maternal and Fetal Health Research Centre, 
University of Manchester, it has been shown that high-dose Ad.VEGF has no obvious adverse 
effects on the structure and function of human placental explants in culture. This has also been 
evaluated in the ex vivo dual perfused lobule. In both sets of experiments there was no 
detrimental effect of Ad.VEGF on placental cell survival, enzyme activity and hormone 
secretion. In the present studies, there were no gross abnormalities in fetal or maternal tissue 
at the time of necropsy. This is important as sustained over-expression of VEGF has been 
associated with tumorigenesis and reduced life span in mice (Lee et al. 2000; Kotimaa et al. 
2012). This is one rationale for the use of a short acting vector such as the adenovirus, which 
prevents the long term expression that may otherwise occur with the use of lentiviral VEGF, 
for example (Azzouz et al. 2004; Jiang et al. 2008). Previous work in normal sheep pregnancy 
has included microscopic examination of a range of H&E-stained maternal and fetal tissues 
(including heart, lung, liver, kidney, adrenal, spleen, brain, thymus and gonad) and similarly 
failed to reveal any abnormalities following prenatal adenoviral delivery (David et al. 2008). 
Furthemore there were no adverse effects on maternal or fetal haemodynamic parameters 
when these were directly measured and no undesirable expression of Ad.VEGF was detectable 
in the peripheral maternal circulation or in any fetal tissues when examined by RT-PCR (David 
et al. 2008; Mehta et al. 2011).  
Further toxicology studies are planned using the pregnant New Zealand white rabbit, which is 
considered to be the best model for this purpose as it most closely mimics human placentation 
during the second trimester, which is haemodichorial rather than haemomonochorial as is the 
case in the third trimester. This is important considering the timing of Ad.VEGF treatment for 
the eventual clinical trial, which would probably be around 22 to 24 weeks gestation. This work 
will involve exposing the pregnant rabbit to extremely high concentrations of vector in order 
to determine the safety window between therapeutic and toxic (titrated up to lethal) doses. 
Detailed histological examination of maternal and fetal tissues will be performed, as well as an 
investigation of vector biodistribution using quantitative PCR. For any subsequent clinical study 
it will be important to determine the most appropriate vector dose to maximise the treatment 
effect whilst minimising any potential adverse side-effects. 
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7.1.3.2    Delivery of the vector to the human uterine artery 
During these studies there were no obvious adverse fetal responses to the injection procedure, 
although no vital signs were specifically monitored. In the previous studies in normal sheep 
pregnancy, fetal heart rate and blood pressure (measured invasively) were unaffected by UtA 
occlusion. Unlike the present study, in these experiments flow probes were implanted prior to 
vector injection in order to record baseline measurements of UBF. This revealed an acute drop 
in UBF of approximately 10% in the first three days following injection of Ad.VEGF or Ad.LacZ. 
It was supposed that this was due to the 5-minute vascular occlusion and associated trauma to 
the vessel wall. However in all cases UBF was restored by 5 to 7 days. In the longer term there 
was no evidence of damage to the UtA vessel wall, and no obvious oedema, inflammation or 
leucocyte infiltration at the time of necropsy (Mehta et al. 2011). It is not possible to say 
whether a similar drop in UBF occurred in the present studies as no baseline measurements 
were made. This was due to the fact that the adolescent ewes had already undergone a mini-
laparotomy for embryo transfer, and two further laparotomies for flow probe placement and 
gene therapy administration, respectively, would have required additional regulatory approval 
from the Home Office, which we were advised by the local inspector would not be forthcoming 
on welfare grounds. Moreover monitoring did not begin until the third post-operative day to 
allow ewes to fully recover from the midline laparotomy. This potential acute drop in UBF 
remains a concern from the point of view of clinical translation as severely growth-restricted 
fetuses are already likely to be hypoxaemic (Akalin-Sel et al. 1994; Nicolini et al. 1990). 
However, on the other hand it could be argued that chronically hypoxaemic fetuses might be 
more tolerant of further temporary hypoxia. For example, it is recognised that uncompromised 
term fetuses are more vulnerable to hypoxic-ischaemic insults due to intrapartum asphyxia 
than compromised (preterm or growth-restricted) fetuses. Although the most compromised 
fetuses of overnourished adolescent ewes are modestly hypoxaemic in late gestation (Wallace 
et al. 2002), it is not known whether this is also the case mid-gestation. 
In view of the risks of preterm labour and fetal loss following maternal laparotomy ± uterine 
manipulation during pregnancy in humans (McGory et al. 2007), access to the UtA for the trial 
will be via transfemoral catheterisation (Delotte et al. 2009). This is a clinical procedure that is 
already approved by the National Institute for Health and Clinical Excellence (NICE) and is used 
for the management of postpartum haemorrhage and menorrhagia due to uterine fibroids by 
embolisation. Occlusion would still be required but could be achieved via intraluminal balloon 
inflation. A critical safety consideration with respect to UtA occlusion is the availability of a 
collateral circulation to maintain oxygen supply to the fetus during the occlusion. Collateral 
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supply might come from the contralateral UtA or via the ovarian blood vessels. This was not a 
problem in the sheep experiments however there is evidence that the ovine uterus is relatively 
hyperperfused, which might protect the fetus against short term reductions in UBF of <50% 
(Skillman et al. 1985). It will be important to monitor the fetal heart rate using an external 
ultrasonic transducer during vascular occlusion and to have a low threshold to abandon the 
occlusion should a significant fetal bradycardia develop. Pre-oxygenation of the mother may 
be considered and is unlikely to be harmful in the short term, although there is evidence that 
prolonged exposure to maternal oxygen therapy is detrimental to the fetus (NICE 2007). In the 
context of a pre-viable fetus with absent growth velocity, the risk of the injection procedure 
and occlusion is likely to be outweighed by the high risk of intrauterine death in this particular 
scenario. However in less severe cases, this risk : benefit ratio may be altered. Extra-luminal 
delivery of Ad.VEGF (as used in the guinea pig experiments outlined above) is unlikely to be 
feasible in the human as this would probably necessitate a laparotomy. 
7.1.3.3    Ethical barriers to implementation 
Gene therapy treatment raises a great number of ethical issues, particularly where the fetus is 
involved. One specific concern about prenatal gene therapy in general is potential transmission 
to the fetal germline, which may potentially result in transgenerational adverse effects. There 
is also a potential risk of insertional mutagenesis, leading to tumour formation. One of the real 
benefits of using adenoviral vectors is that these risks are negated by the fact that they are 
non-integrating in nature. Any fetal intervention can precipitate preterm birth and this would 
further compound the problem for an affected fetus. However if Ad.VEGF were to be given at 
a non-viable stage then the risk imposed would be miscarriage rather than a potentially poor 
neonatal outcome, which is arguably less of a burden. 
Informed consent will be essential for recruitment to the phase 1 clinical trial and for potential 
widespread dissemination of this therapy in the longer term. One particular issue is likely to be 
the potentially short interval between diagnosis and the proposed intervention. This may not 
allow women the time to fully process all the information in order to make an informed choice.  
A further issue is that, in the UK, the fetus officially has no rights per se until the time of birth. 
Nevertheless, understandably mothers do bestow moral status on their fetuses. This is based 
upon the fact that the fetus has an undeniable potential to become a person in its own right. 
The point of gestation at which the fetus is considered to satisfy such criteria is variable across 
cultures. Some would argue that this only occurs at the point of viability. Potential target 
pregnancies for this therapy would be those where the estimated fetal weight remains below 
500g, which would technically not meet the criteria for viability.  
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After consenting to prenatal Ad.VEGF gene therapy, the mother essentially takes on the risks 
of the procedure. This is similar to the situation with respect to fetal surgical intervention. For 
example, prenatal repair of myelomeningocoele (spina bifida) when compared with standard 
postnatal surgery is associated with a reduced need for ventriculoperitoneal shunting and 
better neurological outcomes at 2 years of age, despite a significant increase in preterm birth 
rates and iatrogenic membrane rupture (Adzick et al. 2011). However this approach requires a 
hysterotomy in mid-pregnancy that is associated with considerable maternal morbidity due to 
uterine scar dehiscence and infection, and an increased risk of complications in future 
pregnancies (Clow & Crompton 1973). This highlights the potential fetomaternal conflict that 
may arise where an intervention for fetal benefit can cause maternal harm. It is essential that 
the mother maintains her autonomy in such situations, and that health professionals do not 
pressure her in any way towards interventions based on their own consideration of the fetus 
as a patient (Chervenak & McCullough 2002). 
Another consideration that is unique to Fetal Medicine practice is the option of termination of 
pregnancy in some countries, which provides the parents with a 100% guarantee that the child 
will not suffer any residual morbidity. At University College Hospital between 2000 and 2012, 
approximately 10% of parents (n=7) chose to terminate pregnancies that were diagnosed as 
affected by severe early-onset FGR (DJ Carr, unpublished data) rather than take the risk of 
having a child with potentially severe handicap. However in some countries and cultures, 
termination of pregnancy may not be acceptable. Parents faced with severe early-onset FGR 
with a very poor outlook will still have the option of not continuing with the pregnancy, and it 
could be argued that choosing to receive experimental gene therapy represents a "gamble". 
Attitudes towards termination will be important to consider in developing the clinical trial 
protocol as this may introduce bias into recruitment, e.g. an ethnic mix that is not completely 
representative of the general population to which the results will be extrapolated. 
Furthermore, particularly as it seems unlikely that Ad.VEGF therapy will completely normalise 
fetal growth (see Section 7.1.1.1 above), it might be possible that treatment may shift a fetus 
otherwise destined to be stillborn just across the threshold of viability and constitute a poor 
perinatal outcome. This issue is not limited to consideration of Ad.VEGF gene therapy for FGR 
alone, but is relevant when considering other fetal interventions, such as maternal steroids to 
mature the fetal lungs, intrauterine fetal blood transfusion, fetoscopic tracheal occlusion for 
congenital diaphragmatic hernia or open fetal surgery for spina bifida surgery. Some parents 
might argue that a "partial cure" of this nature might be worse than no cure. This would be 
particularly true for patients who would not have otherwise chosen to continue the pregnancy, 
had the prenatal gene therapy option not been available. This possibility of a poor outcome 
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despite an attempt at in utero therapy will need to be explicitly discussed in order to ensure 
that the parents fully understand the implications, as such decisions cannot be reversed. In 
some cases, termination of pregnancy may remain an option following prenatal Ad.VEGF if 
beneficial effects on fetal growth and/or wellbeing are not seen. If preterm delivery ensues it 
may also be a reasonable option not to resuscitate the neonate, depending on birth weight 
and gestational age. This is currently the case for spontaneous preterm birth near the limit of 
viability. Such decisions require a detailed discussion with the neonatologists about prognosis. 
Ultimately the risk-benefit ratio for prenatal gene therapy is still not clear, unlike some of the 
more common invasive fetal procedures such as laser ablation of placental vessels in twin-twin 
transfusion syndrome and fetal blood transfusion for haemolytic disease, where analysis of 
outcomes over the last 20 years has determined the risks and benefits. Consequently the issue 
of informed consent is challenging (Burger & Wilfond 2000). The relative lack of qualitative 
research in this area of practice leaves many questions unanswered about what parents would 
consider acceptable in the realm of fetal therapy. This highlights the need for a bioethical 
study, which will be performed prior to a phase I/IIa clinical trial. This study will aim to explore 
the attitudes of mothers and fathers, health professionals and other relevant stakeholders 
towards maternal Ad.VEGF gene therapy for fetal benefit across the European Union. 
7.1.3.4    Wider applications: pre-eclampsia and late-onset FGR 
As mentioned above, the proposed phase I/IIa clinical trial will aim to recruit only pregnancies 
affected by severe early-onset FGR (incidence 1:500) for which the only current alternatives 
are to perform a termination of pregnancy or to await fetal demise in utero should fetal weight 
never reach a viable threshold. However, should Ad.VEGF prove to be effective and safe, then 
the therapy may be of use for placental disorders in a much wider sense. Milder and later 
onset forms of FGR are much more common, affecting around 8% of pregnancies 
(Mandruzzato et al. 2008). Unlike early-onset FGR, the problem is usually more one of 
identification, as cases tend to present after the routine second trimester anomaly scan. Once 
FGR is diagnosed, the prospect of delivering the compromised fetus is far less of a problem at 
later gestations, however delivery does not appear to improve outcome, according to the 
results of the DIGITAT trial (see Section 1.1.4.6). Consequently treatment with Ad.VEGF in the 
late second or even third trimester may still be helpful depending on the safety profile of the 
therapy. The burden of mild FGR is considerable, as a large proportion of stillborn babies have 
evidence of unrecognised growth restriction (Cousens et al. 2011). 
Pre-eclampsia is a pregnancy complication that is closely related to FGR and shares a similar
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pathogenesis, i.e. impaired trophoblastic invasion of the spiral arteries (see Section 1.1.2.3).  
Pre-eclampsia complicates up to 10% of pregnancies (Sibai et al. 2005) and is a leading cause 
of maternal death (Cantwell et al. 2011), mainly due to complications of stroke and eclampsia. 
In addition to causing FGR, pre-eclampsia produces a maternal syndrome that is characterised 
by gestational hypertension, oedema and proteinuria. There is often widespread endothelial 
dysfunction that can lead to a number of superimposed crises including pulmonary oedema, 
renal failure, placental abruption, haemorrhagic stroke, HELLP (haemolysis, elevated liver 
enzymes and low platelets) syndrome. For the planned phase I/IIa trial of Ad.VEGF in FGR it 
will be important to exclude cases of established pre-eclampsia where possible, as maternal 
complications may indicate delivery before an assessment of the fetal response to therapy can 
be made. Ultimately maternal health takes priority over that of the fetus. However, should 
Ad.VEGF therapy prove effective for isolated FGR, an improvement in uteroplacental perfusion 
may also mitigate endothelial dysfunction and thereby reduce the severity of the maternal 
syndrome. The effects on maternal parameters such as blood pressure and urinary protein will 
need to be evaluated in due course. 
7.2 Conclusions 
In a well-established sheep model of placentally-mediated FGR induced by overnourishment of 
the pregnant adolescent ewe, bilateral uterine artery injections of Ad.VEGF in mid-gestation: 
 Significantly increased fetal growth velocity (reflected by greater abdominal circumference 
± renal volume measurements) at 3 and 4 weeks post-injection: ultrasonographic growth 
assessed by single operator blind to treatment; findings replicated in two separate studies 
 Mitigated brain sparing, reflected by lower biparietal diameter : abdominal circumference 
ratios throughout the final third of gestation / lower brain : liver weight ratios at necropsy 
 Reduced the incidence of marked FGR in late gestation (resulting in fewer fetuses with a 
birth weight >2 standard deviations below the normally-grown control-intake mean) 
 Tended to increase lamb birth weight near term, gestation length and placental efficiency 
 Attenuated disproportionate relative growth of the fetal adrenal gland and small intestine  
 Increased the relaxation response of the uterine artery in response to bradykinin 
 Increased caruncular expression of both VEGF receptors, FLT1 and KDR 
 Tended to increase caruncular expression of GLUT1 and plasma glucose levels at birth 
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 Was not associated with any maternal, fetal or neonatal complications around the time of 
gene therapy treatment, at delivery near to term and during the first 12 weeks of life  
 Increased absolute postnatal growth velocity without affecting fractional growth rates or 
the epigenetic status of key genes of the somatotrophic axis 
 Increased glucose-stimulated insulin secretion and non-esterified fatty acid suppression 
without affecting indices of insulin resistance 
 Tended to increase lean tissue mass and bone mineral density and significantly increased 
perirenal fat weight in female lambs only at 12 weeks of age 
Despite these positive effects, no measurable effect of Ad.VEGF was seen on serial in vivo 
measurements of UBF. The lack of any sustained differences in UBF between control- and high- 
intake adolescent pregnancies however was highly suspicious, as was the lack of a normal 2-3 
fold gestational increase in UBF during the second half of gestation. It appears likely therefore 
that the telemetric monitoring equipment used in this study was not functioning properly. The 
alternative explanation is that Ad.VEGF had no genuine impact on UBF and that its effect on 
fetal growth was mediated by other factors, such as placental nutrient transport capactity. No 
effect of Ad.VEGF was seen on IMR or neovascularisation in the perivascular adventitia. This 
may reflect differences in study design or adaptive responses to uteroplacental insufficiency, 
given that the latter was significantly increased in high- relative to control-intake pregnancies. 
This work has demonstrated proof of principle that prenatal maternal Ad.VEGF gene therapy 
safely improves fetal growth in pregnancies complicated by FGR. There was no measurable 
effect on UBF, intima to media ratios or neovascularisation (all proposed mechanisms of action 
from previous work) however there was evidence of effects mediated downstream at the 
placental level, particularly an upregulation of FLT1, KDR and GLUT1 in the maternal caruncular 
tissues. These findings have led on to additional work to examine the effect of Ad.VEGF on 
placental vascularity and genes involved in placental nutrient transport in order to further 
investigate the mechanisms of action. In addition, funding has been secured to perform 
reproductive toxicology experiments, a bioethical study and first-in-woman phase I/IIa clinical 
trial in the move towards translation of this novel therapy into the clinic. There are likely to be 
considerable practical and ethical barriers to overcome in developing this treatment for human 
use. Safety will be key, given the limitations of the present study and the differences between 
species, particularly with respect to placentation. Nevertheless, prenatal maternal Ad.VEGF 
gene therapy has the potential to become the first effective treatment for severe early-onset 
fetal growth restriction.  
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 Appendix 1 - Reference Charts for Normal Ovine Fetal Growth:  AC and RV 
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Appendix 2 - Reference Charts for Normal Ovine Fetal Growth:  BPD and FL  
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Appendix 3 - Late Gestation Necropsy Fetal Record Sheet 
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Appendix 4 - Late Gestation Necropsy Placental Record Sheet 
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Appendix 5 - Late Gestation Necropsy Maternal Record Sheet 
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Appendix 6 -  Lambing Baseline Data Collection Form 
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Appendix 7 -  Postnatal (Lamb) Necropsy Record Sheet 
 
 
 
 
 
